<html lang="en"><head>
	<!-- Required meta tags -->
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
	<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

	<!-- Favicon -->
	<!-- cpcommit -->
	<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

	<script>
		(function () {
			var hostName = window.location.hostname;

			var browserAccepted = function () {

				var ua = window.navigator.userAgent;
				var trident = ua.indexOf('Trident/'); //IE 11;
				var msie = ua.indexOf('MSIE '); // IE 10 or older
				if (msie > 0) {
					return false;
				}
				return true;
			}();

			var pathToLibs = './js';
			var pathToError = './';
			// uncomment following lines only when running ix symlink to ix.xhtml on *.sec.gov
			/* commented out for running ix redirector script
			if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
				pathToLibs = './ixviewer/js';
				pathToError = '/ixviewer/';
			}
			*/
			if (browserAccepted) {

				// css
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

				// js
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.7.1.slim.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

				var date = new Date();
				var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
				document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
			} else {
				// user us on a browser that we do not support
				var currentUrl = window.location.href.split('?')[0];
				var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
				browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
				window.location.href = browserError;
			}
		})();
	</script><link rel="stylesheet" href="./js/css/custom-bootstrap.css"><link rel="stylesheet" href="./js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="./js/css/app.css"><script type="text/javascript" src="./js/lib/jquery-3.7.1.slim.min.js"></script><script type="text/javascript" src="./js/lib/popper.min.js"></script><script type="text/javascript" src="./js/lib/bootstrap.min.js"></script><script type="text/javascript" src="./js/lib/moment.js"></script><script type="text/javascript" src="./js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="./js/lib/he.js"></script><script type="text/javascript" defer="true" src="./js/production.min.js?d=22-4-2024"></script>
	<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} #dynamic-xbrl-form .text-block-indicator-left{border-left:.75rem solid ##003768;} #dynamic-xbrl-form .text-block-indicator-right{border-right:.75rem solid ##003768;} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>

<body>
	<noscript>This application relies heavily on JavaScript, you
		will need to allow JavaScript to use this application.</noscript>
	<nav class="reboot navbar navbar-expand-md navbar-dark navbar-height bg-sec fixed-top w-100 pl-0">
		<button class="reboot navbar-toggler ml-1" type="button" data-test="" data-toggle="collapse" data-target="#main-navbar" aria-controls="main-navbar" aria-expanded="false" aria-label="Toggle navigation">Inline Viewer</button>
		<div class="reboot navbar-height collapse navbar-collapse bg-sec w-100" data-test="main-navbar" id="main-navbar">
			<ul class="reboot navbar-nav mr-auto bg-inherit">
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a id="menu-dropdown-link" data-test="menu-dropdown-link" class="reboot nav-link dropdown-toggle click disabled" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="1" accesskey="1">
						<i class="reboot nav-loading fas fa-bars" title="Menu"></i>
						<span class="reboot d-md-none d-lg-inline">Menu</span>
						<span class="reboot sr-only sr-only-focusable">Menu</span>
					</a>
					<div class="reboot dropdown-menu">
						<a id="menu-dropdown-information" data-test="menu-dropdown-information" class="reboot dropdown-item click text-body" tabindex="1">Information</a>
						<a id="form-information-instance" data-test="form-information-instance" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Save XBRL
							Instance</a>
						<a id="form-information-zip" data-test="form-information-zip" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Save XBRL Zip
							File</a>
						<a id="form-information-html" data-test="form-information-html" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Open as HTML</a>
						<a id="menu-dropdown-settings" data-test="menu-dropdown-settings" class="reboot dropdown-item click text-body" tabindex="1">Settings</a>
						<a id="form-information-help" data-test="form-information-help" class="reboot dropdown-item click text-body" tabindex="1">Help</a>
						<span id="form-information-version" class="reboot dropdown-item-text text-body" tabindex="1"></span>
					</div>
				</li>
				<li class="reboot nav-item my-auto ml-1">
					<a id="sections-dropdown-link" data-test="sections-dropdown-link" class="reboot nav-link click disabled meta-required" tabindex="2" accesskey="2">
						<i class="reboot fas fa-layer-group" title="Sections"></i>
						<span class="reboot d-md-none d-lg-inline">Sections</span>
						<span class="reboot sr-only sr-only-focusable">Sections</span>
					</a>
				</li>
				<li class="reboot nav-item my-auto ml-1 mr-1">
					<form id="global-search-form" data-test="global-search-form" class="reboot my-2 my-lg-0 input-group disabled" novalidate="">
						<div class="reboot input-group-prepend">
							<button data-name="global-search-options" class="reboot dropdown btn btn-outline-light disabled" type="button" data-toggle="dropdown" tabindex="3">
								<i class="reboot nav-loading fas fa-cog" title="Additional Search Options">
									<span class="reboot sr-only sr-only-focusable">Additional
										Search Options</span>
								</i>
							</button>
							<div class="reboot dropdown-menu px-2">
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="1" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Fact Name</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="2" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Fact Content</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="3" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Labels</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="4" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Definitions</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="5" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Dimensions</span>
									</label>
								</div>
								<div class="reboot bg-light border p-1">
									<span class="reboot dropdown-item-text">Reference
										Options</span>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="6" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Topic</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="7" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Sub-Topic</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="8" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Paragraph</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="9" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Publisher</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="10" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="disabled">Include Section</span>
										</label>
									</div>
								</div>
								<div class="reboot form-check">
									<input class="reboot form-check-input" type="checkbox" name="search-options" value="11" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Match Case</span>
									</label>
								</div>
							</div>
						</div>
						<input type="text" class="reboot form-control disabled" id="global-search" data-test="global-search" placeholder="Search Facts" disabled="" aria-label="Search all Facts and highlight them accordingly." tabindex="4">
						<div class="reboot input-group-append">
							<button id="search-btn-clear" data-name="global-search-clear" class="reboot btn btn-outline-light disabled" type="button" tabindex="5">
								<i class="reboot nav-loading fas fa-times-circle" title="Clear Search"></i>
								<span class="reboot sr-only sr-only-focusable">Clear
									Search</span>
							</button>
							<button class="reboot btn btn-outline-light disabled" type="submit" tabindex="6">
								<i class="reboot nav-loading fas fa-search" title="Submit Search"></i>
								<span class="reboot sr-only sr-only-focusable">Submit
									Search</span>
							</button>
						</div>
					</form>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-data" data-test="nav-filter-data" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="7" accesskey="3">
						<i class="reboot nav-loading fas fa-list-alt" title="Data"></i>
						<span class="reboot d-md-none d-lg-inline">Data</span>
						<span class="reboot sr-only sr-only-focusable">Data</span>
					</a>
					<div class="reboot dropdown-menu">
						<form id="nav-filter-dropdown" data-name="data-dropdown" class="reboot px-2">
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="0" checked="" tabindex="7">
								<label class="reboot form-check-label mb-0">All</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="1" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Amounts Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="2" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Text Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input meta-required" type="radio" name="data-radios" value="3" disabled="" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Calculations Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="4" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Negatives Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="5" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Additional Items Only</span>
								</label>
							</div>
						</form>
					</div>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-tags" data-test="nav-filter-tags" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="8" accesskey="4">
						<i class="reboot nav-loading fas fa-tags" title="Tags"></i>
						<span class="reboot d-md-none d-lg-inline">Tags</span>
						<span class="reboot sr-only sr-only-focusable">Tags</span>
					</a>
					<div class="reboot dropdown-menu">
						<form id="nav-filter-tags-dropdown" data-name="tags-dropdown" class="reboot px-2">
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="tags-radios" value="0" aria-label="Radio Button for All Tag Types" checked="" tabindex="8">
								<label class="reboot form-check-label mb-0">All</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="tags-radios" value="1" aria-label="Radio Button for Standard Only Tag Types" tabindex="8">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span>Standard Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input meta-required" type="radio" name="tags-radios" value="2" disabled="" aria-label="Radio Button for Custom Only Tag Types" tabindex="8">
								<label class="reboot form-check-label mb-0">
									<i title="Facts whose tags are outside the realm of DEI, US-GAAP, etc." class="reboot far fa-question-circle"></i>
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Custom Only</span>
								</label>
							</div>
						</form>
					</div>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-more" data-test="nav-filter-more" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="9" accesskey="5">
						<i id="loading-more-filters" class="reboot nav-loading fas fa-filter" title="More Filters"></i>
						<span class="reboot d-md-none d-lg-inline">More Filters</span>
						<span class="reboot sr-only sr-only-focusable">More Filters</span>
						<span title="Total active filters." class="reboot badge badge-warning"></span>
					</a>
					<div class="reboot dropdown-menu dropdown-menu-width">
						<label class="reboot dropdown-item-text d-none performance-concern">
							Selecting any of the below will take a few moments.</label>
						<div class="reboot accordion" id="more-filters-accordion">
							<form class="reboot" data-test="more-filters-form">
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Period" data-target="#user-filters-periods" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Periods</span>
											<span data-test="Period-count" id="filters-periods-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-periods" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Measures" data-target="#user-filters-measures" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Measures</span>
											<span data-test="Measures-count" id="filters-measures-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-measures" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot  px-0 py-0">
										<a href="#" data-test="Axis" data-target="#user-filters-axis" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Axis</span>
											<span data-test="Axis-count" id="filters-axis-count" class="reboot badge badge-secondary">
												<i class="fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-axis" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="axes-all-0" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#axes-filters-accordion-0" data-toggle="collapse" tabindex="9">Explicit</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="axis-explicit-count"></span>
											</div>
										</div>
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="axes-all-1" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#axes-filters-accordion-1" data-toggle="collapse" tabindex="9">Typed</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="axis-typed-count"></span>
											</div>
										</div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Members" data-target="#user-filters-members" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Members</span>
											<span data-test="Members-count" id="filters-members-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-members" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="members-all-0" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#members-filters-accordion-0" data-toggle="collapse" tabindex="9">Explicit</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="members-explicit-count"></span>
											</div>
										</div>
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="members-all-1" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#members-filters-accordion-1" data-toggle="collapse" tabindex="9">Typed</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="members-typed-count"></span>
											</div>
										</div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Scale" data-target="#user-filters-scales" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Scale</span>
											<span data-test="Scale-count" id="filters-scales-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-scales" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Balance" data-target="#user-filters-balances" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Balance</span>
											<span data-test="Balance-count" id="filters-balances-count" class="reboot badge badge-secondary">2</span>
										</a>
									</div>
									<div id="user-filters-balances" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot d-flex justify-content-between align-items-center w-100 px-2">
											<div class="reboot form-check">
												<input id="user-filters-balances-debit" title="Select/Deselect this option." class="reboot form-check-input" type="checkbox" tabindex="9">
												<label class="reboot form-check-label mb-0">Debit</label>
											</div>
										</div>
										<div class="reboot d-flex justify-content-between align-items-center w-100 px-2">
											<div class="reboot form-check">
												<input id="user-filters-balances-credit" title="Select/Deselect this option." class="reboot form-check-input" type="checkbox" tabindex="9">
												<label class="reboot form-check-label mb-0">Credit</label>
											</div>
										</div>
									</div>
								</div>
							</form>
						</div>
					</div>
				</li>
				<li id="current-filters-reset" data-test="current-filters-reset" class="reboot nav-item d-none my-auto ml-1">
					<a href="#" id="current-filters-reset-all" data-name="current-filters-reset" class="reboot nav-link dropdown-toggle text-danger disabled click" tabindex="11" accesskey="7">
						<i class="reboot nav-loading fas fa-redo"></i>
						<span class="reboot d-md-none d-lg-inline">Reset All
							Filters</span>
					</a>
				</li>
				<li id="links-dropdown" data-test="links-dropdown" class="reboot nav-item dropdown d-none my-auto ml-1">
					<a href="#" id="additional-links-dropdown" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="12" accesskey="8">
						<i class="reboot nav-loading fas fa-link"></i>
						<span class="reboot d-md-none d-lg-inline">Links</span>
					</a>
					<div id="links-dropdown-content" class="reboot dropdown-menu dropdown-menu-width w-auto"></div>
				</li>
			</ul>
			<ul class="reboot navbar-nav pull-right bg-inherit">
				<li class="reboot nav-item my-auto ml-1">
					<a id="facts-menu" data-test="facts-menu" class="reboot nav-link click" tabindex="13" accesskey="9">
						Facts
						<span class="reboot taxonomy-total-count badge badge-light"><i class="fas fa-spinner fa-spin"></i></span>
					</a>
				</li>
			</ul>
		</div>
	</nav>
	<div class="reboot main-container">
		<div id="error-container" data-test="error-container" class="reboot px-0"></div>
		<div id="xbrl-form-loading" data-test="xbrl-form-loading" class="reboot jumbotron h-100 d-none">
			<h2 class="reboot display-4 text-center">
				<i class="reboot fas fa-spinner fa-spin"></i>
				Loading Inline Form.
			</h2>
		</div>
		<div id="sections-menu" data-test="sections-menu" class="reboot left-sidenav col-sm-3 bg-light overflow-x-auto invisible">
			<div class="reboot mb-2">
				<span class="reboot lead">Tagged Sections</span>
				<a id="sections-menu-toggle" class="reboot float-right click color-inherit" tabindex="2">
					<i class="reboot fas fa-times-circle mt-2 text-dark"></i>
				</a>
			</div>
			<form id="sections-menu-search-submit" data-name="sections-menu-search" class="reboot my-2 my-lg-0 input-group" novalidate="">
				<div id="sections-search-additional" class="reboot input-group-prepend d-none">
					<button class="reboot dropdown btn btn-sec" type="button" data-toggle="dropdown" tabindex="2">
						<i class="reboot nav-loading fas fa-cog"></i>
					</button>
					<div class="reboot dropdown-menu px-2">
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="1" checked="" tabindex="2">
							<label class="reboot form-check-label">Search in All.</label>
						</div>
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="2" tabindex="2">
							<label class="reboot form-check-label">Search in Internal
								Sections Only.</label>
						</div>
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="3" tabindex="2">
							<label class="reboot form-check-label">Search in External
								Sections Only.</label>
						</div>
					</div>
				</div>
				<input type="text" class="reboot form-control" id="sections-search" data-test="sections-search" placeholder="Search Sections" aria-label="Search all Sections by their associated label." name="search-sections" tabindex="2" required="">
				<div class="reboot input-group-append">
					<button id="section-menu-search-btn-clear" data-name="sections-menu-search-clear" class="reboot btn btn-sec" type="button" tabindex="2">
						<i class="nav-loading fas fa-times-circle" title="Clear Sections Search"></i>
						<span class="reboot sr-only sr-only-focusable">Clear
							Sections Search</span>
					</button>
					<button class="reboot btn btn-sec" type="submit" tabindex="2">
						<i class="reboot nav-loading fas fa-search" title="Submit Sections Search"></i>
						<span class="reboot sr-only sr-only-focusable">Submit
							Sections Search</span>
					</button>
				</div>
			</form>
			<hr>

			<div class="reboot accordion" id="tagged-sections">
				<!-- Below is populated dynamically VIA JS -->
			</div>
		</div>



		<div id="help-menu" data-test="help-menu" class="reboot left-sidenav col-sm-3 bg-light overflow-x-auto invisible">

			<div class="reboot mb-2">
				<span class="reboot lead">Help</span> <a id="help-menu-close" data-test="help-menu-close" class="reboot float-right click"> <i class="reboot fas fa-times-circle mt-2"></i>
				</a>
			</div>
			<div class="reboot accordion" id="help-sections">
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-getting-started">
								<span class="reboot font-size-1 ">Getting Started</span>
							</button>
						</h5>
					</div>
					<div id="help-getting-started" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The Inline XBRL viewer allows a user
							to quickly and easily review details of the tagged information in
							an Inline document by automatically placing a top and bottom
							highlight border around each tagged numeric fact and left and
							right border for each block tagged fact. Hovering over a tagged
							fact will highlight (shade) all content related to the tagged
							fact, and clicking on a tagged fact will reveal its tagging
							details in the Fact Review Window. Navigation, search and filter
							options are also provided to easily refine and identify specific
							types of tagged information.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-fact-review-window">
								<span class="reboot font-size-1">Fact Review Window</span>
							</button>
						</h5>
					</div>
					<div id="help-fact-review-window" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The Fact Review Window shows the tagging
							details for the currently selected fact, which is highlighted
							with a solid blue border. There are four categories of fact detail
							which can be viewed; an "N/A" value indicates there is no
							available information for the item within the given category:</p>
						<ul class="reboot">
							<li class="reboot">Attributes - All primary information (as
								applicable) describing the tagged fact including period, sign,
								decimals, dimensional detail (axes and members), scale, measure
								and data type.</li>
							<li class="reboot">Labels - Detailed documentation
								(definition) for the tag used, and other labels.</li>
							<li class="reboot">References - Authoritative reference
								information (as applicable) for the selected tag.</li>
							<li class="reboot">Calculation - Balance and calculation
								hierarchy details (numeric non-dimensioned items only).</li>
						</ul>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-search">
								<span class="reboot font-size-1">Searching</span>
							</button>
						</h5>
					</div>
					<div id="help-search" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">There are two ways to search the
							document: FACTS AND SECTIONS. To search information, enter a
							keyword in a search box and select the magnifying glass icon to
							return matching results. Search operators "and" (via "AND" or
							"&amp;") and "or" (via "OR" or "|") are available to further refine a
							search.</p>
						<p class="reboot m-2">
							<strong>FACTS</strong>
						</p>
						<p class="reboot m-2">The Search Facts box can be used to find
							tagged facts matching entered keywords. By default, tag name, tag
							labels, and tagged content are included in Search. Tagged facts
							matching the search criteria are shown with a yellow-colored
							(default) shading on the page and appear in the Facts List.
							Select the "X" button to the left of the magnifying glass icon to
							clear the search.</p>
						<p class="reboot m-2">The content included in Search can be increased to
							included tag definitions, dimensions, and authoritative
							references by selecting the cog / wheel icon to the left of the
							search box. See Settings for more information.</p>

						<p class="reboot m-2">
							<strong>SECTIONS</strong>
						</p>
						<p class="reboot m-2">The Search Sections box can be used to
							filter the tagged sections of the financial statements.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-filter">
								<span class="reboot font-size-1">Filters</span>
							</button>
						</h5>
					</div>
					<div id="help-filter" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">Filters change the number of highlighted
							facts and items in the fact list by providing several ways to
							review and pinpoint certain tagged information. Multiple filters
							can be used at once.</p>
						<p class="reboot m-2">
							<strong>DATA FILTERS</strong>
						</p>
						<p class="reboot m-2">These filter options allow the user to
							refine the highlighted tagged facts by data type:</p>
						<ul class="reboot">
							<li class="reboot">All - Displays all tagged data (default)</li>
							<li class="reboot">Amounts Only - Numeric facts only</li>
							<li class="reboot">Text Only - Textual facts only</li>
							<li class="reboot">Calculations Only - Numeric facts
								participating in a calculation only</li>
							<li class="reboot">Negatives Only - Negative Numeric amounts
								only</li>
							<li class="reboot">Additional Items Only - Tagged facts
								without a corresponding HTML presentation (i.e., hidden facts)
								only</li>
						</ul>
						<p class="reboot m-2">
							<strong>TAGS FILTER</strong>
						</p>
						<p class="reboot m-2">These filters allow the user to refine
							the highlighted facts by tag type:</p>
						<ul class="reboot">
							<li class="reboot">All - Displays all tagged data (default)</li>
							<li class="reboot">Standard Only- Facts with standard tags
								from a common taxonomy (e.g., US_GAAP, IFRS, DEI).</li>
							<li class="reboot">Custom Only - Facts with extension
								"custom" tags unique to the entity's document.</li>
						</ul>
						<p class="reboot m-2">
							<strong>MORE FILTERS</strong>
						</p>
						<p class="reboot m-2">Additional filters that allow user to
							further refine the highlighted facts:</p>
						<ul class="reboot">
							<li class="reboot">Periods - List of all used context years
								and reporting periods</li>
							<li class="reboot">Measures - List of all used units of
								measure (e.g., US Dollars); as applicable</li>
							<li class="reboot">Axis - List of all used axis
								(dimensions); as applicable (dimensions); as applicable</li>
							<li class="reboot">Scale - List of all used scaled options
								(e.g., thousands, millions); as applicable</li>
							<li class="reboot">Balance - Debit, credit; as applicable</li>
						</ul>
						<p class="reboot m-2">Multiple filters work in conjunction
							with each other. For example, selecting the "Amounts Only" Data
							filter and "Custom Only" Tags filter will highlight only numeric
							tagged facts using custom tags and list them in the fact list.
							Active filters are displayed in the Filter toolbar as they are
							selected. Active filters can be removed individually by
							unchecking or selecting ALL option for each filter, or all at
							once via the "Reset All Filters" option.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-facts-results-list">
								<span class="reboot font-size-1">Facts List (Results)</span>
							</button>
						</h5>
					</div>
					<div id="help-facts-results-list" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">On the toolbar, select the "count" to
							the right of the word Facts (e.g., Facts 234) to reveal the Facts
							List results - a navigable listing of all currently highlighted
							tagged facts. The count represents the current number of facts.</p>
						<p class="reboot m-2">By default, all tagged facts are
							displayed in the Fact List Results. The list content and count
							reflects the currently highlighted facts (i.e., both Filters and
							Search criteria refine the list to match the highlighted tagged
							facts). Navigation controls are available to move through the
							list as well as move the current view to the corresponding
							highlighted fact location automatically. When a fact in the Facts
							Results List is selected, it will reveal the Fact Review Window.</p>
						<p class="reboot m-2">Certain letters may appear to the right
							of an item in the Fact Result list to indicate a certain
							property. If the letter "A" appears for a fact, it indicates the
							fact is additional data (i.e., hidden with potentially no
							corresponding HTML presentation). If the letter "C" appears, the
							fact is tagged with a custom tag. If the letter "D" appears, the
							fact is tagged with dimensional information.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-tagged-sections">
								<span class="reboot font-size-1">Sections</span>
							</button>
						</h5>
					</div>
					<div id="help-tagged-sections" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The SECTIONS toolbar item provides a
							listing of the tagged sections of the Inline document. Sections
							are divided into three groups:</p>
						<ul class="reboot">
							<li class="reboot">Document &amp; Entity Information</li>
							<li class="reboot">Financial Statements</li>
							<li class="reboot">Notes to the Financial Statements</li>
						</ul>
						<p class="reboot m-2">By expanding a group and selecting a
							section item in the listing, Inline XBRL viewer will navigate to that section.
							When the Tagged Sections feature is open, the Search Sections box
							will additionally filter the list of sections to only those
							sections that match the entered criteria.</p>
					</div>
				</div>

				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-tagged-menu">
								<span class="reboot font-size-1">Menu</span>
							</button>
						</h5>
					</div>
					<div id="help-tagged-menu" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">
							<strong>Information</strong>
						</p>
						<p class="reboot m-2">The Information menu item provides
							additional detail about the current Inline document and
							customizable viewer settings.</p>
						<ul class="reboot">
							<li class="reboot">Company and Document - Basic company and document
								information</li>
							<li class="reboot">Tags - Fact and tag (standard and custom)
								information</li>
							<li class="reboot">Files - Files used</li>
							<li class="reboot">Additional Items - Additional hidden data
								that's been tagged but potentially does not have a corresponding
								location in the HTML</li>
						</ul>
						<p class="reboot m-2">
							<strong>Save XBRL Instance</strong>
						</p>
						<p class="reboot m-2">The Save XBRL Instance menu item allows
							an XBRL instance document (*.xml) that is extracted from the
							Inline document to be saved locally for use by software
							supporting the XBRL format.</p>
						<p class="reboot m-2">
							<strong>Save XBRL Zip</strong>
						</p>
						<p class="reboot m-2">The Save XBRL Zip menu item allows a zip
							file (*.zip) that contains the as-provided XBRL instance document
							and related custom taxonomy files to be saved locally.</p>
						<p class="reboot m-2">
							<strong>Settings</strong>
						</p>
						<p class="reboot m-2">The Settings menu item provides the
							ability to customize Viewer features.</p>
						<p class="reboot m-2">
							<strong>Tagged Fact Hover</strong>
						</p>
						<ul class="reboot">
							<li class="reboot">On - Displays the hover fact review
								window for any tagged fact*</li>
							<li class="reboot">Off - Hides the hover fact review window
								for any tagged fact (default)</li>
						</ul>
						<p class="reboot m-2">* May impact performance with certain
							web browsers.</p>
						<p class="reboot m-2">
							<strong>Auto Scrolling Position </strong>(This setting will have
							no effect on IE 10 or Safari)
						</p>
						<ul class="reboot">
							<li class="reboot">Top - Selecting a fact from the Sections
								Menu or the Fact Menu will automatically scroll that element to
								the Top of the Inline XBRL viewer window (default)</li>
							<li class="reboot">Center - Selecting a fact from the
								Sections Menu or the Fact Menu will automatically scroll that
								element to the middle of the Inline XBRL viewer window</li>
						</ul>
						<p class="reboot m-2">
							<strong>Highlight Colors</strong> (Use the save and reset buttons
							to save the selected setting or reset to default)
						</p>
						<ul class="reboot">
							<li class="reboot">Tagged Data - Change the highlight color
								of the tagged fact border</li>
							<li class="reboot">Search Results - Change the background
								color of tagged items matching the Search results</li>
							<li class="reboot">Selected Fact - Change the color of
								highlight border used to identify the currently selected fact</li>
							<li class="reboot">Tag Shading (hover) - Change the color of
								the shading applied to tagged data on hover</li>
						</ul>
						<p class="reboot m-2">
							<strong>Search Options</strong>
						</p>
						<ul class="reboot">
							<li class="reboot">Match Case - Matches the specific case of
								the entered Search keyword</li>
							<li class="reboot">Include Labels - Extends Search to
								include tag labels</li>
							<li class="reboot">Include Definitions - Extends Search to
								include tag definitions</li>
							<li class="reboot">Include Dimensions - Extends Search to
								include dimensional detail</li>
							<li class="reboot">Include References - Extends Search to
								include authoritative reference information. Optionally specify
								the reference parts to include in the search (e.g., topic,
								subtopic, section)</li>
						</ul>
						<p class="reboot m-2">
							<strong>Help</strong>(this content)
						</p>
						<p class="reboot m-2">
							<strong>Version</strong>
						</p>
						<p class="reboot m-2">Indicates the current build of the Inline XBRL viewer
							application.</p>
					</div>
				</div>

			</div>
		</div>



		<div data-test="taxonomies-menu" id="taxonomies-menu" class="reboot right-sidenav col-sm-3 bg-light invisible">
			<div class="reboot d-flex flex-column flex-fill h-100">
				<div class="reboot mb-2">
					<span class="reboot lead">Facts</span>
					<a id="taxonomy-menu-secondary-toggle" data-test="taxonomy-secondary-toggle" class="reboot float-right click">
						<i class="reboot fas fa-times-circle mt-2"></i>
					</a>
				</div>
				<div id="taxonomies-menu-list-pagination" class="reboot d-flex flex-column flex-fill h-100 w-100">
					<div class="reboot pagination"></div>
					<div class="reboot form-group">
						<select id="taxonomies-menu-page-select" class="reboot form-control" aria-label="Quickly jump to a page in the Fact Menu." tabindex="13">
							<option class="reboot">Select Page</option>
						</select>
					</div>
					<div class="reboot list-group list-group-flush overflow-x-auto w-100"><span class="text-center py-5">Loading.</span></div>
				</div>
			</div>
		</div>
		<div id="back-to-top" class="reboot d-none">
			<button id="back-to-top-btn" type="button" class="btn btn-sm btn-primary">
				<i class="reboot fas fa-arrow-up"></i>
			</button>
		</div>

		<div id="dynamic-xbrl-form" class="position-relative"><!--?xml version="1.0" ?--><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:4c556788-0507-4c9d-9834-e0b6901ea738,g:022c6c87-f748-4d61-a6d0-f067acb873af,d:0aef9eb56eca43689ac2ec1e1a127ae4--><meta http-equiv="Content-Type" content="text/html">


<title>pfe-20210404</title><div style="display:none"><ix:header><ix:hidden><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80L2ZyYWc6ODRhNWQ0ZDRlZTI4NDM2MGI3YjViY2UwN2Q0NmFlODIvdGFibGU6Njk4ZWE1NTJlMDU2NGI0ZWFlNTIwZjc4M2FmYjY2NGEvdGFibGVyYW5nZTo2OThlYTU1MmUwNTY0YjRlYWU1MjBmNzgzYWZiNjY0YV8zLTEtMS0xLTA_999fa771-f59b-438c-8991-469683c56f7a">0000078003</ix:nonnumeric><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80L2ZyYWc6ODRhNWQ0ZDRlZTI4NDM2MGI3YjViY2UwN2Q0NmFlODIvdGFibGU6Njk4ZWE1NTJlMDU2NGI0ZWFlNTIwZjc4M2FmYjY2NGEvdGFibGVyYW5nZTo2OThlYTU1MmUwNTY0YjRlYWU1MjBmNzgzYWZiNjY0YV80LTEtMS0xLTA_e801aec7-c6e3-4085-be06-c51848ddec22">12/31</ix:nonnumeric><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80L2ZyYWc6ODRhNWQ0ZDRlZTI4NDM2MGI3YjViY2UwN2Q0NmFlODIvdGFibGU6Njk4ZWE1NTJlMDU2NGI0ZWFlNTIwZjc4M2FmYjY2NGEvdGFibGVyYW5nZTo2OThlYTU1MmUwNTY0YjRlYWU1MjBmNzgzYWZiNjY0YV81LTEtMS0xLTA_941f9883-afd7-4474-afcb-342afcca7de0">2021</ix:nonnumeric><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80L2ZyYWc6ODRhNWQ0ZDRlZTI4NDM2MGI3YjViY2UwN2Q0NmFlODIvdGFibGU6Njk4ZWE1NTJlMDU2NGI0ZWFlNTIwZjc4M2FmYjY2NGEvdGFibGVyYW5nZTo2OThlYTU1MmUwNTY0YjRlYWU1MjBmNzgzYWZiNjY0YV82LTEtMS0xLTA_1049a104-6dc4-4182-9c8b-a10262e2109a">Q1</ix:nonnumeric><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80L2ZyYWc6ODRhNWQ0ZDRlZTI4NDM2MGI3YjViY2UwN2Q0NmFlODIvdGFibGU6Njk4ZWE1NTJlMDU2NGI0ZWFlNTIwZjc4M2FmYjY2NGEvdGFibGVyYW5nZTo2OThlYTU1MmUwNTY0YjRlYWU1MjBmNzgzYWZiNjY0YV83LTEtMS0xLTA_32e188ce-eda7-4197-9d1f-662ef449cdd1">false</ix:nonnumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaref xlink:type="simple" xlink:href="pfe-20210404.xsd"></link:schemaref></ix:references><ix:resources><xbrli:context id="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4496054b52a54a16aceb2f67e29a7bfb_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie333f6bdc2be453e8d5e08554e2aa8c2_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20220.250Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i24d8ad43358743c2b835a08ae5c1a1e6_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i3e0981b1456245b78310dd84b94917d6_I20210510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitnumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitnumerator><xbrli:unitdenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitdenominator></xbrli:divide></xbrli:unit><xbrli:context id="i05f859e329d9409390fed7a56b8d7dbd_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icab05669a9bf4c4b91e115cdf8dcca85_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad96abb481364caa9a72671a1c67d82f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib68a5c0cb0954eccb168987e68a66426_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8432d19709754d54aa8831d0e0b91a10_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c973a878f6147f9b9e876adcd8e5e8f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2e941de2442495c8df2676e0be6391b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44dea6398b1c4543b9115d73e959887b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76e4e86836694234959a3a15070601ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i670092d056fe431492c1724b7d5cfb67_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bfb317024c0464a96ac8ab3059000e9_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6fbbd3bfca8e40e296c6cc30e4795081_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i60d67bdb2f284fd182a95d2a52c7716c_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i10b77ced98304d95b944ba6386fd39b0_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie49d615429ac4b0995cf746ac7c1f785_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5d8f42c5270044fbbc1af652f196d457_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie833b3ce9ec74b68b4a3a09b2f97de4a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8cc8f792ccf4742a85390af1b808b26_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f98424f39a64dedb002aa58aa06d599_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc01d70f4491494899c4a1be59cde841_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de311ba542e4a8d8822b0ff73cf88dd_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ffb761b6f624168a62f72e12228bb5a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i298e3f59dab144afadd3175e4b2e4702_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ba782e27bc644768676d5050e11dd16_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice7f96cabae24782889c935aac35f1e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a8120f033f4276941d48877f9a9489_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if706bef9ba9e4a8087b6638c1a298410_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5802b7b756774508be8ac80fe45d2d09_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeb048b2301e439f88254780ad40d688_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6876e4533642569b2b72a9c6fd043b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9748b402be914193b56e1300e8f8d640_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7ae0369567d42bba15dd6a743487769_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67a0a3b5e3a447628cfe527319aaf597_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47f5513825544a8381d81fce8b6348be_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i00864a6cffcd489689813f7229308d3e_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6fcf639c28b94eb4a8d37f4643a7d948_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie7ad5d9febdd434aa5035c0e28693909_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ieef927be5af84f0e86e41dc8958cc61a_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4702654caf394c4098db2cd85620b59d_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib8bae868241a468bb7466bc282e5f3f5_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i85e4221392cf4b89ae9dee6d9e3a6128_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2556ae3270c74ff5ae9b0ef6ae5dfae6_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id47b6b8fdd594ac3b929fd46636184eb_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98cea540ef86451da18644ee8a6e2767_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c5d25c9530040899006db8fed3c6271_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i887f2cb651164ba79b51cf28563d8588_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4d5adc78bce463e9b9fae90b48b4ce9_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5affdf158b6444899bba4d555d785d25_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i793a6170d7114594b0f7282bca5807aa_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08a420875e0f49f2a79116b4b03bde63_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5ab1163b18294401849660276bdbc17a_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ide9e1b38766a45f1b70fef289bf08b46_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i171b297bb091460caae274aa6fd2034c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12997ed07c6d40178b3062b257ac83bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99fcec41f64847ed86b1c89a56896531_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4a2b9079bc742749949e93c782f4af9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6c618bad6c74bfa8eb2909c5ea37002_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i940e3dc38ca547fdbc8e066fc92a3705_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib09c41fb46464505bcc32a3c43731505_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0fac9c964894676b74a3dfea4fc6f74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fb4d5f76cd341e2a3579da45c669e20_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3781297f71ce4123a78cf0ccdb2f46c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0e1c16f8ac04992b4a1223cc9982917_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i82a840208e554416a672c485a012d030_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="if62466171dbf47ec977eb962afa99747_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec8f63c6623f49adbf67a41d2e87119b_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84d3a404ba354ee580c13bbafde8881a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c9fa610ebea414a8e6bdc725a6ef091_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fd9a8583a894369a0802010c20fb64a_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i38b38c32e3974b6d8a66d36b03ee36af_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-10-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ConsumerHealthcareJVMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-10-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ice6f2159d3d7436abcb7d83886acbb6f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49562007fd9547a48d0eb81e74591431_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4407292bed544ddd98da354a852701ac_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7156c3363822440b89afce39f1a1c27e_D20191001-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-10-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8aceb51cc0bf45ed95b1955ecc6fb23c_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i98e974ef3b1d4e2daccb139c441bf188_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i276123bbbe4c45e787729f28b9ca251b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1722674e9e1442d7a819050b2b7326e6_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0bbb409c662d47279fe6413cb12de8ab_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id81a2e2f25e144ec9494eaff2bd3e792_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia2e7bece604541d19d4b22b186b717b3_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idb3917b19d6f4c6dab6872ff7d889d77_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1617049205a64a65b14f81a3f84a1390_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:AcquisitionRelatedCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ieae0a64a2dae4656b4cca345c9c51c55_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CostReductionInitiativesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i023c394fbcc94e588c67d1f493d78a48_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CostReductionInitiativesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2f7055066225454fbd6b963b51debc30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6e22c74513c4463863976ef5f21b01a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f00f1a9cab940258f6eed860c0bc028_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5572a7c38929471c8c2fe740ba880ed1_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2f0c1e7ebf7f4bd0b2d81f264503a9aa_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iacaebf2f64444de881dd6e9949fe01bb_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8b6820f138a34d1a88125938e6c7587e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia29f6c9175e74ba2832cbc36256b21b7_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6af0bbbd035c4089b2b81e2a9a39bc08_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i158ef04c51064fada1c617473cc9bd6d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneAndBioNTechMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5449bfe370c3433fa88f59a54216e649_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i798490452fbf42df810cc73fc79edd72_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3b069b5bb3c145049eca9ec38c30a2d4_I20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:CK1AssetsSoldToBiogenIncMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8b83c2cd80e47b696ed34be0beb8d4c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if15de68e82a04995aadbd09ef4f4de3e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2c9aa8e82394528ad00529819678ef4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2113534f48f444f8fad64562140b4ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4533886f346447ddb2e4466be3decd58_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i678c35b0c5d8447399b0041252ff2bcd_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9f0bbf068f4d48828cc4f595bbced296_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4e9bff2637eb45e1878d0c41dda792cc_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie3532a573af84231901dcba3a9f69146_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31ea1419793e4e3c9ae577b69a5abe6e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4864e09f901546cc81c976b2cae73fb3_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62019f9f689b4fc982e85dd8eb7b261b_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67345ed70af0415f9ed8e94420f395ec_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c794ced60c54e86a7bdc532fdfce9e3_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aae410224d44016a7744837424466a6_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c17032a023943b39d6fe6d61373d0ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i046ca4e1125f4096b86c8813e2f8970e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88f1d50b4ddd4407b234fba600ed5d57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c579a22aaf5437eb8bdad6b83a2dba3_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b4cc1d3bd5845298aa73c6e6c7e6357_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49e3912c87b642259d22066a4deeedf3_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic11c0659a9ae43fc82bd309b9f944e9d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie39df5fe991d423c8bb366a5753affb5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e21972aa8834adbb2e62df36a9290a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4a996c859684b9ebfddd6a039f0965a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief1336b9d91143e39d2fea5006a742b3_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97291e5a5ab24b64b3dccb07c9c1d5f7_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc333032422c470d9c553a603fed07e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i217da8c7f6f349b8b0412339d3adcdab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b273a61589b42c5baea01aad3398d3d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5660e344b7ed4a1797ded4fe7f7d545c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i521c003f78f74a16bf69168b25516b44_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bb11cd15cf3432681d969a29d7dca79_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00a5767a890d4b86844c4cfd8ee6d1dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47d95591fc234e93b4fc8c6f0abcc2ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c84a33617f945aa95602f65e14fe7fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i693fbbcedb904e0ca5820547935b4eeb_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2496243c18b44e05838d5575a5b19b92_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2827e9872a441058d1e02032d2d742a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dad755ef938483cb63df05993af440c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3809c9b7e2b440a39caf0a40ae7e8f83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49b785935ffe4cc39bc8792585014a3b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieee10c8479ce4db4bf4cb325e7581b0f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6590c03231c94832ab710135c629b5d6_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2a8285101fd4a4787791fc4108af409_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib397545be8ed42a894b7225f81be7b8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8c6a57df8544c48b668c58d680c53a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie209ada8ef774920a8094ff1ffa8c791_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6402b69d96a94b11983f4c4aff358cd9_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8629e44fcf74299947158c6cf1db447_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic918fd2704ed4d59aa54d300420bf854_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia422b966324146868d032d47dda6f321_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd8e1a1c11cb40788c6dd041f5862427_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic12158fe468140509e594e5c9bea2ff0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idef140b7ed3b4d09bed3385bae6d504d_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b810fe2ae184c5097d5595af97f1ee9_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia267f32cf11e4a86a297aa0b2be67c44_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida5dcb775c5545cea010daed613c3d15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3354f5abddd4996bf3ccd71244e3b56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91073b1fe1b54677a90882344df8e229_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3537ba539cf4490799a0a791b894bbf6_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbdb406e79c94c318635d1add0655a54_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07835653ec374195b2d79068ec153977_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea25168e02e94f08b514acffde4e38cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5a83ae2aba2486f95fe642a4c774464_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f9c25dfb8094cb598d568e3dac3e194_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d7738ac04034c2db9a1b09fd2554159_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic017f9df9d9941eeb7f48073600c8293_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i235004b31ec442a1a5ebf8037790737f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3112b7bd4ca945039be216b55807356f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5959213e06f24defac36f7a0fb92bbb4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b990b5de1ed4f4db641cc793879a698_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc2af150083d47d0bcf678532db4a34a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6648e1e65204f4eb444cb895f52ec9c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5fd3e97335545368349e1b54a37f7ca_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93b72ae9514a4dfdb73d54037e4297c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60f3e802e12546cf9fa1294b3ad1be57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d1bff202dda47268a07043474884dcb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a0d3ef6ac6b472b84a7134822008fef_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia77e241651c349ada1bf16e3b6ecf828_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dfae630a4fe4e298addafa278e16b50_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ca9b4205ec749cd9646fbbf2aa209e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2697970c25514e279413521fb973bba7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ea7690129214a9195f0424e82617486_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4105c4d1d064369a467bf34c99b66d9_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b19f59cbd344d648155105fd82aed69_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if37d3d76e48f4447a75e62b5aaf63c5d_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba8bc471a60a4b02bd124ad08e30d367_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d27878b3c524d4ab463f64f7d71c33e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8199248d8cf4446faaaa1c8a52dc73f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bc1645da50f4723ac5e11374a83165e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2636525965a44944a8b505ad44b6fb94_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a1d1c34d3c44f8c8bc642f70cdd9352_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78f1b3c2124740a9b1eb0ab5b86a614a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i467531120efd4d1eb7bbc63d03b66773_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i863eb072936745e9a6b8f3a4ef7207a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0074575f0ac44757b22db2f3767d4ee4_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ce6613fe4614fca82227e4d2d7ec93f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ff43b50014b4281a9126121e4136253_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a4a937627fa4ef29f9ec8b085eaa50c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i033c256fd9284f3c8ccdc121aeead211_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3c4a625f98844cb89cf576d5f951717_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic844430bda8d4a429c4c1873dec0c67b_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1774875f27f34e3c942fbcdb9216c45c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f9e05206d5d44bcb2b4c816762b2196_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0901fcaa75c4458bc09ff2e135283ae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad6218d250ab4b7588c930240dbe77bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e356b3ffe4f46d786b299299e8c73c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddecd2f6220e465abe9653d482f98cd7_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0122d1ba5cd6421b87248774e8dd8097_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b4bf8afa38545638247e4f6360ddf24_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38dfe51f567c4463b153c45da57afb62_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie43a5c73f58e4950ab051b0f60f22af2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if25ff69c6c384a5e9bec30440b609aaf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib45fc05f17594d9a8b7e66f58c93a14a_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if552fb30ac3f4a9986d136fac40d1ba0_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadfb31e704964e379fa031ac9764d117_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide9db44961644d99bc4a1be0ceaf3427_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i105edd316071419483c29294542bf610_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc91087bf2c84f9db4657e286128b4ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71eb1561917b4fc8b8dd253cd6535303_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia19135b26e5944d48147d848103fa4ab_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a8cd9da07dd4e199ef24979ea8fe61c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if72626af54aa43d29c3a57a81672472f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i361062f6aa914630bda2a1decde3d5fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9154af5cf4f54064a345265618b24fb4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3cb663f517041b2b748758fddfc3042_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2b7c33ade3f427b87cdc02e591b5d89_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d38e2b9e8994ef9852e5d9449770d9c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id184353eda00420aa146f68eca8520d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6329d29a2efa4bf6be2047d1f4b55270_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife6665bcfdc84fd9847decd31aab5d74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib94b4929257f4fa59c82eaf1fff65f72_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7b674e4d7af40b19cd6ebf04d26614b_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3dd217f408a4c11b63dad378ca98d22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id54070b71d25429da086e63afcf1c41c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcf94ef1797d492b92164bec12798fd6_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i311aff5e47cb4f0aaa689dd672a89de7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea7507c4602c4b85b91614510bb349ea_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3118a605697e4b6299c3e3e70f504737_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6816514d37f949999a1c366c3691d629_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22e189428ea0418bafaae25d5406511e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea6892b733bc4dcf856bf74153b9127f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd7df84abf8144f9838662606d730b41_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59506893ef984409b375dbf340e24a0f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i436945b9fb544d1485596c97366973bf_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9a0b2bb17c2c45038528dc9568158637_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic74e1896b3c246a98ee4bce0ead976d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if854a67683b84997921e0c8d08721493_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d11d6f169eb4129873cfe8da015081e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5584c105e0a1417da14d21d850e54027_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53d153096cf74722befa5ea904fa6b4f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadd4196e1e1c4fc3aad00b7ec39c703e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a2e45a40ac242e5b77f0ae9900f205a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3d739b69c924476ab9fc489134e052f_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb10ca24fc0e45e6bae4be5820f1dff1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64de3286a8b8400bbce978e6cea1d671_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifef8b9d4d3e046d592fc82570ee103a1_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9f0f92f69aad4b42ad7f9609f172e6b5_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iabbfa3f9ccef409da83eabaca9738f24_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0bca21fbf2904883a085a3674cef4c6e_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib89068696ad04d0c87ddb69c02123499_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0aca22e7341d474d8732744e945f51a2_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3529ff523d8547968d5d7fa49c71f62d_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icb17d3fe588e4ef1b03208dc7427d2a7_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5234a8c9b04f4d00b6a9ef7a66016121_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i047b2efe1e6d4b28a79abcf7dd2cacf6_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iea6d2dbe36bd4602854331362bceb449_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ieb313744a4ff4c738c28ac93f0ece8ed_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if0230812ef754324a78b78b19c2ad59b_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaf10dace7da6444c8b3bd4e5b19c2f01_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i914bc944c4df47e3b143d5f7368a2ca4_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id93efcbc68c042ac81cb1c4bbab42032_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3891b89285f1406aad5672f9c4bdcd51_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if1d52a16c5554d699a0a822678e6667d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i43f6bf204fcd4af486dbfea36e77b0ac_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i737854cc340040fdb4542a4e543b0d3b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i02e8db8e9e5a4913987fc32f5df85fe3_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i57a23120d69645968a1c386fbbdf419a_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaddd627ba50c44d083b799ad5cf8c833_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i57e439f229dd4b1ab3d42ad8f3b57f5a_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idcaa753284e740be9e09512ba86381ee_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5f3171903a684fc3919479487e325172_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia581dfcf0c7b4d1ab5d3a8181506ad81_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iea937bd52464448b93d716a8cf093ae8_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0661f5622ccf41418edc8cfa0839da72_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief79afe80dd041288f169705b94e7059_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1a28ce98dd3469bbc9492040cdde3c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if40f67d115f744f597392dd0dafbaa4e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie113bce7166d40bdacd5506226e15172_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb29d5d4227b48adb270b164dfc6d257_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4317cb0568ef4d6aa675535e255cdab3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i459a8736cc184b2cb5e7c93468cdf4a3_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0635462155884026ba26888ed78b96f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if36997883bf644fda424001760b39437_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5127eeed7ea340e29c6a52d21a2be3cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f5d302584f242a887a90c5ba675f0f7_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d9cb52c2c4d4db882a1c475c695052f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96110322c78c4e7d8e3fd05494f58fbb_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4631e305af2483e8890f326b9fef89d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3aa408a10c644979d8878d88bca2e75_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0edc1ad3738e4c83885d8c61ab8ae1eb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3ff295f54e9472ba2c6bba76b13a2a0_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i746d22257d304c3e9cf195e54a9d68d2_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie8b8aec1ecf94df0812360e000ba75a7_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i088397c030f64354a28cbf48f10fa861_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>pfe:patent</xbrli:measure></xbrli:unit><xbrli:context id="ibd06277310a247e19d913965e50d3c9a_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PneumococcalVaccinePatentInfringementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2017-01-01</xbrli:startdate><xbrli:enddate>2017-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if6ed390d7e6d457a85351411ac49ff84_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PneumococcalVaccinePatentInfringementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibcde84e257a34f8aba9469464f6a8ba4_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:OtherPatentInfringementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iba6607878e43427890e6ccd44b3997ef_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusZydusMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2017-01-01</xbrli:startdate><xbrli:enddate>2017-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i30e58814751d471dbf0e4d56ae80ce59_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusGenericCompaniesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="defendant"><xbrli:measure>pfe:defendant</xbrli:measure></xbrli:unit><xbrli:context id="i680ce5436aa84610a971aecbf2137e35_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerandBMSVersusSeveralGenericManufacturersMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2017-01-01</xbrli:startdate><xbrli:enddate>2017-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>pfe:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i02973e07500446c182f01c27b105cb67_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="manufacturer"><xbrli:measure>pfe:manufacturer</xbrli:measure></xbrli:unit><xbrli:context id="i104649887c064a40a045fee23a147e9b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:DocetaxelMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-01-01</xbrli:startdate><xbrli:enddate>2018-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="classaction"><xbrli:measure>pfe:classAction</xbrli:measure></xbrli:unit><xbrli:context id="i6ceee5bfd67f426f8c340bd9abb34799_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:ArraySecuritiesLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2017-01-01</xbrli:startdate><xbrli:enddate>2017-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i51f98e1eee134a89abb86e9cdaf82d40_D20200601-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">pfe:ZantacRanitidineNDMALitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-06-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="lagoon"><xbrli:measure>pfe:lagoon</xbrli:measure></xbrli:unit><xbrli:context id="ibfb1ec9a79f94d8da08be5657414c50b_D20130101-20131231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2013-01-01</xbrli:startdate><xbrli:enddate>2013-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4472fb58be8742ad81a2c341ffc7d058_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-01-01</xbrli:startdate><xbrli:enddate>2018-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3825cb911e8746189fdd8101073ce536_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i973c7ce48fd14978a74f16d3965dfc72_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iabba33f0ee264ea4b6013fb48174438a_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i46127568c53c4ff5b497c5dc02e2e2ec_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6eaaa06d729d4a1fafede89416db3d6d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9ff0e601b789486fb77a51e10c286054_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if348e4ec7c2140e2b59c8963847d20a6_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ied2bd6c4e76b4aef88e6910cc93da95c_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7a62d297308d46f0a9799ad6fea97d4f_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i66c5094c3226447689dc0560d6f61760_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9603e0d9b21d49c5be55c622f6c795ab_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0b12a7dd0f7b4be885c4d81f9a10294b_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i48c388983a924b6787e90a61d46de5f0_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie5476b3cacd54534a52733f327d22fc7_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9f019e8fef0d46fa970e6bc5a1606a83_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6f610d9fc6ff421a90a019b47027d494_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6d1b68c28ca4410bbffb116c280fada0_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i723d931b4dd942deb55d06022abc27b4_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5379efbc23eb4a779088ea894fa877b5_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3f45e6f0db0f4577abe662b6796b5220_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i78cf066e90684b7b9df9958aafecc327_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id63a1c5781954d4487fc6f59bd931096_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i00018897a8a546288611fca2330ad40d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idf5ed2f322594ee1a086eb8e8b569a78_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic7a56e228c8c4fb4af59ee8e308b2807_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3b5df41672ce4b05b07f62621c5b4d49_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i537596ddf57f4a02b104006ed602b6aa_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i23ef789e0d534d02a1d7359c4552b130_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie31e114d3b7d417390a43e68a76ebc7b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ica83de5b1ca741fdbb60e419050e2337_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i77afd14fb72e417497c4103c75f24f02_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2453457b9d7b4895b48538c2ca504312_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i008eb0e1b2034f1a97d37cb6b298b6e0_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib4c081afebe342a6b9d104a24173c945_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibe5482ff3ca74e99a4c471902be880ff_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6cda2992619a419ca7c9ae5072ee991f_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8ad7ac7bd7d14b64a515ad16d41b265b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6f763c6d5acd44fb8b527b172b7e91a9_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1415dbe0431b4ff585e117766d30b66c_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5fbb1d5760b442aeb54eaba81c729d04_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib84490e61d7441ce9086b7e638bc5377_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4075ba37701d4e64a9fcf6e9155c2dba_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i43b1b3aec0ed4785abc75ad1926500ec_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i98ca505a108f49e5be75f181e05d725b_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i73a3f8cd3c9946348a58b845ed6f7e1e_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idaee0a8c94344749aad179a107f5379d_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8563afcb0c364449a9f8acafeecd9fc8_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i21f664fb57c14f3eb0d15f6894cda787_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0c04f02279024c998c82e2f2712f7a23_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0efc4311285f4a58a9b66dfe1c45d6ac_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idd8e8f340f0d4abbbc967ccada7c06fa_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia1ea3ea7ccfe4c16a02d1e5b63dc0790_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i27789be69eed4d90a1bb6fcbaf530eda_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1e9c2a5b4d4f4d0bb33f0e98cfa16271_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6d86911b85754856a091d39a9a619036_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id6557f9893994f8b99b848935d3da8b7_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib41c041fc3524f8a90b93fef087c22d2_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2cbd34f66a8a4776bed2e8377de9c487_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i15547904869341898a05e8608012fdf7_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia665187179da484eb6e599146133e64c_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i69c7ad6f75474c3ab9031f754ef595f3_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3d6f5d1fb3b543a5aa2e3769810c7d71_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7affcb9aacad4720924821d952eff5b5_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6217a5b597e247debffac06a2be42229_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iab6ee95b0dc4487192c28cf5e2a3b682_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i39d647526b664456a53481f1fcd29c09_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6abdfcdbb14841da92a891ebbfffe427_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i156fe6a2c9c142f59b72145e6b6d5cab_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia9f9a5b9fdbd404e9d13e74900d30aa9_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2046e8ddbd51408ba08ecc31135c57f1_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i94c8e4cc97e94f1591aeeffcdff6f216_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie83ffc748ed9440c9519ce6855fc53ce_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie5a2f657b1f24eeea52ac417440d6370_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i734d2d6b65984271810bcacb4e2423ec_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if9b9deb8c9634ec182507e244ef8c655_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7869ec1912fc40b5a5c2b2c112e0983d_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0eb988cb37cf421ba9e886afde505719_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0137cdc4b152445aa75e142d90ce256c_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i621a67aa4d754b1886dda75ad4da9448_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ida6c3bed72aa4d57a4caa9581c28ddb4_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if35eed0bbfbe41e0a453f1b92ef34eda_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3dc26321ad144544b2f9b6dc158b96c3_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i986fa1dea9aa41ccb4de85b6f8353db8_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia251f6f252be4fca87be237b62587e21_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5fe2ee5e9785471286d6b2002d7635bb_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1ca2d88252f54285811dd499c60a38ab_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7b016a02fe0d4861a331ec2814ec7032_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i468ab4f9aacd4ffa939463e8952be105_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9846250722404133a31c34c978297518_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:IVIgProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i92325ad08a5f49bc9682465145b3e8f0_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:IVIgProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i75641ceea2e34c678a6bb185ce58971b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib9903f105558492aac6500bc30eaadca_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4ec32a5a6aac40fc97766a55aaac3493_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i47fd13e918014bc1beff32e5257f9f57_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9c8c261f6f0e45e39af9f5f51c35243d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4810d15cbffd4e4e802a5445668fd1ea_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i61794ea5f5cf48fab62bb32a45f1fc0d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9654ceb739fe46b9b9a038074b9fac50_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib0708bd9e2c4460398370ad240ac8c5b_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia324f10d774b4091bbc7a6595d84d40f_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i50e8b3687c444ba79acdad03ee09eed1_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id1c88ca089644d47a86f894f06a3ded6_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i00ea7513fe484af08288a189e3eda7f2_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2017ebae1b07422f89732732bb7b67c1_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5b7ba8b676774d95816f5a4a38800825_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib0ac15d44c884c33968f6d0c1d612c81_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9d19ebf19eb9447ba701f3dca966a943_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i99936a11a4df47b7ae544a9001ca9265_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1255cd3269234799ad20eb6dc24d727d_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i43f8898c614547fa9e42f50327b951e1_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i690c1c21d3d94500b32a53210d291dc4_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i217f041566f14b16a835176fc12cebe4_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib4d2e2ea75bb4adcb1cb4ef2d161cabe_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic6672c1127314ac3ad703dc29ee3f887_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9c1f70a9b9434f289ed936ac2da591e2_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5449776d21c54ff6954e42801e8440c0_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i72ef4ea1309e41eebd2560fcbcc68553_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4045f62b3268485d984a63420d9173d9_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib30014db01a64fe096085aec05ab20b5_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6cc0aa456d204aef9a0446f3dc171a16_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i99dc09055ced42e9a643ccb1053a29e4_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4c70725bb41743c3b9117721c78de8af_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i46ee056942d049b998140d1e6ca61d11_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4aa4603d496a4463b3977ffbc8fc8ab1_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i16a3000e73e34ab596e85f929ac44904_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i337a50db1f214928b242e8095a90fa5b_D20200101-20200329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-03-29</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaa3543d0a7d3439fa27ca8d61cd453f5_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadcb9082716e49ad8217f6c35c00c9da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fe7d67ab99549b986734218b58c0a78_D20210101-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-04-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6496cc9734fa4410878f18fd2a5cfa91_D20210405-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">pfe:BNT162b2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-04-05</xbrli:startdate><xbrli:enddate>2021-04-30</xbrli:enddate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTItMS0xLTA_e487941c-a6d5-4f26-99eb-b30b8920dac7" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTItMS0xLTA_e487941c-a6d5-4f26-99eb-b30b8920dac7" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTAtMS0xLTA_38abe664-19a3-4ce7-8d2f-e01fe447a203" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTAtMS0xLTA_38abe664-19a3-4ce7-8d2f-e01fe447a203" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktOC0xLTEtMA_433cc087-adc0-4244-ba52-ad1cca1cdc52" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktOC0xLTEtMA_433cc087-adc0-4244-ba52-ad1cca1cdc52" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTItMS0xLTA_c7681184-980e-4796-b7c0-a4af93f32108" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTItMS0xLTA_c7681184-980e-4796-b7c0-a4af93f32108" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTItMS0xLTA_57ce0137-001d-49cf-80d4-ea8394b52c68" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTItMS0xLTA_57ce0137-001d-49cf-80d4-ea8394b52c68" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTItMS0xLTA_57c168cc-d793-4fdc-ba87-ebb6f01a52c2" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTItMS0xLTA_57c168cc-d793-4fdc-ba87-ebb6f01a52c2" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTAtMS0xLTA_79687469-7e5d-4eef-a237-2d10164f6ac9" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTAtMS0xLTA_79687469-7e5d-4eef-a237-2d10164f6ac9" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTAtMS0xLTA_e8afbd86-b183-4f2f-8414-aecc51c7e492" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTAtMS0xLTA_e8afbd86-b183-4f2f-8414-aecc51c7e492" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItNi0xLTEtMA_8bbfed7a-80cb-4388-b221-a1ae0159afee" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItNi0xLTEtMA_8bbfed7a-80cb-4388-b221-a1ae0159afee" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktNi0xLTEtMA_c2dc19a4-4603-4290-9c8d-f29b695d43bf" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktNi0xLTEtMA_c2dc19a4-4603-4290-9c8d-f29b695d43bf" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTItMS0xLTA_a9781e89-8df5-4f0b-8325-a3975386d974" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTItMS0xLTA_a9781e89-8df5-4f0b-8325-a3975386d974" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTAtMS0xLTA_089f335b-7bad-440a-905c-b0efc085953d" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTAtMS0xLTA_089f335b-7bad-440a-905c-b0efc085953d" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDEzMg_38933c3a-26f9-44e0-9c40-4a762bf4d149" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtNi0xLTEtMA_215c3409-48e4-4aaf-862d-331a2f993785" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDEzMg_38933c3a-26f9-44e0-9c40-4a762bf4d149" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtNi0xLTEtMA_215c3409-48e4-4aaf-862d-331a2f993785" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktOC0xLTEtMA_f8e14eb2-ce57-4e32-8510-642d94d8687a" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktOC0xLTEtMA_f8e14eb2-ce57-4e32-8510-642d94d8687a" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTItMS0xLTA_da6ee283-167b-482c-83fc-8282e2bee05f" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTItMS0xLTA_da6ee283-167b-482c-83fc-8282e2bee05f" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDEzMg_38933c3a-26f9-44e0-9c40-4a762bf4d149" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtNi0xLTEtMA_7f6ddc24-9260-41ff-8b52-d527b14d3cff" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtNi0xLTEtMA_7f6ddc24-9260-41ff-8b52-d527b14d3cff" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTAtMS0xLTA_7d9a0f0e-536c-47c2-9819-1c2a1e633fb9" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTAtMS0xLTA_7d9a0f0e-536c-47c2-9819-1c2a1e633fb9" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctOC0xLTEtMA_34c02743-6ebb-40b3-a5c7-bbbbda92dd1f" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctOC0xLTEtMA_34c02743-6ebb-40b3-a5c7-bbbbda92dd1f" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItOC0xLTEtMA_9f93fdc3-050d-4af6-b9a3-b8614daa9ab2" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItOC0xLTEtMA_9f93fdc3-050d-4af6-b9a3-b8614daa9ab2" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtOC0xLTEtMA_87a455b9-04f5-421e-b3f2-31e761170f52" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtOC0xLTEtMA_87a455b9-04f5-421e-b3f2-31e761170f52" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTAtMS0xLTA_ac30a357-c6f3-418b-acc0-b699913a4bc9" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTAtMS0xLTA_ac30a357-c6f3-418b-acc0-b699913a4bc9" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktNi0xLTEtMA_8531ba32-f2c0-4a2f-958f-f80ac1c5a323" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktNi0xLTEtMA_8531ba32-f2c0-4a2f-958f-f80ac1c5a323" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctNi0xLTEtMA_4eadca26-50de-45fb-97f1-1e4622f02ea0" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctNi0xLTEtMA_4eadca26-50de-45fb-97f1-1e4622f02ea0" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtOC0xLTEtMA_67e0eaa3-0f83-4584-9c85-27460c2e4dd5" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDEzMg_38933c3a-26f9-44e0-9c40-4a762bf4d149" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtOC0xLTEtMA_67e0eaa3-0f83-4584-9c85-27460c2e4dd5" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ3LTQtMS0xLTA_be14bc2e-0760-49f9-a752-48d428e0d10c id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTQtMS0xLTE1NDg4_a9b177ab-0ac4-41f0-a70f-28e31c98297b id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTYtMS0xLTE1NDg4_4c6b8103-ef3c-4039-a343-78e7a1d44861 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE4LTQtMS0xLTE1NDkz_77ca2450-768e-473f-98ee-23db6a13816f id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE4LTYtMS0xLTE1NDkz_b52649c0-a128-4e02-8a16-6bca54f98db9 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE2LTQtMS0xLTQyMQ_49e2457f-6199-4916-90ed-9ef32a01281a id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ3LTYtMS0xLTA_d72b1e89-0069-4365-8bf9-5230e168cf49 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU3LTYtMS0xLTA_e9fd7eb9-fb8f-48f6-bd7b-8da313ce7353 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU3LTQtMS0xLTA_5e84cba2-75ed-4233-89d2-054841fe56e5 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE2LTYtMS0xLTQyMQ_749c3f1a-cb62-4705-801f-671cc447fa93" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NDQ_dd7a49f2-0b67-46aa-84b2-adc27b58f7bb" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMy00LTEtMS00NTAx_2d60da68-8c35-4a08-95c2-af1ef06eb8e3 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMy0yLTEtMS00NTAx_4a2a2626-8355-4956-9981-edce371d4937" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzI_e7a4de72-f456-497e-ac8d-09a777cf7c04" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy04LTEtMS0w_78531e70-b9c4-43f1-8200-a7869fc5bf8b id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy0yLTEtMS0w_e2d39cca-ba70-4846-a9c4-4dc880bd0289" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Nw_eddb205f-17b1-4a52-8031-9748bab11f5b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNi00LTEtMS0w_2d469204-b8dd-44f2-842a-0a2eb215dec3 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNi0yLTEtMS0w_02501141-c347-41a8-88bf-a9cd139e10dc" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzYz_54cbbcce-4732-4004-b827-66bae4504347" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0xMi0xLTEtMA_fa829054-3448-433c-a733-3e711e0a8f9f id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0xMC0xLTEtMA_c94c6cd9-67da-477d-a0ae-5d0d940ebc1e id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0yLTEtMS0w_9b44143a-e8d7-474c-b7cb-ef917a1ab13c id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC00LTEtMS0w_b94a3818-9ce2-4a30-b42f-3f0cb2f6b802 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC02LTEtMS0w_aac8c8e0-6bc5-4ea0-aebd-d9c3319dc5f5" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfODA2_a24e44c3-59a0-4326-9be8-f9ca04edca65" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNy00LTEtMS0w_cd7f3079-195a-46fe-b073-6993223883f4 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNy0yLTEtMS0w_5e0dff33-7e97-4d09-ac1a-80be7e6e6500" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTU5NDI5MTg2MjA1MzI_6b6e4f36-5f04-4ca9-9035-b986fd3a4b1b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTEtMi0xLTEtMA_9a746ba0-bd22-43b4-bfc3-2e9f7aba935b id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTEtNC0xLTEtMA_c4b208b6-0303-451d-8329-d9c8484039f7" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTU5NDI5MTg2MjEyMzg_9ce23b20-625d-4f24-9157-eb389b4fb9a3" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQzLTYtMS0xLTE1OTQ1_40e8ebc2-4614-4da4-b723-7f92d2ccbd2d id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQzLTQtMS0xLTE1OTQz_2dab6a30-5162-4382-9300-d08f644c3b8c" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY2_d5f7e806-d50b-47ea-a73d-f1c044face2c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjItMi0xLTEtMA_9f2fc647-9c1e-47d2-b834-73e520846e5a id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTgtNC0xLTEtMA_191e940d-499e-4944-9b76-8b7ea2581301 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTktMi0xLTEtMA_7363a2b9-77d0-4824-8636-f110e68e33c8 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTktNC0xLTEtMA_55e7339a-3620-4bde-97cd-c357aed02fd4 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTgtMi0xLTEtMA_59b42e17-1173-4eb5-bbec-a4f1881d52d9 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjItNC0xLTEtMA_622d2523-3b1f-4408-8c5a-0bac6a2cc96f" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE0MQ_770ee945-b49d-4e4e-a7bc-2d0e98447487" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTMtNC0xLTEtMA_9ef8be88-1959-40c9-81bf-ea16b8e248a4 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTYtNC0xLTEtMA_bc1d4ec4-ea5f-43ba-b558-2f379081fc1d id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTUtNC0xLTEtMA_e1dc8120-708b-49b8-81ad-a203b059d66b id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTYtMi0xLTEtMA_f906d911-a49b-4178-8717-f19e16a6dc40 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTUtMi0xLTEtMA_b1d8a154-fdc2-4f8a-a02c-d8faddf9caac id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTMtMi0xLTEtMA_87327130-7cf3-4c72-9008-b2b271f98d46" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE5Mw_61ed027d-4f79-4d99-8790-a80b2a75ecb3" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNC0yLTEtMS0w_70fd4264-8d05-4bcd-8721-897615f28e4d id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNC00LTEtMS0w_65d63aa1-b0f0-4b0c-9656-164f5fb48c9a" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RleHRyZWdpb246NGU0NTgxZjI0ZDc5NGE1ZGExODk4M2ViZGNlZjAyN2JfMTE1_089a3599-215a-4b28-a7dc-964822000c8e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM1LTQtMS0xLTA_58ef7360-8332-446f-9bee-f9fe3b84fa0f id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM1LTYtMS0xLTA_dce1c85b-ec79-4fe2-bc3f-3097afcb1a19" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzQyODgwOTUzNTEwNjk5_d79e0e6a-f2d7-4e24-90aa-b3b16147cdf0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMy0yLTEtMS0w_bc055cc4-19b7-4e70-aa3e-746366976622 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMy00LTEtMS0w_b7a2e616-a715-48ef-abf5-651ea73587ea" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMzE4OA_845efd3a-4453-49fe-9b6e-a23b42b5643d" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfMy04LTEtMS0w_38fd5062-c049-4a65-9052-2bbeccff8a34 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfMy02LTEtMS0w_e7e2ad47-c133-45b8-a556-46be93776729" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjk0_deb9e89d-cde1-4276-a4ef-dee2a77d9fbf" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS04LTEtMS0w_f6d577a2-1634-4c28-8f08-48433e837113 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS0yLTEtMS0w_2dbd2070-6998-4f79-8772-924259ed4b7d id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS02LTEtMS0w_84c26127-4105-48e3-a04f-11df24b975ac id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS00LTEtMS0w_85f923b1-0d70-4b19-9ff5-aabb123ca60c" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE4NQ_c7fa08fe-4e7b-466f-9088-caf8aa4d3e9a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTMtMi0xLTEtNDUwMQ_1f16e604-1d62-48bf-bdf2-f40da0b006c7 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTMtNC0xLTEtNDUwMQ_2513f11e-bbde-410e-bbf2-d01420013143" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzM_9083eca6-91cb-44b3-a612-f84549b6adef" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMTItMS0xLTA_fdf0e030-51d6-433a-b5cd-93c3846721f6 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtNC0xLTEtMA_808d5237-d474-4124-8030-8cf6b32f844a id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtOC0xLTEtMA_bf820cec-978b-452b-b90e-b32e890f0610 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMTAtMS0xLTA_e818ddff-e506-4e51-8303-4d9af48d61c7 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMi0xLTEtMA_e44275fb-b0e0-4975-9725-b68803fe9858 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtNi0xLTEtMA_155baa90-f88d-4b5b-9292-fbc220385934" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTgwOQ_77a5c552-dd08-4463-a98e-d5bc97ed0afc" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC04LTEtMS0w_e761edee-d110-4151-966b-72d12a040682 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC0yLTEtMS0w_ecd33fc1-36e8-4ce4-b191-bd8d042f0b68 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC00LTEtMS0w_88fdb5ac-4adf-4238-958e-b22cac16bf1f id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC02LTEtMS0w_ac840666-4a79-4099-b296-a593bb099c69" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE2OQ_e7c211dc-c7b6-412a-b086-9441f0974a65" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU4LTYtMS0xLTA_d4811ed8-85b6-4d0e-9e39-660dc6e07b3d id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU4LTQtMS0xLTA_83e58576-d825-4c37-8e30-af7101c1e50c" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0MDg_8d635d1c-7c5d-42ca-8dd6-093dc2eca4fc" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTYtOC0xLTEtMA_417017aa-b9dc-4b36-b2a7-7204764bff2a id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTYtNi0xLTEtMA_2cb781d7-78a3-404f-ba8e-5ec94dedbda6" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA2Ng_a5781013-36b5-4be0-827e-f8f866a37b63" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTItMS0xLTA_9d23a004-cc86-42bd-8e78-669e60b0f378 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTAtMS0xLTA_23b7865b-22c7-49cd-88e2-700ae0a54698 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMi0xLTEtMA_3446b9f7-178e-4398-99f6-782ad773cca9 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItNi0xLTEtMA_eff2220d-aadc-49bc-b779-cdc895f346fb id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItNC0xLTEtMA_fc8c93a1-57f0-4c41-b6d2-112c34819c35 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTQtMS0xLTA_a5fdb9f7-a8d1-4e4b-b23c-201e9bac2519" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTc_c4635b74-95b3-4fcd-b208-1b5b015d752a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0yLTEtMS0w_fdd52536-f1cf-4d43-93fa-616a59bd42f4 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy00LTEtMS0w_79b88eaa-28b3-4cbc-9bba-99c212e74953 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0xMi0xLTEtMA_8a216c2c-f7ab-466f-9586-31bdb0086033 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0xMC0xLTEtMA_c08b6ace-4bde-4010-ba61-fb062e878f5c id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy02LTEtMS0w_7a12e7f2-2a6d-45fb-81b0-b619bbf36eb9" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfMTU5NDI5MTg2MDY1NTA_46975bac-46b6-4297-9aae-1a8c567a8fce" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOC0yLTEtMS0w_b6771aba-6f3b-40c3-962c-8f8114960d69 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOC00LTEtMS0w_b529326e-fc93-43e3-81b0-c43c7c8fd2cc" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEyNg_d92a1bf3-a2fd-4e8d-8cb3-f3125a6020dc" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfOC02LTEtMS0w_a828a942-8b0a-4c98-89a5-5a43ada1975e id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfOC04LTEtMS0w_4c1103fe-4d7f-4ae6-960f-9d89a54e5b2e" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMTU5NDI5MTg2MTIyOTM_10ad1090-2c7b-484c-b959-5254b01a065a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNS02LTEtMS0w_167caf3c-7fb9-42ea-bbf0-c76e30e98334 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNS04LTEtMS0w_e4c6a8de-b038-45e5-bf8b-537ffea130a8" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjkw_1235bd27-2240-4dc2-8cbf-13a138176241" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi02LTEtMS0w_2613ca5e-b41d-4f70-b5dc-bf0ac09fb1d3 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi04LTEtMS0w_343986d5-ab4b-435d-b91d-3f972bdeec5e id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi00LTEtMS0w_f2fc31da-a6e7-4b80-bce2-fd59decb9a07 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi0yLTEtMS0w_650f9092-5643-48af-ba89-93b927563b9b" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE1Mg_e634017b-e6dc-4654-8e14-232b212d6d2b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOC02LTEtMS0w_9f6c648b-af79-4769-971f-34c66fc3eb45 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOC04LTEtMS0w_5d84d0b5-0517-45da-ac3c-4fbfc0066a9a" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RleHRyZWdpb246NzVjMTdjOTU0MDQxNDMyZjhjYjdmNzNkODg2ZTgyODJfMTU5NDI5MTg2MDY2MTQ_ab14a6d0-8169-4614-bad9-d8c75dcca746" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTQtMS0xLTA_324f1ec6-7e05-4f0f-8ca1-4e0f24204579 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMi0xLTEtMA_2977df70-fa87-4f8a-9978-63a849cb2625 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktNC0xLTEtMA_6a7e9cc0-959e-4a08-b7b0-4367a8ec9e7b id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTItMS0xLTA_46e199fe-fe1b-4fbe-b039-3030c04adca2 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktNi0xLTEtMA_40df5344-1bae-4db8-befb-2270c0c3cb1d id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTAtMS0xLTA_aa60fa3b-f250-4678-a091-18c07f338365" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTg_3776dbfb-2b5c-40a5-a560-56379abc2a78" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOS00LTEtMS0w_546dee0e-69c6-40bc-966d-0e83da52f191 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOS0yLTEtMS0w_3ffb2d8a-61e5-4039-8773-05842cb74df3" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEyNA_0fae7530-2ac8-48f2-8f63-b1eb8fd75fde" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNC04LTEtMS0w_5674d587-0794-4c11-8487-92d148c77d56 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNS04LTEtMS0w_26f51fa4-4018-4704-93da-182394b046fc id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNi04LTEtMS0w_2dda5e12-1a5d-4e39-8e17-bd0b1bb7a126 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNi02LTEtMS0w_e0904f26-cf4c-4e73-ab47-df8d5e5071a2 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNS02LTEtMS0w_fa794ba5-1d5b-47c5-bfec-722e578eebae id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNC02LTEtMS0w_974c9923-1e16-4738-aeb4-328bb13c76bd" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RleHRyZWdpb246NTgxMTllNGYwM2EzNDk4NzhlOWQ5NTc2MTc3NDAyNDBfNTAx_80c33ba9-4367-4e4a-ba34-04df1321871f" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIxLTYtMS0xLTA_c080b5f6-9126-42b2-b9cd-88eac733fc67 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIxLTgtMS0xLTA_ea9562e8-096d-4e8c-a6c9-eb1d67314663" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90ZXh0cmVnaW9uOmEzMjgxNWI3MDUyNTQwN2ViMTQzMzFjMjFkMTM3Y2ZiXzIzOA_8e1dfb84-e1e5-4dc8-8ba3-e2cbc619d574" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC00LTEtMS0w_c646eb10-4536-4a72-897b-b7b5b447399e id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0yLTEtMS0w_e4c24e65-e70e-4200-a66f-1e4589658a2f id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC04LTEtMS0w_3c852bbe-299d-49b5-872a-8f35c357c06e id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC02LTEtMS0w_669200c6-6042-455d-9c5d-ad48da82d9e7 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0xMC0xLTEtMA_4da38dbf-65a4-40ba-b3f6-0b6700ffe2c4 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0xMi0xLTEtMA_1581c541-e838-41c1-9bcf-a4e0ce56e0b5" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc1Nw_788b9a53-3f31-4fb6-9881-b8ef81b2a730" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtMTAtMS0xLTA_57561963-0984-43cd-80e0-17add1612789 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDYtMi0xLTEtMA_4a0d9f48-72c5-4602-ab57-af4d853f856d id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzMtNC0xLTEtMA_e7c5b3ff-0c18-4db9-8c2c-7bcc281ce056 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMTItMS0xLTA_c1c5b91c-c61a-4b66-912b-d1adf188e153 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtMTItMS0xLTA_7e94e1af-67a9-4487-b6db-c5d39bb9920e id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzMtMi0xLTEtMA_c390d922-f827-46b8-aecd-65c7f50b5ba3 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMTAtMS0xLTA_c9dc934e-b1f1-4e5f-a211-cb7a955d6adc id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtOC0xLTEtMA_75fc5998-c585-4576-a997-b3d439bfe28a id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzItNC0xLTEtMA_a58335bb-8cb0-4224-aff5-28d29f627fcc id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtNi0xLTEtMA_62d54685-d8ad-4b88-b3a8-21d97cad82ab id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtOC0xLTEtMA_36a33900-7f9f-4c1b-a0a8-7fddf3eb8a31 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtNi0xLTEtMA_c45eb24c-d84e-49cf-9aa6-3f9c2d089b0e id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtNC0xLTEtMA_b36a048e-5c56-4227-a607-345212848dee id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzItMi0xLTEtMA_877bace4-21a4-465d-90f5-7e1ef5aa709b id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMi0xLTEtMA_bc653640-2403-4b16-88c9-3786c7f3a7f5 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDYtNC0xLTEtMA_12853fe2-e6bf-4e59-a8f9-ae79d9de507a" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTEtNi0xLTEtMA_c1a1429e-882f-4027-bbcf-3f41f12e4ed8 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTEtOC0xLTEtMA_6e14edd0-a1a5-4415-b4ae-ffee5d89573b" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RleHRyZWdpb246NzVjMTdjOTU0MDQxNDMyZjhjYjdmNzNkODg2ZTgyODJfMTU5NDI5MTg2MDY2MTM_20ade658-6fbd-4bd2-b6af-e911252f9a09" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMTkwMg_d46cc6c0-4889-4b8b-af58-62cfb49be0b1 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS00LTEtMS0w_2c12f3da-492c-47ab-aaee-2f2eb1eb7d5c id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0yLTEtMS0w_d232c6a6-3b16-4ec1-a860-01e1b4ee054c id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS02LTEtMS0w_186cd312-d3b9-4f67-b356-1c4cd9282822 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMTg4Ng_4ddeddb8-bb77-476c-8b54-0dd72dfd3595 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0xMi0xLTEtMA_23abe29d-8a0a-41fa-a8c8-55878aaeff9e id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS04LTEtMS0w_e020c56e-ee43-489f-b3d8-fdb02cc496e8 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0xMC0xLTEtMA_947843d1-fed8-4f67-81e3-3b3bcecc23b4" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE2OA_085d6a3b-59ff-473e-b130-ad263afa1566" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTctNC0xLTEtMzU4_91e30a78-1664-48eb-8efa-ec761218c159 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNy00LTEtMS0zNTg_72c25753-50d3-4ffb-a31c-f5e8350d62ef id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNS00LTEtMS0zNTg_b1ad7b50-b4d1-4e25-828a-68a30df68df8 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTEtNC0xLTEtMzU4_97195b69-f37a-46cd-a3e1-fc18f79e441f id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTEtNC0xLTEtMjk1_9d8b5230-4258-4163-96ee-c366e2da39ee id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMy00LTEtMS0zNTg_b3f441c7-1a92-49c9-bd5a-5f5f5059154b id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOS00LTEtMS0yOTU_d102d80d-a898-4ba7-af27-96aa2d0ab7df id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOC00LTEtMS0yOTU_5355b043-1739-4f11-acb1-4570087f0dff id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNi00LTEtMS0zNTg_68b9eefc-6b46-44e3-bc97-f912774e2cb8 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNi00LTEtMS0yOTU_518f99e6-5e96-4c2f-b8de-af7264002918 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTAtNC0xLTEtMzU4_d87c2754-da86-4009-887e-4184a08f8716 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTItNC0xLTEtMzU4_35aa2333-d046-4414-b5e4-8f3fe7362385 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOC00LTEtMS0zNTg_63a6abb2-7c00-49fa-bbc6-4f6ad48c78f2 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTctNC0xLTEtMjk1_f3bc4aa6-0dee-42de-a59e-3bbb31ff39af id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMy00LTEtMS0yOTU_de46aef3-cb8c-46bf-b974-fb23d5283619 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOS00LTEtMS0zNTg_05a64b8a-4b76-456f-b7bd-c35da8682d5c id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNS00LTEtMS0yOTU_d23cc06a-f75c-4e93-8766-c287f811e8e6 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTItNC0xLTEtMjk1_ea6c3568-31eb-4315-b798-e853503078df id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNy00LTEtMS0yOTU_10a5563d-cffd-4fcf-a44f-1e9d8588ccfe id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTAtNC0xLTEtMjk1_a30b4f44-e1d1-4575-a469-b510ae5a5f69" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzItNi0xLTEtMA_591e71b7-7ffb-49fe-9494-4d987672a711 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI0LTQtMS0xLTA_ebc1c2d7-b856-4844-b32d-d781f550ded9 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI0LTYtMS0xLTA_6211b2d9-d19a-4b45-971b-40aa22391ee5 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzItNC0xLTEtMA_bd95e214-c85c-4ca9-a11f-e3c3fea72747" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY0_53ae7d0d-76c7-4217-b122-8dd86b7d3a53" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTAtOC0xLTEtMA_5298a644-1d55-428f-856b-963c3c7d34e1 id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTAtNi0xLTEtMA_6f46671b-e44f-4f70-989b-6aa2b2abfda8" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA0OA_65fb97cf-3186-43e3-895f-da1f63b33e89" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTEtNi0xLTEtMA_c274f477-7672-42c8-b581-b3324d7948cb id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTEtOC0xLTEtMA_5e4564f2-8651-4226-a1fc-9c55fcd5e278" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA1OA_f1afc635-e2e9-4bf8-9f66-21ed40ec92bf" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNS00LTEtMS0w_e7c8b9e7-d0fe-49ed-93c2-830ead64db2f id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNS0yLTEtMS0w_e728931a-0049-43bd-a2e2-d69309827959" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzM2_0ae3661f-6566-4c42-824c-f52314e00d57" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_1"></div><div style="min-height:36pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">FORM <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV84Mg_08e96159-65d6-474a-aa62-622804f3ffa1">10-Q</ix:nonnumeric> </span></div><div><span><br></span></div><div style="text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV84Nw_6a541688-d6bc-46d6-832c-853b2dd5b33b">☒</ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the quarterly period ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8yMTE_3e929d21-0de1-4c3d-8e6e-c7bde83c4b30">April&nbsp;4, 2021</ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"> </span></div><div><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">OR</span></div><div><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8yMjA_cff4a14a-e09e-4c07-9801-332146421349">☐</ix:nonnumeric>  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  TRANSITION REPORT PURSUANT TO SECTION 13</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For the transition period from _______ to _______</span></div><div><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">COMMISSION FILE NUMBER </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8zOTI_e07c1201-8838-4787-8d00-b83353d967fb">1-3619</ix:nonnumeric></span></div><div><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">----</span></div><div><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV80MDI_301742a9-dc6f-4bcf-ba0a-c366d9029362">PFIZER INC</ix:nonnumeric>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6MTFjNDY1NGU3ZjU1NGU0ZmJlNmNkYzI4Mjk0OWFhYmIvdGFibGVyYW5nZToxMWM0NjU0ZTdmNTU0ZTRmYmU2Y2RjMjgyOTQ5YWFiYl8wLTAtMS0xLTA_8f0fba66-4257-473d-a9b2-c8d16eaf8534">Delaware</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6MTFjNDY1NGU3ZjU1NGU0ZmJlNmNkYzI4Mjk0OWFhYmIvdGFibGVyYW5nZToxMWM0NjU0ZTdmNTU0ZTRmYmU2Y2RjMjgyOTQ5YWFiYl8wLTEtMS0xLTA_16305be9-2aeb-4f8a-bec4-dbb7f5f1cc24">13-5315170</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(State of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></tbody></table></div><div><span><br></span></div><div style="text-align:center"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8yMTk1_58ba744a-afb0-4944-858a-55616d672281" continuedat="i4067a375fa5846c3b34a38b80b7bdc82"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">235 East 42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">nd</span></ix:nonnumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:continuation id="i4067a375fa5846c3b34a38b80b7bdc82"> Street</ix:continuation>, <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV80ODg_bf062ef8-3831-4075-a3f0-c010d8fd716b">New York</ix:nonnumeric>, <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV80OTI_8a3c1f47-8eea-4a1f-923c-ae81b0391d9e">New York</ix:nonnumeric>&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV80OTY_8c744406-ef50-47b1-8982-6ea852711237">10017</ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Address of principal executive offices)&nbsp;&nbsp;(zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV81NTQ_f8e40062-659a-48ca-88b6-00ebd2305cf2">212</ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">) <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV81NTg_b0faf57e-775c-4b16-af16-740c42b70830">733-2323</ix:nonnumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Registrant’s telephone number)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tbody><tr><td style="width:1.0%"></td><td style="width:30.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i4496054b52a54a16aceb2f67e29a7bfb_D20210101-20210404" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl8zLTAtMS0xLTA_09b24bae-7753-4580-9921-a91b53c8ba04">Common Stock, $.05 par value</ix:nonnumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i4496054b52a54a16aceb2f67e29a7bfb_D20210101-20210404" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl8zLTItMS0xLTA_d910026e-da26-442d-b31d-19415639b9fd">PFE</ix:nonnumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i4496054b52a54a16aceb2f67e29a7bfb_D20210101-20210404" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl8zLTQtMS0xLTA_9d62c8d4-7eb4-477d-990d-74af97847f58">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ie333f6bdc2be453e8d5e08554e2aa8c2_D20210101-20210404" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl80LTAtMS0xLTA_0d0a45bf-1f6e-4d15-aabb-41c2c9426500">0.250% Notes due 2022</ix:nonnumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ie333f6bdc2be453e8d5e08554e2aa8c2_D20210101-20210404" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl80LTItMS0xLTA_5d480107-61cc-4958-a919-dcedf31a2016">PFE22</ix:nonnumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ie333f6bdc2be453e8d5e08554e2aa8c2_D20210101-20210404" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl80LTQtMS0xLTA_478ec0a6-bc26-479d-84dc-3668d706d1cd">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i24d8ad43358743c2b835a08ae5c1a1e6_D20210101-20210404" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl81LTAtMS0xLTA_5d6cc54d-1757-40d1-9bac-f075b0148eb2">1.000% Notes due 2027</ix:nonnumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i24d8ad43358743c2b835a08ae5c1a1e6_D20210101-20210404" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl81LTItMS0xLTA_563da661-e643-407a-98e0-ea44ffbfb40f">PFE27</ix:nonnumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i24d8ad43358743c2b835a08ae5c1a1e6_D20210101-20210404" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NjM4YWRmNzkyOTcxNDBkMzhmYTMyZTI3ZjBjNTY0OGYvdGFibGVyYW5nZTo2MzhhZGY3OTI5NzE0MGQzOGZhMzJlMjdmMGM1NjQ4Zl81LTQtMS0xLTA_d19a3f37-ce2f-4467-9c96-8523ecc53743">New York Stock Exchange</ix:nonnumeric></span></td></tr></tbody></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:21.345%"><tbody><tr><td style="width:1.0%"></td><td style="width:29.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6OGFkYmIwMmU3NTAwNGFiMWIzMjI1NzQ4MDczZmM3N2EvdGFibGVyYW5nZTo4YWRiYjAyZTc1MDA0YWIxYjMyMjU3NDgwNzNmYzc3YV8wLTAtMS0xLTA_1d5c067a-4f80-42aa-8390-0cdfd876ef67">Yes</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">☐</span></div></td></tr></tbody></table></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:21.345%"><tbody><tr><td style="width:1.0%"></td><td style="width:29.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6OTE0OGViMzgzOTQ3NDMyZTlkZjIyZjI2YmYxNWJlZjkvdGFibGVyYW5nZTo5MTQ4ZWIzODM5NDc0MzJlOWRmMjJmMjZiZjE1YmVmOV8wLTAtMS0xLTA_6a75608f-aedf-4019-ba8c-e5a412b47f78">Yes</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">☐</span></div></td></tr></tbody></table></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8xNjA1_0b13429a-2451-42f6-9411-ac922445b2bb">Large Accelerated filer</ix:nonnumeric>  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accelerated filer  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">☐</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-accelerated filer&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">☐</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Smaller reporting company&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8xNzIy_a4005452-5931-426b-a5f1-67595cce2fa2">☐</ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;Emerging growth company&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8xNzUw_9c51cf51-0806-42ab-8036-835ada900f11">☐</ix:nonnumeric> </span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">☐</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:21.345%"><tbody><tr><td style="width:1.0%"></td><td style="width:29.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.242%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.132%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGFibGU6NWMyNmYyM2I2M2QxNGMwZGFhYTY3OGU1N2M0NjgwNjUvdGFibGVyYW5nZTo1YzI2ZjIzYjYzZDE0YzBkYWFhNjc4ZTU3YzQ2ODA2NV8wLTEtMS0xLTA_fbd0685e-aab9-4aa3-875e-7027fbfc4e2c">☐</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td></tr></tbody></table></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At May&nbsp;10, 2021,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="shares" contextref="i3e0981b1456245b78310dd84b94917d6_I20210510" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xL2ZyYWc6MDZjNTYzNDczNDU2NDMyMzhkMDk5YzkyYzRmMzRjNWUvdGV4dHJlZ2lvbjowNmM1NjM0NzM0NTY0MzIzOGQwOTljOTJjNGYzNGM1ZV8yMTMz_f3e64ca4-fd98-4371-a22f-cf02f4b0c278">5,597,693,867</ix:nonfraction> shares of the issuer’s voting common stock were outstanding.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_7"></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:36.111%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #0a2299;border-top:1pt dotted #0a2299;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</span></td></tr></tbody></table></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.614%"><tbody><tr><td style="width:1.0%"></td><td style="width:92.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_13">PART I.&nbsp;&nbsp;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_19">Condensed Consolidated Statements of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_19">5</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_22">Condensed Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_22">6</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Condensed Consolidated Balance Sheets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_25">7</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_31">Condensed Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_31">8</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_34">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_34">9</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_37">10</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management’<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_133">s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_133">34</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_220">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_220">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_220">51</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_223">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_223">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_223">51</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_226">PART II.&nbsp;&nbsp;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_229">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_229">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_229">52</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_232">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_232">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_232">52</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_238">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_238">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_238">52</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mine Safety Disclosures</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_250">Item </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_250">6</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_250">.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_250">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_250">52</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_253">Signature</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0aef9eb56eca43689ac2ec1e1a127ae4_253">53</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A = Not Applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:36.111%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #05497c;border-top:1pt dotted #05497c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DEFINED TERMS </span></td></tr></tbody></table></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. References to “Notes” in this Form 10-Q are to the notes to the condensed or consolidated financial statements in this Form 10-Q or our 2020 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tbody><tr><td style="width:1.0%"></td><td style="width:23.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2020 Form 10-K</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Annual Report on Form 10-K for the fiscal year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ACIP</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Advisory Committee on Immunization Practices</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ALK</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">anaplastic lymphoma kinase</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Alliance revenues</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Allogene</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Allogene Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">AML</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acute Myeloid Leukemia</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Array</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Array BioPharma Inc.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Astellas</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. </span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ATTR-CM</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">transthyretin amyloid cardiomyopathy</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BioNTech</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioNTech SE</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BLA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Biologics License Application</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BMS</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bristol-Myers Squibb Company</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BNT162b2</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer-BioNTech COVID-19 Vaccine</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">BOD</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Board of Directors</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">CDC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Centers for Disease Control and Prevention</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">CMA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">conditional marketing authorization</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Consumer Healthcare JV</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK Consumer Healthcare JV</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">novel coronavirus disease of 2019</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the following markets: Western Europe, Scandinavian countries and Finland</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Developed Markets</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the following markets: U.S., Developed Europe, Japan, Canada, Australia, South Korea and New Zealand</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes the following markets: Japan, Canada, Australia, South Korea and New Zealand</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EMA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">European Medicines Agency</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Eastern Europe, Latin America, Central Europe, the Middle East, Africa and Turkey</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EPS</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">earnings per share</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">European Union</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">EUA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">emergency use authorization</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Exchange Act</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities Exchange Act of 1934, as amended</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Food and Drug Administration</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Form 10-Q</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Quarterly Report on Form 10-Q for the quarterly period ended April 4, 2021</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Generally Accepted Accounting Principles</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GIST</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">gastrointestinal stromal tumors</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GlaxoSmithKline plc</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Hospira</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Hospira, Inc.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">in-process research and development</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">IRS</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Internal Revenue Service</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">JV</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">joint venture</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">King</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">LIBOR</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">London Interbank Offered Rate</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lilly</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Eli Lilly &amp; Company</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">LOE</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">loss of exclusivity</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MCO</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">managed care organization</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mCRC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">metastatic colorectal cancer</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mCRPC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">metastatic castration-resistant prostate cancer </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">mCSPC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">metastatic castration-sensitive prostate cancer</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management’s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Meridian</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Meridian Medical Technologies, Inc.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MTM</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">mark-to-market</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Mylan</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Mylan N.V.</span></td></tr></tbody></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tbody><tr><td style="width:1.0%"></td><td style="width:23.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Mylan-Japan collaboration</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan that terminated on December 21, 2020</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Myovant</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Myovant Sciences Ltd.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">nmCRPC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">non-metastatic castration-resistant prostate cancer </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">NSCLC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">non-small cell lung cancer</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">OPKO</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">OPKO Health, Inc.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">OTC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">over-the-counter</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PBM</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">pharmacy benefit manager</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PGS</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer Global Supply</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Pharmacia</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmacia Corporation</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">PsA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">psoriatic arthritis</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">RA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">rheumatoid arthritis</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">RCC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">renal cell carcinoma</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">research and development</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Sandoz</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sandoz, Inc., a division of Novartis AG</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">SI&amp;A</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">selling, informational and administrative</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">UC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ulcerative colitis</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">U.K.</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United Kingdom</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">United States</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Upjohn Business</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer’s global, primarily off-patent branded and generics business, which includes a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Viatris</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Viatris Inc.</span></td></tr></tbody></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained on our website, our Facebook, YouTube and LinkedIn pages or our Twitter accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_13"></div><hr style="page-break-after:always"><div style="min-height:49.5pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:47.222%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #0a2299;border-top:1pt dotted #0a2299;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PART I.&nbsp; FINANCIAL INFORMATION</span></td></tr></tbody></table></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_16"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_19"></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMi02LTEtMS0w_0462800b-6f25-45c0-b1e3-8777053d63b0">14,582</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMi04LTEtMS0w_08750704-3781-40b4-a61b-fed2de241e6f">10,083</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNC02LTEtMS0w_974c9923-1e16-4738-aeb4-328bb13c76bd">4,211</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNC04LTEtMS0w_5674d587-0794-4c11-8487-92d148c77d56">1,940</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNS02LTEtMS0w_fa794ba5-1d5b-47c5-bfec-722e578eebae">2,783</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNS04LTEtMS0w_26f51fa4-4018-4704-93da-182394b046fc">2,541</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNi02LTEtMS0w_e0904f26-cf4c-4e73-ab47-df8d5e5071a2">2,014</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNi04LTEtMS0w_2dda5e12-1a5d-4e39-8e17-bd0b1bb7a126">1,672</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNy02LTEtMS0w_c15c26ed-5813-4012-a38a-129be83423ba">872</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfNy04LTEtMS0w_9a3d6d0d-4347-4412-9558-f5b1496e3263">849</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfOC02LTEtMS0w_f41f95b1-a6d2-4984-9e65-2cd903255bad">23</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfOC04LTEtMS0w_ebe5fbeb-b685-4132-bacb-3048968b70d2">54</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DeconsolidationGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfOS02LTEtMS0w_4ca070a1-0f32-4bde-a041-9813ca34b413">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:DeconsolidationGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfOS04LTEtMS0w_554a687d-cbf7-4d27-913b-7a7871fa254b">6</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income)/deductions––net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTAtNi0xLTEtMA_203cb90a-a50d-4aa1-92bc-8db2f6057681">1,004</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTAtOC0xLTEtMA_7428b9b0-6ab1-423e-b4da-93afa243cd13">190</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTEtNi0xLTEtMA_ba619ce6-0ee6-48a3-aabd-43e6948dd2cf">5,683</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTEtOC0xLTEtMA_82638985-d87e-4d19-83f9-35ac23cb0316">2,842</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTItNi0xLTEtMA_d6a31f7c-a51a-4074-9737-47e32947c8ef">805</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTItOC0xLTEtMA_b8472e14-0a68-41d2-9348-eb9d50c460a3">359</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTMtNi0xLTEtMA_9ac659e3-4349-42bc-990d-f4cde183a0e7">4,877</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTMtOC0xLTEtMA_cab68903-79e4-434f-8480-22af9c902f33">2,483</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTUtNi0xLTEtMA_33b79d80-57b2-425b-8cb8-a4c3b19b5192">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTUtOC0xLTEtMA_11166465-dd3c-4aba-b037-16fb7e609c74">881</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTgtNi0xLTEtMA_b93a5f55-b8ee-41e9-ae00-863374a23097">4,886</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTgtOC0xLTEtMA_cad182ae-42d2-4615-922c-b2e1dcaeb3ac">3,364</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTktNi0xLTEtMA_8ed91be1-1847-4b68-96b9-b6fc37642b75">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMTktOC0xLTEtMA_1492d746-172c-42c1-8601-49d85ea42956">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjAtNi0xLTEtMA_f7319f6b-201b-4644-bf83-f647ec7dbf11">4,877</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjAtOC0xLTEtMA_3ad21e9d-4916-46a3-be5d-5e9916f84c40">3,355</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share––basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjMtNi0xLTEtMA_75b7133b-7b8d-4749-ae65-9eca8dc2ec41">0.87</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjMtOC0xLTEtMA_0ad41313-4c51-4bb7-b815-6df61bc17314">0.45</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income from discontinued operations––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjQtNi0xLTEtMA_f1d431d7-e33e-49e8-81e9-b399c079757d">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjQtOC0xLTEtMA_b38d95a7-f497-451a-a668-541c33faf446">0.16</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjUtNi0xLTEtMA_5fae1b27-b998-4f4d-8b17-ea0c71804d2a">0.87</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjUtOC0xLTEtMA_a85c270d-3dd9-4d4f-b87a-b672be7959e3">0.60</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share––diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjgtNi0xLTEtMA_83a08fc6-5a94-455d-bd21-674b27a0506a">0.86</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjgtOC0xLTEtMA_20550d10-89e1-4fac-81dd-154718ea283b">0.44</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income from discontinued operations––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjktNi0xLTEtMA_eb0b828b-e1f2-42da-a9cd-00ad72d78436">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMjktOC0xLTEtMA_d533696a-7d6b-4c6b-9843-f64b3d7d9d23">0.16</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzAtNi0xLTEtMA_ccebed80-aeef-40fa-bade-64f59e94c84c">0.86</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzAtOC0xLTEtMA_f11106ea-d63e-4bab-9b51-2cebf2989dd4">0.60</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares––basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzItNi0xLTEtMA_ed0cf43d-acd3-4cb9-83f6-f1eca4095da9">5,584</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzItOC0xLTEtMA_5bf044da-3a7b-4e82-ba6f-54ebfda40193">5,545</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares––diluted</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzMtNi0xLTEtMA_1345c3e6-9e15-4350-b9b3-e38c6a1d30da">5,662</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RhYmxlOmZlNGUyYTg1MzY3ZTQ3MWU5NjNmN2UzYmQ4YjliZDBiL3RhYmxlcmFuZ2U6ZmU0ZTJhODUzNjdlNDcxZTk2M2Y3ZTNiZDhiOWJkMGJfMzMtOC0xLTEtMA_56fa12c0-55ed-4708-b561-3527a11165d8">5,613</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xOS9mcmFnOjU4MTE5ZTRmMDNhMzQ5ODc4ZTlkOTU3NjE3NzQwMjQwL3RleHRyZWdpb246NTgxMTllNGYwM2EzNDk4NzhlOWQ5NTc2MTc3NDAyNDBfNTAx_80c33ba9-4367-4e4a-ba34-04df1321871f" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Exclusive of amortization of intangible assets, except as disclosed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 9 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in this Form 10-Q and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1L </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our 2020 Form 10-K.</span></ix:footnote></div><div style="margin-top:175pt;padding-right:-13.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_22"></div><hr style="page-break-after:always"><div style="min-height:49.5pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER&nbsp;INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMi02LTEtMS0w_b93a5f55-b8ee-41e9-ae00-863374a23097">4,886</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMi04LTEtMS0w_cad182ae-42d2-4615-922c-b2e1dcaeb3ac">3,364</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfNC02LTEtMS0w_ec8b72ab-43b3-43d5-99eb-0891b6fcf1fa">465</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfNC04LTEtMS0w_4ce7ab71-b29d-4913-8f59-d9e6e17d89d0">1,256</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfNy02LTEtMS0w_0d4b6fde-99cd-422e-a285-4370395347d7">214</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfNy04LTEtMS0w_0648e13d-ed25-45f8-81b0-5f67f2baae56">501</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOC02LTEtMS0w_9f6c648b-af79-4769-971f-34c66fc3eb45">259</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOC04LTEtMS0w_5d84d0b5-0517-45da-ac3c-4fbfc0066a9a">19</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOS02LTEtMS0w_3b77c99c-d45b-4101-8c70-984b04268053">473</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfOS04LTEtMS0w_512efd4b-b6bc-4a07-921f-0a7269e640e4">482</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTAtNi0xLTEtMA_5c332a77-26be-4995-899d-581a58d4b46c">79</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTAtOC0xLTEtMA_bb0555b5-1327-4b22-8c73-92008b069f62">51</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTEtNi0xLTEtMA_c1a1429e-882f-4027-bbcf-3f41f12e4ed8">242</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTEtOC0xLTEtMA_6e14edd0-a1a5-4415-b4ae-ffee5d89573b">15</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTMtNi0xLTEtMA_4ff72b90-b8d1-4de3-8703-cf6e8b70634f">163</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMTMtOC0xLTEtMA_67e821cf-11f8-494b-a5d9-21c5ef4b4c95">36</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjAtNi0xLTEtMA_0343269b-d169-459d-b91f-4842a7e556a4">40</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjAtOC0xLTEtMA_4fd6d728-d7c8-4066-85a6-91067b5009e6">45</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjItNi0xLTEtMA_f95c299b-8217-47f7-8a34-bf2933f46094">3</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjItOC0xLTEtMA_adccab60-e35e-4b21-8d24-b56a66ea336d">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjMtNi0xLTEtMA_5eb4ed92-385a-460d-8769-d7d2a55ca764">43</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjMtOC0xLTEtMA_1b6152fc-ee61-450e-ac36-36894364e0b8">45</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income/(loss), before tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjQtNi0xLTEtMA_78f653e8-6899-4cb7-97f1-e9457b00cd10">732</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjQtOC0xLTEtMA_90da3b81-38b0-4eb0-99d8-97b6d2accb52">1,821</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjUtNi0xLTEtMA_491a1642-d58b-44cc-b6f4-9543a582ef04">84</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjUtOC0xLTEtMA_5951f2d0-71ca-4d8f-8b42-a45bbaf37291">380</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income/(loss) before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjYtNi0xLTEtMA_b819206f-1bae-4c0b-9b25-9081eac6f8cc">647</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjYtOC0xLTEtMA_8c70dd79-c2ed-44eb-b89d-bf5c95798677">1,441</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income/(loss) before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjctNi0xLTEtMA_448b9828-e7c3-4d2d-b206-f033542d3312">5,533</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjctOC0xLTEtMA_030628f9-8ff8-4e5d-ae66-c4f05de34ba1">1,923</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Comprehensive income/(loss) attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjgtNi0xLTEtMA_b59edafa-61b7-4757-8c32-1673da1f46d6">10</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjgtOC0xLTEtMA_8e63f5d7-483b-4b42-9d65-7785d409cec8">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income/(loss) attributable to Pfizer Inc.</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjktNi0xLTEtMA_bbf62bfa-d4ba-486d-b9be-7c41613edef9">5,523</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RhYmxlOjgzNDM4MWU0YjdlZjQ2ZTViNmJjM2NlOTYyNTEyZDRlL3RhYmxlcmFuZ2U6ODM0MzgxZTRiN2VmNDZlNWI2YmMzY2U5NjI1MTJkNGVfMjktOC0xLTEtMA_18c29f2f-6988-4eb3-9582-8a5b44fdebaa">1,914</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RleHRyZWdpb246NzVjMTdjOTU0MDQxNDMyZjhjYjdmNzNkODg2ZTgyODJfMTU5NDI5MTg2MDY2MTQ_ab14a6d0-8169-4614-bad9-d8c75dcca746" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yMi9mcmFnOjc1YzE3Yzk1NDA0MTQzMmY4Y2I3ZjczZDg4NmU4MjgyL3RleHRyZWdpb246NzVjMTdjOTU0MDQxNDMyZjhjYjdmNzNkODg2ZTgyODJfMTU5NDI5MTg2MDY2MTM_20ade658-6fbd-4bd2-b6af-e911252f9a09" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net.</span></ix:footnote></div><div style="text-indent:9pt"><span><br></span></div><div style="margin-top:315pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_25"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMy0yLTEtMS0w_740fe0b8-5c10-4ce3-a223-ad0ef459b73c">1,768</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMy00LTEtMS0w_f23ded50-6fa8-4a10-872b-c69af92c5195">1,784</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNC0yLTEtMS0w_00ffa628-db0a-4047-b367-6cf694c33b0c">11,899</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNC00LTEtMS0w_1e5daf97-ed2d-45fc-aaa2-1138ac95672e">10,437</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts: 2021—$<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNi0wLTEtMS0wL3RleHRyZWdpb246YTgyZTE0NjJhM2VjNDEzZThlZmY0MDllMTM1MGI5ZTFfNzQ_a8fc3ed7-198e-49fd-b073-6f5184221071">512</ix:nonfraction>; 2020—$<ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNi0wLTEtMS0wL3RleHRyZWdpb246YTgyZTE0NjJhM2VjNDEzZThlZmY0MDllMTM1MGI5ZTFfODM_7902fc25-fb04-4d99-96b4-ec8bc99f3cdc">508</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNi0yLTEtMS0w_b56f4006-fe18-4b22-ab79-1c4435a8de6e">9,864</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNi00LTEtMS0w_3cb2c394-8919-423c-9e96-4807bff41a07">7,930</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNy0yLTEtMS0w_bdc110a8-3c29-4f42-a711-0e18f650dd73">8,493</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNy00LTEtMS0w_130ebac4-9795-4b77-9e08-984726214796">8,046</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:OtherTaxAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfOC0yLTEtMS0w_2cd071e6-f7a4-41d3-9666-53cbfe4d64a5">3,419</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:OtherTaxAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfOC00LTEtMS0w_b0527ab6-6493-43e1-9c0c-67c0484bb4b7">3,264</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfOS0yLTEtMS0w_1b3f7369-7fb9-4dac-8af9-94a4662590a1">4,091</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfOS00LTEtMS0w_6eb4d8ec-c016-4873-8848-4f9650aad311">3,605</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTEtMi0xLTEtMA_0ba231dd-c9ba-4e9a-be42-80c886cc3b78">39,533</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTEtNC0xLTEtMA_14e92f3f-4580-449f-853a-08a57be436fa">35,067</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTItMi0xLTEtMA_5c92dc31-9fff-4341-9299-461153d89a0a">16,532</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTItNC0xLTEtMA_e26b48c4-5f59-4651-904c-47868c1d92b5">16,856</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTMtMi0xLTEtMA_3ea33e1f-4f93-40f3-9a15-5982a2668c13">3,696</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTMtNC0xLTEtMA_8fddbcf9-4fb2-4ef9-a1ee-516f13599c49">3,406</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, less accumulated depreciation: 2021—$<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOmFkZjc4YjQ0NTU2YzRkMzc4NDI0MGY0NWQzZjJlMTczXzcx_f8a5cc0d-ccf1-4b80-95b4-1532c7f74e9c">15,105</ix:nonfraction>; 2020—$<ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOmFkZjc4YjQ0NTU2YzRkMzc4NDI0MGY0NWQzZjJlMTczXzgw_a0357d2b-6f1a-45f9-8e4e-7f32002a600b">14,812</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTQtMi0xLTEtMA_b6a0166a-9bc3-4a85-9e30-1421af996464">14,011</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTQtNC0xLTEtMA_97cbdbbf-b05a-48d3-8318-5b250bd8db62">13,900</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTUtMi0xLTEtMA_22ec22b2-a4fa-40fd-b07d-473b01878660">27,974</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTUtNC0xLTEtMA_54427191-5d1f-4af4-b844-58b6b3565eb5">28,471</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTYtMi0xLTEtMA_a69b69e1-e128-44b0-af88-51092e42206d">49,791</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTYtNC0xLTEtMA_f9308906-407a-4261-81dc-96b01eb28224">49,577</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent deferred tax assets and other noncurrent tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTctMi0xLTEtMA_58e3aa1e-50c9-41c9-80b9-72002976df4d">2,537</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTctNC0xLTEtMA_9e45962a-7ea1-4519-9a95-a293f3ec83bc">2,383</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTgtMi0xLTEtMA_95d738e4-7e0a-4d31-9830-d4e80d439dcd">4,744</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTgtNC0xLTEtMA_34f1ecd6-4611-416e-8c7a-f43f856fa8c6">4,569</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTktMi0xLTEtMA_66224ce2-ec14-46e0-8bac-0f77c996c04f">158,818</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMTktNC0xLTEtMA_0aa1ccba-a043-4727-9334-6f26c16d0195">154,229</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Liabilities and Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt: 2021—$<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjItMC0xLTEtMC90ZXh0cmVnaW9uOjAzNmE2NWQ5ZTQyYTRlMGI5YjBiN2M4NjI3OWE2NjVhXzc3_209a44f0-bff7-4d61-8fce-81334abd5757">3,676</ix:nonfraction>; 2020—$<ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjItMC0xLTEtMC90ZXh0cmVnaW9uOjAzNmE2NWQ5ZTQyYTRlMGI5YjBiN2M4NjI3OWE2NjVhXzg2_051458c7-1e4a-41f9-b88b-d469a1301929">2,002</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjItMi0xLTEtMA_1f272255-31e2-48fc-b08f-290921eb77e3">4,352</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjItNC0xLTEtMA_88681e3e-690f-437d-825c-c2d4d1e04de4">2,703</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjMtMi0xLTEtMA_0722fceb-c9bc-434f-8668-3f0787b0b561">4,064</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjMtNC0xLTEtMA_731b2735-2a61-4935-89e3-d103124892aa">4,309</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjQtMi0xLTEtMA_b8f8f76a-46da-4a66-833a-1b045c22c618">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjQtNC0xLTEtMA_3bea0501-6eb0-4aac-b385-01a868de15a9">2,162</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjUtMi0xLTEtMA_ba2b86c8-d641-4897-9e3c-2aaa4371567a">1,401</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjUtNC0xLTEtMA_6bafe616-32c9-4a2d-95dd-a190a54060a4">1,049</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjYtMi0xLTEtMA_8b601138-908d-4dbf-a205-7239762d4e56">1,985</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjYtNC0xLTEtMA_b0592247-8aba-446c-8912-b02f034e61b5">3,058</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjctMi0xLTEtMTI2MzA_c91d6654-9dd8-4c99-9396-fb2f34f619b5">2,052</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjctNC0xLTEtMTI2MzQ_aec0376d-dcc4-4187-a724-eadfd26cfa6b">1,113</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjctMi0xLTEtMA_5c40c5d8-9bc6-4735-95f0-7d3328bc15be">12,798</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjctNC0xLTEtMA_a6774203-968a-4f04-ab53-27e9fab2bae8">11,527</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjktMi0xLTEtMA_b0298880-5183-4a00-b0a4-5b1b07893b08">26,652</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMjktNC0xLTEtMA_230e2d0e-5fd2-4196-84f4-87e6b43b1a93">25,920</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzEtMi0xLTEtMA_edc917e8-d303-4298-a1ff-0c05ef9ce044">35,347</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzEtNC0xLTEtMA_e7f1b6bc-818e-4c0d-bc9b-fe02a10ab80c">37,133</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension benefit obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzItMi0xLTEtMA_9bda7105-004b-4ad9-b67c-7f36661c8dfc">4,526</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzItNC0xLTEtMA_11cefec6-2605-4e1f-b0ce-910df4f36339">4,766</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Postretirement benefit obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzMtMi0xLTEtMA_f13fc6a8-7051-4d58-8257-a340ba70a084">635</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzMtNC0xLTEtMA_ec6315ef-4f3a-43f3-9da5-5479db3e32af">645</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzQtMi0xLTEtMA_134ee9af-92a8-4ebd-a3c7-8a2a0590f363">4,355</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzQtNC0xLTEtMA_e9398da8-8afb-42f0-8db8-8662dff89240">4,063</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other taxes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzUtMi0xLTEtMA_a51b83b9-1421-457f-99d8-df7db3d38cc3">11,759</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzUtNC0xLTEtMA_cebcbfc5-d6ba-4873-8dd2-4db96c7e6c75">11,560</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzYtMi0xLTEtMA_614b2251-30ad-4608-9fd5-fac9be199afc">6,677</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzYtNC0xLTEtMA_a00e8651-5626-4f21-8d6e-02167648a446">6,669</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzctMi0xLTEtMA_a65bd4ba-1820-4b22-abc8-5d7f3f3d1e2a">89,953</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzctNC0xLTEtMA_7ab205c7-c38b-48d1-a711-c7eb0d55ca7a">90,756</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and Contingencies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzktMi0xLTEtMA_db66f237-38ba-41f8-afba-81484e69caa0"></ix:nonfraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfMzktNC0xLTEtMA_e16b226d-65da-4e2e-a89a-5550600d098f"></ix:nonfraction></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDItMi0xLTEtMA_65002b14-afa2-4cd3-aa13-a4adc4c9010c">472</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDItNC0xLTEtMA_079a2b96-79f3-4ebd-b3d5-80ea09bfbd9c">470</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDMtMi0xLTEtMA_7b19a4a2-fed5-4b91-9292-4493e7679b22">89,002</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDMtNC0xLTEtMA_78b4f964-01a2-46c1-a807-92a9a119244f">88,674</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDUtMi0xLTEtMA_88c35372-b1b7-4891-955c-27b937077475">111,349</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDUtNC0xLTEtMA_d6ac26b6-92e4-44e5-bdb3-cb7c3f43a309">110,988</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDYtMi0xLTEtMA_4230f24a-8374-427f-871b-86020d61874e">95,158</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDYtNC0xLTEtMA_6e45a608-125b-446f-9410-ffed17eef45e">90,392</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDctMi0xLTEtMA_82d67c83-f36b-4492-af61-5ad383337bed">4,664</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDctNC0xLTEtMA_2a43c97a-bec1-453d-8e24-b4c3002d34a5">5,310</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Pfizer Inc. shareholders’ equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDgtMi0xLTEtMA_0e2008fb-9408-43fe-a6ee-d9a7b65a466f">68,620</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDgtNC0xLTEtMA_887d4715-307b-4df0-9abf-a8a4ffea4cc0">63,238</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDktMi0xLTEtMA_fae1e498-49c0-4e4d-9881-5320e27def8a">245</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNDktNC0xLTEtMA_5b9a1299-e345-4667-9c4b-a51bc6d78143">235</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNTAtMi0xLTEtMA_f83933a8-7029-4e83-af83-a7b500489083">68,865</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNTAtNC0xLTEtMA_7b05c05d-5019-425a-beac-7115e3f28c02">63,473</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNTEtMi0xLTEtMA_c29302e6-1b07-4403-9902-b837be498a6b">158,818</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8yNS9mcmFnOmQ1MDUxNTE4ZWYwMDQ1MTBhNmY4NzA0NDdmNzhiZjE0L3RhYmxlOmUyZDA5NjkzZjQ5OTQzZGY4ZmU0ZTg5MDhlZjVjZTAyL3RhYmxlcmFuZ2U6ZTJkMDk2OTNmNDk5NDNkZjhmZTRlODkwOGVmNWNlMDJfNTEtNC0xLTEtMA_0e7ded34-07fd-4b5e-ace4-42244a13ce42">154,229</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:65pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_31"></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.583%"><tbody><tr><td style="width:1.0%"></td><td style="width:23.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.045%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="75" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.583%"><tbody><tr><td style="width:1.0%"></td><td style="width:23.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.045%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="57" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PFIZER INC. SHAREHOLDERS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PREFERRED SHARES)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Stated Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Add’l<br>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Accum. Other Comp.<br>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-<br>holders’ Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Equity</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Balance, January&nbsp;1, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="iad96abb481364caa9a72671a1c67d82f_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0yLTEtMS0w_f15b5774-2bbe-4a35-b407-84d721ea8e80">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iad96abb481364caa9a72671a1c67d82f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy00LTEtMS0w_5bdb67ae-50cf-43ea-b010-7d1a289ccdd1">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ib68a5c0cb0954eccb168987e68a66426_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy02LTEtMS0w_2c9b6c1e-66ca-4973-aae4-0b8f2a158e19">9,407</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib68a5c0cb0954eccb168987e68a66426_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy04LTEtMS0w_cc8431de-fb76-457f-a4cb-d55ffc25a74e">470</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8432d19709754d54aa8831d0e0b91a10_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0xMC0xLTEtMA_e702f24d-6dcd-4075-a74c-2f27e22a157f">88,674</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="i2c973a878f6147f9b9e876adcd8e5e8f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0xMi0xLTEtMA_b1b3407d-0c3e-4277-bcb9-cdc0fa1e3703">3,840</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i2c973a878f6147f9b9e876adcd8e5e8f_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0xNC0xLTEtMA_a2ef4872-ef20-45e1-a359-0b47f3ec1d64">110,988</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if2e941de2442495c8df2676e0be6391b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0xNi0xLTEtMA_daad96ed-65cc-42c3-9fbf-84f58baf8e68">90,392</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i44dea6398b1c4543b9115d73e959887b_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0xOC0xLTEtMA_b8b06f10-4b5f-4c60-a268-4976ac867c38">5,310</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i76e4e86836694234959a3a15070601ef_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0yMC0xLTEtMA_c29b4cc5-b0ba-4dd5-9bb6-70c93f80cbae">63,238</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i670092d056fe431492c1724b7d5cfb67_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0yMi0xLTEtMA_abcdce4a-ae84-4989-abbb-4b8a8b62b387">235</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMy0yNC0xLTEtMA_3cd68fd2-561f-47b1-b3d9-bab9234fa77a">63,473</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4bfb317024c0464a96ac8ab3059000e9_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNC0xNi0xLTEtMA_0961e0ea-cc17-46aa-aae0-9845bd2a2d60">4,877</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNC0yMC0xLTEtMA_69bf811c-445d-4be6-8b44-dd7f1672f72d">4,877</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6fbbd3bfca8e40e296c6cc30e4795081_D20210101-20210404" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNC0yMi0xLTEtMA_93827e26-b2a6-4807-8468-95af0ad762c9">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNC0yNC0xLTEtMA_61233e8c-0c58-4e6e-87d1-44969d11da6a">4,886</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other&nbsp;comprehensive income/(loss), net of tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i60d67bdb2f284fd182a95d2a52c7716c_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNS0xOC0xLTEtMA_f0afb907-4c72-4938-8b45-cb84cb709efc">646</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNS0yMC0xLTEtMA_47055b71-5341-404d-814d-45444679060b">646</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6fbbd3bfca8e40e296c6cc30e4795081_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNS0yMi0xLTEtMA_db94dd9c-420a-48da-9858-5b7bd1800777">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNS0yNC0xLTEtMA_16e952a4-7089-43a1-a496-9a4802a487c3">647</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cash dividends declared, per share: $<ix:nonfraction unitref="usdPerShare" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNy0wLTEtMS02MTU5L3RleHRyZWdpb246M2UwODhkZjU1MWYyNDQyOTlhYzdhY2EzNDM0OTkxZGNfMjc0ODc3OTA2OTQ2OQ_3be1813e-7605-4f06-aa0d-cf642672cbcd">—</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Common stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4bfb317024c0464a96ac8ab3059000e9_D20210101-20210404" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNy0xNi0xLTEtMA_39e8a983-43a7-4559-9481-205398d4064f">84</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNy0yMC0xLTEtMA_9a168129-f87f-4358-b323-bbb1de338a2f">84</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfNy0yNC0xLTEtMA_728c4207-5710-494f-8ce3-d22a59243b2c">84</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Preferred stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DividendsPreferredStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfOC0yNC0xLTEtMA_4133dd05-252b-478e-9495-388f0b591ddf">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Noncontrolling interests</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfOS0yNC0xLTEtMA_2c658a56-8aba-4885-803d-c84f6ec06c59">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-based payment transactions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i10b77ced98304d95b944ba6386fd39b0_D20210101-20210404" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtNi0xLTEtMA_fc5b028a-04da-4a91-839b-f47ac7553c40">38</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i10b77ced98304d95b944ba6386fd39b0_D20210101-20210404" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtOC0xLTEtMA_3e972744-97a3-4993-8e3f-20b80e7dd284">2</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie49d615429ac4b0995cf746ac7c1f785_D20210101-20210404" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtMTAtMS0xLTA_a8317233-11a6-4b1f-9f07-a6be958c517b">329</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="i5d8f42c5270044fbbc1af652f196d457_D20210101-20210404" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtMTItMS0xLTA_fd37cea9-1831-4e27-acc4-54057dd69ccd">11</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5d8f42c5270044fbbc1af652f196d457_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtMTQtMS0xLTA_236f3c9c-9ce3-4f74-99ff-30211da83255">361</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtMjAtMS0xLTA_01ac7a3e-4540-4d20-895e-487262adeebd">30</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTAtMjQtMS0xLTA_4486d61e-0dbb-42c1-86aa-e8b877e8b696">30</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Purchases of common stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTEtMjQtMS0xLTA_319c9084-e7e9-4c50-92e3-56d4777e5211">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Preferred stock conversions and redemptions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTItMjQtMS0xLTA_5fa61122-2cc1-40ba-9376-efd72a449702">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4bfb317024c0464a96ac8ab3059000e9_D20210101-20210404" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTMtMTYtMS0xLTA_ecfa475f-bb12-48e8-b2d7-9e56d3c97f0c">27</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6e27fa93efd54c13becc93c7a6d0a8f2_D20210101-20210404" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTMtMjAtMS0xLTA_e715b706-a35d-4e4d-aa0c-bc8b28e6c777">27</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTMtMjQtMS0xLTA_e94ee728-56ce-4eae-8be7-bedc3b1831fa">27</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Balance, April 4, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ie833b3ce9ec74b68b4a3a09b2f97de4a_I20210404" decimals="0" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMi0xLTEtMA_d60df586-5b6b-41ac-8636-93ea0a5aa7e0">—</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie833b3ce9ec74b68b4a3a09b2f97de4a_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtNC0xLTEtMA_45d53a65-712f-4e75-989e-7f41aa7ee8d2">—</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="if8cc8f792ccf4742a85390af1b808b26_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtNi0xLTEtMA_e8f99745-96de-4f72-83c6-b88ba54f6355">9,445</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if8cc8f792ccf4742a85390af1b808b26_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtOC0xLTEtMA_6b7f1174-4c8a-4544-ac3a-10c3acb39c55">472</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6f98424f39a64dedb002aa58aa06d599_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMTAtMS0xLTA_7b640c08-a265-4d93-9431-97f035b66c70">89,002</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="icc01d70f4491494899c4a1be59cde841_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMTItMS0xLTA_2af89896-69d5-48e1-b246-5214b7d256e7">3,851</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icc01d70f4491494899c4a1be59cde841_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMTQtMS0xLTA_9fc2fb48-94c7-484c-879f-f3304f046ca9">111,349</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6de311ba542e4a8d8822b0ff73cf88dd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMTYtMS0xLTA_9ba829a1-53b0-4250-b71b-14e86d585468">95,158</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4ffb761b6f624168a62f72e12228bb5a_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMTgtMS0xLTA_ac1a2838-a7c4-494f-8ae4-4d8e5c0cded0">4,664</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i298e3f59dab144afadd3175e4b2e4702_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMjAtMS0xLTA_648f9162-821f-4b23-83a5-65df4a0f36e8">68,620</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0ba782e27bc644768676d5050e11dd16_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMjItMS0xLTA_c5214294-ed17-4072-ad98-094cf47c1148">245</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTQtMjQtMS0xLTA_6454bd49-d058-4dca-afe1-e874de0f37b5">68,865</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="75" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="57" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PFIZER INC. SHAREHOLDERS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PREFERRED SHARES)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Stated Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Add’l<br>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Accum. Other Comp.<br>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-<br>holders’ Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total Equity</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Balance, January&nbsp;1, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ice7f96cabae24782889c935aac35f1e1_I20191231" decimals="0" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMi0xLTEtMA_c6a8a055-e5b5-4bfc-b3a6-c112bdf6349d">431</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ice7f96cabae24782889c935aac35f1e1_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktNC0xLTEtMA_b7016aa1-a5e6-48eb-a7da-f60d7017b423">17</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i96a8120f033f4276941d48877f9a9489_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktNi0xLTEtMA_3356b2d8-681e-4b57-9945-4afef80f577b">9,369</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i96a8120f033f4276941d48877f9a9489_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktOC0xLTEtMA_5662ebe6-16ad-4b9f-84fd-d80e5bb730a1">468</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if706bef9ba9e4a8087b6638c1a298410_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMTAtMS0xLTA_8d726f32-d157-44e8-8f86-c55c3bcddcf4">87,428</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="i5802b7b756774508be8ac80fe45d2d09_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMTItMS0xLTA_33345091-314a-4617-b893-abe085066083">3,835</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5802b7b756774508be8ac80fe45d2d09_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMTQtMS0xLTA_d4856369-e06d-4b03-87b7-3a474268a1ca">110,801</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieeb048b2301e439f88254780ad40d688_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMTYtMS0xLTA_4b608b45-0eab-4b68-b744-ae81c451247a">91,397</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ice6876e4533642569b2b72a9c6fd043b_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMTgtMS0xLTA_0db18202-8771-446a-9b29-04325ba46993">5,367</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9748b402be914193b56e1300e8f8d640_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMjAtMS0xLTA_6d224647-ef74-4d1a-a417-34f8d07fdf85">63,143</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if7ae0369567d42bba15dd6a743487769_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMjItMS0xLTA_b783645f-2129-4c16-8a85-15dcb3dddfda">303</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i67a0a3b5e3a447628cfe527319aaf597_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMTktMjQtMS0xLTA_89c9c5a5-c3b3-45cf-8598-8dcd13c5cdb8">63,447</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i47f5513825544a8381d81fce8b6348be_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjAtMTYtMS0xLTA_025e2da8-c497-4549-bb23-f27c0b6625c4">3,355</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjAtMjAtMS0xLTA_f67fad01-af63-4898-8cd0-59b774b2e483">3,355</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i00864a6cffcd489689813f7229308d3e_D20200101-20200329" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjAtMjItMS0xLTA_dc696168-7e0a-49f5-ac7b-f6968ec66f08">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjAtMjQtMS0xLTA_7e3df2d9-a9e8-4d6e-b434-6dd0dd6e5e81">3,364</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other&nbsp;comprehensive income/(loss), net of tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6fcf639c28b94eb4a8d37f4643a7d948_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjEtMTgtMS0xLTA_079d6547-3044-4a5f-86d5-e78a7b828ead">1,441</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjEtMjAtMS0xLTA_1b1e8f80-4886-4c48-afe8-60cecc3497cc">1,441</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjEtMjQtMS0xLTA_3e71f848-2eaa-48a6-8c00-76ac3326e102">1,441</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cash dividends declared, per share: $<ix:nonfraction unitref="usdPerShare" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" format="ixt:zerodash" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjItMC0xLTEtNTE5OC90ZXh0cmVnaW9uOjVlNmIyYWZlY2M0ZTQwYTliYjVhZTQ5NWNkNDM4NDViXzI3NDg3NzkwNjk1MDQ_8b7d4a58-60d4-4dfd-8f3d-1154a4fc5641">—</ix:nonfraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Common stock </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i47f5513825544a8381d81fce8b6348be_D20200101-20200329" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjMtMTYtMS0xLTA_da29de7d-12e2-499c-b25f-2bc7ca52bc69">71</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjMtMjAtMS0xLTA_5cb53328-3657-48b0-8381-a6119f808969">71</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjMtMjQtMS0xLTA_f8398f0b-15c3-4a8d-aca1-25304957dd3c">71</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Preferred stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DividendsPreferredStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjQtMjQtMS0xLTA_69dd7e3c-80ce-4b67-a375-ed04e7bca374">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Noncontrolling interests</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjUtMjQtMS0xLTA_dd04f700-c9e2-48ec-80f2-feed8e4ef29a">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Share-based payment transactions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ie7ad5d9febdd434aa5035c0e28693909_D20200101-20200329" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtNi0xLTEtMA_c739731f-32fa-4636-854f-7263a9d9fe4e">23</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie7ad5d9febdd434aa5035c0e28693909_D20200101-20200329" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtOC0xLTEtMA_7f4b8dbc-8c6a-4314-ba1e-58cc587c3915">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieef927be5af84f0e86e41dc8958cc61a_D20200101-20200329" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtMTAtMS0xLTA_513d27a9-6b5a-413a-bcb0-8c2c00b26c09">252</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="i4702654caf394c4098db2cd85620b59d_D20200101-20200329" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtMTItMS0xLTA_357f32f2-70a1-4303-a30a-dadd9a25318c">6</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4702654caf394c4098db2cd85620b59d_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtMTQtMS0xLTA_c3295571-92f9-4397-97d2-fc6a535da768">209</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtMjAtMS0xLTA_2fec075d-92b5-41ff-b74e-9f08aa419706">44</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjYtMjQtMS0xLTA_0ddf063a-6bb8-4c9e-9131-f66c2949e313">44</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Purchases of common stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjctMjQtMS0xLTA_3bb47f19-e2dd-48de-a953-3b00f26e186d">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Preferred stock conversions and redemptions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="ib8bae868241a468bb7466bc282e5f3f5_D20200101-20200329" decimals="0" name="pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjgtMi0xLTEtMA_ebc17ad1-cad6-48c6-8e1c-33953cf8ceba">14</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib8bae868241a468bb7466bc282e5f3f5_D20200101-20200329" decimals="-6" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjgtNC0xLTEtMA_97f79acc-1105-4d39-9b96-784249f301bf">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ieef927be5af84f0e86e41dc8958cc61a_D20200101-20200329" decimals="-6" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjgtMTAtMS0xLTA_c9eb8e23-8c74-420e-bf59-cd9b22074f32">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i513c0df0ec3542b689f69f4d87b9da04_D20200101-20200329" decimals="-6" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjgtMjAtMS0xLTA_9d52c371-c5f0-4913-aaab-58c0341e1293">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjgtMjQtMS0xLTA_eb3a96d1-23ac-483b-8c11-d5d0c24fd469">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMjktMjQtMS0xLTA_97352884-c446-420b-a8f1-ab99fdc240df">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Balance, March 29, 2020</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i85e4221392cf4b89ae9dee6d9e3a6128_I20200329" decimals="0" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMi0xLTEtMA_5767c048-2391-4586-9a33-9462b898f13a">417</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i85e4221392cf4b89ae9dee6d9e3a6128_I20200329" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtNC0xLTEtMA_07a86f4d-8da3-4d2f-98ea-7eae12b46e5b">17</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i2556ae3270c74ff5ae9b0ef6ae5dfae6_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtNi0xLTEtMA_8c436f94-1f1d-49cc-9b68-b5765b910501">9,393</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2556ae3270c74ff5ae9b0ef6ae5dfae6_I20200329" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtOC0xLTEtMA_a208530c-3305-47fe-b104-d303b837b81a">470</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id47b6b8fdd594ac3b929fd46636184eb_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMTAtMS0xLTA_2ac8c3b9-7ae5-495b-a574-1c9f01b434cf">87,680</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="i98cea540ef86451da18644ee8a6e2767_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMTItMS0xLTA_83be8de5-0406-45b6-8c2d-a382ffa27844">3,841</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i98cea540ef86451da18644ee8a6e2767_I20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMTQtMS0xLTA_9ba2660a-3af9-4aec-8a48-b484cdfe0e70">111,010</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8c5d25c9530040899006db8fed3c6271_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMTYtMS0xLTA_3dc36453-8c6a-449b-a6f5-c9ffc3ba2630">94,680</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i887f2cb651164ba79b51cf28563d8588_I20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMTgtMS0xLTA_373ed0f1-e737-4928-b845-1cdba1102087">6,808</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id4d5adc78bce463e9b9fae90b48b4ce9_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMjAtMS0xLTA_227e91fd-7b8d-447c-ae13-5ddfb0a9c3ac">65,028</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5affdf158b6444899bba4d555d785d25_I20200329" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMjItMS0xLTA_1ecc22cd-f50c-47a8-a836-6730a8a5dd45">312</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i793a6170d7114594b0f7282bca5807aa_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zMS9mcmFnOmY0MTM2MmJhNWZkYjRjMzI4YjQ1MmQwYjQ5Nzk3MmIzL3RhYmxlOjQ2MjNiMTNmNTBmYzRjNGI5MTBjMzNmODI4ZjljYTk0L3RhYmxlcmFuZ2U6NDYyM2IxM2Y1MGZjNGM0YjkxMGMzM2Y4MjhmOWNhOTRfMzAtMjQtMS0xLTA_6e58f181-01e0-4b5d-9a2f-e410096c3fcb">65,341</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:220pt;padding-right:-13.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_34"></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Operating Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMy0yLTEtMS0w_b93a5f55-b8ee-41e9-ae00-863374a23097">4,886</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMy00LTEtMS0w_cad182ae-42d2-4615-922c-b2e1dcaeb3ac">3,364</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income from discontinued operations—net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNC0yLTEtMS00NDcz_db0ebba8-3fd7-4565-aaf5-efe9613f3091">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNC00LTEtMS00NDcz_eae0c9bd-0a1a-4f1b-bf43-0c8e939219d3">881</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income from continuing operations before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNS0yLTEtMS00NDcz_9f5eb126-01e0-443f-9fff-ae69f589e878">4,877</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNS00LTEtMS00NDcz_a60fe1c1-dafe-455a-a520-26ef02e167ac">2,483</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNS0yLTEtMS0w_34ad4ab7-792f-4752-adb5-034667c57e29">1,226</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNS00LTEtMS0w_695b90c5-9d58-47d5-b3e4-bae522498a38">1,166</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Asset write-offs and impairments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNi0yLTEtMS0w_d7dc09db-217e-4b6e-b603-cee16c9570df">46</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNi00LTEtMS0w_23412bf2-68a9-4c64-84f6-43d604ff0e94">44</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:DeconsolidationGainLossAmountNetOfCashConveyed" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfOC0yLTEtMS0w_e104219f-58b6-4444-ad17-1af7f79179f4">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:DeconsolidationGainLossAmountNetOfCashConveyed" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfOC00LTEtMS0w_99778cad-166c-4c54-a6db-d05c20a7f8e3">6</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Deferred taxes from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfOS0yLTEtMS0w_1ea33e6c-7708-4c00-b5c9-2651169adf48">199</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfOS00LTEtMS0w_015e7392-390f-48a2-9831-f50f2622e334">82</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTEtMi0xLTEtMA_0ce0c4e8-66fc-4968-b02d-2a3a6aaeb69a">172</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTEtNC0xLTEtMA_1519ce42-fb9a-48fa-a911-af267d85844d">57</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Benefit plan contributions in excess of expense/income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTItMi0xLTEtMA_edcd0655-8b98-45b0-8ca0-4b6e06b18860">373</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTItNC0xLTEtMA_584b8975-f8f2-4d84-aa6f-9bb76e4b5a9d">276</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other adjustments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTMtMi0xLTEtMA_c019a12f-677f-4dd9-a0e1-1075c720183d">291</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTMtNC0xLTEtMA_758f03c3-70a8-4ae2-87c6-06d28099658e">120</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other changes in assets and liabilities, net of acquisitions and divestitures</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTQtMi0xLTEtMA_254eaf9d-75cc-4d2a-94f0-9db515048fc1">1,327</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTQtNC0xLTEtMA_f5f3a07c-f5eb-411d-b598-f1955722f297">1,515</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTctMi0xLTEtNDQ4NA_ef040139-1c85-4172-9204-607523073595">4,530</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTctNC0xLTEtNDQ4NA_56e3c096-4efc-422f-974e-650c16500ee4">2,155</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTgtMi0xLTEtNDQ4NA_b8e3494b-7584-4888-bfc3-9c002c0c3d6d">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTgtNC0xLTEtNDQ4NA_b21a14af-601d-4969-9838-eeb52caf8fb2">978</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTUtMi0xLTEtMA_286dd32f-26fa-448e-8474-34202419f304">4,538</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTUtNC0xLTEtMA_a93cf4af-9457-4e58-9cce-f3e856e8abc8">3,133</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Investing Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTgtMi0xLTEtMA_de34efc3-eeaf-4416-91be-8e23366b2159">554</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTgtNC0xLTEtMA_31319a43-4f88-47ab-889f-8c23f765d55b">449</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTktMi0xLTEtMA_d6be0354-08ef-4ff3-847a-7907999762e1">6,054</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMTktNC0xLTEtMA_f9e00c31-5988-4158-9235-c70146f75c4b">2,551</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from redemptions/sales of short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjAtMi0xLTEtMA_37d1fac3-fa92-47d0-9417-1352578091f1">5,465</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjAtNC0xLTEtMA_1074effd-4f49-4eea-b467-a70533f5326a">3,257</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjEtMi0xLTEtMA_7dcaa28d-bf38-4289-95d2-58d1ea2bbdaf">996</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjEtNC0xLTEtMA_d21bc066-280e-4cd6-9507-e7302d7f51f1">416</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Purchases of long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjItMi0xLTEtMA_cbb2f89d-1b3a-41b5-9946-15af486ba36c">27</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjItNC0xLTEtMA_d16636c3-1549-4500-bf15-e194652780bc">22</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from redemptions/sales of long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjMtMi0xLTEtMA_81773875-5156-4561-b878-9b3eb4e95f20">256</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjMtNC0xLTEtMA_2acb95d2-60e3-4c87-8d5b-050e665645df">152</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other investing activities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjctMi0xLTEtMA_711cdfd0-132d-42a6-bca3-50885ca83911">163</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjctNC0xLTEtMA_2fc77c15-9e2e-47f6-995f-fb1ebe9a2797">24</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzEtMi0xLTEtNDQ5MA_aa468a25-1dfb-4b04-8e1a-48b80697b71e">1,747</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzEtNC0xLTEtNDQ5MA_cee2d8ba-0fdd-4af1-ab4a-330447e93035">53</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzItMi0xLTEtNDQ5MA_668d7fa5-3dd6-4257-9cb5-e09563b47e82">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzItNC0xLTEtNDQ5MA_b75e3fdb-83e8-4807-ae37-4aa185fa9e33">19</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjgtMi0xLTEtMA_14cd609a-2135-45e4-b235-5b721bad35fd">1,747</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMjgtNC0xLTEtMA_8e2b1d2b-38c8-47ad-9d9e-e73c42e35568">71</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Financing Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzEtMi0xLTEtMA_00eaef87-7032-4eee-9cc8-e2ab901bddb4">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzEtNC0xLTEtMA_14130354-dbe7-4d76-aa8b-fd709264e90d">5,302</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Principal payments on short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzItMi0xLTEtMA_19b32bfb-855f-4cad-ae5c-314dca61eb5a">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzItNC0xLTEtMA_f3d452a9-a292-471c-80e7-e574a6db0ac4">7,551</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzMtMi0xLTEtMA_85d37f78-e030-4f24-96b4-73c5312d98a8">25</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzMtNC0xLTEtMA_e4f4931d-7e64-44d3-8052-8c5e831be111">3,207</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzQtMi0xLTEtMA_ab96f559-9a8b-4f9b-80da-679699f1702c">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzQtNC0xLTEtMA_84ce470d-0aa9-454c-8550-4acdfac719e3">1,241</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Principal payments on long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzUtMi0xLTEtMA_4b2f0fc7-cb53-489c-9a38-97d0e2aef4b6">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzUtNC0xLTEtMA_21bf8e65-fb29-4351-9681-6b77ec19f66d">2,181</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash dividends paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfOrdinaryDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzctMi0xLTEtMA_e83cf0c2-292e-406b-9257-2c1125e6c4cd">2,172</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfOrdinaryDividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzctNC0xLTEtMA_17c5bd85-e12d-4c6f-a1c3-383fb2539528">2,105</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other financing activities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzktMi0xLTEtMA_9c0ea444-d93f-48ad-8cf5-e25baff85eb0">610</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfMzktNC0xLTEtMA_7fbc7f61-35c2-4aa8-85ac-fa0d4a6cde47">113</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) financing activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDUtMi0xLTEtNDQ5NA_5d1f84e9-247f-4848-8abb-cc0768a30c1e">2,807</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDUtNC0xLTEtNDQ5NA_d1c3d278-edbe-4e39-af3e-3c8c5ff971a5">2,200</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDEtMi0xLTEtMA_186b0d02-4fa1-462d-a084-7b0809883da4">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDEtNC0xLTEtMA_367ae77c-36c2-494f-91f7-39e03656449b">15</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDItMi0xLTEtMA_d6a6733a-22c7-4acd-93b8-3385c85a022b">15</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDItNC0xLTEtMA_23381d8f-4fd7-4bbb-aea8-ec623bef4777">846</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDMtMi0xLTEtMA_1b02424a-10a0-41fd-8e99-9d4348c3047a">1,825</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i67a0a3b5e3a447628cfe527319aaf597_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDMtNC0xLTEtMA_fc2e07f8-9b12-4a61-85aa-579a99fee24b">1,350</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDQtMi0xLTEtMA_663c02cc-3e50-43e2-8c44-d3a29be0f409">1,809</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i793a6170d7114594b0f7282bca5807aa_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNDQtNC0xLTEtMA_702d2f60-010b-4e95-bbea-f4335925ea0b">2,196</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%;text-decoration:underline">Supplemental Cash Flow Information</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cash paid (received) during the period for:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Income taxes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTQtMi0xLTEtMA_0f7d9b37-4660-466e-bf27-3bd56ef85f2b">394</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTQtNC0xLTEtMA_91bf8f47-9ad1-4b3a-bde5-0fbdeaaf02fb">239</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Interest paid</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTUtMi0xLTEtMA_b4a37513-5a1b-4633-9d3b-968102b80d74">445</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTUtNC0xLTEtMA_28de0820-c712-4149-a66f-ded950d90766">472</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Interest rate hedges</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:InterestPaidReceivedInterestRateHedges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTYtMi0xLTEtMA_1579cb8d-5f64-4f33-946f-198a6b8fbffe">10</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="pfe:InterestPaidReceivedInterestRateHedges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8zNC9mcmFnOjI5MzRiOGEyYzUwNTQzODJiZjBkZGMyY2NlYTI0ZWUzL3RhYmxlOjQ2ZmJhNzE1YjE3MDQwZDZiMTVkZTBiZmM0ODhlOTEwL3RhYmxlcmFuZ2U6NDZmYmE3MTViMTcwNDBkNmIxNWRlMGJmYzQ4OGU5MTBfNTYtNC0xLTEtMA_9089d041-6a7b-4819-8321-6ec658f7caac">11</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:55pt;padding-right:-13.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_37"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><div><span><br></span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_40"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfODI4OA_7c0851ba-5089-4c21-a853-242939e447c1" continuedat="ib3723758b8994aceb4d340618f1c68e0" escape="true">Basis of Presentation and Significant Accounting Policies</ix:nonnumeric></span></div><div><span><br></span></div><ix:continuation id="ib3723758b8994aceb4d340618f1c68e0" continuedat="i88d8fcc7580a4ae49041cf57a1a51c41"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfODMyOQ_34978c98-23a9-425f-9f9c-53aa2eeca2ec" continuedat="i0637b0f1d044423f8d74a8b68b0ed6cb" escape="true">Basis of Presentation</ix:nonnumeric></span></div><div><span><br></span></div><ix:continuation id="i0637b0f1d044423f8d74a8b68b0ed6cb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2020 Form 10-K, except as disclosed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2020 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer’s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February&nbsp;28, 2021 and February&nbsp;23, 2020, and for U.S. subsidiaries is as of and for the three months ended April&nbsp;4, 2021 and March&nbsp;29, 2020.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business development activities impacted financial results in the periods presented. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&nbsp;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2B </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 Form 10-K. On December 21, 2020, which falls in Pfizer’s international first quarter of 2021, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration pursuant to an agreement dated November&nbsp;13, 2020 and we transferred related inventories and operations that were part of the Mylan-Japan collaboration to Viatris. As a result, the financial position and results of operations of the Upjohn Business and the Mylan-Japan collaboration are presented as discontinued operations for all periods presented. Prior-period information has been restated to reflect our current organization structure.</span></div></ix:continuation><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfODI5MA_51711fb1-8391-4988-80de-12acbb9be2f5" continuedat="i9019764cae164c92b64ff81581425894" escape="true">New Accounting Standard Adopted in 2021</ix:nonnumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9019764cae164c92b64ff81581425894">On January 1, 2021, we adopted a new accounting standard for income tax that eliminates certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.</ix:continuation></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on new accounting standards adopted in 2020, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K.</span></div><div><span><br></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:PensionAndOtherPostretirementPlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfMTU5NDI5MTg2OTM2MTE_a89d8a41-6dbb-450d-aa96-e9dced05fd39" continuedat="i0ab475c025b942e5938ec60dcf1886cc" escape="true">Change in Accounting Principle</ix:nonnumeric></span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br></span></div><div><ix:continuation id="i0ab475c025b942e5938ec60dcf1886cc" continuedat="i160d33e6413a4e0e9fe553522d091fa5"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2021, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (“MTM Accounting”).</span><span style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the prior policy, we deferred recognition of these gains and losses in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. The accumulated actuarial gains/losses outside of a “corridor” were then amortized into net periodic benefit costs over the average remaining service period or the average life expectancy of participants. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2020, resulted in a cumulative effect decrease to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Retained earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of $<ix:nonfraction unitref="usd" contextref="i08a420875e0f49f2a79116b4b03bde63_I20200101" decimals="-8" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfOTg5NTYwNDc0MzQzMQ_8d8646ae-fc98-4927-ba4f-f3ce611419fe"><ix:nonfraction unitref="usd" contextref="i08a420875e0f49f2a79116b4b03bde63_I20200101" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfOTg5NTYwNDc0MzQzMQ_b5653272-8d5e-475f-8b89-bcb9f92e8b72">6.3</ix:nonfraction></ix:nonfraction> billion, with a corresponding offset to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></ix:continuation></div><div><span><br></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i160d33e6413a4e0e9fe553522d091fa5">We believe that MTM Accounting is a more preferable policy as it provides improved transparency of results and performance, better alignment with fair value accounting principles and a better reflection of current economic and interest rate trends on plan investments and assumptions and the actuarial impact of plan remeasurements.</ix:continuation> </span></div></ix:continuation><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfMTU5NDI5MTg2OTM2MDg_f4c2e5d0-778e-400f-b8f7-6294c682241c" continuedat="i04f781aa708044f586fbcb2fe2243a21" escape="true"></ix:nonnumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i88d8fcc7580a4ae49041cf57a1a51c41" continuedat="i7564010e48f64a6192cc4e60d4d48666"><div style="margin-bottom:6pt"><ix:continuation id="i04f781aa708044f586fbcb2fe2243a21"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impacts of the adjustments on our condensed consolidated financial statements are summarized as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April&nbsp;4, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March&nbsp;29, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Income:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions––net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNC0yLTEtMS04Mzgw_5dab9db7-896e-45aa-9206-7c49d1af0780">857</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNi00LTEtMS0xMzY0NQ_7d7bf6e3-9d1e-4ce8-a958-5bce4bf08fa1">146</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMy02LTEtMS04MDk5_203cb90a-a50d-4aa1-92bc-8db2f6057681">1,004</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNi04LTEtMS0xMzY1MA_df171ed0-a427-4ded-bebc-0eda237e083f">216</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNi0xMC0xLTEtMTM2NTA_290ce6ad-87b8-4fc4-8de6-a5a9e14dd406">25</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNC0xMi0xLTEtOTA5MQ_7428b9b0-6ab1-423e-b4da-93afa243cd13">190</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations before provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNS0yLTEtMS04Mzgw_e48a94ef-3c74-43df-a6ec-74c11d480af3">5,536</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNy00LTEtMS0xMzY0NQ_a8ef75f5-edf8-4550-9597-bc0d57d4e3a3">146</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNS02LTEtMS04MjQ1_ba619ce6-0ee6-48a3-aabd-43e6948dd2cf">5,683</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNy04LTEtMS0xMzY1MA_7bc427cd-1e98-4118-8ebc-ebda5b056bce">2,817</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNy0xMC0xLTEtMTM2NTA_6498ecf2-43bd-4a7c-b8d3-132873239af4">25</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNS0xMi0xLTEtOTA5MQ_82638985-d87e-4d19-83f9-35ac23cb0316">2,842</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNi0yLTEtMS04Mzgw_bf39697a-ced1-4cef-a87f-0ef7d577b507">773</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOC00LTEtMS0xMzY0NQ_91f42c4a-b118-425e-a118-49661bbe9013">32</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNS02LTEtMS04MTIz_d6a31f7c-a51a-4074-9737-47e32947c8ef">805</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOC04LTEtMS0xMzY1MA_b671c90a-7b41-4de4-952b-8b4e22f66f3b">355</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOC0xMC0xLTEtMTM2NTA_619c9ad4-3594-4c13-bcd7-a50bfc755e25">4</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNi0xMi0xLTEtOTA5MQ_b8472e14-0a68-41d2-9348-eb9d50c460a3">359</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from discontinued operations––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS0yLTEtMS0xMzY0Nw_40fb72b7-01fb-4639-9985-27120145fa82">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS00LTEtMS0xMzY0NQ_503d730e-7a31-4067-b994-fb2a89171a95">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS02LTEtMS0xMDA3NQ_33b79d80-57b2-425b-8cb8-a4c3b19b5192">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS04LTEtMS0xMDA4MQ_b9590803-6217-4104-ba79-b2089aadc9c5">948</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS0xMC0xLTEtMTM2NTA_50ef09c5-cdcb-4ecf-b9b4-cb0986406850">68</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS0xMi0xLTEtMTAwNzc_11166465-dd3c-4aba-b037-16fb7e609c74">881</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMi0xLTEtMTQzNTE_bea51b29-8111-4693-b1aa-5b9bc281e279">4,772</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtNC0xLTEtMTQzNTE_febdf589-16a3-4c4c-9c2f-17b673119d9a">114</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtNi0xLTEtMTQzNTE_b93a5f55-b8ee-41e9-ae00-863374a23097">4,886</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtOC0xLTEtMTQzNTE_60a41266-7cca-41c6-833b-5490bce7025c">3,410</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMTAtMS0xLTE0MzUx_f956ef5d-dc46-48a7-bb24-d0ed6e9e0bfa">47</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMTItMS0xLTE0MzUx_cad182ae-42d2-4615-922c-b2e1dcaeb3ac">3,364</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNy0yLTEtMS04Mzgw_0c1b6c6e-9152-4d26-8b67-d67e50e3405a">4,763</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtNC0xLTEtMTM2NDU_0b27c47c-1205-4de7-91f2-d04fcbe905b3">114</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNS02LTEtMS04MTEx_f7319f6b-201b-4644-bf83-f647ec7dbf11">4,877</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtOC0xLTEtMTM2NTA_7db8681e-dd60-4c10-8768-1770b685b5d1">3,401</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMTAtMS0xLTEzNjUw_4d3fa8b0-43a6-4d4c-ba02-b3284b5a0e9e">47</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNy0xMi0xLTEtOTA5MQ_3ad21e9d-4916-46a3-be5d-5e9916f84c40">3,355</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="21" style="padding:0 1pt 0 10pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share––basic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtMi0xLTEtMTM2NTY_dd252889-722e-41a7-b004-5bf407174997">0.85</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtNC0xLTEtMTMwMzk_cf92f801-dc9a-40d4-ae7e-13049bbab2b5">0.02</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtNi0xLTEtMTMwMjc_75b7133b-7b8d-4749-ae65-9eca8dc2ec41">0.87</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtOC0xLTEtMTM2NjA_10696dfa-6602-4c40-86e5-0173ffcb7613">0.44</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtMTAtMS0xLTEzNjYw_8acfb86a-4096-4c78-91a5-50d287916db8">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtMTItMS0xLTEzMDM3_0ad41313-4c51-4bb7-b815-6df61bc17314">0.45</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from discontinued operations––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtMi0xLTEtMTM2NTY_cf7e27dc-81b6-4b81-9fda-96598e7bd1c3">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtNC0xLTEtMTM2NTg_9bec4602-b014-4973-8ae0-a7963bf61707">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtNi0xLTEtMTMwMjc_f1d431d7-e33e-49e8-81e9-b399c079757d">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtOC0xLTEtMTM2NjA_faa2854b-bdd9-475d-bf3b-b4bdf09e371c">0.17</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usdPerShare" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtMTAtMS0xLTEzNjYw_56375208-0799-443c-aee5-1d674b1fc69b">0.01</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtMTItMS0xLTEzMDM3_b38d95a7-f497-451a-a668-541c33faf446">0.16</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtMi0xLTEtMTM2NTY_b75242d4-1f87-447a-b122-4271dc2d6b71">0.85</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtNC0xLTEtMTM2NTg_6ac6f350-2dee-4a59-9ee9-d1bae43c1c92">0.02</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtNi0xLTEtMTMwMjc_5fae1b27-b998-4f4d-8b17-ea0c71804d2a">0.87</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtOC0xLTEtMTM2NjA_b0739781-3f08-472a-979f-063c3af35045">0.61</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usdPerShare" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtMTAtMS0xLTEzNjYw_b57f8d60-aca4-49f7-bf38-ff4da8772b68">0.01</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtMTItMS0xLTEzMDM3_a85c270d-3dd9-4d4f-b87a-b672be7959e3">0.60</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share––diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctMi0xLTEtMTM2NTY_024eddc5-7310-4864-bc99-77d30ca454e9">0.84</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctNC0xLTEtMTM2NTg_b684e132-229f-4f14-a5f4-97c04e607c1a">0.02</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctNi0xLTEtMTMwMzA_83a08fc6-5a94-455d-bd21-674b27a0506a">0.86</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctOC0xLTEtMTM2NjA_1cf40a4b-3b3e-4dfe-88e8-486a56555a24">0.44</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctMTAtMS0xLTEzNjYw_75395125-4049-48de-8e1f-0fd8c70cd47c">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctMTItMS0xLTEzMDM0_20550d10-89e1-4fac-81dd-154718ea283b">0.44</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from discontinued operations––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS0yLTEtMS04Mzgw_eba685e9-b01a-4551-9a99-5b2383bb1cef">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTgtNC0xLTEtMTMwMzg_7026c5b1-319d-455a-84a6-39a41ec3ad9e">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" format="ixt:zerodash" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOC02LTEtMS04MTUz_eb0b828b-e1f2-42da-a9cd-00ad72d78436">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTgtOC0xLTEtMTM2NjA_e19a9d50-cc92-4ecf-b30b-1ed14e4c8437">0.17</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usdPerShare" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTgtMTAtMS0xLTEzNjYw_ebf0a702-3ed3-4237-ae41-eba838c5e96b">0.01</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS0xMi0xLTEtOTA5Mw_d533696a-7d6b-4c6b-9843-f64b3d7d9d23">0.16</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMi0xLTEtODM4MA_873d32a7-5d8e-4595-a4e9-e8030fd1fe90">0.84</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTktNC0xLTEtMTM2NTg_3011635b-90ef-4123-88f3-76cc6dcfb9ac">0.02</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfOS02LTEtMS04MTU1_ccebed80-aeef-40fa-bade-64f59e94c84c">0.86</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTktOC0xLTEtMTM2NjA_6ecf4906-1f34-45f2-ab90-f4ecf2e8fcaa">0.61</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usdPerShare" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTktMTAtMS0xLTEzNjYw_dfb2cff6-b945-404d-824f-47a2312548dc">0.01</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTAtMTItMS0xLTkwOTM_f11106ea-d63e-4bab-9b51-2cebf2989dd4">0.60</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Comprehensive Income:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtMi0xLTEtMTU4MDk_eefdbbbd-57fb-4a19-8c8a-c11af8925fce">546</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtNC0xLTEtMTU4MDk_0c0e1e51-cd54-4302-8daf-987ba94ec250">81</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtNi0xLTEtMTU4MTY_ec8b72ab-43b3-43d5-99eb-0891b6fcf1fa">465</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtOC0xLTEtMTU4MTM_77c0e017-f41e-4d3f-9c54-d9bf4a5ce366">1,272</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtMTAtMS0xLTE1ODEz_603f9712-c0b0-4899-b620-e38c481e5062">16</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtMTItMS0xLTE1ODIw_4ce7ab71-b29d-4913-8f59-d9e6e17d89d0">1,256</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Benefit plans: actuarial gains/(losses), net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtMi0xLTEtODM4MA_de328a85-7e0f-4afc-85cb-15d114ee2b67">47</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtNC0xLTEtMTM2OTE_a40fb0df-3563-45e9-bb7b-18dae25c2bd3">47</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTMtNi0xLTEtODIzMg_81d619e1-c56d-478c-b00b-bdc4762e66f5">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtOC0xLTEtMTM2OTY_745045e0-c575-4b24-a178-77c6c2ac9899">166</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjMtMTAtMS0xLTEzNjk2_427f4c5c-74fd-4816-a36f-0910e6646fd0">166</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtMTItMS0xLTkwOTU_389a2d98-d4bb-4be1-97a0-f30099054ecf">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Reclassification adjustments related to amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtMi0xLTEtODM4MA_9e04eeed-0457-4cbb-a75f-75cf0b254aca">75</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjQtNC0xLTEtMTM2OTE_afd5b122-b05c-40fb-8811-de18bd289523">75</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTQtNi0xLTEtODIzMg_4a588c90-bf2b-4bef-b074-79334b894fe5">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjQtOC0xLTEtMTM2OTY_52d203a0-c548-4ff5-bca5-ef526a9c5c18">66</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjQtMTAtMS0xLTEzNjk2_f50e3500-d5c6-49f4-8343-30d40ecb4aa6">66</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtMTItMS0xLTkwOTU_d9022c32-4db1-4663-9ed6-349f6053ba28">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Reclassification adjustments related to settlements, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTYtMi0xLTEtODM4MA_0615b6b9-0251-462d-b18d-ad111b73de5e">19</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjUtNC0xLTEtMTM2OTE_2f67ec5d-2bb2-4000-bce3-d4ef5a5f9965">19</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTUtNi0xLTEtODIzMg_5c0bc19b-ae84-42a7-8525-fc30229df49b">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjUtOC0xLTEtMTM2OTY_cdea3887-3b40-4a4c-998a-7a76af9c9849">53</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjUtMTAtMS0xLTEzNjk2_c2856c32-007b-46f3-9699-8026854ba23c">53</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTYtMTItMS0xLTkwOTU_949ddb31-8811-4e31-8486-1b69301fc736">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctMi0xLTEtODM4MA_7bd874d7-b0f4-4fa2-adcc-94e8be7978bd">81</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjYtNC0xLTEtMTM2OTE_80e0b940-3c87-4375-b482-98b0518375f1">81</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTYtNi0xLTEtODIzMg_f033076b-0c76-40f6-aedf-91081fdd6f0b">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjYtOC0xLTEtMTM2OTY_02210909-814b-43d2-8924-3d62f632f8e4">16</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjYtMTAtMS0xLTEzNjk2_7d5c1ece-b94a-438e-85e7-3455a0f7ea89">16</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMTctMTItMS0xLTkwOTU_7a22fba8-c4d4-4a44-8281-048374465961">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctMi0xLTEtMTQzMDE_9695b009-4fc3-45da-9da3-bc7a84205173">72</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctNC0xLTEtMTU3Njg_e1558817-8454-4bae-aa69-59e1530a38b3">12</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctNi0xLTEtMTQyOTQ_491a1642-d58b-44cc-b6f4-9543a582ef04">84</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctOC0xLTEtMTQ4Nzg_03de7da4-0a2b-4cab-b71e-126614e429bf">377</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctMTAtMS0xLTE1Nzcz_cfbfa4ff-c663-4a8f-9afb-19b529c18a75">3</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjctMTItMS0xLTE0Mjk2_5951f2d0-71ca-4d8f-8b42-a45bbaf37291">380</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="21" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Statements of Cash Flows:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Deferred taxes from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtMi0xLTEtMTU3Mzc_2c929d65-b71f-4fe9-99b6-afe42c66f26c">167</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtNC0xLTEtMTU3ODM_db8c6e57-8d93-4e2c-a589-4144ac80c1f5">32</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtNi0xLTEtMTU3MjU_1ea33e6c-7708-4c00-b5c9-2651169adf48">199</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtOC0xLTEtMTU3MzM_dcb6064e-e710-4aef-a49b-e4f40320434b">77</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtMTAtMS0xLTE1Nzc4_b591beb4-892e-4a2b-bd5e-69490e66f533">4</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtMTItMS0xLTE1NzI3_015e7392-390f-48a2-9831-f50f2622e334">82</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Benefit plan contributions in excess of expense/income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i0334f31ee57f45eabc99bd07eec69bca_D20210101-20210404" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjItMi0xLTEtODM4MA_d6eddeb4-ee9f-472b-b46c-eeb23caa351d">226</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5ab1163b18294401849660276bdbc17a_D20210101-20210404" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtNC0xLTEtMTM3MDA_1a61d7a0-6036-41d3-a40a-20bace06b0f0">146</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjgtNi0xLTEtODMyNg_edcd0655-8b98-45b0-8ca0-4b6e06b18860">373</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="idec9c360c17e44b0b25fec1f8dd6a0d3_D20200101-20200329" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjQtOC0xLTEtMTE3OTA_1195e993-5355-4c17-bdb8-924f7fd2ec3a">250</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if7f840f97b29478c94aea8edf70c57ee_D20200101-20200329" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtMTAtMS0xLTEzNzA0_0967c9ea-066b-471b-aa7b-63ca44b58b13">25</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjEtMTItMS0xLTkwOTc_584b8975-f8f2-4d84-aa6f-9bb76e4b5a9d">276</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April&nbsp;4, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Condensed Consolidated Balance Sheets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Noncurrent deferred tax assets and other noncurrent tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ide9e1b38766a45f1b70fef289bf08b46_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctMi0xLTEtMTUwODY_fecb5532-694a-404d-b182-bfb4904dd5ff">2,569</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i171b297bb091460caae274aa6fd2034c_I20210404" decimals="-6" sign="-" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzgtNC0xLTEtMTU3ODQ_8e8dc98a-b221-4645-9679-36b98609d7d5">32</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctNi0xLTEtMTUwNzY_58e3aa1e-50c9-41c9-80b9-72002976df4d">2,537</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctOC0xLTEtMTUwODI_f1ca5888-a423-4d2c-92e4-38871f63c28f">2,383</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i12997ed07c6d40178b3062b257ac83bc_I20201231" decimals="-6" format="ixt:zerodash" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzgtMTAtMS0xLTE1Nzkz_26138068-b065-4e93-8fcb-be140261e21f">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctMTItMS0xLTE1MDc5_9e45962a-7ea1-4519-9a95-a293f3ec83bc">2,383</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ide9e1b38766a45f1b70fef289bf08b46_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtMi0xLTEtMjA2NTc_3e3274a3-c7d7-4cb0-ad0e-d5c9ae4e82b1">4,738</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i171b297bb091460caae274aa6fd2034c_I20210404" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtNC0xLTEtMjA2NjA_e3e8f388-f2f5-4549-936a-34e87d2ef190">6</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtNi0xLTEtMjA2NDk_95d738e4-7e0a-4d31-9830-d4e80d439dcd">4,744</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtOC0xLTEtMjA2Njk_1f2be8d9-b433-4c15-8449-0f9a0b9084ad">4,569</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i12997ed07c6d40178b3062b257ac83bc_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtMTAtMS0xLTIwNjY5_64d51ccc-b643-4ace-a1b2-71925d5248d7">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtMTItMS0xLTIwNjUx_34f1ecd6-4611-416e-8c7a-f43f856fa8c6">4,569</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Pension benefit obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ide9e1b38766a45f1b70fef289bf08b46_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjktMi0xLTEtODM4NA_ee06e3a6-6bfa-4c3a-b9be-cc419eba2c2b">4,527</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i171b297bb091460caae274aa6fd2034c_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctNC0xLTEtMTM3MTM_048ac843-d653-4e16-8db9-34362ec2884e">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzUtNi0xLTEtODI2Mg_9bda7105-004b-4ad9-b67c-7f36661c8dfc">4,526</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctOC0xLTEtMTM3MTU_6b7e7465-0ceb-4a47-8405-4438d1bb4fa7">4,766</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i12997ed07c6d40178b3062b257ac83bc_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctMTAtMS0xLTEzNzE1_8e59d7b3-ce77-44f3-950d-e8264ed2d972">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMjgtMTItMS0xLTkwOTk_11cefec6-2605-4e1f-b0ce-910df4f36339">4,766</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ide9e1b38766a45f1b70fef289bf08b46_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzEtMi0xLTEtODM4NA_d602c50f-ca60-4269-9ee4-f718b8b15d5c">95,044</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i171b297bb091460caae274aa6fd2034c_I20210404" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzktNC0xLTEtMTM3MTM_d473b86e-5f9f-4c12-9df6-2d00930fe30b">114</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzctNi0xLTEtODI3Ng_4230f24a-8374-427f-871b-86020d61874e">95,158</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzktOC0xLTEtMTM3MTU_7580f644-c600-4231-bbd3-e67bb4574450">96,770</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i12997ed07c6d40178b3062b257ac83bc_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzktMTAtMS0xLTEzNzE1_dc6788e4-94b9-4e5f-86cb-bbded14c4a5c">6,378</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzAtMTItMS0xLTkwOTk_6e45a608-125b-446f-9410-ffed17eef45e">90,392</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ide9e1b38766a45f1b70fef289bf08b46_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzItMi0xLTEtODM4NA_cfcd4507-2a87-4f30-81ff-c6b3f0f5e239">4,523</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i171b297bb091460caae274aa6fd2034c_I20210404" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtNC0xLTEtMTM3MTM_9b5943fb-9452-427b-a756-7fadf972440c">141</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzgtNi0xLTEtODI5OQ_82d67c83-f36b-4492-af61-5ad383337bed">4,664</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia131e2982b6c4b3ab337e024dcb6d31f_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtOC0xLTEtMTM3MTU_cb7dfdf0-f063-4d27-9bd8-81cd8a433119">11,688</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i12997ed07c6d40178b3062b257ac83bc_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfNDAtMTAtMS0xLTEzNzE1_f27e39b6-6fd4-4442-a088-4f4e5d199fd9">6,378</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmZhNjdkYWRlNDI5YTQyMjA5NWE0OWQwMGM0YTI4NWI2L3RhYmxlcmFuZ2U6ZmE2N2RhZGU0MjlhNDIyMDk1YTQ5ZDAwYzRhMjg1YjZfMzEtMTItMS0xLTkwOTk_2a43c97a-bec1-453d-8e24-b4c3002d34a5">5,310</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></ix:continuation></div><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfODM0OA_9a96f313-1767-408b-89f4-03bdd57e4dca" continuedat="ida8a45f5e65d4d719fcfc03aed87d430" escape="true">Revenues and Trade Accounts Receivable</ix:nonnumeric></span></div><div style="margin-top:8pt"><ix:continuation id="ida8a45f5e65d4d719fcfc03aed87d430" continuedat="ie90f112fb2804faa8bbdef53a711a49e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customers––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccines products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.</span></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i7564010e48f64a6192cc4e60d4d48666"><ix:continuation id="ie90f112fb2804faa8bbdef53a711a49e"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deductions from Revenues––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="pfe:ScheduleOfMedicareRebatesMedicaidAndRelatedStateProgramRebatesPerformanceBasedContractRebatesChargebacksSalesAllowancesAndSalesReturnsAndCashDiscountsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RleHRyZWdpb246ZTBmYTE5NDc3YjA4NGI5YmE4OWMwODg3NDlhOTZlMzlfODI5OA_91d136b2-f031-4290-a0c7-e9628c53eb7e" continuedat="i8e52cc7958844a799b3faa5d251a37e7" escape="true">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:</ix:nonnumeric></span></div><div style="margin-bottom:3pt"><ix:continuation id="i8e52cc7958844a799b3faa5d251a37e7"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve against </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i99fcec41f64847ed86b1c89a56896531_I20210404" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfMS0yLTEtMS0w_68aef472-330b-488e-b305-ffab9c991fd7">848</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie4a2b9079bc742749949e93c782f4af9_I20201231" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfMS00LTEtMS0w_057c355f-e8b7-4712-aafe-bbf71bd1383e">861</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie6c618bad6c74bfa8eb2909c5ea37002_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:AccruedRebates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfMy0yLTEtMS0w_97f6047f-ac20-4623-b409-c7cb97449d91">3,211</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i940e3dc38ca547fdbc8e066fc92a3705_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:AccruedRebates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfMy00LTEtMS0w_75640e3b-54fa-470c-8100-fc6da00652f2">3,017</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie6c618bad6c74bfa8eb2909c5ea37002_I20210404" decimals="-6" name="pfe:OtherAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNC0yLTEtMS0w_8cfb899d-1e89-4ce7-a0e3-21dec094bbc3">449</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i940e3dc38ca547fdbc8e066fc92a3705_I20201231" decimals="-6" name="pfe:OtherAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNC00LTEtMS0w_9440259a-8bf7-49e8-92f5-2b0c96f6a9d7">436</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib09c41fb46464505bcc32a3c43731505_I20210404" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNS0yLTEtMS0w_bb0f4e42-cf04-4a5e-bd64-64384657929e">340</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0fac9c964894676b74a3dfea4fc6f74_I20201231" decimals="-6" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNS00LTEtMS0w_27606924-0656-4d84-b891-bebb28ef50c4">399</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued rebates and other sales-related accruals</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNi0yLTEtMS0w_1792f97f-2172-45ce-9d39-7231a477dc79">4,848</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:RebatesAndDiscountsAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80MC9mcmFnOmUwZmExOTQ3N2IwODRiOWJhODljMDg4NzQ5YTk2ZTM5L3RhYmxlOmNlM2QwN2Q4ZjdlOTRiZTQ5MDIzNTY1M2EzZWVlOTA1L3RhYmxlcmFuZ2U6Y2UzZDA3ZDhmN2U5NGJlNDkwMjM1NjUzYTNlZWU5MDVfNi00LTEtMS0w_ad863a6a-7370-4d15-975e-c45a13adf941">4,712</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade Accounts Receivable––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div></ix:continuation><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended April&nbsp;4, 2021 and March&nbsp;29, 2020, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K.</span></div></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_46"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfOTc3OQ_ba908374-5f20-47da-8017-88149f62cde1" continuedat="i8da9a5ba79894b1ba17b377add1230b5" escape="true">Discontinued Operations and Equity-Method Investment</ix:nonnumeric></span></div><ix:continuation id="i8da9a5ba79894b1ba17b377add1230b5" continuedat="i0d8c9f7189724770b014b78e8967006e"><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Discontinued Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Upjohn Separation and Combination with Mylan</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&nbsp;16, 2020, we completed the spin-off and the combination of the Upjohn Business with Mylan to form Viatris. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1A. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, Pfizer and Viatris entered into various agreements to effect the separation and combination to provide a framework for our relationship after the combination, including a separation and distribution agreement, interim operating models, including agency arrangements, manufacturing and supply agreements (MSAs), transition service agreements (TSAs), a tax matters agreement, and an employee matters agreement, among others. The interim agency operating model arrangements primarily include billings, collections and remittance of rebates that we are performing on a transitional basis on behalf of Viatris. Under the MSAs, Pfizer or Viatris, as the case may be, manufactures, labels and packages products for the other party. In the first three months of 2021, the amounts recorded under the above agreements were not material to our consolidated results of operations. Net amounts due from Viatris under the above agreements were approximately $<ix:nonfraction unitref="usd" contextref="i1fb4d5f76cd341e2a3579da45c669e20_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NontradeReceivablesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTA5OTUxMTY0MjUzMg_50774283-f6ba-43df-a9c0-40a28e34fa82">871</ix:nonfraction> million as of April&nbsp;4, 2021 and $<ix:nonfraction unitref="usd" contextref="i3781297f71ce4123a78cf0ccdb2f46c0_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NontradeReceivablesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTY0OTI2NzQ3NzY3OQ_6aca0054-cc97-4954-8ee1-a7145065e166">401</ix:nonfraction> million as of December 31, 2020. The cash flows associated with the above agreements are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities from continuing operations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">except for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a $<ix:nonfraction unitref="usd" contextref="ie0e1c16f8ac04992b4a1223cc9982917_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfOTg5NTYwNDc0MTUwNw_1d818c86-cf20-4276-bdcf-4ce1b88acf35">277</ix:nonfraction> million payment to Viatris made in the first quarter of 2021 pursuant to terms of the separation agreement, which is reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other financing activities, net, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and was recorded as a payable to Viatris in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December 31, 2020. In addition, Pfizer and Mylan had pre-existing arms-length commercial agreements, which are continuing with Viatris and are not material to Pfizer’s consolidated financial statements.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of the Upjohn Business and the Mylan-Japan collaboration are reported as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations––net of tax.</span></div></ix:continuation><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2NzAyMDc_f5625749-9e7d-4e39-a6d0-b74de25ea1a0" continuedat="i922f3ec188d549489ad6ebec14e28143" escape="true"></ix:nonnumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i0d8c9f7189724770b014b78e8967006e"><ix:continuation id="i922f3ec188d549489ad6ebec14e28143"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income from discontinued operations––net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMy00LTEtMS0yOTU_de46aef3-cb8c-46bf-b974-fb23d5283619">27</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMy00LTEtMS0zNTg_b3f441c7-1a92-49c9-bd5a-5f5f5059154b">1,946</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNS00LTEtMS0yOTU_d23cc06a-f75c-4e93-8766-c287f811e8e6">14</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNS00LTEtMS0zNTg_b1ad7b50-b4d1-4e25-828a-68a30df68df8">442</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNi00LTEtMS0yOTU_518f99e6-5e96-4c2f-b8de-af7264002918">8</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNi00LTEtMS0zNTg_68b9eefc-6b46-44e3-bc97-f912774e2cb8">332</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" name="pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNy00LTEtMS0yOTU_10a5563d-cffd-4fcf-a44f-1e9d8588ccfe">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" name="pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfNy00LTEtMS0zNTg_72c25753-50d3-4ffb-a31c-f5e8350d62ef">51</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOC00LTEtMS0yOTU_5355b043-1739-4f11-acb1-4570087f0dff">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOC00LTEtMS0zNTg_63a6abb2-7c00-49fa-bbc6-4f6ad48c78f2">36</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOS00LTEtMS0yOTU_d102d80d-a898-4ba7-af27-96aa2d0ab7df">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" name="pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfOS00LTEtMS0zNTg_05a64b8a-4b76-456f-b7bd-c35da8682d5c">15</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income)/deductions––net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTAtNC0xLTEtMjk1_a30b4f44-e1d1-4575-a469-b510ae5a5f69">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTAtNC0xLTEtMzU4_d87c2754-da86-4009-887e-4184a08f8716">70</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax income from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTEtNC0xLTEtMjk1_9d8b5230-4258-4163-96ee-c366e2da39ee">19</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTEtNC0xLTEtMzU4_97195b69-f37a-46cd-a3e1-fc18f79e441f">1,000</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTItNC0xLTEtMjk1_ea6c3568-31eb-4315-b798-e853503078df">10</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTItNC0xLTEtMzU4_35aa2333-d046-4414-b5e4-8f3fe7362385">119</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income from discontinued operations––net of tax</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i82a840208e554416a672c485a012d030_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTctNC0xLTEtMjk1_f3bc4aa6-0dee-42de-a59e-3bbb31ff39af">9</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4a47cb2d89ab478a900d1616bad533a5_D20200101-20200329" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjk0ODMxNmVjZjU1ODQ2OWZiNmNiZGM5OWVhOThkN2ZmL3RhYmxlcmFuZ2U6OTQ4MzE2ZWNmNTU4NDY5ZmI2Y2JkYzk5ZWE5OGQ3ZmZfMTctNC0xLTEtMzU4_91e30a78-1664-48eb-8efa-ec761218c159">881</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTU5NDI5MTg2ODc0MDA_c73d64bb-5ff8-4071-995c-6a7c0a55b343" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">In the three months ended April 4, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations—net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> primarily relates to the Mylan-Japan collaboration, which did not terminate until December 21, 2020 and which falls in Pfizer’s international first quarter of 2021, and adjustments to tax and legal matters directly related to the disposed Upjohn Business. In the three months ended March 29, 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations—net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> relates to the Upjohn Business and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting, which has been applied on a retrospective basis for all prior periods presented. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div></ix:continuation><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Equity-Method Investment</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Formation of Consumer Healthcare JV</span></div><div style="padding-right:9pt"><span><br></span></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&nbsp;31, 2019, we completed a transaction in which we and GSK combined our respective consumer healthcare businesses into a new JV that operates globally under the GSK Consumer Healthcare name. In exchange, we received a <ix:nonfraction unitref="number" contextref="if62466171dbf47ec977eb962afa99747_I20190731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMjQ4Mg_646bf3f2-97e4-4b5b-b9e7-b0757aca1a05">32</ix:nonfraction>% equity stake in the new company and GSK owns the remaining <ix:nonfraction unitref="number" contextref="iec8f63c6623f49adbf67a41d2e87119b_I20190731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMjU0NA_f7f52eeb-ad64-4267-98fd-e8842ad35705">68</ix:nonfraction>%.</span></div><div style="margin-top:8pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are accounting for our interest in the Consumer Healthcare JV as an equity-method investment. The carrying value of our</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in the Consumer Healthcare JV is $<ix:nonfraction unitref="usd" contextref="i84d3a404ba354ee580c13bbafde8881a_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMzgxMw_4d0505c9-cd85-45d5-a433-876e5cfa35ea">16.3</ix:nonfraction> billion as of April&nbsp;4, 2021 and $<ix:nonfraction unitref="usd" contextref="i1c9fa610ebea414a8e6bdc725a6ef091_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMzgyOQ_aa05ee60-8af5-484c-a368-3c2680acf6d9">16.7</ix:nonfraction> billion as of December 31, 2020 and is reported as a private equity investment in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of April&nbsp;4, 2021 and December 31, 2020. The Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The decrease in the value of our investment from December 31, 2020 is primarily due to $<ix:nonfraction unitref="usd" contextref="i5fd9a8583a894369a0802010c20fb64a_D20210101-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="pfe:EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfNDM3Ng_2fdb8715-0567-4a85-ac5e-c4dbfb060788">126</ix:nonfraction> million in pre-tax foreign currency translation adjustments (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), as well as dividends totaling approximately $<ix:nonfraction unitref="usd" contextref="i5fd9a8583a894369a0802010c20fb64a_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfNDQ4OQ_bbcc03b5-4446-47de-92fc-5ddd7ee33281">274</ix:nonfraction> million, partially offset by our share of the JV’s earnings. We record our share of earnings from the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our total share of the JV’s earnings generated in the fourth quarter of 2020, which we recorded in our operating results in the first quarter of 2021, was $<ix:nonfraction unitref="usd" contextref="i5fd9a8583a894369a0802010c20fb64a_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTA5OTUxMTcwNTcxNg_28ac2727-3769-4b63-85fd-750476acff82">71</ix:nonfraction> million. Our total share of the JV’s earnings generated in the fourth quarter of 2019, which we recorded in our operating results in the first quarter of 2020 was $<ix:nonfraction unitref="usd" contextref="i38b38c32e3974b6d8a66d36b03ee36af_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfMTA5OTUxMTY1NzA3Mg_d753092b-100f-4fd8-ad2f-9799c9e48782">11</ix:nonfraction> million. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and was not material to our results of operations in the periods presented. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4.</span></div><div style="margin-top:5pt;padding-right:9pt"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RleHRyZWdpb246OTY4NWRiZDZkZjk5NDA3NjhjMTJkOGQxZDMxNWM0ZWZfOTc3NA_44a44697-50d5-4dee-8e93-3ca8dcdd3af4" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tbody><tr><td style="width:1.0%"></td><td style="width:53.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.776%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three months ending December 31, 2020, the most recent period available and for the three months ending December 31, 2019, is as follows:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfMi0yLTEtMS0w_4532fe78-d3d4-432f-b8d7-92112e58b778">3,096</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfMi00LTEtMS0xNTk5_982aacd9-051d-4422-97e2-d19bc4103353">3,188</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfMy0yLTEtMS0w_9539cada-5336-4daf-a8e0-1afda6f9d024">1,188</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfMy00LTEtMS0xNTk5_202ea05f-df1a-42a3-9633-8d77416531d8">1,811</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNC0yLTEtMS0w_3df5fdae-2e06-4dba-a770-a45a8ec78ccb">1,908</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNC00LTEtMS0xNTk5_2c6886cd-75cd-4422-a3b8-e609edf2ae4a">1,377</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNS0yLTEtMS0w_aba530f0-e913-44e1-b132-9a647a0fed0b">233</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNS00LTEtMS0xNTk5_79073324-7f00-45f7-b5dc-3bd73fe42d99">46</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNi0yLTEtMS0w_416dc2a5-e841-4dfc-82c5-438425bee612">233</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNi00LTEtMS0xNTk5_17e970e6-b55e-4f20-899e-d0e5351332bc">46</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income attributable to shareholders</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7a74c6bbce7a4843bcdb7ddca3862e48_D20201001-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNy0yLTEtMS0w_cd87a5c4-e88e-41df-9ba3-d564c9f38e97">221</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6fa8c9d671e04698839f5e69e1fd6a60_D20191001-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF80Ni9mcmFnOjk2ODVkYmQ2ZGY5OTQwNzY4YzEyZDhkMWQzMTVjNGVmL3RhYmxlOjcxZDA3Y2U0YjhhNzQ5ZjY4MDE0ZTlmNTRkMjJjMjcxL3RhYmxlcmFuZ2U6NzFkMDdjZTRiOGE3NDlmNjgwMTRlOWY1NGQyMmMyNzFfNy00LTEtMS0xNTk5_dd4ec1e2-8496-4f2d-b912-8eae9eb45dd2">37</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></ix:nonnumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_52"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjExOA_27eb074a-149b-45fa-98f9-adc9fd28e25c" continuedat="ib9e1fbccfd5b47b78a06b16ca1f95c22" escape="true">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</ix:nonnumeric></span></div><ix:continuation id="ib9e1fbccfd5b47b78a06b16ca1f95c22" continuedat="iecd2e6400c0d471db9f9e89fa1d0e708"><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Transforming to a More Focused Company Program</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the formation of the Consumer Healthcare JV in 2019 and the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer has transformed into a focused, global leader in science-based innovative medicines and vaccines. We have undertaken efforts to ensure our cost base aligns appropriately with our revenue base. While certain direct costs transferred to the Consumer Healthcare JV and to the Upjohn Business in connection with the spin-off, there are indirect costs which did not transfer. In addition, we are taking steps to restructure our corporate enabling functions to appropriately support and drive the purpose of our business and R&amp;D and PGS platform functions. The program costs discussed below are expected to be incurred primarily from 2020 through 2022, and may be rounded and represent approximations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect costs for this program, primarily related to corporate enabling functions, to total $<ix:nonfraction unitref="usd" contextref="ice6f2159d3d7436abcb7d83886acbb6f_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNDk0NzgwMjMzMzQxMA_07e6fc4c-e559-42bc-90ab-26497f16abb9">1.6</ix:nonfraction> billion on a pre-tax basis, with substantially all costs to be cash expenditures. Actions will include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, as part of this program, we expect to incur costs related to manufacturing network optimization, including certain legacy cost-reduction initiatives, of $<ix:nonfraction unitref="usd" contextref="i49562007fd9547a48d0eb81e74591431_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNDk0NzgwMjMzNDAxMw_14041156-967c-4d93-87b0-3f155bc2ac32">500</ix:nonfraction> million, with approximately <ix:nonfraction unitref="number" contextref="i4407292bed544ddd98da354a852701ac_D20210101-20210404" decimals="2" name="pfe:RestructuringandRelatedCostNoncashChargesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNDk0NzgwMjMzNDAzNw_29eccbf6-131e-466e-a149-d380d1c91f84">20</ix:nonfraction>% of the costs to be non-cash. The costs for this effort will include, among other things, implementation costs, product transfer costs, site exit costs, as well as accelerated depreciation.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the start of this program in the fourth quarter of 2019 through April&nbsp;4, 2021, we incurred costs of $<ix:nonfraction unitref="usd" contextref="i7156c3363822440b89afce39f1a1c27e_D20191001-20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjQz_baecc405-330d-422d-8204-69e27bab3e74">1.0</ix:nonfraction>&nbsp;billion.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Key Activities</span></div><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE0Nw_4bee2ea2-188a-4a08-8602-2e647072a22e" escape="true"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits, which are composed primarily of the Transforming to a More Focused Company program:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee terminations</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNC0yLTEtMS0w_301ae934-f19f-4d8f-bf13-608344d6369d">22</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNC00LTEtMS0w_93bfa226-828b-494b-a432-d2d2e66d9031">10</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset impairments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="pfe:RestructuringAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNS0yLTEtMS0w_b586cc58-6854-42c6-9603-9998af0221df">4</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:RestructuringAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNS00LTEtMS0w_c3a57e3c-3266-44a2-8dff-3a8f35f458ab">31</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNy0yLTEtMS0w_5e0dff33-7e97-4d09-ac1a-80be7e6e6500">18</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfNy00LTEtMS0w_cd7f3079-195a-46fe-b073-6993223883f4">41</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOC0yLTEtMS0w_b6771aba-6f3b-40c3-962c-8f8114960d69">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOC00LTEtMS0w_b529326e-fc93-43e3-81b0-c43c7c8fd2cc">3</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Integration costs and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOS0yLTEtMS0w_3ffb2d8a-61e5-4039-8773-05842cb74df3">5</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfOS00LTEtMS0w_546dee0e-69c6-40bc-966d-0e83da52f191">10</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTAtMi0xLTEtMA_6bd7a23a-9c47-462b-8783-c08797543a15">23</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTAtNC0xLTEtMA_1bff97d6-aa66-4f36-88ae-16aa7084c06f">54</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net periodic benefit costs recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8aceb51cc0bf45ed95b1955ecc6fb23c_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTEtMi0xLTEtMA_9a746ba0-bd22-43b4-bfc3-2e9f7aba935b">8</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i98e974ef3b1d4e2daccb139c441bf188_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTEtNC0xLTEtMA_c4b208b6-0303-451d-8329-d9c8484039f7">1</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Additional depreciation––asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">recorded in our condensed consolidated statements of income as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i276123bbbe4c45e787729f28b9ca251b_D20210101-20210404" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTMtMi0xLTEtMA_87327130-7cf3-4c72-9008-b2b271f98d46">10</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1722674e9e1442d7a819050b2b7326e6_D20200101-20200329" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTMtNC0xLTEtMA_9ef8be88-1959-40c9-81bf-ea16b8e248a4">5</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0bbb409c662d47279fe6413cb12de8ab_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTUtMi0xLTEtMA_b1d8a154-fdc2-4f8a-a02c-d8faddf9caac">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id81a2e2f25e144ec9494eaff2bd3e792_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTUtNC0xLTEtMA_e1dc8120-708b-49b8-81ad-a203b059d66b">5</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total additional depreciation––asset restructuring</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTYtMi0xLTEtMA_f906d911-a49b-4178-8717-f19e16a6dc40">10</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTYtNC0xLTEtMA_bc1d4ec4-ea5f-43ba-b558-2f379081fc1d">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Implementation costs recorded in our condensed consolidated statements of income as follows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i276123bbbe4c45e787729f28b9ca251b_D20210101-20210404" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTgtMi0xLTEtMA_59b42e17-1173-4eb5-bbec-a4f1881d52d9">11</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1722674e9e1442d7a819050b2b7326e6_D20200101-20200329" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTgtNC0xLTEtMA_191e940d-499e-4944-9b76-8b7ea2581301">8</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia2e7bece604541d19d4b22b186b717b3_D20210101-20210404" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTktMi0xLTEtMA_7363a2b9-77d0-4824-8636-f110e68e33c8">64</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idb3917b19d6f4c6dab6872ff7d889d77_D20200101-20200329" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMTktNC0xLTEtMA_55e7339a-3620-4bde-97cd-c357aed02fd4">15</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total implementation costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjItMi0xLTEtMA_9f2fc647-9c1e-47d2-b834-73e520846e5a">75</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjItNC0xLTEtMA_622d2523-3b1f-4408-8c5a-0bac6a2cc96f">22</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjMtMi0xLTEtMA_f8a24f99-7e34-4283-b997-d8fed6896efe">116</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOjk2MDczZTRlNjFjOTQ2OTBhMzBhMTAxMDQ4ZjQ2ZTMwL3RhYmxlcmFuZ2U6OTYwNzNlNGU2MWM5NDY5MGEzMGExMDEwNDhmNDZlMzBfMjMtNC0xLTEtMA_afe902ec-0a48-4d46-ad48-43be71df2391">77</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTU5NDI5MTg2MjA1MzI_6b6e4f36-5f04-4ca9-9035-b986fd3a4b1b" footnoterole="http://www.xbrl.org/2003/role/footnote">Represents acquisition-related costs ($<ix:nonfraction unitref="usd" contextref="i1617049205a64a65b14f81a3f84a1390_D20210101-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNDk4_6f7d1cd7-fedc-45ac-9084-86d11b0a67d2">6</ix:nonfraction> million credit in 2021) and cost-reduction/productivity initiatives ($<ix:nonfraction unitref="usd" contextref="ieae0a64a2dae4656b4cca345c9c51c55_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNTY3_01a1911d-d185-4baf-95af-00ea682001ba">25</ix:nonfraction> million charge in 2021 and a $<ix:nonfraction unitref="usd" contextref="i023c394fbcc94e588c67d1f493d78a48_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfNTg3_084cef96-bf16-432a-bcfe-42e6851b8e72">40</ix:nonfraction> million charge in 2020).</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEyNg_d92a1bf3-a2fd-4e8d-8cb3-f3125a6020dc" footnoterole="http://www.xbrl.org/2003/role/footnote">Represents external costs for banking, legal, accounting and other similar services.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEyNA_0fae7530-2ac8-48f2-8f63-b1eb8fd75fde" footnoterole="http://www.xbrl.org/2003/role/footnote">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTU5NDI5MTg2MjEyMzg_9ce23b20-625d-4f24-9157-eb389b4fb9a3" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Amount for the three months ended March&nbsp;29, 2020 includes the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE5Mw_61ed027d-4f79-4d99-8790-a80b2a75ecb3" footnoterole="http://www.xbrl.org/2003/role/footnote">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE0MQ_770ee945-b49d-4e4e-a7bc-2d0e98447487" footnoterole="http://www.xbrl.org/2003/role/footnote">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</ix:footnote></span></div></ix:nonnumeric></ix:continuation><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE4NA_60a80000-3ea5-492d-9a39-7eecee55dbeb" continuedat="i1d4fb77728484994b5ead409fa00c65a" escape="true"></ix:nonnumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="iecd2e6400c0d471db9f9e89fa1d0e708"><ix:continuation id="i1d4fb77728484994b5ead409fa00c65a"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.953%"><tbody><tr><td style="width:1.0%"></td><td style="width:40.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components and changes in restructuring accruals:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Employee<br>Termination<br>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Asset<br>Impairment<br>Charges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exit Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrual</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2f7055066225454fbd6b963b51debc30_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi0yLTEtMS0w_650f9092-5643-48af-ba89-93b927563b9b">782</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie6e22c74513c4463863976ef5f21b01a_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi00LTEtMS0w_f2fc31da-a6e7-4b80-bce2-fd59decb9a07">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2f00f1a9cab940258f6eed860c0bc028_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi02LTEtMS0w_2613ca5e-b41d-4f70-b5dc-bf0ac09fb1d3">15</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMi04LTEtMS0w_343986d5-ab4b-435d-b91d-3f972bdeec5e">798</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5572a7c38929471c8c2fe740ba880ed1_D20210101-20210404" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMy0yLTEtMS0w_865c6d73-5164-4256-a6d8-cf036e933a1d">22</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i2f0c1e7ebf7f4bd0b2d81f264503a9aa_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMy00LTEtMS0w_c7253501-a393-4ef2-a534-85fbd644a092">4</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iacaebf2f64444de881dd6e9949fe01bb_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMy02LTEtMS0w_da606571-9143-48cb-8a28-5d9b4f2f97b7">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfMy04LTEtMS0w_aa52b20e-aa2e-4ad4-ac30-0a24298e0cb3">18</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5572a7c38929471c8c2fe740ba880ed1_D20210101-20210404" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC0yLTEtMS0w_ecd33fc1-36e8-4ce4-b191-bd8d042f0b68">102</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2f0c1e7ebf7f4bd0b2d81f264503a9aa_D20210101-20210404" decimals="-6" sign="-" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC00LTEtMS0w_88fdb5ac-4adf-4238-958e-b22cac16bf1f">4</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iacaebf2f64444de881dd6e9949fe01bb_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC02LTEtMS0w_ac840666-4a79-4099-b296-a593bb099c69">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNC04LTEtMS0w_e761edee-d110-4151-966b-72d12a040682">99</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance, April&nbsp;4, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8b6820f138a34d1a88125938e6c7587e_I20210404" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS0yLTEtMS0w_2dbd2070-6998-4f79-8772-924259ed4b7d">702</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia29f6c9175e74ba2832cbc36256b21b7_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS00LTEtMS0w_85f923b1-0d70-4b19-9ff5-aabb123ca60c">—</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6af0bbbd035c4089b2b81e2a9a39bc08_I20210404" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS02LTEtMS0w_84c26127-4105-48e3-a04f-11df24b975ac">15</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RhYmxlOmQ4Yzc0Y2JjMDU2MjQ1OTVhNjAyYTA5NTYxMjU3ZmY0L3RhYmxlcmFuZ2U6ZDhjNzRjYmMwNTYyNDU5NWE2MDJhMDk1NjEyNTdmZjRfNS04LTEtMS0w_f6d577a2-1634-4c28-8f08-48433e837113">717</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE1Mg_e634017b-e6dc-4654-8e14-232b212d6d2b" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($<ix:nonfraction unitref="usd" contextref="i940e3dc38ca547fdbc8e066fc92a3705_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTkzMw_104c0158-0022-4de4-a313-c68b266f49f1">628</ix:nonfraction> million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($<ix:nonfraction unitref="usd" contextref="ic0fac9c964894676b74a3dfea4fc6f74_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMTk3MQ_9c317e36-dc75-4c3b-a9fa-6cc29266d2f3">169</ix:nonfraction> million).</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE2OQ_e7c211dc-c7b6-412a-b086-9441f0974a65" footnoterole="http://www.xbrl.org/2003/role/footnote">Includes adjustments for foreign currency translation.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjE4NQ_c7fa08fe-4e7b-466f-9088-caf8aa4d3e9a" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($<ix:nonfraction unitref="usd" contextref="ie6c618bad6c74bfa8eb2909c5ea37002_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjA3MA_38e0c684-ece5-48da-b31a-176a4b43deb5">561</ix:nonfraction> million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($<ix:nonfraction unitref="usd" contextref="ib09c41fb46464505bcc32a3c43731505_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81Mi9mcmFnOjdkN2Y4MWQwNzEwMzQ4ZTI4Y2E4MjI3ZDM0N2ZjMzIzL3RleHRyZWdpb246N2Q3ZjgxZDA3MTAzNDhlMjhjYTgyMjdkMzQ3ZmMzMjNfMjEwOA_6ac882f8-c550-4ac0-a185-02e8cfdecc8f">156</ix:nonfraction> million).</span></ix:footnote></div></ix:continuation></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_58"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA3Mg_d3d8f1ec-587e-436c-8a9a-441ebeacec6b" continuedat="i981e382c415e4e04b96ef66801e78c84" escape="true">Other (Income)/Deductions—Net</ix:nonnumeric></span></div><ix:continuation id="i981e382c415e4e04b96ef66801e78c84"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA2MQ_d6c96c7b-836b-44e6-bbec-0883a4f640a4" escape="true"><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions––net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMy02LTEtMS0w_93dd2970-806f-4c10-bec3-5c467be54c26">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMy04LTEtMS0w_6789808f-b98c-4eb2-9de8-10920a76c88f">34</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNC02LTEtMS0w_c0df218b-66f2-4928-b011-5b00ba100a27">336</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNC04LTEtMS0w_1192c25e-e2f9-4cd2-9a4c-ee46ccd197b5">390</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net interest expense</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:InterestRevenueExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNS02LTEtMS0w_7aa993ba-85c5-4ec9-8063-b1625a2ea0ad">336</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:InterestRevenueExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNS04LTEtMS0w_3ff4f4a3-0b8d-459a-a15e-a8d97668cfc8">356</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Royalty-related income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNi02LTEtMS0w_092bdb67-0a71-49af-aea0-cfa327c33724">176</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNi04LTEtMS0w_dcf39154-57d1-4fc3-9419-59727f37ed9f">119</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net (gains)/losses on asset disposals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNy02LTEtMS0w_d8d30f59-4029-4a00-b55f-b620fa5c81c2">39</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfNy04LTEtMS0w_54439b9e-8f96-405c-bd79-64698286b690">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfOC02LTEtMS0w_a828a942-8b0a-4c98-89a5-5a43ada1975e">401</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfOC04LTEtMS0w_4c1103fe-4d7f-4ae6-960f-9d89a54e5b2e">255</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTAtNi0xLTEtMA_6f46671b-e44f-4f70-989b-6aa2b2abfda8">231</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTAtOC0xLTEtMA_5298a644-1d55-428f-856b-963c3c7d34e1">115</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) other than service costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTEtNi0xLTEtMA_c274f477-7672-42c8-b581-b3324d7948cb">266</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTEtOC0xLTEtMA_5e4564f2-8651-4226-a1fc-9c55fcd5e278">103</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Certain legal matters, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTItNi0xLTEtMA_ffbcf04b-f605-4c80-ae5f-ad22998d3069">51</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTItOC0xLTEtMA_2b67ee07-94e2-48b2-b117-264f5fdaa0d4">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Consumer Healthcare JV equity method (income)/loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTYtNi0xLTEtMA_2cb781d7-78a3-404f-ba8e-5ec94dedbda6">62</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTYtOC0xLTEtMA_417017aa-b9dc-4b36-b2a7-7204764bff2a">33</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:OtherNonoperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTctNi0xLTEtMA_76cd50fb-1e50-47e6-8353-716a69717150">216</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:OtherNonoperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTctOC0xLTEtMA_c1380247-7818-4355-b379-ee288ed8bf80">126</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions––net</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTgtNi0xLTEtMA_203cb90a-a50d-4aa1-92bc-8db2f6057681">1,004</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RhYmxlOjNiMzY3ZjgzNTk2ZDQwYmU4MjY4MzcwODYzYTg0ZjE2L3RhYmxlcmFuZ2U6M2IzNjdmODM1OTZkNDBiZTgyNjgzNzA4NjNhODRmMTZfMTgtOC0xLTEtMA_7428b9b0-6ab1-423e-b4da-93afa243cd13">190</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMTU5NDI5MTg2MTIyOTM_10ad1090-2c7b-484c-b959-5254b01a065a" footnoterole="http://www.xbrl.org/2003/role/footnote">The gains in the first quarter of 2021 include, among other things, unrealized gains of $<ix:nonfraction unitref="usd" contextref="i158ef04c51064fada1c617473cc9bd6d_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjc0ODc3OTA3MTYwOQ_f215fd58-5b81-41f5-b934-e70bcea046aa">409</ix:nonfraction>&nbsp;million related to investments in Allogene and BioNTech. The losses in the first quarter of 2020 include, among other things, unrealized losses of $<ix:nonfraction unitref="usd" contextref="i5449bfe370c3433fa88f59a54216e649_D20200101-20200329" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfOTc_e7e8be57-77a4-4566-8a7b-aa1e101fecab">134</ix:nonfraction> million related to our investment in Allogene. </ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA0OA_65fb97cf-3186-43e3-895f-da1f63b33e89" footnoterole="http://www.xbrl.org/2003/role/footnote">The first quarter of 2021 includes, among other things, $<ix:nonfraction unitref="usd" contextref="i798490452fbf42df810cc73fc79edd72_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjc0ODc3OTA3ODY4Mg_37a0c2b5-21cd-406f-8e77-3af73fab5b07">188</ix:nonfraction>&nbsp;million of net collaboration income from BioNTech related to the COVID-19 vaccine. The first quarter of 2020 mainly includes, among other things, an upfront payment to us of $<ix:nonfraction unitref="usd" contextref="i3b069b5bb3c145049eca9ec38c30a2d4_I20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjc0ODc3OTA4ODA4MQ_6f5f92f7-c39a-45a6-835d-190051bcd613">75</ix:nonfraction> million from our sale of our CK1 assets to Biogen, Inc.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA1OA_f1afc635-e2e9-4bf8-9f66-21ed40ec92bf" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes 1C </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF81OC9mcmFnOjA5ZDAwNDFiZDMyYjQzYzM4ZTNjNDQyMTM0ODA5MDVhL3RleHRyZWdpb246MDlkMDA0MWJkMzJiNDNjMzhlM2M0NDIxMzQ4MDkwNWFfMjA2Ng_a5781013-36b5-4be0-827e-f8f866a37b63" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">See </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div></ix:nonnumeric></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_64"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMzIwNg_966a7b07-774f-4aee-aeca-5719f3589cb6" continuedat="i60f43a67b4fe44c689604670e4966259" escape="true">Tax Matters</ix:nonnumeric></span></div><ix:continuation id="i60f43a67b4fe44c689604670e4966259" continuedat="ieeae66e703064ba594f07bfb1d127d56"><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Taxes on Income from Continuing Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for continuing operations was <ix:nonfraction unitref="number" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMTE2_2ce20265-e7d2-40ea-96a8-df63fff720f2">14.2</ix:nonfraction>% for the first quarter of 2021, compared to <ix:nonfraction unitref="number" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMTU3_a2cc1bdc-a838-4c18-8441-030e8750b634">12.6</ix:nonfraction>% for the first quarter of 2020. The higher effective tax rate was primarily due to an unfavorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-9" format="ixt:numdotdecimal" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMjE5OTAyMzI2MDQ1OQ_85d3d084-6d2b-420b-9771-6ddb878399e2">15</ix:nonfraction> billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The third annual installment of this liability was paid by its April 15, 2021 due date and is reported in current </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of April&nbsp;4, 2021. The remaining liability is reported in noncurrent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.</span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Tax Contingencies</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued Revenue Agent’s Reports (RARs) for tax years 2011-2013 and 2014-2015. We are not in agreement with the RARs and are currently appealing certain disputed issues. Tax years 2016-2018 are currently under audit. Tax years 2019-2021 are open </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="ieeae66e703064ba594f07bfb1d127d56"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in certain major international tax jurisdictions dating back to 2010.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 Form 10-K.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)</span></div><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMzE3NA_b97df153-2aa9-4966-89c8-0dbf6efdfa4d" escape="true"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMy0yLTEtMS0w_bc055cc4-19b7-4e70-aa3e-746366976622">21</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMy00LTEtMS0w_b7a2e616-a715-48ef-abf5-651ea73587ea">247</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNC0yLTEtMS0w_fa7d641b-6695-42a1-85f2-e77e3910f9b6">59</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNC00LTEtMS0w_7c4708de-27e0-45e9-9f61-0eabed9a0861">133</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNS0yLTEtMS0w_f45df937-a876-4a1f-9a07-a9214eea0722">34</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNS00LTEtMS0w_bdfc137a-0f29-41cb-83da-87e30c6f54a2">15</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNi0yLTEtMS0w_bb3f16b6-f4fc-4e62-9152-fce24b4d23ec">93</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNi00LTEtMS0w_7301bc21-74af-4001-8194-a3657d24a992">118</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNy0yLTEtMS0w_6e6680fb-8deb-48ff-8c26-58d89ac486da">10</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfNy00LTEtMS0w_1b230f48-9cb6-4b5c-9d5f-ac3313a8606f">6</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfOC0yLTEtMS0w_498ddd0d-ba18-49a3-b29d-a80b023fe87e">30</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfOC00LTEtMS0w_3ebabdf5-e730-47eb-84d4-0e622db07442">2</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfOS0yLTEtMS0w_7a688379-bf48-4e2f-ab82-439303d6da9f">20</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfOS00LTEtMS0w_e7810623-4689-421b-81c9-64727ca768ab">5</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTYtMi0xLTEtMA_f5f79b1f-8d87-4e56-bcac-7daabf972fd9">10</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTYtNC0xLTEtMA_727ca201-9284-412c-b244-f322850fd7cf">11</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTgtMi0xLTEtMA_b5825082-d0e0-4755-a950-9287668bc2d5">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTgtNC0xLTEtMA_ba7ba68b-4e8d-4cfa-9306-eb5a8e7dec65">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTktMi0xLTEtMA_3bb0ec19-82a9-4f7a-b307-ca76d16e5f27">10</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMTktNC0xLTEtMA_1661a2cb-f7e9-4f76-a1de-caafb1c74ec2">11</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMjAtMi0xLTEtMA_abd44777-fa20-4f82-99e3-ac0891a50623">84</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RhYmxlOjdjNmU1YzQ3MWUxODQ2ODhhMjM5OGJhZGY4MmYzODdmL3RhYmxlcmFuZ2U6N2M2ZTVjNDcxZTE4NDY4OGEyMzk4YmFkZjgyZjM4N2ZfMjAtNC0xLTEtMA_3320ae5d-664b-4748-a2c5-c280dddd68de">380</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82NC9mcmFnOmJjMTczNTUxZTgyMjRkNWNhOWZmOGE5YTA3YTliMzc2L3RleHRyZWdpb246YmMxNzM1NTFlODIyNGQ1Y2E5ZmY4YTlhMDdhOWIzNzZfMzE4OA_845efd3a-4453-49fe-9b6e-a23b42b5643d" footnoterole="http://www.xbrl.org/2003/role/footnote">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.</ix:footnote></span></div></ix:nonnumeric></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_67"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfNzk5_8dec60aa-09ab-42f1-9a3d-81e765da40e2" continuedat="i11a6fc7f0db64e02845c4bd5fc181d45" escape="true">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</ix:nonnumeric></span></div><ix:continuation id="i11a6fc7f0db64e02845c4bd5fc181d45"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfODEx_cec26bc2-4128-4406-bdbd-abccf3c95895" escape="true"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.818%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the changes, net of tax, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Unrealized Gains/(Losses)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-For-Sale Securities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior Service (Costs)/Credits and Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia8b83c2cd80e47b696ed34be0beb8d4c_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0yLTEtMS0w_fdd52536-f1cf-4d43-93fa-616a59bd42f4">5,450</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if15de68e82a04995aadbd09ef4f4de3e_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy00LTEtMS0w_79b88eaa-28b3-4cbc-9bba-99c212e74953">428</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id2c9aa8e82394528ad00529819678ef4_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy02LTEtMS0w_7a12e7f2-2a6d-45fb-81b0-b619bbf36eb9">116</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia2113534f48f444f8fad64562140b4ea_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0xMC0xLTEtMA_c08b6ace-4bde-4010-ba61-fb062e878f5c">452</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i44dea6398b1c4543b9115d73e959887b_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfMy0xMi0xLTEtMA_8a216c2c-f7ab-466f-9586-31bdb0086033">5,310</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4533886f346447ddb2e4466be3decd58_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0yLTEtMS0w_9b44143a-e8d7-474c-b7cb-ef917a1ab13c">442</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i678c35b0c5d8447399b0041252ff2bcd_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC00LTEtMS0w_b94a3818-9ce2-4a30-b42f-3f0cb2f6b802">380</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9f0bbf068f4d48828cc4f595bbced296_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC02LTEtMS0w_aac8c8e0-6bc5-4ea0-aebd-d9c3319dc5f5">142</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4e9bff2637eb45e1878d0c41dda792cc_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0xMC0xLTEtMA_c94c6cd9-67da-477d-a0ae-5d0d940ebc1e">33</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i60d67bdb2f284fd182a95d2a52c7716c_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNC0xMi0xLTEtMA_fa829054-3448-433c-a733-3e711e0a8f9f">646</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, April 4, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie3532a573af84231901dcba3a9f69146_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNi0yLTEtMS0w_a09c29ce-324a-4478-990d-395016c176e7">5,008</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i31ea1419793e4e3c9ae577b69a5abe6e_I20210404" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNi00LTEtMS0w_e6ee5e01-a667-4cbc-9046-765a019d7763">48</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4864e09f901546cc81c976b2cae73fb3_I20210404" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNi02LTEtMS0w_cd029b4c-f232-45fc-b99d-5d977a96ccab">26</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i62019f9f689b4fc982e85dd8eb7b261b_I20210404" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNi0xMC0xLTEtMA_033e1787-ecc0-426c-b652-4a63af44335a">419</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4ffb761b6f624168a62f72e12228bb5a_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RhYmxlOmU1OTAxZWVmYzAzODQ2MjE4NWVjMTMyNGVmMDFmOTFiL3RhYmxlcmFuZ2U6ZTU5MDFlZWZjMDM4NDYyMTg1ZWMxMzI0ZWYwMWY5MWJfNi0xMi0xLTEtMA_e2e2e7bf-4409-43c8-9c6d-8a3d4bdbd3f1">4,664</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfMTU5NDI5MTg2MDY1NTA_46975bac-46b6-4297-9aae-1a8c567a8fce" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF82Ny9mcmFnOjAwNDM2MmFlNTM4NTQ3YWU4YjgyZmViMmUxYzBmZDE3L3RleHRyZWdpb246MDA0MzYyYWU1Mzg1NDdhZThiODJmZWIyZTFjMGZkMTdfODA2_a24e44c3-59a0-4326-9be8-f9ca04edca65" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments primarily include gains from the strengthening of the U.K. pound, euro and Australian dollar against the U.S. dollar, and net gains related to the impact of our net investment hedging program, partially offset by net losses from foreign currency translation adjustments related to our equity-method investment in the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></ix:footnote></div></ix:nonnumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_70"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMjQyMQ_a5739606-ec0d-4e33-bf89-86e61a06550e" continuedat="i0c41ecae481e4d048992892633dd0b7e" escape="true">Financial Instruments</ix:nonnumeric></span></div><div><span><br></span></div><ix:continuation id="i0c41ecae481e4d048992892633dd0b7e" continuedat="ia9769bc32afc46fe8ddf31ea4e49e8cb"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Fair Value Measurements</span></div><div><span><br></span></div><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMjUzNQ_ffefc116-646e-4f43-818c-0197e239c005" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as equity securities with readily determinable fair values:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i67345ed70af0415f9ed8e94420f395ec_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS0yLTEtMS0w_39c27294-e181-4cd2-a2e3-fd35df45bef8">1,427</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c794ced60c54e86a7bdc532fdfce9e3_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS00LTEtMS0w_1c85c489-9d18-43a3-a7c4-a0218bdc0a11">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8aae410224d44016a7744837424466a6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS02LTEtMS0w_82cf3568-1c97-4bf6-a440-2af7ab298f63">1,427</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c17032a023943b39d6fe6d61373d0ef_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS0xMC0xLTEtMA_edfae60c-2a95-4c4b-81db-fd348be30d1e">567</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i046ca4e1125f4096b86c8813e2f8970e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS0xMi0xLTEtMA_d10c70b7-c8a5-4cfc-bf82-6e880f23f5ee">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i88f1d50b4ddd4407b234fba600ed5d57_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNS0xNC0xLTEtMA_81f2fce3-988c-4855-bde9-64bbe639a769">567</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency—non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1c579a22aaf5437eb8bdad6b83a2dba3_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC0yLTEtMS0w_7612d814-1429-4b44-beaf-8b9f83f3b70d">6,169</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1b4cc1d3bd5845298aa73c6e6c7e6357_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC00LTEtMS0w_15999192-fe21-42d2-9a36-fc3d4f120122">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i49e3912c87b642259d22066a4deeedf3_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC02LTEtMS0w_192292da-2145-431e-8c1d-8a8a7555bc81">6,169</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic11c0659a9ae43fc82bd309b9f944e9d_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC0xMC0xLTEtMA_e8c41fb5-9730-450f-87ac-83226e49af1c">7,719</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie39df5fe991d423c8bb366a5753affb5_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC0xMi0xLTEtMA_6da90f81-d984-40d6-a3fa-267afda94fbf">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8e21972aa8834adbb2e62df36a9290a9_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOC0xNC0xLTEtMA_a505431a-048d-4cba-9d86-18714383a2fd">7,719</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency—U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4a996c859684b9ebfddd6a039f0965a_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS0yLTEtMS0w_2ef48b90-dd37-4fe9-949b-37355044a781">1,221</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ief1336b9d91143e39d2fea5006a742b3_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS00LTEtMS0w_4e8b94a5-25c4-43d2-a8c4-adda65038eb4">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i97291e5a5ab24b64b3dccb07c9c1d5f7_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS02LTEtMS0w_65bceaad-4ae9-4ee6-a1b3-10f3990ac087">1,221</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibc333032422c470d9c553a603fed07e7_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS0xMC0xLTEtMA_e8d58585-ee47-44cd-8218-ca215c1c5c40">982</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i217da8c7f6f349b8b0412339d3adcdab_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS0xMi0xLTEtMA_dad94c05-0449-4652-a1f1-94a88720dbba">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5b273a61589b42c5baea01aad3398d3d_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfOS0xNC0xLTEtMA_1d8a1b6f-9f1b-492e-ab8f-42b076d8e15e">982</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5660e344b7ed4a1797ded4fe7f7d545c_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtMi0xLTEtMA_25a887c3-a89e-4f6d-b78f-4d14f6ae8d04">902</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i521c003f78f74a16bf69168b25516b44_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtNC0xLTEtMA_2dbab1a8-c7a7-44d3-9f9a-a97faab0d175">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4bb11cd15cf3432681d969a29d7dca79_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtNi0xLTEtMA_40f76bdb-6cf2-42a1-9f1b-776443334496">902</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i00a5767a890d4b86844c4cfd8ee6d1dc_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtMTAtMS0xLTA_e159b30e-9548-451e-9e1f-3f065dbd2520">1,008</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i47d95591fc234e93b4fc8c6f0abcc2ad_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtMTItMS0xLTA_5ccd829b-1cc7-408f-a952-c32282048958">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6c84a33617f945aa95602f65e14fe7fd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTAtMTQtMS0xLTA_65aa9f82-c5b0-46c8-a765-6d988a3f12f2">1,008</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i693fbbcedb904e0ca5820547935b4eeb_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtMi0xLTEtMA_196bbf1c-a073-4b3c-97df-5748def8ddd4">8,292</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2496243c18b44e05838d5575a5b19b92_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtNC0xLTEtMA_da75f563-8a34-4494-9ca1-c58236d77420">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia2827e9872a441058d1e02032d2d742a_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtNi0xLTEtMA_e1c7d04f-ff26-49e0-9df0-50a8d72b39b2">8,292</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7dad755ef938483cb63df05993af440c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtMTAtMS0xLTA_1e3e00aa-5465-408a-8e5c-e7039652db10">9,709</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3809c9b7e2b440a39caf0a40ae7e8f83_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtMTItMS0xLTA_03fd2647-ca29-43a1-bad5-978794638608">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i49b785935ffe4cc39bc8792585014a3b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTEtMTQtMS0xLTA_18ab15ba-8aa7-4248-a8e4-ee3e83a26f30">9,709</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i693fbbcedb904e0ca5820547935b4eeb_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItMi0xLTEtMA_553b3ee5-dda5-4472-8cdf-4f7429059136">9,719</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2496243c18b44e05838d5575a5b19b92_I20210404" decimals="-6" format="ixt:zerodash" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItNC0xLTEtMA_06ad4c61-71f9-4b2d-a536-00f4c486d185">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia2827e9872a441058d1e02032d2d742a_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItNi0xLTEtMA_62d45867-a6ed-48f3-8361-dd356dc5eb8d">9,719</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7dad755ef938483cb63df05993af440c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItMTAtMS0xLTA_479b529a-fa10-48a6-b8f8-e2465c756ece">10,276</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3809c9b7e2b440a39caf0a40ae7e8f83_I20201231" decimals="-6" format="ixt:zerodash" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItMTItMS0xLTA_a43c8e66-03f8-4b29-a9f9-14baa1151d80">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i49b785935ffe4cc39bc8792585014a3b_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTItMTQtMS0xLTA_45069de7-1bc5-4e47-add3-5797764129af">10,276</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieee10c8479ce4db4bf4cb325e7581b0f_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtMi0xLTEtMA_33aac98e-f994-44fa-9aa1-c02b6b3c457f">5</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6590c03231c94832ab710135c629b5d6_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtNC0xLTEtMA_335ed2c2-70d1-4bff-96a6-8d0ce8977505">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id2a8285101fd4a4787791fc4108af409_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtNi0xLTEtMA_8950ba41-025c-47b4-a719-258056b8ddf9">5</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib397545be8ed42a894b7225f81be7b8c_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtMTAtMS0xLTA_b1cb523f-ade7-4cd6-a0f2-7e613b67becb">18</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic8c6a57df8544c48b668c58d680c53a8_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtMTItMS0xLTA_5d7c4dab-0943-4a3a-b67b-2c0dd4bf162e">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie209ada8ef774920a8094ff1ffa8c791_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTUtMTQtMS0xLTA_06fe8cbd-1030-4cf8-b221-a83b2be65f39">18</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6402b69d96a94b11983f4c4aff358cd9_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtMi0xLTEtMA_606e56cd-8006-4328-ac58-c5fd32206201">389</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie8629e44fcf74299947158c6cf1db447_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtNC0xLTEtMA_de99f44c-2a06-4701-a478-e92a50742c3f">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic918fd2704ed4d59aa54d300420bf854_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtNi0xLTEtMA_c23d4c7f-b6e9-44f5-aa53-8aed75e2f366">389</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia422b966324146868d032d47dda6f321_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtMTAtMS0xLTA_feb5ba34-3f58-4e98-9431-bb780e037c54">234</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd8e1a1c11cb40788c6dd041f5862427_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtMTItMS0xLTA_75202bf0-4b49-4b0e-92a9-6307c74f7fbd">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic12158fe468140509e594e5c9bea2ff0_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTYtMTQtMS0xLTA_d8e5556d-4610-4e33-9ada-49e32948e934">234</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idef140b7ed3b4d09bed3385bae6d504d_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctMi0xLTEtMA_2fb36fd3-05db-429f-a3e8-2ab0d8555b0d">394</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1b810fe2ae184c5097d5595af97f1ee9_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctNC0xLTEtMA_477b8fb4-325a-4a97-9a92-a88b7cdfacd6">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia267f32cf11e4a86a297aa0b2be67c44_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctNi0xLTEtMA_9789c228-57dc-4cce-90ea-d5797baad736">394</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ida5dcb775c5545cea010daed613c3d15_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctMTAtMS0xLTA_b3cc0765-30ba-400b-babd-3acd2d21b76f">251</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie3354f5abddd4996bf3ccd71244e3b56_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctMTItMS0xLTA_da47ef13-2dfd-43f5-99b9-76d106703c88">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i91073b1fe1b54677a90882344df8e229_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTctMTQtMS0xLTA_29cf1cc4-e21b-4c5e-bea8-ee3c40a9f02a">251</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3537ba539cf4490799a0a791b894bbf6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMi0xLTEtMA_2977df70-fa87-4f8a-9978-63a849cb2625">3,123</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icbdb406e79c94c318635d1add0655a54_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktNC0xLTEtMA_6a7e9cc0-959e-4a08-b7b0-4367a8ec9e7b">3,046</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i07835653ec374195b2d79068ec153977_I20210404" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktNi0xLTEtMA_40df5344-1bae-4db8-befb-2270c0c3cb1d">77</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea25168e02e94f08b514acffde4e38cd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTAtMS0xLTA_aa60fa3b-f250-4678-a091-18c07f338365">2,809</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id5a83ae2aba2486f95fe642a4c774464_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTItMS0xLTA_46e199fe-fe1b-4fbe-b039-3030c04adca2">2,776</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1f9c25dfb8094cb598d568e3dac3e194_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMTktMTQtMS0xLTA_324f1ec6-7e05-4f0f-8ca1-4e0f24204579">32</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency—non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4d7738ac04034c2db9a1b09fd2554159_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItMi0xLTEtMA_90869fbb-28d6-4b16-8210-6951936f5e36">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic017f9df9d9941eeb7f48073600c8293_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItNC0xLTEtMA_5435e736-ec3c-4792-a06b-14afdf9cfc0b">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i235004b31ec442a1a5ebf8037790737f_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItNi0xLTEtMA_12c1a6b7-4a62-4629-8706-564e7da92a29">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3112b7bd4ca945039be216b55807356f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItMTAtMS0xLTA_d2cbe56f-0e14-4d54-9858-96298978b4a3">6</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5959213e06f24defac36f7a0fb92bbb4_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItMTItMS0xLTA_d9d60376-3849-4c09-9fd6-445dcc46501e">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1b990b5de1ed4f4db641cc793879a698_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjItMTQtMS0xLTA_ca05ab39-1ed3-4de3-8542-5c4e443e7da1">6</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency—U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibc2af150083d47d0bcf678532db4a34a_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtMi0xLTEtMA_ee1bca5d-8a4d-4113-a9c4-06860af944f4">66</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia6648e1e65204f4eb444cb895f52ec9c_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtNC0xLTEtMA_28b39024-dc70-41c0-847b-fac11bbc421c">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5fd3e97335545368349e1b54a37f7ca_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtNi0xLTEtMA_73e13363-1cc2-4b47-ab39-7098c5308657">66</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93b72ae9514a4dfdb73d54037e4297c5_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtMTAtMS0xLTA_d8433eff-77e8-4d18-ae1a-579eaa72825b">121</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i60f3e802e12546cf9fa1294b3ad1be57_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtMTItMS0xLTA_594b689c-e34c-4025-830c-220846d02612">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6d1bff202dda47268a07043474884dcb_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjMtMTQtMS0xLTA_c0c563f7-7207-4288-9bb4-de08fb430d50">121</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a0d3ef6ac6b472b84a7134822008fef_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtMi0xLTEtMA_90fe0c4d-d173-4693-b64e-b0c050a2b639">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia77e241651c349ada1bf16e3b6ecf828_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtNC0xLTEtMA_ea79e0a1-07b0-4c6f-b1f2-51cc4adb71f9">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3dfae630a4fe4e298addafa278e16b50_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtNi0xLTEtMA_22a4b13c-eb74-4e2e-acf1-067b3aacbd04">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0ca9b4205ec749cd9646fbbf2aa209e3_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtMTAtMS0xLTA_e9d5a851-c96f-4c03-9003-08e07f68577b">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2697970c25514e279413521fb973bba7_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtMTItMS0xLTA_ac0799fc-9731-4eb8-bbee-28c75aea77d7">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9ea7690129214a9195f0424e82617486_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjQtMTQtMS0xLTA_ca2cd08f-dbd7-47ad-8740-edb9bb8639f5">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3537ba539cf4490799a0a791b894bbf6_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtMi0xLTEtMA_f2e6af77-ea84-40b8-b9ec-25cee0b93052">75</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icbdb406e79c94c318635d1add0655a54_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtNC0xLTEtMA_81f3aed5-da25-40da-8dca-d5c618561922">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i07835653ec374195b2d79068ec153977_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtNi0xLTEtMA_b5d21d46-f03f-4adc-8bb9-45c0cde5a3f6">75</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea25168e02e94f08b514acffde4e38cd_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtMTAtMS0xLTA_214d34a3-19b6-40f2-a55d-ac46e108f603">128</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id5a83ae2aba2486f95fe642a4c774464_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtMTItMS0xLTA_27c73584-1d65-40bc-9647-d815ea03b0f4">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1f9c25dfb8094cb598d568e3dac3e194_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjUtMTQtMS0xLTA_649a19b0-1674-41c1-87c2-6dd029baab88">128</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3537ba539cf4490799a0a791b894bbf6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtMi0xLTEtMA_7191b257-cfd1-495c-aab6-e132444eefd9">3,198</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icbdb406e79c94c318635d1add0655a54_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtNC0xLTEtMA_52b13242-b757-49d9-82fe-1370db13bf55">3,046</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i07835653ec374195b2d79068ec153977_I20210404" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtNi0xLTEtMA_ec4657ae-3dc9-4d24-9693-37105de97fba">152</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea25168e02e94f08b514acffde4e38cd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtMTAtMS0xLTA_34c7a5de-27e2-4990-80d0-9c0b1625891b">2,936</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id5a83ae2aba2486f95fe642a4c774464_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtMTItMS0xLTA_279a2d3a-2b4b-4a08-993f-9351dafe29bd">2,776</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1f9c25dfb8094cb598d568e3dac3e194_I20201231" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjYtMTQtMS0xLTA_20aa55e1-e073-4d9c-a4ac-13d7c255188d">160</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4105c4d1d064369a467bf34c99b66d9_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktMi0xLTEtMA_39cbb353-3cdf-4754-b6f1-6e951c24dd35">21</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3b19f59cbd344d648155105fd82aed69_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktNC0xLTEtMA_ba32453b-5c59-4d17-8630-21c2e24aa45d">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if37d3d76e48f4447a75e62b5aaf63c5d_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktNi0xLTEtMA_5bbe4d70-40a8-4823-b6c8-808f048e2a8a">21</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iba8bc471a60a4b02bd124ad08e30d367_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktMTAtMS0xLTA_66029dd0-c662-4664-b737-018bc1066a4f">117</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9d27878b3c524d4ab463f64f7d71c33e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktMTItMS0xLTA_c5a8ff6f-16f3-44b3-aa3b-4c7baa13623e">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8199248d8cf4446faaaa1c8a52dc73f1_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMjktMTQtMS0xLTA_4cde7ade-e883-4a4c-9cc2-1480462d2a37">117</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1bc1645da50f4723ac5e11374a83165e_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtMi0xLTEtMA_b534b43b-8d17-4f35-84bf-f611ea67ce0e">106</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2636525965a44944a8b505ad44b6fb94_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtNC0xLTEtMA_367f2eaa-1ed7-48f6-8706-15d2694c0d54">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0a1d1c34d3c44f8c8bc642f70cdd9352_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtNi0xLTEtMA_e82a9b42-5069-4b41-8ee5-aaf48b4d4eed">106</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i78f1b3c2124740a9b1eb0ab5b86a614a_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtMTAtMS0xLTA_7223fa27-0c05-450a-b7c1-6f727f958b5f">5</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i467531120efd4d1eb7bbc63d03b66773_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtMTItMS0xLTA_704c447c-82e9-40d6-8586-3cea528fbea6">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i863eb072936745e9a6b8f3a4ef7207a6_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzAtMTQtMS0xLTA_3e60bd95-69a8-45fc-ad83-92ebb74d901e">5</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0074575f0ac44757b22db2f3767d4ee4_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtMi0xLTEtMA_212299f9-ee5c-4521-bc12-1316b6cfc442">127</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8ce6613fe4614fca82227e4d2d7ec93f_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtNC0xLTEtMA_2406de4f-c4ec-4cdc-93b7-a050b28da72c">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7ff43b50014b4281a9126121e4136253_I20210404" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtNi0xLTEtMA_d01f18a7-4ba4-419e-a203-46817dfabce8">127</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8a4a937627fa4ef29f9ec8b085eaa50c_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtMTAtMS0xLTA_c7af8c39-7306-40a3-85ab-e80c18935379">122</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i033c256fd9284f3c8ccdc121aeead211_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtMTItMS0xLTA_a0d204a1-6d06-40de-a2ee-df15949c1ce1">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic3c4a625f98844cb89cf576d5f951717_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzEtMTQtMS0xLTA_a52f1996-2caa-4cec-9fa0-a13c45654587">122</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0074575f0ac44757b22db2f3767d4ee4_I20210404" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMi0xLTEtMA_3446b9f7-178e-4398-99f6-782ad773cca9">726</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8ce6613fe4614fca82227e4d2d7ec93f_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItNC0xLTEtMA_fc8c93a1-57f0-4c41-b6d2-112c34819c35">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7ff43b50014b4281a9126121e4136253_I20210404" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItNi0xLTEtMA_eff2220d-aadc-49bc-b779-cdc895f346fb">726</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8a4a937627fa4ef29f9ec8b085eaa50c_I20201231" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTAtMS0xLTA_23b7865b-22c7-49cd-88e2-700ae0a54698">693</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i033c256fd9284f3c8ccdc121aeead211_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTItMS0xLTA_9d23a004-cc86-42bd-8e78-669e60b0f378">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic3c4a625f98844cb89cf576d5f951717_I20201231" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzItMTQtMS0xLTA_a5fdb9f7-a8d1-4e4b-b23c-201e9bac2519">693</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0074575f0ac44757b22db2f3767d4ee4_I20210404" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtMi0xLTEtMA_32d08bcb-e4f8-4e02-9224-d2b53c44b419">853</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8ce6613fe4614fca82227e4d2d7ec93f_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtNC0xLTEtMA_9e9b9d1c-39c2-45b4-9be6-80618aabb702">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7ff43b50014b4281a9126121e4136253_I20210404" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtNi0xLTEtMA_391bfe5d-0a17-4c5e-b339-848ba931f7d9">853</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8a4a937627fa4ef29f9ec8b085eaa50c_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtMTAtMS0xLTA_cfdd753e-b8bc-449b-a1ed-b0f7833b54cf">814</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i033c256fd9284f3c8ccdc121aeead211_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtMTItMS0xLTA_19b9b6a8-1f01-4132-a497-51d750472ad6">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic3c4a625f98844cb89cf576d5f951717_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzMtMTQtMS0xLTA_3487a75a-0351-4649-b2b5-10008121546a">814</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic844430bda8d4a429c4c1873dec0c67b_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtMi0xLTEtMA_9332f2e0-06c8-48d6-a999-58a6a2b74ac6">14,165</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1774875f27f34e3c942fbcdb9216c45c_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtNC0xLTEtMA_5b4d1345-9f7b-44e9-ae2c-454b2d12c355">3,046</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3f9e05206d5d44bcb2b4c816762b2196_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtNi0xLTEtMA_720e3fe3-d498-49a5-9cb0-786fbdbaf086">11,119</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if0901fcaa75c4458bc09ff2e135283ae_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtMTAtMS0xLTA_96911fd7-4893-4065-9fc8-1747aec85293">14,278</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iad6218d250ab4b7588c930240dbe77bb_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtMTItMS0xLTA_19685fd7-bd4c-416f-8ece-c7a510a3e599">2,776</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7e356b3ffe4f46d786b299299e8c73c4_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfMzQtMTQtMS0xLTA_600cadd0-c5a7-483b-b77c-bc47bee517a3">11,501</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iddecd2f6220e465abe9653d482f98cd7_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtMi0xLTEtMA_89d821e0-edca-4290-9825-a9ee9259c57f">239</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0122d1ba5cd6421b87248774e8dd8097_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtNC0xLTEtMA_015c2414-aa6d-4104-b3f8-bf1f59dedd98">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6b4bf8afa38545638247e4f6360ddf24_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtNi0xLTEtMA_9794113d-60d3-45e6-8440-beae5f1bbe3a">239</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i38dfe51f567c4463b153c45da57afb62_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtMTAtMS0xLTA_f2879ab7-3334-433f-bc89-7734a62125c5">501</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie43a5c73f58e4950ab051b0f60f22af2_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtMTItMS0xLTA_7022fd12-9cbe-4b48-a0b7-ee8bd49c9e29">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if25ff69c6c384a5e9bec30440b609aaf_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDAtMTQtMS0xLTA_906ecbef-80e3-4a09-bc95-e8db2103f978">501</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib45fc05f17594d9a8b7e66f58c93a14a_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtMi0xLTEtMA_97699ac4-1a52-4c81-a907-528b5a13473f">239</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if552fb30ac3f4a9986d136fac40d1ba0_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtNC0xLTEtMA_7b49cdd8-454e-4622-8846-b76e957e413b">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iadfb31e704964e379fa031ac9764d117_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtNi0xLTEtMA_f2038a8b-9a16-40f9-a2e7-8ce386ce240e">239</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ide9db44961644d99bc4a1be0ceaf3427_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtMTAtMS0xLTA_111a7671-fd11-42e1-afea-d29b99427ee2">501</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i105edd316071419483c29294542bf610_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtMTItMS0xLTA_70a35d71-12f5-49dc-9ba7-1395d08cf943">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icc91087bf2c84f9db4657e286128b4ce_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDEtMTQtMS0xLTA_ba565120-308b-4c26-be47-19e73cf38be9">501</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i71eb1561917b4fc8b8dd253cd6535303_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtMi0xLTEtMA_f1fcdebb-4eb4-4d41-8a48-64f766981d59">494</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia19135b26e5944d48147d848103fa4ab_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtNC0xLTEtMA_31bafd5a-fd8f-414e-9bbb-7eb936aced89">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9a8cd9da07dd4e199ef24979ea8fe61c_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtNi0xLTEtMA_9aad64e5-b0f3-4354-b882-29f55410f5f9">494</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if72626af54aa43d29c3a57a81672472f_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtMTAtMS0xLTA_dd5c0e74-7816-486d-a134-1468d5d1a5d3">599</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i361062f6aa914630bda2a1decde3d5fd_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtMTItMS0xLTA_b44809d4-2e63-4d48-b098-3deb9ac770d6">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9154af5cf4f54064a345265618b24fb4_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDUtMTQtMS0xLTA_b65c4d69-f5ba-423a-ac56-4f66eddcd0f9">599</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie3cb663f517041b2b748758fddfc3042_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtMi0xLTEtMA_5ccfe6af-a813-4c31-9622-075f6f1261ec">494</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id2b7c33ade3f427b87cdc02e591b5d89_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtNC0xLTEtMA_283d2fda-a288-4306-a12d-07b7a222527d">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8d38e2b9e8994ef9852e5d9449770d9c_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtNi0xLTEtMA_10d0091d-1f1c-48cb-b4d2-b36fc5d7d2ea">494</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id184353eda00420aa146f68eca8520d9_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtMTAtMS0xLTA_98d25155-d83d-453b-8155-3ff66905df94">599</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6329d29a2efa4bf6be2047d1f4b55270_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtMTItMS0xLTA_1e70e188-0d2e-4618-b05a-6453011fedec">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ife6665bcfdc84fd9847decd31aab5d74_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDYtMTQtMS0xLTA_dbe0e900-097f-4935-bba3-c0eea74207bd">599</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic844430bda8d4a429c4c1873dec0c67b_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctMi0xLTEtMA_be677e6b-1557-4558-ae5f-80b2b7f0d6eb">732</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1774875f27f34e3c942fbcdb9216c45c_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctNC0xLTEtMA_cbb3c4ee-f272-4f62-91dc-b65c2dd4c29b">—</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3f9e05206d5d44bcb2b4c816762b2196_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctNi0xLTEtMA_6b00fbc9-e589-4296-8238-ede807ea589f">732</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if0901fcaa75c4458bc09ff2e135283ae_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctMTAtMS0xLTA_e67dafe0-8ed2-4c38-8f1a-c24ab18571ad">1,100</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iad6218d250ab4b7588c930240dbe77bb_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctMTItMS0xLTA_6f66ba72-16f7-4314-a19b-d38a7774632b">—</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7e356b3ffe4f46d786b299299e8c73c4_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmYxYjk3YTFhOThlODRjYjc4OWQyODNmM2Q4MjZhODViL3RhYmxlcmFuZ2U6ZjFiOTdhMWE5OGU4NGNiNzg5ZDI4M2YzZDgyNmE4NWJfNDctMTQtMS0xLTA_af8bb059-432e-4fd0-9a9d-992c2f266c09">1,100</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTg_3776dbfb-2b5c-40a5-a560-56379abc2a78" footnoterole="http://www.xbrl.org/2003/role/footnote">Long-term equity securities of $<ix:nonfraction unitref="usd" contextref="ic844430bda8d4a429c4c1873dec0c67b_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:EquitySecuritiesFVNIRestrictedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMjc0ODc3OTA3MjM1Mg_eab63920-0c1f-486b-b954-e10cc4438fa9">168</ix:nonfraction> million as of April&nbsp;4, 2021 and $<ix:nonfraction unitref="usd" contextref="if0901fcaa75c4458bc09ff2e135283ae_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:EquitySecuritiesFVNIRestrictedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMjc0ODc3OTA3MjQwMg_2ab03d8c-ad25-4300-9626-b759a59bf2d1">190</ix:nonfraction> million as of December 31, 2020 were held in restricted trusts for employee benefit plans.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMTU5NDI5MTg2MTA2NTc_c4635b74-95b3-4fcd-b208-1b5b015d752a" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></ix:footnote></div></ix:nonnumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="ia9769bc32afc46fe8ddf31ea4e49e8cb" continuedat="i32fe2ceb6ae54d47ae9dcca803b29f00"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:3pt"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RleHRyZWdpb246NThkM2EwZjAzZjJjNGRhMTg0Y2Y2N2FjN2QyMWE2YTBfMjUwNQ_a3f573d3-55b2-4829-9f68-0430eed83639" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying values and estimated fair values using a market approach:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value at Level 2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value at Level 2</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, excluding the current portion</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib94b4929257f4fa59c82eaf1fff65f72_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmUxMzM1ZDg5ODRmZDQ2OTdiMjM4NTRkODc3OTllY2Y0L3RhYmxlcmFuZ2U6ZTEzMzVkODk4NGZkNDY5N2IyMzg1NGQ4Nzc5OWVjZjRfNS0yLTEtMS0w_0fc8b902-1c63-485b-9fcc-9897ce477bd8">35,347</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib7b674e4d7af40b19cd6ebf04d26614b_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmUxMzM1ZDg5ODRmZDQ2OTdiMjM4NTRkODc3OTllY2Y0L3RhYmxlcmFuZ2U6ZTEzMzVkODk4NGZkNDY5N2IyMzg1NGQ4Nzc5OWVjZjRfNS02LTEtMS0w_82c8bc47-e8db-4715-a6f0-12111a0bd6da">40,504</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic3dd217f408a4c11b63dad378ca98d22_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmUxMzM1ZDg5ODRmZDQ2OTdiMjM4NTRkODc3OTllY2Y0L3RhYmxlcmFuZ2U6ZTEzMzVkODk4NGZkNDY5N2IyMzg1NGQ4Nzc5OWVjZjRfNS0xMC0xLTEtMA_5abd8e26-f222-4149-a203-042f3c60ecd3">37,133</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id54070b71d25429da086e63afcf1c41c_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83MC9mcmFnOjU4ZDNhMGYwM2YyYzRkYTE4NGNmNjdhYzdkMjFhNmEwL3RhYmxlOmUxMzM1ZDg5ODRmZDQ2OTdiMjM4NTRkODc3OTllY2Y0L3RhYmxlcmFuZ2U6ZTEzMzVkODk4NGZkNDY5N2IyMzg1NGQ4Nzc5OWVjZjRfNS0xNC0xLTEtMA_a1d2d60f-0400-4dbd-9290-5ab7ef54a14c">45,533</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:nonnumeric></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of April&nbsp;4, 2021 and December 31, 2020. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.</span></div></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_73"></div><ix:continuation id="i32fe2ceb6ae54d47ae9dcca803b29f00" continuedat="i8b5aa3f235884378a2d9df5387d169d6"><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Investments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Total Short-Term, Long-Term and Equity-Method Investments</span></div><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzE_15442d9d-9eeb-4150-93a3-c532d4d33be9" escape="true"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:62.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes our investments by classification type:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMy0yLTEtMS00NTAx_4a2a2626-8355-4956-9981-edce371d4937">1,427</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMy00LTEtMS00NTAx_2d60da68-8c35-4a08-95c2-af1ef06eb8e3">567</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNC0yLTEtMS00NTAx_00e8a2bc-954d-43e2-905b-754ad656db1e">8,292</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNC00LTEtMS00NTAx_8cd28a90-b102-464c-8d4c-f7fd1c15a6ce">9,709</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNS0yLTEtMS00NTAx_b26ef72c-2631-43be-ae05-da9f8c3ccc4e">2,180</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNS00LTEtMS00NTAx_73f95e2a-36de-4b24-888f-303fefed9a5e">161</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNi0yLTEtMS00NTAx_5d5f4a34-3d71-4066-8387-3aac9965227e">11,899</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfNi00LTEtMS00NTAx_8688b140-ba2c-4c5b-86a6-6cfd4cb5d1b1">10,437</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfOS0yLTEtMS00NTAx_9ec2c979-8c6e-489d-a9bd-b3a5250c54b6">3,123</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:EquitySecuritiesFVNINoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfOS00LTEtMS00NTAx_361315d0-52c2-435c-a5b0-c287dc5a19c9">2,809</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTEtMi0xLTEtNDUwMQ_67541eb0-c530-4cc3-8715-133343085dc8">75</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTEtNC0xLTEtNDUwMQ_459338be-6398-4ce8-8bbb-2062b6f596a5">128</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTItMi0xLTEtNDUwMQ_8f689449-587a-466f-b267-94c31b861f01">31</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTItNC0xLTEtNDUwMQ_d7652dc1-28b3-4cd4-834a-40d7f9840880">37</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private equity securities at cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="pfe:PrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTMtMi0xLTEtNDUwMQ_1f16e604-1d62-48bf-bdf2-f40da0b006c7">467</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="pfe:PrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTMtNC0xLTEtNDUwMQ_2513f11e-bbde-410e-bbf2-d01420013143">432</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Total Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTQtMi0xLTEtNDUwMQ_3ea33e1f-4f93-40f3-9a15-5982a2668c13">3,696</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTQtNC0xLTEtNDUwMQ_146265da-bdd3-4973-8182-f4f47692966c">3,406</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTUtMi0xLTEtNDUwMQ_5c92dc31-9fff-4341-9299-461153d89a0a">16,532</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTUtNC0xLTEtNDUwMQ_c8ca2aa1-944d-425e-8079-a9cc750d2d8c">16,856</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term investments and equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTYtMi0xLTEtNDUwMQ_c6968b7f-dbba-4ed0-883a-6d94354a7d10">20,228</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTYtNC0xLTEtNDUwMQ_362fb2ec-2587-4867-8014-69a15ee1ef37">20,262</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Held-to-maturity cash equivalents</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="pfe:HeldToMaturityCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTctMi0xLTEtNDUwMQ_ed8fdc5c-96c2-41e6-be85-3490add9040c">60</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="pfe:HeldToMaturityCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjZiMDg0ZDA1NmZkNTQ5YjE4NzhlNGUxOTJlODM4MTY5L3RhYmxlcmFuZ2U6NmIwODRkMDU2ZmQ1NDliMTg3OGU0ZTE5MmU4MzgxNjlfMTctNC0xLTEtNDUwMQ_66ab2d23-7257-4339-b086-6d6a0620f252">89</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzI_e7a4de72-f456-497e-ac8d-09a777cf7c04" footnoterole="http://www.xbrl.org/2003/role/footnote">As of April&nbsp;4, 2021 and December 31, 2020, includes money market funds primarily invested in U.S. Treasury and government debt.</ix:footnote> </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfMTU5NDI5MTg2MDUwNzM_9083eca6-91cb-44b3-a612-f84549b6adef" footnoterole="http://www.xbrl.org/2003/role/footnote">Represent investments in the life sciences sector</ix:footnote>.</span></div></ix:nonnumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Debt Securities</span></div><div style="margin-bottom:8pt;margin-top:3pt"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjY1_b8eed8d4-98a0-4ecf-a320-14a08823bf35" escape="true"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:HeldToMaturitySecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjY3_84bc4319-9f30-4871-8144-5a8a6b829ae5" escape="true"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjky_39001d03-a4b4-4b71-abb1-688dd6e01550" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="72" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">At April 4, 2021, our debt investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="42" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 1<br>to 5</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0yLTEtMS0w_a3998398-a7c2-4eda-bba2-a4b111d6ac9c">6,209</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS00LTEtMS0w_6bbeda6a-d77c-41c5-bebe-ff7e0ceba734">23</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS02LTEtMS0w_6e83696e-2c05-4c01-ba03-c3471fd7f715">54</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS04LTEtMS0w_f9dc7afa-ad04-4684-a6ba-b5dafca39c59">6,178</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0xMC0xLTEtMA_26d03eb4-99f7-4ff0-bfac-26d6ba6b0d9d">6,169</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0xMi0xLTEtMA_2a0ac447-afc8-421a-9f10-9b78eec7a615">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:zerodash" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0xNC0xLTEtMA_46bb6121-3571-40c3-983a-3ba985d7d6ee">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i311aff5e47cb4f0aaa689dd672a89de7_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0xOC0xLTEtMA_f7463dc5-e815-49a5-91d6-7d9195c18037">7,593</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i311aff5e47cb4f0aaa689dd672a89de7_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0yMC0xLTEtMA_6305f883-63bb-4b93-b18b-0913ee945900">136</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i311aff5e47cb4f0aaa689dd672a89de7_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0yMi0xLTEtMA_1acf2f15-7d6e-49d3-ba21-25b7aca0be1f">4</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i311aff5e47cb4f0aaa689dd672a89de7_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNS0yNC0xLTEtMA_867bb904-2835-43d7-b840-0f4b0aedbff8">7,725</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency––U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea7507c4602c4b85b91614510bb349ea_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0yLTEtMS0w_cd68fe98-061d-4133-8506-dece5731acb6">1,288</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea7507c4602c4b85b91614510bb349ea_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi00LTEtMS0w_69eeee87-a0e4-444b-8876-9a3bcb992064">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iea7507c4602c4b85b91614510bb349ea_I20210404" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi02LTEtMS0w_3cdaf98a-d2ca-4f97-b7cf-93eb6cc60cf0">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea7507c4602c4b85b91614510bb349ea_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi04LTEtMS0w_dfab7f29-227a-4f7e-9ece-beafd1aae312">1,287</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea7507c4602c4b85b91614510bb349ea_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0xMC0xLTEtMA_eeb607c8-b603-47ce-a32f-6805b870d20f">1,221</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea7507c4602c4b85b91614510bb349ea_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0xMi0xLTEtMA_38477d12-f8c0-48aa-b256-f9362c61be51">66</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea7507c4602c4b85b91614510bb349ea_I20210404" decimals="-6" format="ixt:zerodash" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0xNC0xLTEtMA_acd60349-5779-43c3-b960-3056af64c58e">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3118a605697e4b6299c3e3e70f504737_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0xOC0xLTEtMA_3315eef7-ab12-47b5-bd40-4dc31a5a0589">1,104</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3118a605697e4b6299c3e3e70f504737_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0yMC0xLTEtMA_99e8c318-6d60-4128-a739-b2f4c5122eb7">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3118a605697e4b6299c3e3e70f504737_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0yMi0xLTEtMA_2ef93a16-23f8-409b-87d5-35dbcb398123">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3118a605697e4b6299c3e3e70f504737_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNi0yNC0xLTEtMA_10bbb966-76ef-4f89-8fcc-b24c800947d7">1,103</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6816514d37f949999a1c366c3691d629_I20210404" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0yLTEtMS0w_d781df9d-a0f4-492d-bea8-dd5576e1a397">900</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6816514d37f949999a1c366c3691d629_I20210404" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy00LTEtMS0w_e32b5e1d-95fa-451a-be8b-04640c74eae0">3</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6816514d37f949999a1c366c3691d629_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy02LTEtMS0w_9dc69f6e-5f96-40dc-b047-4a2d899dd543">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6816514d37f949999a1c366c3691d629_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy04LTEtMS0w_57cefaf3-cfb1-4e8b-9cbb-3607567bf323">903</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6816514d37f949999a1c366c3691d629_I20210404" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0xMC0xLTEtMA_842cd1af-b0d8-49da-bc75-f1567abca27a">902</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6816514d37f949999a1c366c3691d629_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0xMi0xLTEtMA_29814f0e-bc7e-4100-bad3-1714e261b4a0">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6816514d37f949999a1c366c3691d629_I20210404" decimals="-6" format="ixt:zerodash" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0xNC0xLTEtMA_1b5679be-f28f-421b-8cd7-4c0d796062c8">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i22e189428ea0418bafaae25d5406511e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0xOC0xLTEtMA_8319d658-af6e-4107-9a2b-97469a2e0e23">1,006</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i22e189428ea0418bafaae25d5406511e_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0yMC0xLTEtMA_981a195b-99eb-4375-84ac-946bb1f7f744">2</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i22e189428ea0418bafaae25d5406511e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0yMi0xLTEtMA_81714873-dfd0-4416-8789-c809f10bb3b6">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i22e189428ea0418bafaae25d5406511e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfNy0yNC0xLTEtMA_b1f9e746-2cd7-4443-ae8b-4e5de58aaa2e">1,008</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0yLTEtMS0w_07bbd241-db3f-4a76-b736-99f2072855e5">423</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS00LTEtMS0w_b7846d78-10ec-4f7c-90cf-c886a14027ca">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS02LTEtMS0w_a7992b20-5a4f-4174-97f5-628b30dc042b">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS04LTEtMS0w_78835436-7ff8-495b-b41f-abf30d90a7a3">423</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0xMC0xLTEtMA_22980516-f8eb-457a-9de6-8cc2f78bdec8">397</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0xMi0xLTEtMA_6692adbd-eb15-4881-a102-93a4de78a7ac">16</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie01249c5a9e245db87f723cd3bc7ce0c_I20210404" decimals="-6" name="pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0xNC0xLTEtMA_64da2a00-bd0e-49e7-a2ca-9bc072ca1e1f">10</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea6892b733bc4dcf856bf74153b9127f_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0xOC0xLTEtMA_47315d7a-2b13-404f-9ffd-5f8a7518b943">283</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea6892b733bc4dcf856bf74153b9127f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0yMC0xLTEtMA_694901df-c7ec-440a-a097-f71dfeaf6ebf">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea6892b733bc4dcf856bf74153b9127f_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0yMi0xLTEtMA_25e4299c-38ee-4e88-aa6b-71916287f8a2">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea6892b733bc4dcf856bf74153b9127f_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfOS0yNC0xLTEtMA_12143adf-04af-40c4-a3c0-87f8235ed8bc">283</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMi0xLTEtMA_0523175b-ee1d-46d7-811d-5f135f4d589d">1,847</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtNC0xLTEtMA_6af4f2b7-0a49-4fc0-9068-36b5478505d1">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtNi0xLTEtMA_4693f36a-e15e-4431-89cd-8bf768a6e3f2">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtOC0xLTEtMA_62e4d649-4206-4b52-bd13-bfa6637effb0">1,847</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMTAtMS0xLTA_40030f7e-df23-487c-a49e-28ad16b8b90b">1,842</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMTItMS0xLTA_b9fa7a41-59b6-4511-96c3-1b5215401bbe">4</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibcf94ef1797d492b92164bec12798fd6_I20210404" decimals="-6" name="pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMTQtMS0xLTA_5d809b8a-31cb-432a-b8c6-3e0fc17388da">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i311aff5e47cb4f0aaa689dd672a89de7_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMTgtMS0xLTA_3ef76328-6b43-4a30-9082-f8c75e27488a">5</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i311aff5e47cb4f0aaa689dd672a89de7_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMjAtMS0xLTA_ebb48102-cfe5-4d68-a70d-852d743ed8af">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i311aff5e47cb4f0aaa689dd672a89de7_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMjItMS0xLTA_69502d65-af09-4fcd-a2d3-014eada26b1d">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i311aff5e47cb4f0aaa689dd672a89de7_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTAtMjQtMS0xLTA_af444c52-e807-41ae-a980-f256bb800d5f">5</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:DebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMi0xLTEtMA_2faf7650-002d-4131-8034-d67a61917359">10,667</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtNC0xLTEtMA_fc634e99-2a61-41e2-9b77-9cf00174d592">25</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtNi0xLTEtMA_ffc30947-e969-4c8b-a5e9-9d4ca68add49">55</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtOC0xLTEtMA_5d541135-bd56-4c0c-bbb4-4f86bc9fdf8c">10,637</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMTAtMS0xLTA_93ccaafd-26c3-4d9e-a492-d2f0b7ae6d17">10,531</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMTItMS0xLTA_3fda55ac-4a62-48f1-8a1a-81063c6fe543">94</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMTQtMS0xLTA_8923ff43-4923-45cd-be72-6901c801e610">11</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:DebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMTgtMS0xLTA_ffd865e9-c609-4b22-97c0-f77c11a56627">9,991</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMjAtMS0xLTA_b3cc89a9-6569-4657-9d0e-13e558185759">138</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMjItMS0xLTA_08cb45b6-7f51-48a2-b469-86e85d181e0b">5</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOjE5YzA4MGYzMTM0NTQ4M2M5ZDk4ODljNTk3MDU2N2U1L3RhYmxlcmFuZ2U6MTljMDgwZjMxMzQ1NDgzYzlkOTg4OWM1OTcwNTY3ZTVfMTEtMjQtMS0xLTA_de5d4ba9-2770-4d85-843c-7ba91c4fee4f">10,124</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:nonnumeric></ix:nonnumeric></ix:nonnumeric></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any expected credit losses to these portfolios would be immaterial to our financial statements. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i8b5aa3f235884378a2d9df5387d169d6" continuedat="i99a8dbddbb254d9c992631c8a88fad0c"><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Securities</span></div><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjc3_fbaabee9-676b-4c51-83ac-148affb14314" escape="true"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfMy02LTEtMS0w_e7e2ad47-c133-45b8-a556-46be93776729">401</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfMy04LTEtMS0w_38fd5062-c049-4a65-9052-2bbeccff8a34">255</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNC02LTEtMS0w_e85d31b4-7e34-4f7d-8ab3-f6eaaffff246">28</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNC04LTEtMS0w_4e4c035e-a8b9-4f2a-9c76-72cba39d4df9">19</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNS02LTEtMS0w_167caf3c-7fb9-42ea-bbf0-c76e30e98334">372</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RhYmxlOmMxZWUwNTczN2JlMDQ2NTliZDYzYjdlMmViMDcxMTdiL3RhYmxlcmFuZ2U6YzFlZTA1NzM3YmUwNDY1OWJkNjNiN2UyZWIwNzExN2JfNS04LTEtMS0w_e4c6a8de-b038-45e5-bf8b-537ffea130a8">274</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjk0_deb9e89d-cde1-4276-a4ef-dee2a77d9fbf" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNjkw_1235bd27-2240-4dc2-8cbf-13a138176241" footnoterole="http://www.xbrl.org/2003/role/footnote">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNTM0_0d4bbf9f-5b32-49d9-bb4d-4669d501516e">87</ix:nonfraction> million and upward adjustments of $<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83My9mcmFnOmE0YjU5OWE4ZGE5OTQ3ZTdiZjE5ODgyMGVhOGUwNDYzL3RleHRyZWdpb246YTRiNTk5YThkYTk5NDdlN2JmMTk4ODIwZWE4ZTA0NjNfNTYz_89b19814-08e4-4b5d-8e72-15ab252b4446">61</ix:nonfraction> million. Impairments, downward and upward adjustments were not significant in the first quarters of 2021 and 2020.</ix:footnote></span></div></ix:nonnumeric></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_76"></div><ix:continuation id="i99a8dbddbb254d9c992631c8a88fad0c" continuedat="iee6c6446a01143c7937854f8171c0bed"><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Short-Term Borrowings</span></div><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfShortTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RleHRyZWdpb246NGU0NTgxZjI0ZDc5NGE1ZGExODk4M2ViZGNlZjAyN2JfMTE0_2e959cd4-7572-43ce-a292-c4e0d5e72883" escape="true"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term borrowings include:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfMi0yLTEtMS0w_33657463-feab-4e9c-9752-b9c2821c3791">416</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfMi00LTEtMS0w_61ac9564-751f-4e2e-9782-64e1817f61f4">556</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfMy0yLTEtMS0w_2987c532-4e30-4a8e-89f5-615455f56a88">3,679</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfMy00LTEtMS0w_aecda62c-763e-4896-9ae4-7346eccd4a09">2,004</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other short-term borrowings, principal amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:OtherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNC0yLTEtMS0w_70fd4264-8d05-4bcd-8721-897615f28e4d">260</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:OtherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNC00LTEtMS0w_65d63aa1-b0f0-4b0c-9656-164f5fb48c9a">145</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term borrowings, principal amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:ShorttermDebtGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNS0yLTEtMS0w_cee0442c-b1d5-4c26-9de7-ab31e1b9a44b">4,355</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:ShorttermDebtGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNS00LTEtMS0w_10467dc7-0814-4205-8366-d8380d31b429">2,705</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:zerodash" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNi0yLTEtMS0w_5c714e3e-bbe1-4700-8c94-380bb5f111d5">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:zerodash" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNi00LTEtMS0w_4d88a5d4-2002-47db-b7a7-c945cfb04edf">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNy0yLTEtMS0w_5f37b799-925c-46b6-9cbd-0ddd5a2c992c">3</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfNy00LTEtMS0w_bce079da-fccd-48f2-8ecd-7bbce2d61982">2</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, carried at historical proceeds, as adjusted</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfOC0yLTEtMS0w_72d93fda-5e7d-4a9e-ab3d-27e50241651a">4,352</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RhYmxlOjczODY5Yzc0MmUxNjQ3M2Q4ZWNiNjE4ZTU5ZGE0MWIxL3RhYmxlcmFuZ2U6NzM4NjljNzQyZTE2NDczZDhlY2I2MThlNTlkYTQxYjFfOC00LTEtMS0w_34c6a606-76ad-4f8f-a649-1c75df868591">2,703</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83Ni9mcmFnOjRlNDU4MWYyNGQ3OTRhNWRhMTg5ODNlYmRjZWYwMjdiL3RleHRyZWdpb246NGU0NTgxZjI0ZDc5NGE1ZGExODk4M2ViZGNlZjAyN2JfMTE1_089a3599-215a-4b28-a7dc-964822000c8e" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Includes cash collateral. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7F</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:footnote></div></ix:nonnumeric></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_79"></div><ix:continuation id="iee6c6446a01143c7937854f8171c0bed" continuedat="i7a6cde35a74a4f2289b13fd6c2546276"><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Long-Term Debt</span></div><div style="margin-top:3pt"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RleHRyZWdpb246YTJiNTIxYWM4ZDIwNDRjNWI0MTcyYjBkY2M4MDg3MjNfMjY5OQ_ef125897-ae55-4ce5-9b1c-1fe095cb4fbf" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibd7df84abf8144f9838662606d730b41_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfMi0yLTEtMS0w_7ae6da20-02a6-4aa6-be34-6a266ff518fa">34,032</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i59506893ef984409b375dbf340e24a0f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfMi00LTEtMS0w_123082d4-f070-4e47-8476-67495d947c49">35,774</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibd7df84abf8144f9838662606d730b41_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfMy0yLTEtMS0w_b1a01d0f-4bec-4784-a867-3211eb25f89d">1,512</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i59506893ef984409b375dbf340e24a0f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfMy00LTEtMS0w_1d5f8428-95f5-41ac-8282-0e23ea473d69">1,562</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ibd7df84abf8144f9838662606d730b41_I20210404" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNC0yLTEtMS0w_d7a3d27a-4774-4d96-b381-b557c28a2376">200</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i59506893ef984409b375dbf340e24a0f_I20201231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNC00LTEtMS0w_d58506eb-d78b-41ae-9dd0-4eb75115a2b0">207</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibd7df84abf8144f9838662606d730b41_I20210404" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNS0yLTEtMS0w_943aa348-2aff-4bb7-87bf-bc8b6333802a">4</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i59506893ef984409b375dbf340e24a0f_I20201231" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNS00LTEtMS0w_64512150-c4f6-4a12-88f6-2b55681cf12d">4</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt, carried at historical proceeds, as adjusted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibd7df84abf8144f9838662606d730b41_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNi0yLTEtMS0w_79f9ca2e-83e2-4623-86c3-1e5bdf895193">35,347</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i59506893ef984409b375dbf340e24a0f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNi00LTEtMS0w_aa736eec-6a59-454e-b1f8-be5ca74d6d11">37,133</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibd7df84abf8144f9838662606d730b41_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNy0yLTEtMS0w_2f0637f7-0995-4145-82fe-d4562b1c7875">3,676</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i59506893ef984409b375dbf340e24a0f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF83OS9mcmFnOmEyYjUyMWFjOGQyMDQ0YzViNDE3MmIwZGNjODA4NzIzL3RhYmxlOjY3NzFiNzEzOWNjOTQwMjg4NjJiMDJkZjRkYTZhMTY2L3RhYmxlcmFuZ2U6Njc3MWI3MTM5Y2M5NDAyODg2MmIwMmRmNGRhNmExNjZfNy00LTEtMS0w_84c71c8f-ee4b-4f08-b614-53956d38e8b2">2,002</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:nonnumeric></div></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_85"></div><ix:continuation id="i7a6cde35a74a4f2289b13fd6c2546276" continuedat="iea3da355ddad499bb0743c90458d2c64"><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Derivative Financial Instruments and Hedging Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Exchange Risk</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen, Swedish krona, Canadian dollar and Chinese renminbi. Additionally, we hedge a portion of our forecasted intercompany inventory sales denominated in euro, Japanese yen, Chinese renminbi, Canadian dollar, U.K. pound and Australian dollar for up to <ix:nonnumeric contextref="i436945b9fb544d1485596c97366973bf_D20210101-20210404" format="ixt-sec:durwordsen" name="us-gaap:DerivativeTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjc0ODc3OTA3NDg1Ng_2be46d00-b5e6-419b-b38c-59d7da129be2">two years</ix:nonnumeric>.</span></div></ix:continuation><div><span><br></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="iea3da355ddad499bb0743c90458d2c64" continuedat="icc14df8fac83414fa39b13be4a48e62f"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.</span></div><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE0MQ_1c965ef1-4037-4b1c-a709-2106ed1a2aa2" escape="true"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE0Nw_0e008520-46e6-4e1a-b7a7-1f83810219d0" escape="true"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE5MA_78a3ddf3-a5c0-4bb8-bfdb-d38b7dc4edc9" escape="true"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:41.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.702%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations): </span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9a0b2bb17c2c45038528dc9568158637_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0yLTEtMS0w_d232c6a6-3b16-4ec1-a860-01e1b4ee054c">22,799</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9a0b2bb17c2c45038528dc9568158637_I20210404" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS00LTEtMS0w_2c12f3da-492c-47ab-aaee-2f2eb1eb7d5c">408</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9a0b2bb17c2c45038528dc9568158637_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS02LTEtMS0w_186cd312-d3b9-4f67-b356-1c4cd9282822">654</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic74e1896b3c246a98ee4bce0ead976d8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS04LTEtMS0w_e020c56e-ee43-489f-b3d8-fdb02cc496e8">24,369</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic74e1896b3c246a98ee4bce0ead976d8_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0xMC0xLTEtMA_947843d1-fed8-4f67-81e3-3b3bcecc23b4">145</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic74e1896b3c246a98ee4bce0ead976d8_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNS0xMi0xLTEtMA_23abe29d-8a0a-41fa-a8c8-55878aaeff9e">1,005</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if854a67683b84997921e0c8d08721493_I20210404" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi0yLTEtMS0w_3a958cba-4715-48e1-8bb7-118dd66db395">450</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if854a67683b84997921e0c8d08721493_I20210404" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi00LTEtMS0w_1761eb60-97cf-4e7f-8d8d-481e46a55a77">26</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if854a67683b84997921e0c8d08721493_I20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi02LTEtMS0w_9f3fc9a6-1fa2-46c5-9642-7c3d1dc517e3">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8d11d6f169eb4129873cfe8da015081e_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi04LTEtMS0w_614ca566-8364-4220-96d7-5960680b1d3f">1,950</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8d11d6f169eb4129873cfe8da015081e_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi0xMC0xLTEtMA_db9464c2-fb50-483b-8021-e3b88a258c0a">135</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8d11d6f169eb4129873cfe8da015081e_I20201231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNi0xMi0xLTEtMA_b5e88ff0-b256-4656-8387-d6ee84a20841">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5584c105e0a1417da14d21d850e54027_I20210404" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNy00LTEtMS0w_c588893a-0845-4e72-9819-a2e904364b09">435</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5584c105e0a1417da14d21d850e54027_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNy02LTEtMS0w_f199ce52-5ac3-44a8-974c-f9a0bb93c456">654</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i53d153096cf74722befa5ea904fa6b4f_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNy0xMC0xLTEtMA_f9c16a73-bec2-4cd4-9f61-295c27518fc7">280</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i53d153096cf74722befa5ea904fa6b4f_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfNy0xMi0xLTEtMA_d948488b-07c5-4ceb-971a-556c1ebcb51b">1,005</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iadd4196e1e1c4fc3aad00b7ec39c703e_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtMi0xLTEtMA_8e74d3fb-6a23-4430-aa81-982b1650df63">14,726</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iadd4196e1e1c4fc3aad00b7ec39c703e_I20210404" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtNC0xLTEtMA_45a603dd-2b5d-49dd-8f8d-280f75196dbd">86</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iadd4196e1e1c4fc3aad00b7ec39c703e_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtNi0xLTEtMA_35d7698a-ca6b-4088-af1b-b9ef133a3cd1">78</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a2e45a40ac242e5b77f0ae9900f205a_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtOC0xLTEtMA_bb0052e3-9ef7-47c7-9893-83a429516f00">15,063</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a2e45a40ac242e5b77f0ae9900f205a_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtMTAtMS0xLTA_0efdf456-38a8-4ff8-ae56-e0fc881d0434">94</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a2e45a40ac242e5b77f0ae9900f205a_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTAtMTItMS0xLTA_c67f3af8-1e1b-4b8a-91ee-179cc84bfdd1">95</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTItNC0xLTEtMA_588bf4de-9f3b-4fd6-bac3-b554a2f9a1cb">521</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTItNi0xLTEtMA_afdae661-fa74-47b4-918e-6720f8f866c9">732</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTItMTAtMS0xLTA_56603fdf-c2cb-4086-b264-66f70613f317">373</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjFkZThkMzMwNTU5ZDQzNDBiNzQ3NDZjNmViY2Y2M2FhL3RhYmxlcmFuZ2U6MWRlOGQzMzA1NTlkNDM0MGI3NDc0NmM2ZWJjZjYzYWFfMTItMTItMS0xLTA_3aa28942-fc2f-4020-8f84-4d3807740f23">1,100</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE2OA_085d6a3b-59ff-473e-b130-ad263afa1566" footnoterole="http://www.xbrl.org/2003/role/footnote">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $<ix:nonfraction unitref="usd" contextref="ie3d739b69c924476ab9fc489134e052f_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMTg4Ng_4ddeddb8-bb77-476c-8b54-0dd72dfd3595">5.1</ix:nonfraction> billion as of April&nbsp;4, 2021 and $<ix:nonfraction unitref="usd" contextref="ibb10ca24fc0e45e6bae4be5820f1dff1_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMTkwMg_d46cc6c0-4889-4b8b-af58-62cfb49be0b1">5.0</ix:nonfraction> billion as of December 31, 2020.</ix:footnote></span></div></ix:nonnumeric></ix:nonnumeric></ix:nonnumeric><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE0NA_259b0f86-551d-4f94-aca0-5a7d19cf623f" continuedat="i79a3908baa7e4b95b52c7f492342ff58" escape="true"><div style="margin-bottom:5pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br>Recognized in OID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br>Recognized in OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Gains/(Losses)<br>Reclassified from<br>OCI into OID and COS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i64de3286a8b8400bbce978e6cea1d671_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtNi0xLTEtMA_215c3409-48e4-4aaf-862d-331a2f993785">202</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ifef8b9d4d3e046d592fc82570ee103a1_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtOC0xLTEtMA_67e0eaa3-0f83-4584-9c85-27460c2e4dd5">529</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9f0f92f69aad4b42ad7f9609f172e6b5_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTAtMS0xLTA_089f335b-7bad-440a-905c-b0efc085953d">268</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabbfa3f9ccef409da83eabaca9738f24_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjgtMTItMS0xLTA_da6ee283-167b-482c-83fc-8282e2bee05f">46</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0bca21fbf2904883a085a3674cef4c6e_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktNi0xLTEtMA_c2dc19a4-4603-4290-9c8d-f29b695d43bf">12</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib89068696ad04d0c87ddb69c02123499_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktOC0xLTEtMA_433cc087-adc0-4244-ba52-ad1cca1cdc52">29</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0aca22e7341d474d8732744e945f51a2_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTAtMS0xLTA_38abe664-19a3-4ce7-8d2f-e01fe447a203">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3529ff523d8547968d5d7fa49c71f62d_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMjktMTItMS0xLTA_e487941c-a6d5-4f26-99eb-b30b8920dac7">27</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icb17d3fe588e4ef1b03208dc7427d2a7_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzItMi0xLTEtMA_877bace4-21a4-465d-90f5-7e1ef5aa709b">26</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5234a8c9b04f4d00b6a9ef7a66016121_D20200101-20200329" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzItNC0xLTEtMA_a58335bb-8cb0-4224-aff5-28d29f627fcc">386</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Hedged item</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icb17d3fe588e4ef1b03208dc7427d2a7_D20210101-20210404" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzMtMi0xLTEtMA_c390d922-f827-46b8-aecd-65c7f50b5ba3">26</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5234a8c9b04f4d00b6a9ef7a66016121_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzMtNC0xLTEtMA_e7c5b3ff-0c18-4db9-8c2c-7bcc281ce056">386</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i64de3286a8b8400bbce978e6cea1d671_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtNi0xLTEtMA_c45eb24c-d84e-49cf-9aa6-3f9c2d089b0e">154</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifef8b9d4d3e046d592fc82570ee103a1_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtOC0xLTEtMA_75fc5998-c585-4576-a997-b3d439bfe28a">384</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9f0f92f69aad4b42ad7f9609f172e6b5_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtMTAtMS0xLTA_57561963-0984-43cd-80e0-17add1612789">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabbfa3f9ccef409da83eabaca9738f24_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzgtMTItMS0xLTA_7e94e1af-67a9-4487-b6db-c5d39bb9920e">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The portion of foreign exchange contracts excluded from the assessment of hedge effectiveness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i047b2efe1e6d4b28a79abcf7dd2cacf6_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktNi0xLTEtMA_8531ba32-f2c0-4a2f-958f-f80ac1c5a323">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iea6d2dbe36bd4602854331362bceb449_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktOC0xLTEtMA_f8e14eb2-ce57-4e32-8510-642d94d8687a">147</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieb313744a4ff4c738c28ac93f0ece8ed_D20210101-20210404" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTAtMS0xLTA_ac30a357-c6f3-418b-acc0-b699913a4bc9">29</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if0230812ef754324a78b78b19c2ad59b_D20200101-20200329" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfMzktMTItMS0xLTA_57ce0137-001d-49cf-80d4-ea8394b52c68">41</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaf10dace7da6444c8b3bd4e5b19c2f01_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItNi0xLTEtMA_8bbfed7a-80cb-4388-b221-a1ae0159afee">38</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i914bc944c4df47e3b143d5f7368a2ca4_D20200101-20200329" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItOC0xLTEtMA_9f93fdc3-050d-4af6-b9a3-b8614daa9ab2">8</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id93efcbc68c042ac81cb1c4bbab42032_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTAtMS0xLTA_79687469-7e5d-4eef-a237-2d10164f6ac9">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3891b89285f1406aad5672f9c4bdcd51_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDItMTItMS0xLTA_a9781e89-8df5-4f0b-8325-a3975386d974">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if1d52a16c5554d699a0a822678e6667d_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtNi0xLTEtMA_7f6ddc24-9260-41ff-8b52-d527b14d3cff">56</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i43f6bf204fcd4af486dbfea36e77b0ac_D20200101-20200329" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtOC0xLTEtMA_87a455b9-04f5-421e-b3f2-31e761170f52">45</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i737854cc340040fdb4542a4e543b0d3b_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTAtMS0xLTA_7d9a0f0e-536c-47c2-9819-1c2a1e633fb9">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i02e8db8e9e5a4913987fc32f5df85fe3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDMtMTItMS0xLTA_c7681184-980e-4796-b7c0-a4af93f32108">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i57a23120d69645968a1c386fbbdf419a_D20210101-20210404" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDYtMi0xLTEtMA_4a0d9f48-72c5-4602-ab57-af4d853f856d">42</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iaddd627ba50c44d083b799ad5cf8c833_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDYtNC0xLTEtMA_12853fe2-e6bf-4e59-a8f9-ae79d9de507a">59</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">All other net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctNi0xLTEtMA_4eadca26-50de-45fb-97f1-1e4622f02ea0">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctOC0xLTEtMA_34c02743-6ebb-40b3-a5c7-bbbbda92dd1f">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i57e439f229dd4b1ab3d42ad8f3b57f5a_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTAtMS0xLTA_e8afbd86-b183-4f2f-8414-aecc51c7e492">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idcaa753284e740be9e09512ba86381ee_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDctMTItMS0xLTA_57c168cc-d793-4fdc-ba87-ebb6f01a52c2">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8aceb51cc0bf45ed95b1955ecc6fb23c_D20210101-20210404" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMi0xLTEtMA_bc653640-2403-4b16-88c9-3786c7f3a7f5">42</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i98e974ef3b1d4e2daccb139c441bf188_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtNC0xLTEtMA_b36a048e-5c56-4227-a607-345212848dee">59</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtNi0xLTEtMA_62d54685-d8ad-4b88-b3a8-21d97cad82ab">460</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtOC0xLTEtMA_36a33900-7f9f-4c1b-a0a8-7fddf3eb8a31">83</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i57e439f229dd4b1ab3d42ad8f3b57f5a_D20210101-20210404" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMTAtMS0xLTA_c9dc934e-b1f1-4e5f-a211-cb7a955d6adc">230</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idcaa753284e740be9e09512ba86381ee_D20200101-20200329" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjI4OGZhNWE3MWE4NjRiMWE5Y2JhNmI4ZGUzM2Q3NjgxL3RhYmxlcmFuZ2U6Mjg4ZmE1YTcxYTg2NGIxYTljYmE2YjhkZTMzZDc2ODFfNDgtMTItMS0xLTA_c1c5b91c-c61a-4b66-912b-d1adf188e153">23</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3Mw_a18e18a9-ef71-4b10-8786-4134ebcb6c9f" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">OID = Other (income)/deductions—net, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions—net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income</span></ix:footnote><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div></ix:nonnumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="icc14df8fac83414fa39b13be4a48e62f" continuedat="i5dd47355cfd2448d9310d0e1df2634b9"><ix:continuation id="i79a3908baa7e4b95b52c7f492342ff58"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDEzMg_38933c3a-26f9-44e0-9c40-4a762bf4d149" continuedat="i175226f007db4092b6cb44061ed091af" footnoterole="http://www.xbrl.org/2003/role/footnote">The amounts reclassified from OCI into COS were:</ix:footnote></span></div><ix:continuation id="i175226f007db4092b6cb44061ed091af"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net loss of $<ix:nonfraction unitref="usd" contextref="i5f3171903a684fc3919479487e325172_D20210101-20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjYwMw_b0a8ecb0-2cfa-4532-b323-63e4b6ecec6b">45</ix:nonfraction> million in the first quarter of 2021; and</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net gain of $<ix:nonfraction unitref="usd" contextref="ia581dfcf0c7b4d1ab5d3a8181506ad81_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjYzOQ_52488f92-a4e6-4772-aa85-547239d4eaf6">70</ix:nonfraction> million in the first quarter of 2020. </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjgzMQ_6400a353-5a9e-45a7-9a99-8ef9cfb5aded">20</ix:nonfraction> million within the next 12 months into income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately <ix:nonnumeric contextref="i64de3286a8b8400bbce978e6cea1d671_D20210101-20210404" format="ixt-sec:duryear" name="us-gaap:DerivativeRemainingMaturity1" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjc0ODc3OTA4MzA0OQ_7920a480-e60e-4a8f-9bd0-ccaaa2fc75c9">22</ix:nonnumeric> years and relates to foreign currency debt. </span></div></ix:continuation><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE4Mw_1364db8e-62e3-4204-af90-9736c5b1352c" footnoterole="http://www.xbrl.org/2003/role/footnote">The amounts reclassified from OCI were reclassified into OID.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Ng_845e6876-647c-4032-81eb-f302be149715" footnoterole="http://www.xbrl.org/2003/role/footnote">Short-term borrowings and long-term debt include foreign currency borrowings which are used in net investment hedges. The short-term borrowings carrying value as of April&nbsp;4, 2021 was $<ix:nonfraction unitref="usd" contextref="iea937bd52464448b93d716a8cf093ae8_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjc0ODc3OTA4MTY3NQ_a4a55cd9-af84-436c-9b3a-a90fc1d23ba5">1.2</ix:nonfraction> billion. The long-term debt carrying values as of April&nbsp;4, 2021 and December 31, 2020 were $<ix:nonfraction unitref="usd" contextref="iea937bd52464448b93d716a8cf093ae8_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMzE1MA_35ea1271-218c-40e1-a508-2807fc83ed0b">872</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i0661f5622ccf41418edc8cfa0839da72_I20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfMjc0ODc3OTA4MjIwMg_2591fdf1-2144-4862-9168-41b1bbc579a5">2.1</ix:nonfraction> billion, respectively.</ix:footnote></span></div></ix:continuation><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE3MQ_d0dd2570-be24-49ff-b8e0-ff2a06aeabb9" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tbody><tr><td style="width:1.0%"></td><td style="width:27.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.35pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes cumulative basis adjustments for fair value hedges to our long-term debt:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br>Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ief79afe80dd041288f169705b94e7059_I20210404" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy0yLTEtMS0w_e2d39cca-ba70-4846-a9c4-4dc880bd0289">494</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ief79afe80dd041288f169705b94e7059_I20210404" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy00LTEtMS0w_770f16d8-49ea-49e3-bf14-98b4833707ad">21</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ief79afe80dd041288f169705b94e7059_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy02LTEtMS0w_e0fe65e8-9aca-48cd-90dc-9c488dfe8ebe">1,202</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1a28ce98dd3469bbc9492040cdde3c1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy04LTEtMS0w_78531e70-b9c4-43f1-8200-a7869fc5bf8b">2,016</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1a28ce98dd3469bbc9492040cdde3c1_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy0xMC0xLTEtMA_4178d95c-8f13-4b8f-847e-07bcf294c65c">117</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib1a28ce98dd3469bbc9492040cdde3c1_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RhYmxlOjg1NTM4OTVmNmU2ODQ1YmY5MTJjNzg1Mjk1MjE3M2IxL3RhYmxlcmFuZ2U6ODU1Mzg5NWY2ZTY4NDViZjkxMmM3ODUyOTUyMTczYjFfNy0xMi0xLTEtMA_bf551ad1-557c-43d9-92d6-7c9b8dda588a">1,149</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF84NS9mcmFnOjYxZGFiYTA5NTBkMTRmZmQ5YTgwNWNiODIwNTlkMTc5L3RleHRyZWdpb246NjFkYWJhMDk1MGQxNGZmZDlhODA1Y2I4MjA1OWQxNzlfNDE1Nw_eddb205f-17b1-4a52-8031-9748bab11f5b" footnoterole="http://www.xbrl.org/2003/role/footnote">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</ix:footnote></span></div></ix:nonnumeric></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_91"></div><ix:continuation id="i5dd47355cfd2448d9310d0e1df2634b9" continuedat="i4a648fb11ce847fa821c421efb98310b"><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">F. Credit Risk</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our trade accounts receivable balances are due from drug wholesalers. For additional information on our trade accounts receivables with significant customers, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17B </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 Form 10-K. </span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&nbsp;4, 2021, the largest investment exposures in our portfolio represent primarily sovereign debt instruments issued by the U.S., U.K., Germany, France, Japan and Canada.</span></div></ix:continuation><div><span><br></span></div><div><ix:continuation id="i4a648fb11ce847fa821c421efb98310b"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association (ISDA) master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of April&nbsp;4, 2021, the aggregate fair value of these derivative financial instruments that are in a net payable position was $<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeNetLiabilityPositionAggregateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85MS9mcmFnOjUxNzE0NjFlZWI0MzRiY2ViODBjMWYzMTU5YTIyOTUyL3RleHRyZWdpb246NTE3MTQ2MWVlYjQzNGJjZWI4MGMxZjMxNTlhMjI5NTJfMjc0ODc3OTA3MjQ4OA_b1ec973b-7377-41c3-b716-5a93e7aa0bbd">613</ix:nonfraction> million, for which we have posted collateral of $<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85MS9mcmFnOjUxNzE0NjFlZWI0MzRiY2ViODBjMWYzMTU5YTIyOTUyL3RleHRyZWdpb246NTE3MTQ2MWVlYjQzNGJjZWI4MGMxZjMxNTlhMjI5NTJfMjc0ODc3OTA3MjUzMg_06037b28-5528-4ce2-b957-14eb2f05c586">675</ix:nonfraction> million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Short-term investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of April&nbsp;4, 2021, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:DerivativeNetReceivablePositionAggregateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85MS9mcmFnOjUxNzE0NjFlZWI0MzRiY2ViODBjMWYzMTU5YTIyOTUyL3RleHRyZWdpb246NTE3MTQ2MWVlYjQzNGJjZWI4MGMxZjMxNTlhMjI5NTJfMjc0ODc3OTA3MjczMg_d1ae70fc-a071-4554-b119-0f7d9f415b12">53</ix:nonfraction>&nbsp;million, for which we have received collateral of $<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SecuritiesReceivedAsCollateral" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85MS9mcmFnOjUxNzE0NjFlZWI0MzRiY2ViODBjMWYzMTU5YTIyOTUyL3RleHRyZWdpb246NTE3MTQ2MWVlYjQzNGJjZWI4MGMxZjMxNTlhMjI5NTJfMjc0ODc3OTA3Mjc3OA_87068f9e-1540-4a59-b911-ae15fb63db72">124</ix:nonfraction> million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Short-term borrowings, including current portion of long-term debt.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_94"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzUw_3e7953e3-b4ea-4ff9-a04a-7a47f34d5ab3" continuedat="ib96f70fe9f5f46cfbe1cedbab4185083" escape="true">Other Financial Information</ix:nonnumeric></span></div><ix:continuation id="ib96f70fe9f5f46cfbe1cedbab4185083" continuedat="i2b10f177a6d84b0bb3e3efc576b3c138"><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A.</span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:0.4pt;text-decoration:underline"> Inventories</span></div><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzM1_a36b9ba9-a689-4188-a72d-47a010f6647e" escape="true"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzU5_3332a7de-1085-4771-8a8c-d29eacb33bed" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfMi0yLTEtMS0w_661eb3d8-831f-467d-b168-e26c414f81fc">3,289</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfMi00LTEtMS0w_d1a6fc00-5937-4ead-8286-a5475ddfd251">2,878</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfMy0yLTEtMS0w_402e2127-d6fb-40d6-9756-054e3866e171">4,364</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfMy00LTEtMS0w_0d8c0f2b-2520-4da7-981b-115bc6924801">4,430</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNC0yLTEtMS0w_959c1455-3c94-463b-a3a1-5d097abaf83a">840</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNC00LTEtMS0w_4bac4008-392a-45ab-8d95-fb42212dabd9">738</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNS0yLTEtMS0w_e728931a-0049-43bd-a2e2-d69309827959">8,493</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNS00LTEtMS0w_e7c8b9e7-d0fe-49ed-93c2-830ead64db2f">8,046</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNi0yLTEtMS0w_02501141-c347-41a8-88bf-a9cd139e10dc">981</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RhYmxlOmI2NmRhZTNkOWE0MjQyZmJhZDFjM2FkYTE2NjY1NzUyL3RhYmxlcmFuZ2U6YjY2ZGFlM2Q5YTQyNDJmYmFkMWMzYWRhMTY2NjU3NTJfNi00LTEtMS0w_2d469204-b8dd-44f2-842a-0a2eb215dec3">890</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzM2_0ae3661f-6566-4c42-824c-f52314e00d57" footnoterole="http://www.xbrl.org/2003/role/footnote">The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches and market demand, and an increase due to foreign exchange.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMzYz_54cbbcce-4732-4004-b827-66bae4504347" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. There are no recoverability issues for these amounts.</span></ix:footnote></div></ix:nonnumeric></ix:nonnumeric><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Other Current Liabilities</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i2b10f177a6d84b0bb3e3efc576b3c138" continuedat="i0def74b84d6841d783ff6bcdbe7253fb">Other current liabilities</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0def74b84d6841d783ff6bcdbe7253fb"> related to the gross margin split with BioNTech for BNT162b2 totaled $<ix:nonfraction unitref="usd" contextref="if40f67d115f744f597392dd0dafbaa4e_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMjc0ODc3OTA3MTcyNQ_1e3e8133-5bad-4af6-973d-c230e6ac3938">1.4</ix:nonfraction>&nbsp;billion as of April 4, 2021 and $<ix:nonfraction unitref="usd" contextref="ie113bce7166d40bdacd5506226e15172_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85NC9mcmFnOjE0NmFiOTkzZTg2MDRlNmY5YzE0Mzk5NTA4YTY1YWQ1L3RleHRyZWdpb246MTQ2YWI5OTNlODYwNGU2ZjljMTQzOTk1MDhhNjVhZDVfMjc0ODc3OTA3MTc0NA_7f23cac2-a3d1-48de-a85f-bf20d048b160">25</ix:nonfraction>&nbsp;million as of December 31, 2020.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_97"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTgwMw_cfab5511-c498-4695-81c3-e9902fa1a5ca" continuedat="i7c111a9cc1b14abeadaacc83652577cc" escape="true">Identifiable Intangible Assets</ix:nonnumeric></span></div><ix:continuation id="i7c111a9cc1b14abeadaacc83652577cc"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc1OQ_240060ae-aa21-4342-a5ca-6d2fd61a610b" escape="true"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc3Ng_411ebbe7-a724-4981-b743-ae3dd88c4500" escape="true"><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:28.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br>Carrying<br>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable<br>Intangible<br>Assets, less<br>Accumulated<br>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross<br>Carrying<br>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated<br>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable<br>Intangible<br>Assets, less<br>Accumulated<br>Amortization</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icb29d5d4227b48adb270b164dfc6d257_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0yLTEtMS0w_e4c24e65-e70e-4200-a66f-1e4589658a2f">74,056</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icb29d5d4227b48adb270b164dfc6d257_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC00LTEtMS0w_c646eb10-4536-4a72-897b-b7b5b447399e">51,840</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icb29d5d4227b48adb270b164dfc6d257_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC02LTEtMS0w_669200c6-6042-455d-9c5d-ad48da82d9e7">22,217</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4317cb0568ef4d6aa675535e255cdab3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC04LTEtMS0w_3c852bbe-299d-49b5-872a-8f35c357c06e">73,545</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4317cb0568ef4d6aa675535e255cdab3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0xMC0xLTEtMA_4da38dbf-65a4-40ba-b3f6-0b6700ffe2c4">50,902</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4317cb0568ef4d6aa675535e255cdab3_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNC0xMi0xLTEtMA_1581c541-e838-41c1-9bcf-a4e0ce56e0b5">22,643</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i459a8736cc184b2cb5e7c93468cdf4a3_I20210404" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS0yLTEtMS0w_57ffaeb8-ef50-4f03-96bf-85e8e1debe68">922</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i459a8736cc184b2cb5e7c93468cdf4a3_I20210404" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS00LTEtMS0w_1c436919-9f5b-46fa-ae00-2db25b374627">782</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i459a8736cc184b2cb5e7c93468cdf4a3_I20210404" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS02LTEtMS0w_e66d8482-0a5a-4d6e-93bd-52628b3bf06a">140</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0635462155884026ba26888ed78b96f6_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS04LTEtMS0w_5c3156eb-a804-46ec-aaea-76b7c63c4b3b">922</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i0635462155884026ba26888ed78b96f6_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS0xMC0xLTEtMA_eea1ccc3-f558-4bcd-98e4-5a203e57c583">774</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0635462155884026ba26888ed78b96f6_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNS0xMi0xLTEtMA_2eb936e2-e300-4733-829e-b7d774fbb0e3">148</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if36997883bf644fda424001760b39437_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi0yLTEtMS0w_d2a4d4eb-792d-469d-8cd2-8d03787db944">2,305</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="if36997883bf644fda424001760b39437_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi00LTEtMS0w_903337d3-be4c-4ebc-ba30-c7eb59f70b95">1,223</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if36997883bf644fda424001760b39437_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi02LTEtMS0w_afd53bde-ae40-485b-a3cc-315b5f5756c7">1,082</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5127eeed7ea340e29c6a52d21a2be3cd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi04LTEtMS0w_b2c909d4-864f-4ae2-9aa5-e945ece94dd0">2,292</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5127eeed7ea340e29c6a52d21a2be3cd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi0xMC0xLTEtMA_948d361f-08f3-4ff2-957d-70dee7dd975c">1,186</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5127eeed7ea340e29c6a52d21a2be3cd_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfNi0xMi0xLTEtMA_ea5d323f-80e2-4126-8cf9-b30b00a2067d">1,106</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC0yLTEtMS0w_17f0d32f-fc4a-4638-b53d-cab80a618b42">77,284</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC00LTEtMS0w_aa39b511-1159-4618-a7d3-8efb650bc89e">53,845</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC02LTEtMS0w_49a0e508-ab6f-4056-8305-2aa8c460fe00">23,439</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC04LTEtMS0w_d4dbb544-4a8b-479f-a6a0-661df11bfb7d">76,759</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC0xMC0xLTEtMA_808eabda-ba6c-42ef-844d-acc2cf61c368">52,862</ix:nonfraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfOC0xMi0xLTEtMA_7cce6d33-2af3-4fef-8ed3-8bf619184a9f">23,896</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9f5d302584f242a887a90c5ba675f0f7_I20210404" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTAtMi0xLTEtMA_21e0af34-2a12-46e2-b8d9-e49cab2d4696">827</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9f5d302584f242a887a90c5ba675f0f7_I20210404" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTAtNi0xLTEtMA_92421b8b-a67c-4818-8eff-e48b38da0df6">827</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3d9cb52c2c4d4db882a1c475c695052f_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTAtOC0xLTEtMA_efacb928-2066-41fd-a3f7-6a6d22774775">827</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3d9cb52c2c4d4db882a1c475c695052f_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTAtMTItMS0xLTA_03e9776c-6053-47ef-b7b5-1424442aae28">827</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i96110322c78c4e7d8e3fd05494f58fbb_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTEtMi0xLTEtMA_a275d43a-7336-432f-a95c-7cee9c1861ab">3,135</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i96110322c78c4e7d8e3fd05494f58fbb_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTEtNi0xLTEtMA_77d8c623-6b87-4997-b311-01049540d5c9">3,135</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia4631e305af2483e8890f326b9fef89d_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTEtOC0xLTEtMA_e4becf38-ee61-4cbb-8e99-2daf35227ff7">3,175</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia4631e305af2483e8890f326b9fef89d_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTEtMTItMS0xLTA_28d8c399-5add-4f29-81ec-7d543142f052">3,175</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib3aa408a10c644979d8878d88bca2e75_I20210404" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTItMi0xLTEtMA_4c8ca8de-e276-48c0-b518-986b8566fb19">573</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib3aa408a10c644979d8878d88bca2e75_I20210404" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTItNi0xLTEtMA_7f2667b7-d939-4d7e-ba0c-f07c315852ac">573</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0edc1ad3738e4c83885d8c61ab8ae1eb_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTItOC0xLTEtMA_84186afa-80e2-40dc-ab67-16603619fc4a">573</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0edc1ad3738e4c83885d8c61ab8ae1eb_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTItMTItMS0xLTA_785b6755-5573-4c6d-ad4a-59fcdfd38ca2">573</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTMtMi0xLTEtMA_1a1aa527-03b0-4f20-92e2-afb58c8f7eb1">4,535</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTMtNi0xLTEtMA_9b8f0a38-2570-4e77-8aa5-b0bfcc8cd912">4,535</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTMtOC0xLTEtMA_cba7b496-64b2-4e5b-bbe5-6df7c075fa48">4,575</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTMtMTItMS0xLTA_7d6cbbd7-70a8-4b97-b1c1-d8c421231cdb">4,575</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMi0xLTEtMA_e44275fb-b0e0-4975-9725-b68803fe9858">81,819</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtNC0xLTEtMA_808d5237-d474-4124-8030-8cf6b32f844a">53,845</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtNi0xLTEtMA_155baa90-f88d-4b5b-9292-fbc220385934">27,974</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtOC0xLTEtMA_bf820cec-978b-452b-b90e-b32e890f0610">81,334</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMTAtMS0xLTA_e818ddff-e506-4e51-8303-4d9af48d61c7">52,862</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icab05669a9bf4c4b91e115cdf8dcca85_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RhYmxlOjcxNTIwNzY4OGU2NzQzNThhODUzNmY0YWFhYzIwNTgyL3RhYmxlcmFuZ2U6NzE1MjA3Njg4ZTY3NDM1OGE4NTM2ZjRhYWFjMjA1ODJfMTQtMTItMS0xLTA_fdf0e030-51d6-433a-b5cd-93c3846721f6">28,471</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTc1Nw_788b9a53-3f31-4fb6-9881-b8ef81b2a730" footnoterole="http://www.xbrl.org/2003/role/footnote">The increase in the gross carrying amount primarily reflects $<ix:nonfraction unitref="usd" contextref="ib3ff295f54e9472ba2c6bba76b13a2a0_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMjE5OTAyMzI2MzYzMg_ec8a44d4-8876-45ea-9f2e-7366615c50b2">300</ix:nonfraction> million of capitalized BNT162b2 sales milestones due to BioNTech.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTgwOQ_77a5c552-dd08-4463-a98e-d5bc97ed0afc" footnoterole="http://www.xbrl.org/2003/role/footnote">The decrease is primarily due to amortization, partially offset by the capitalization of the BNT162b2 milestone payments described above.</ix:footnote></span></div></ix:nonnumeric></ix:nonnumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nearly all of our identifiable intangible assets are managed by our commercial organization, with only <ix:nonfraction unitref="number" contextref="i96110322c78c4e7d8e3fd05494f58fbb_I20210404" decimals="2" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMjE5OTAyMzI2MzYyNw_52442337-e16e-4ee9-be53-e91ca7a24e8e">9</ix:nonfraction>% of total IPR&amp;D assets managed by our R&amp;D organization.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of finite-lived intangible assets was $<ix:nonfraction unitref="usd" contextref="i746d22257d304c3e9cf195e54a9d68d2_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTQ0Ng_2c508c5e-b98b-47bb-b20a-61ecd80c5f89">883</ix:nonfraction> million for the first quarter of 2021 and $<ix:nonfraction unitref="usd" contextref="ie8b8aec1ecf94df0812360e000ba75a7_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF85Ny9mcmFnOjg0OWU3NzdmNDI1MjQzYjM4OGJiMzY3OTZkYWYwMjY5L3RleHRyZWdpb246ODQ5ZTc3N2Y0MjUyNDNiMzg4YmIzNjc5NmRhZjAyNjlfMTQ3OA_b9eb3dbb-e3b0-48c1-9e6b-51069273e904">861</ix:nonfraction> million for the first quarter of 2020.</span></div></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_103"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90ZXh0cmVnaW9uOjkwOWUzNDIwNWJlNjRkOTk5ZDZiOTRiMGMyMmUzN2E1XzM5OQ_264568b5-6a8d-4797-ab10-591a5e009433" continuedat="ib0daa565a6b04b44bcb55aad52d73389" escape="true">Pension and Postretirement Benefit Plans</ix:nonnumeric></span></div><ix:continuation id="ib0daa565a6b04b44bcb55aad52d73389"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of pension and postretirement plans. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90ZXh0cmVnaW9uOjkwOWUzNDIwNWJlNjRkOTk5ZDZiOTRiMGMyMmUzN2E1XzQxNQ_6a2add9a-9548-4003-b208-30111899700b" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes the components of net periodic benefit cost/(credit), including in 2020 costs/(credits) reported as part of discontinued operations:</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Postretirement<br>Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i088397c030f64354a28cbf48f10fa861_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtMi0xLTEtMA_8687b3ce-db3e-4cb2-bfbf-ec42a396982b">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtNC0xLTEtMA_8a939fa7-2d34-493f-ae2f-9102f6506285">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtMTAtMS0xLTA_a8dfa0cd-d993-4d8a-afd4-456f681bc72c">33</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtMTItMS0xLTA_ce2d5b3a-1a61-4b0c-99be-39e93b20b725">36</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtMTQtMS0xLTA_b6b825d7-439f-4d37-b2c5-995c131591ad">9</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzUtMTYtMS0xLTA_1c911f5c-11cb-4034-86e2-a7b4a69d2795">10</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i088397c030f64354a28cbf48f10fa861_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtMi0xLTEtMA_ba9272fe-72a6-486c-813d-cbdcacfb796c">113</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtNC0xLTEtMA_c75929a4-d3d3-4db7-b2a1-e8f2b84223cb">141</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtMTAtMS0xLTA_20ca625b-08c8-4088-bbc9-a2b47ef13616">36</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtMTItMS0xLTA_70f018c0-3d15-4208-bc06-f0cae88d2201">42</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtMTQtMS0xLTA_0eee66b5-36eb-4ea2-8d19-e94784e66fe6">7</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzYtMTYtMS0xLTA_0ee67451-f51d-46d4-9af9-3dd979d4604f">13</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i088397c030f64354a28cbf48f10fa861_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctMi0xLTEtMA_f23540e6-9c8b-44fe-ae0c-98cc746c5f18">261</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctNC0xLTEtMA_81e605c1-cec9-4885-988e-523c910d6f05">252</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctMTAtMS0xLTA_779c6d88-5c3e-4ebf-8d68-05ddc941f75b">82</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctMTItMS0xLTA_a5768e51-76da-4789-ab9c-ee900aa74cbd">81</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctMTQtMS0xLTA_120b8bfe-2971-4685-b205-11934317ad9f">10</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzctMTYtMS0xLTA_b747664b-d8fa-4585-9ce9-122d619f0076">9</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of prior service credits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i088397c030f64354a28cbf48f10fa861_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTItMS0xLTA_bd80891a-acc2-4214-bc84-1a6ab5c39836">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTQtMS0xLTA_e2322c30-936d-4e52-9fb2-036af65cd0bc">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTEwLTEtMS0w_5ce3488e-10a0-4810-a358-0feadd783023">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTEyLTEtMS0w_964fb994-e5fd-42d7-91b6-b4d0cd226fac">1</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTE0LTEtMS0w_1ce86a28-0f04-4fd2-a084-f040ae3ce5e6">39</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEwLTE2LTEtMS0w_656bd82b-911b-48ba-a196-b19f37c69159">43</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gains)/losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i088397c030f64354a28cbf48f10fa861_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTItMS0xLTA_ff97d46c-fced-476a-b2a5-54106c04e446">47</ix:nonfraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTQtMS0xLTA_5f84e636-9bbf-4595-8639-ea37be2b0c54">163</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTEwLTEtMS0w_044b0c2c-994d-416e-83b6-e67d5f636a87">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTEyLTEtMS0w_d51533d3-6263-4abf-91a0-3da58876c737">3</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTE0LTEtMS0w_0bf5e105-1467-4fb9-8409-5f0d8cd83943">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzEzLTE2LTEtMS0w_b1fbfc66-3292-4a4f-b592-602046d88abb">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Special termination benefits</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i088397c030f64354a28cbf48f10fa861_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTItMS0xLTA_5ae04baf-f60c-4f40-acb6-c2306ef6700f">7</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTQtMS0xLTA_d015451d-2db4-467d-ac30-e4346ce7e5e8">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTEwLTEtMS0w_603a616e-3578-438d-b9ad-ad0ec331fff8">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTEyLTEtMS0w_8842c90b-452f-4485-bdab-713c259e6abe">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTE0LTEtMS0w_dd0e93ac-3718-441e-8a41-4b8d0bc1f4d5">1</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE0LTE2LTEtMS0w_60213122-1ebf-497d-ba70-0f5a512abd03">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit) reported in income</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i088397c030f64354a28cbf48f10fa861_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTItMS0xLTA_9fefa320-0775-408d-a824-2607b2160ab4">187</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id35f13d5f6444cbfb54dbe09a35001f3_D20200101-20200329" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTQtMS0xLTA_68520c5b-b502-4386-a00f-427048342f84">53</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTEwLTEtMS0w_244d5c8d-eaff-472f-a1bb-92d486288ae1">12</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5d7c9fa09944421ca74b7c4a5da47f0d_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTEyLTEtMS0w_2a57a0ab-238e-479f-bcbd-4f94673d4750">1</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTE0LTEtMS0w_6f6beb1f-cefc-4e0c-89b8-90a419443c5e">32</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3b1ddf8b265a4c849c7d2c95c12d0bcc_D20200101-20200329" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90YWJsZTo1ODg0M2M3NTRiODY0YWIzYWM1ODBlNDY5YTM5MDA5MS90YWJsZXJhbmdlOjU4ODQzYzc1NGI4NjRhYjNhYzU4MGU0NjlhMzkwMDkxXzE1LTE2LTEtMS0w_cedf8bff-dc8d-4f66-8a38-261a00606227">30</ix:nonfraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></ix:nonnumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost/(credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended April 4, 2021, we contributed $<ix:nonfraction unitref="usd" contextref="i088397c030f64354a28cbf48f10fa861_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90ZXh0cmVnaW9uOjkwOWUzNDIwNWJlNjRkOTk5ZDZiOTRiMGMyMmUzN2E1XzIxOTkwMjMyNTc1NTE_61d9fc06-f971-4e1a-bd1b-60702afc5d59">83</ix:nonfraction> million, $<ix:nonfraction unitref="usd" contextref="i76939bce4c5b4d98a4fbc1a26929fe6c_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90ZXh0cmVnaW9uOjkwOWUzNDIwNWJlNjRkOTk5ZDZiOTRiMGMyMmUzN2E1XzIxOTkwMjMyNTc1NTY_bceb8feb-be42-41c5-95f8-393229dd26c0">40</ix:nonfraction> million, and $<ix:nonfraction unitref="usd" contextref="i4ef7c4e8ac1449778b560550e8ef05da_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMDMvZnJhZzo5MDllMzQyMDViZTY0ZDk5OWQ2Yjk0YjBjMjJlMzdhNS90ZXh0cmVnaW9uOjkwOWUzNDIwNWJlNjRkOTk5ZDZiOTRiMGMyMmUzN2E1XzIxOTkwMjMyNTc1NjU_d1d72d09-6397-47cf-a422-479864a03710">19</ix:nonfraction> million to our U.S. Pension Plans, International Pension Plans, and Postretirement Plans, respectively, from our general assets, which include direct employer benefit payments.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_112"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90ZXh0cmVnaW9uOmEzMjgxNWI3MDUyNTQwN2ViMTQzMzFjMjFkMTM3Y2ZiXzI1NA_f96deb72-44b6-40d9-9803-8891bc8b5b7b" continuedat="if4a9e3dae89e440ea4608ef2df9be514" escape="true">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</ix:nonnumeric></span></div><ix:continuation id="if4a9e3dae89e440ea4608ef2df9be514"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90ZXh0cmVnaW9uOmEzMjgxNWI3MDUyNTQwN2ViMTQzMzFjMjFkMTM3Y2ZiXzI0MQ_366e801e-c252-4bec-9279-8d6ce96bfe50" escape="true"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents the detailed calculation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EPS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator––Basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzYtNi0xLTEtMA_1125ce2f-542b-4f09-aa91-14cc328e1643">4,868</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzYtOC0xLTEtMA_4c7ca253-9bac-4b7f-939d-2a2c06753108">2,474</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Preferred stock dividends––net of tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzctNi0xLTEtMA_6f8d4680-ddfb-4616-81de-e822e9e17389">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzctOC0xLTEtMA_14a58154-6cc7-4314-a23c-e958f0e54318">—</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzgtNi0xLTEtMA_a73aafb6-82db-4f69-96c9-860c812b3103">4,868</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzgtOC0xLTEtMA_511b2ca2-dbed-45a0-ba60-7fe83af468ab">2,474</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzktNi0xLTEtMA_5944ba14-19d5-4c71-a51c-16b551a6353e">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzktOC0xLTEtMA_4132dcb7-62f2-4428-a3ac-59e2f71702c0">881</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzEyLTYtMS0xLTA_67bad856-d181-47b8-a462-bb33c85c5142">4,877</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzEyLTgtMS0xLTA_a6e25586-5a1b-4152-bc03-0750e704b661">3,354</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator––Diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE0LTYtMS0xLTA_3930246c-ef83-4ef5-9f57-118b0fc5b2f9">4,868</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE0LTgtMS0xLTA_f7a6ccef-0247-4155-84d1-600db8211e57">2,474</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE1LTYtMS0xLTA_ece5396d-10ea-4d1d-96f8-96e7cda58994">9</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE1LTgtMS0xLTA_786e5dfd-6dca-415e-98a5-8c1527a41f8f">881</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE2LTYtMS0xLTA_3bf9d328-0a72-40a8-b86c-8a084ea4d727">4,877</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE2LTgtMS0xLTA_20ae953a-8de0-4b65-9256-3f5d7a042ecc">3,355</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Denominator</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding––Basic</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE4LTYtMS0xLTA_ed0cf43d-acd3-4cb9-83f6-f1eca4095da9">5,584</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE4LTgtMS0xLTA_1ce1f538-b793-443a-8e14-be3400178559">5,545</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE5LTYtMS0xLTA_fade8507-b85c-420b-837d-7b877518ba4b">78</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzE5LTgtMS0xLTA_3ba6178b-fcaf-4f1e-8a63-086f591f54a7">68</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding––Diluted</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIwLTYtMS0xLTA_1345c3e6-9e15-4350-b9b3-e38c6a1d30da">5,662</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIwLTgtMS0xLTA_56fa12c0-55ed-4708-b561-3527a11165d8">5,613</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive common stock equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIxLTYtMS0xLTA_c080b5f6-9126-42b2-b9cd-88eac733fc67">2</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90YWJsZTo4ZmUyMjQxMTY5Y2Q0YTA4YjEyNDY2MTllNGFkMDY5YS90YWJsZXJhbmdlOjhmZTIyNDExNjljZDRhMDhiMTI0NjYxOWU0YWQwNjlhXzIxLTgtMS0xLTA_ea9562e8-096d-4e8c-a6c9-eb1d67314663">3</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTIvZnJhZzphMzI4MTViNzA1MjU0MDdlYjE0MzMxYzIxZDEzN2NmYi90ZXh0cmVnaW9uOmEzMjgxNWI3MDUyNTQwN2ViMTQzMzFjMjFkMTM3Y2ZiXzIzOA_8e1dfb84-e1e5-4dc8-8ba3-e2cbc619d574" footnoterole="http://www.xbrl.org/2003/role/footnote">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</ix:footnote></span></div></ix:nonnumeric></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_115"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzM4MjU0_045665f4-6571-4532-95a6-ced1712f9abe" continuedat="if6f98a86ddd34966a91ba5fc0bedbd88" escape="true">Contingencies and Certain Commitments</ix:nonnumeric></span></div><ix:continuation id="if6f98a86ddd34966a91ba5fc0bedbd88" continuedat="ic51a937890a44a1a91830ac8d0ee8711"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. The following outlines our legal contingencies. For a discussion of our tax contingencies, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Legal Proceedings</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal contingencies include, but are not limited to, the following:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of these contingencies could result in increased expenses and/or losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="ic51a937890a44a1a91830ac8d0ee8711" continuedat="i375e5dd649b945ce872cdcbbce212b30"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. In August 2020, the SEC amended its disclosure rules regarding the threshold for disclosure of proceedings under environmental laws to which a governmental authority is a party. In accordance with the amended rule, we have adopted a disclosure threshold for such proceedings of $<ix:nonfraction unitref="usd" contextref="i05f859e329d9409390fed7a56b8d7dbd_I20210404" decimals="-6" format="ixt:numdotdecimal" name="pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzQ5Mjk4MDg_b242f245-28fd-48cc-b7e2-19d4308d5b7f">1</ix:nonfraction> million in potential or actual governmental monetary sanctions.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A1. Legal Proceedings––Patent Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in suits relating to our patents, including but not limited to, those discussed below. Most involve claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. For example, some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In 2017, the Patent Trial and Appeal Board (PTAB) initiated proceedings, which remain pending, with respect to <ix:nonfraction unitref="patent" contextref="ibd06277310a247e19d913965e50d3c9a_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="pfe:GainContingencyPatentsWithoutCourtProceedingsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzQ5NTYxNDI_b2627468-3145-4b6a-a6ab-2ce69ebcc070">two</ix:nonfraction> of our pneumococcal vaccine patents. However, the PTAB declined to initiate proceedings as to two other pneumococcal vaccine patents; those <ix:nonfraction unitref="patent" contextref="if6ed390d7e6d457a85351411ac49ff84_D20210101-20210404" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzIxOTkwMjM1MTA5NDc_77c6a750-e364-489f-93c0-284ee70769b7">two</ix:nonfraction> patents, and <ix:nonfraction unitref="patent" contextref="ibcde84e257a34f8aba9469464f6a8ba4_D20210101-20210404" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzIxOTkwMjM1MTA5Nzg_5a441330-748b-431a-94d2-f5706f4cd8c7">one</ix:nonfraction> other patent, are now being challenged in federal court in Delaware. Challenges to other pneumococcal vaccine patents remain pending outside the U.S. The invalidation of all of the patents in our pneumococcal portfolio could potentially allow a competitor’s vaccine into the marketplace. In the event that any of the patents are found valid and infringed, a competitor’s vaccine might be prohibited from entering the market or a competitor might be required to pay us a royalty.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i375e5dd649b945ce872cdcbbce212b30" continuedat="ibf6b4773fa134d4e8d6da4aad1bb2ba1"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actions In Which We Are The Plaintiff</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EpiPen</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz’s abbreviated new drug application (ANDA) filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Xeljanz (tofacitinib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate ANDAs with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, we have settled actions with several manufacturers on terms not material to us. The remaining actions continue in the U.S. District Court for the District of Delaware as described below.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) asserting the infringement and validity of <ix:nonfraction unitref="patent" contextref="iba6607878e43427890e6ccd44b3997ef_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzQ5NzEyMjI_288e97f8-41cd-4d69-9b4a-02865f9bcade">three</ix:nonfraction> patents: the patent covering the active ingredient expiring in December 2025 (the 2025 Patent), the patent covering an enantiomer of tofacitinib expiring in 2022, and the patent covering a polymorphic form of tofacitinib expiring in 2023 (the 2023 Patent), which Zydus challenged in its ANDA seeking approval to market a generic version of tofacitinib 5 mg tablets. In November 2020, we settled the case against Zydus on terms not material to us. In February 2021, we brought a separate patent-infringement action against Zydus asserting the infringement and validity of our composition of matter and crystalline form patents challenged by Zydus in its ANDA seeking approval to market a generic version of tofacitinib 22 mg extended release tablets. In April 2021, we settled our remaining action against Zydus on terms not material to us. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we brought a separate patent infringement action against Teva Pharmaceuticals USA, Inc. (Teva) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its ANDA seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we brought a separate patent-infringement action against Aurobindo Pharma Limited (Aurobindo) asserting the infringement and validity of the 2025 Patent and the 2023 Patent, which Aurobindo challenged in its ANDA seeking approval to market a generic version of tofacitinib 5 mg and 10 mg tablets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inlyta (axitinib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2019, Glenmark Pharmaceuticals Limited (Glenmark) notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ibrance (palbociclib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2019, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Ibrance. The companies assert the invalidity and non-infringement of <ix:nonfraction unitref="patent" contextref="i30e58814751d471dbf0e4d56ae80ce59_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzQ5ODI3Mzg_d1cdeca3-fb26-463a-890c-5b8db8696bad">two</ix:nonfraction> composition of matter patents, one of which expires in 2023 and one of which expires in 2027, as a result of a U.S. Patent Term Extension certificate issued in January 2021, and a method of use patent covering palbociclib, which expires in 2023. In 2019, we brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies. Beginning in September 2020, we received correspondence from several generic companies notifying us that they would seek approval to market generic versions of Ibrance. The generic companies assert the invalidity and non-infringement of our crystalline form patent which expires in 2034. Beginning in October 2020, we brought patent infringement actions against each of these generic companies in various federal courts, asserting the validity and infringement of the crystalline form patent.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Matter Involving Our Collaboration/Licensing Partners</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eliquis</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, <ix:nonfraction unitref="defendant" contextref="i680ce5436aa84610a971aecbf2137e35_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="pfe:GainContingencyNumberofDefendants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwMDE5NjI_0814ad79-3138-4bea-bfec-5e4ec5e97291">twenty-five</ix:nonfraction> generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed ANDAs seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the <ix:nonfraction unitref="patent" contextref="i680ce5436aa84610a971aecbf2137e35_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwMDIxODE_b9c86de9-60b5-4db7-8dd9-5e122e5032ae">three</ix:nonfraction> patents listed in the Orange Book for Eliquis. <ix:nonfraction unitref="patent" contextref="i680ce5436aa84610a971aecbf2137e35_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwMDIyMzI_099b6f05-21ef-4f1e-b175-8053924514ed">One</ix:nonfraction> of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="ibf6b4773fa134d4e8d6da4aad1bb2ba1" continuedat="i07abeb37cd424590acaf199ebe49f91b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. District Court for the District of West Virginia, asserting that each of the generic companies’ proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all <ix:nonfraction unitref="patent" contextref="i680ce5436aa84610a971aecbf2137e35_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwMDI5MTY_d113a473-d837-4ddd-b8d6-76bdc1f97633">three</ix:nonfraction> patents. In August 2020, the U.S. District Court for the District of Delaware ruled that both the 2026 patent and the 2031 patent are valid and infringed by the proposed generic products. In August and September 2020, the generic filers appealed the District Court’s decision to the U.S. Court of Appeals for the Federal Circuit. Prior to the August 2020 ruling, we and BMS settled with certain of the companies on terms not material to us, and we and BMS may settle with other generic companies in the future. </span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A2. Legal Proceedings––Product Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asbestos</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There also&nbsp;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effexor</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lipitor</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain Pfizer affiliates, and, in most of the actions, Ranbaxy and certain Ranbaxy affiliates. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants’ allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i07abeb37cd424590acaf199ebe49f91b" continuedat="ia1519dc3968a449ab3110fb1b918a25f"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation in the U.S. District</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2013 and 2014, the District Court dismissed with prejudice the claims of the direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court’s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the Court of Appeals. In 2017, the Court of Appeals reversed the District Court’s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EpiPen</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian, and/or various entities affiliated with Mylan, and Mylan former Chief Executive Officer, Heather Bresch. The plaintiffs in these actions seek to represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants’ allegedly unlawful conduct. In 2020, a similar lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, King, Meridian and the Mylan entities on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants (the 2020 Lawsuit). Against Pfizer and/or its affiliates, plaintiffs in these actions generally allege that Pfizer’s and/or its affiliates’ settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal and various state antitrust laws. At least <ix:nonfraction unitref="lawsuit" contextref="i02973e07500446c182f01c27b105cb67_I20210404" decimals="INF" format="ixt-sec:numwordsen" name="pfe:LossContingencyNumberOfLawsuits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNDMxMzM_4c051b5e-7e11-41d1-99e8-3a143c43e2ea">one</ix:nonfraction> lawsuit also alleges that Pfizer and/or Mylan violated the federal Racketeer Influenced and Corrupt Organizations Act (RICO). Plaintiffs also filed various federal antitrust, state consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan and/or its affiliates regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In 2017, all of these actions, except for the 2020 Lawsuit, were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan and/or its affiliates to which Pfizer, King and Meridian are not parties.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, a new lawsuit was filed in the U.S. District Court for the District of Colorado on behalf of indirect purchasers. Plaintiff represents a putative U.S. nationwide class of persons or entities who paid for any portion of the end-user purchase price of certain refill or replacement EpiPens since 2010. Plaintiff alleges that Pfizer and Meridian misrepresented the shelf-life and expiration date of EpiPen, in violation of the federal RICO statute. Plaintiff seeks treble damages for alleged unnecessary replacement or refill purchases of EpiPens by members of the putative class.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nexium 24HR and Protonix</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the District of New Jersey. As part of our Consumer Healthcare JV transaction with GSK, the JV has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Docetaxel</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Personal Injury Actions</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Eastern District of Louisiana.</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">Mississippi Attorney General Government Action</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and <ix:nonfraction unitref="manufacturer" contextref="i104649887c064a40a045fee23a147e9b_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNDY1NTQ_edc14692-2ca4-4fa7-8989-81c9a2231a3f">eight</ix:nonfraction> other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="ia1519dc3968a449ab3110fb1b918a25f" continuedat="id74b5cfbae8c4d87a67d19b9499b231a"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Array Securities Litigation</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, <ix:nonfraction unitref="classaction" contextref="i6ceee5bfd67f426f8c340bd9abb34799_D20170101-20171231" decimals="INF" format="ixt-sec:numwordsen" name="pfe:LossContingencyClassActionsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNDY4Njc_56f66725-4c77-40f0-a3f3-4bf5f497a549">two</ix:nonfraction> purported class actions were filed in the U.S. District Court for the District of Colorado alleging that Array, which we acquired in 2019 and is our wholly owned subsidiary, and certain of its former officers violated federal securities laws in connection with certain disclosures made, or omitted, by Array regarding the NRAS-mutant melanoma program. In 2018, the actions were consolidated into a single proceeding. In March 2021, the parties reached an agreement in principle to resolve the litigation on terms not material to us, which is subject to Court approval. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zantac </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. Plaintiffs seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Southern District of Florida. From June to December 2020: (i) plaintiffs in the Multi-District Litigation filed against Pfizer and many other defendants a consolidated consumer class action complaint alleging, among other things, violations of the RICO statute and consumer protection statutes of all 50 states, and a consolidated third-party payor class action complaint alleging violation of the RICO statute and seeking reimbursement for payments made for the prescription version of Zantac; (ii) Pfizer received service of <ix:nonfraction unitref="classaction" contextref="i51f98e1eee134a89abb86e9cdaf82d40_D20200601-20201231" decimals="INF" format="ixt-sec:numwordsen" name="pfe:LossContingencyClassActionsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNDg2MTY_dc06a69e-9cf7-46bc-8552-b1b8bb708859">two</ix:nonfraction> Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants’ sale of Zantac in Canada; (iii) the State of New Mexico filed a civil action against Pfizer and many other defendants, alleging various state statutory and common law claims in connection with the defendants’ alleged sale of Zantac in New Mexico; and (iv) Pfizer received service of a suit filed by the Mayor and City Council of Baltimore naming Pfizer and other defendants alleging various claims under Maryland law.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A3. Legal Proceedings––Commercial and Other Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Monsanto-Related Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia’s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto’s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia’s indemnification obligations relating to Former Monsanto’s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto’s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia’s and New Monsanto’s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto’s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto’s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, we submitted to the U.S. Environmental Protection Agency (EPA) a corrective measures study report with regard to Pharmacia’s discontinued industrial chemical facility in North Haven, Connecticut. In 2010, our corrective measures study report was approved by the EPA, and we commenced construction of the site remedy in late 2011 under an Updated </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="id74b5cfbae8c4d87a67d19b9499b231a" continuedat="i3102daf9593f46239357722c0d85a66a"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative Order on Consent with the EPA. In 2019, the EPA acknowledged that construction of the site remedy has been completed. In March 2021, the State of Connecticut, Department of Energy &amp; Environmental Protection issued a Stewardship Permit to Pharmacia &amp; Upjohn Company LLC, our wholly-owned subsidiary, that will govern the ongoing operation, maintenance, and management of the North Haven site, and which will not have a material impact on Pfizer.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in 2009, we submitted a revised site-wide feasibility study with regard to Wyeth Holdings Corporation’s (formerly, American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. In 2011, Wyeth Holdings Corporation executed an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the EPA with regard to the Bound Brook facility. In accordance with the 2011 Administrative Settlement Agreement, we completed construction of an interim remedy to address the discharge of impacted groundwater from the facility to the Raritan River. In 2012, the EPA issued a final remediation plan for the Bound Brook facility’s main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for <ix:nonfraction unitref="lagoon" contextref="ibfb1ec9a79f94d8da08be5657414c50b_D20130101-20131231" decimals="INF" format="ixt-sec:numwordsen" name="pfe:FeasibilityStudyNumberOfLagoons" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNzAyNDQ_0ba37e9b-bfa7-4454-bedd-6bb05d58a2f5">two</ix:nonfraction> adjacent lagoons. In 2015, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. The consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court in 2015. In 2018, the EPA issued a final remediation plan for the <ix:nonfraction unitref="lagoon" contextref="i4472fb58be8742ad81a2c341ffc7d058_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="pfe:FeasibilityStudyNumberOfLagoons" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMTUvZnJhZzpkMzUwNjQ0Y2VkMTg0YmM1ODRiNmQ5YWMxN2JkMDIxNi90ZXh0cmVnaW9uOmQzNTA2NDRjZWQxODRiYzU4NGI2ZDlhYzE3YmQwMjE2XzMyOTg1MzUwNzA3MjY_9a70d49c-7f8b-49b7-b2ea-175879c0f1e6">two</ix:nonfraction> adjacent lagoons, which is generally in accordance with one of the remedies evaluated in our focused feasibility study, and, in 2019, Wyeth Holdings LLC entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the lagoons. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accrued for the estimated costs of the site remedies for the North Haven and Bound Brook facilities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contracts with Iraqi Ministry of Health</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of plaintiffs’ claims. The plaintiffs are appealing the District Court’s decision. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allergan Complaint for Indemnity</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Pfizer was named as a defendant in a third-party complaint for indemnity, along with King, filed by Allergan Finance LLC (Allergan) in a Multi-District Litigation in the U.S. District Court for the Northern District of Ohio. The lawsuit asserted claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. In 2018, the District Court dismissed the lawsuit. In 2019, Allergan filed a similar complaint in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian. That suit was voluntarily discontinued without prejudice in January 2021.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Breach of Contract––Xalkori/Lorbrena</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a defendant in a breach of contract action brought by New York University (NYU) in the Supreme Court of the State of New York (Supreme Court). NYU alleges that it is entitled to royalties on Pfizer’s sales of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xalkori under the terms of a Research and License Agreement between NYU and Sugen, Inc. Sugen, Inc. was acquired by Pharmacia in August 1999, and </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The action was originally filed in 2013. In 2015, the Supreme Court dismissed the action and, in 2017, the New York State Appellate Division reversed the decision and remanded the proceedings to the Supreme Court. In January 2020, the Supreme Court denied both parties’ summary judgment motions.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, NYU filed a separate breach of contract action against Pfizer alleging that it is entitled to royalties on sales of Lorbrena under the terms of the same NYU-Sugen, Inc. Research and Licensing Agreement.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A4. Legal Proceedings––Government Investigations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i3102daf9593f46239357722c0d85a66a" continuedat="iaf3a18971ea4436386818f7e8fd6d938"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Greenstone Investigations</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">U.S. Department of Justice Antitrust Division Investigation</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our former Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. We have produced records relating to this investigation. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.5pt">State Attorneys General Generics Antitrust Litigation</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer, making similar allegations, but concerning a new set of drugs. This complaint was transferred to the Multi-District Litigation in July 2020.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subpoena relating to Manufacturing of Quillivant XR</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we received a subpoena from the U.S. Attorney’s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We have produced records pursuant to the subpoena.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Inquiries relating to Meridian Medical Technologies </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we received a civil investigative demand from the U.S. Attorney’s Office for the SDNY. The civil investigative demand seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at our Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney’s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to Russian Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we received an informal request from the U.S. Department of Justice’s Foreign Corrupt Practices Act (FCPA) Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC’s FCPA Unit. We have produced records pursuant to these requests. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mississippi Attorney General Government Investigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mississippi Attorney General Government Investigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for information regarding a government investigation related to Docetaxel marketing practices.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice Inquiries relating to India Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we received an informal request from the U.S. Department of Justice's Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney’s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We are producing records pursuant to these requests.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to China Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, we received an informal request from the U.S. Department of Justice's FCPA Unit seeking documents relating to our operations in China. In August 2020, we received a similar request from the SEC’s FCPA Unit. We are producing records pursuant to these requests.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zantac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">State of New Mexico Civil Action</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12A2. Contingencies and Certain Commitments: Legal Proceedings––Product Litigation––Zantac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above for information regarding a civil action filed by the State of New Mexico alleging various state statutory and common law claims in connection with the defendants’ alleged sale of Zantac in New Mexico.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Guarantees and Indemnifications</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="iaf3a18971ea4436386818f7e8fd6d938"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of April&nbsp;4, 2021, the estimated fair value of these indemnification obligations was not significant. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with our entry into certain agreements and other transactions, our counterparties may agree to indemnify us. For example, our collaboration agreement with EMD Serono, Inc. to co-promote Rebif in the U.S. expired at the end of 2015 and included certain indemnity provisions. Patent litigation brought by Biogen Idec MA Inc. against EMD Serono Inc. and Pfizer is pending in the U.S. District Court for the District of New Jersey and the United States Court of Appeals for the Federal Circuit. EMD Serono Inc. has acknowledged that it is obligated to satisfy any award of damages. In addition, in November 2020, we and Mylan completed the transaction to spin-off our Upjohn Business and combine it with Mylan to form Viatris. As part of the transaction and as previously disclosed, Viatris has agreed to assume, and to indemnify Pfizer for, liabilities arising out of certain matters.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also guaranteed the long-term debt of certain companies that we acquired and that now are subsidiaries of Pfizer. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Contingent Consideration for Acquisitions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to make payments to sellers for certain prior business combinations that are contingent upon future events or outcomes. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 Form 10-K.</span></div></ix:continuation><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_121"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. <ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NzE_ad2b7d5c-3a7d-499e-b0e6-3ca6da407328" continuedat="i25425e7e7ce548099c029dd20dba2a85" escape="true">Product, Geographic and Other Revenue Information</ix:nonnumeric></span></div><ix:continuation id="i25425e7e7ce548099c029dd20dba2a85" continuedat="i98985c723dcb4553aae15fc7bdfbf59c"><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Geographic Information</span></div><div style="margin-bottom:8pt"><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzMzOTA_bf3f5d34-59cf-4e71-aeeb-171700febc4b" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.360%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes revenues by geographic area:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%<br>Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3825cb911e8746189fdd8101073ce536_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzMtMi0xLTEtMA_de616e87-1519-47cd-9d73-0bcf081dad42">7,597</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i973c7ce48fd14978a74f16d3965dfc72_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzMtNC0xLTEtMA_b5af4009-5eda-4358-a596-188d87a9f7df">5,289</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="number" contextref="i3825cb911e8746189fdd8101073ce536_D20210101-20210404" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzMtNi0xLTEtMA_e5ff1e2c-68e3-4b01-ae44-60d27e63a162">44</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabba33f0ee264ea4b6013fb48174438a_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzQtMi0xLTEtMA_01253d63-32a6-4ac7-99b6-3af454234e37">3,038</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i46127568c53c4ff5b497c5dc02e2e2ec_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzQtNC0xLTEtMA_1eb771c2-4ae9-446f-bb60-dd7ac1730661">1,708</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="number" contextref="iabba33f0ee264ea4b6013fb48174438a_D20210101-20210404" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzQtNi0xLTEtMA_a356971f-6228-4e86-b047-2c6d428572a0">78</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6eaaa06d729d4a1fafede89416db3d6d_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzUtMi0xLTEtMA_caa8c2c5-70f2-4f42-a281-455ba55a28bb">1,123</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9ff0e601b789486fb77a51e10c286054_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzUtNC0xLTEtMA_77192e04-c3ab-4179-8c09-24e7cb03264f">919</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="number" contextref="i6eaaa06d729d4a1fafede89416db3d6d_D20210101-20210404" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzUtNi0xLTEtMA_d82da09a-6f12-483a-83ce-4051f6ccdc81">22</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if348e4ec7c2140e2b59c8963847d20a6_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzYtMi0xLTEtMA_f4d97e43-ba99-43e5-bfbb-054297d02cf4">2,824</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ied2bd6c4e76b4aef88e6910cc93da95c_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzYtNC0xLTEtMA_4cc4c45d-28e1-4d20-b64d-41e921c59925">2,166</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="number" contextref="if348e4ec7c2140e2b59c8963847d20a6_D20210101-20210404" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzYtNi0xLTEtMA_5e8e94de-c1f4-4740-9605-a313777e45c9">30</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzctMi0xLTEtMA_b07bfd7f-a947-4f55-8fbf-7c1b292bb668">14,582</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzctNC0xLTEtMA_37369dd6-3ee5-4f7a-a187-378163a1cc80">10,083</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="number" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="2" name="pfe:PercentageChangeInRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTo2ZDkwYWI3MzU0MGM0ZGU4OTYwZmRjYjQ2NTNhMWExZS90YWJsZXJhbmdlOjZkOTBhYjczNTQwYzRkZTg5NjBmZGNiNDY1M2ExYTFlXzctNi0xLTEtMA_e2672cd5-c588-4984-a57b-33a273632093">45</ix:nonfraction>&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></ix:nonnumeric></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaboration partner, BioNTech, have entered into agreements to supply pre-specified doses of BNT162b2 with multiple developed and emerging nations around the world and are continuing to deliver doses of BNT162b2 under such agreements. We currently sell the BNT162b2 vaccine directly to government and government sponsored customers. This includes supply agreements entered into in November 2020 and February 2021 with the European Commission (EC) on behalf of the different EU member states and certain other countries. Each EU member state submits its own BNT162b2 vaccine order to us and is responsible for payment pursuant to terms of the supply agreements negotiated by the EC.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Other Revenue Information</span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Significant Customers</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our significant wholesale customers, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K. Additionally, revenues from sales of BNT162b2 to the U.S. Government represented <ix:nonfraction unitref="number" contextref="i7a62d297308d46f0a9799ad6fea97d4f_D20210101-20210404" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzEwOTk1MTE2NjA4NzM_201eed17-5824-4b80-b7e8-ba039c52ba9e">14</ix:nonfraction>% of total revenues for the three months ended April&nbsp;4, 2021. Accounts receivable from sales of BNT162b2 to the U.S. Government represented <ix:nonfraction unitref="number" contextref="i66c5094c3226447689dc0560d6f61760_D20210101-20210404" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzEwOTk1MTE2NjA4Nzk_f2fd3772-681a-4779-a755-28b9caf83164">12</ix:nonfraction>% of total trade accounts receivable as of April&nbsp;4, 2021.</span></div></ix:continuation><div style="margin-bottom:5pt;margin-top:8pt"><span><br></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i98985c723dcb4553aae15fc7bdfbf59c" continuedat="i123d02fa33c34cd0ab980020160d5226"><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Significant Product Revenues</span></div><ix:nonnumeric contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzMzODY_c0e2d0ec-3d0b-4518-aee1-3f82aff1a47f" continuedat="i8ffe1a600d0042c7b31b644dc5739386" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following provides detailed revenue information for several of our major products:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tbody><tr><td style="width:1.0%"></td><td style="width:31.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.856%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">TOTAL REVENUES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i657b850568b24dd6b7d8ee1bb5b89883_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzItNC0xLTEtMA_bd95e214-c85c-4ca9-a11f-e3c3fea72747">14,582</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="iabf38cfff33c42d486bd8078e74842e3_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzItNi0xLTEtMA_591e71b7-7ffb-49fe-9494-4d987672a711">10,083</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Vaccines</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9603e0d9b21d49c5be55c622f6c795ab_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMtNC0xLTEtNDEx_b6cd2341-d5eb-423a-b6f7-bd4311b1fcd3">4,894</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0b12a7dd0f7b4be885c4d81f9a10294b_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMtNi0xLTEtNDEx_1239f2e4-df26-4abe-912d-6aa92d6c05da">1,611</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BNT162b2 alliance revenues and direct sales</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Active immunization to prevent COVID-19 </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i48c388983a924b6787e90a61d46de5f0_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQtNC0xLTEtNDEx_047f2551-2d31-4a04-945d-b1aee1a1574a">3,462</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5476b3cacd54534a52733f327d22fc7_D20200101-20200329" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQtNi0xLTEtNDEx_75508515-00df-4d48-b53e-e1f8f79259ca">—</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Prevnar 13/Prevenar 13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Pneumococcal disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9f019e8fef0d46fa970e6bc5a1606a83_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUtNC0xLTEtNDEx_8afd91f6-c82c-4872-aa5c-593b5b1a1dc2">1,284</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6f610d9fc6ff421a90a019b47027d494_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUtNi0xLTEtNDEx_76e08ad5-aa23-4561-9c06-72739acbfba5">1,450</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">FSME/IMMUN-TicoVac</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tick-borne encephalitis disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6d1b68c28ca4410bbffb116c280fada0_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNC0xLTEtMTU0Njk_cdd602b5-de4f-421a-8c2c-916e3ada821f">53</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i723d931b4dd942deb55d06022abc27b4_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNi0xLTEtMTU0Njk_b9f4d774-f901-4bb3-96f6-a35e5d73852f">48</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Nimenrix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Meningococcal disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5379efbc23eb4a779088ea894fa877b5_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNC0xLTEtNDEx_8726d48d-8349-4710-bd7c-e0f10a7c0b99">46</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3f45e6f0db0f4577abe662b6796b5220_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNi0xLTEtNDEx_acc2ac48-92c9-470a-9769-004bccb56a5b">75</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Vaccines</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i78cf066e90684b7b9df9958aafecc327_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzgtNC0xLTEtNDEx_6ce406ec-37a0-4b1e-9221-b03994d0e0c8">49</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id63a1c5781954d4487fc6f59bd931096_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzgtNi0xLTEtNDEx_5f483b36-9728-4c58-b9fd-29878c1e5ace">38</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Oncology</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i00018897a8a546288611fca2330ad40d_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzktNC0xLTEtNDIx_928ced8e-9364-4991-91fd-c1d23fb2a965">2,862</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="idf5ed2f322594ee1a086eb8e8b569a78_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzktNi0xLTEtNDIx_e7f64f4b-8131-40ee-8a62-3d37973a10d3">2,435</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ibrance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">HR-positive/HER2-negative metastatic breast cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic7a56e228c8c4fb4af59ee8e308b2807_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEwLTQtMS0xLTQyMQ_8a6df27e-b519-48c7-adc2-6729f72aeaf0">1,254</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3b5df41672ce4b05b07f62621c5b4d49_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEwLTYtMS0xLTQyMQ_bb8a2b8e-6188-45bd-82b6-17110ded7572">1,248</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xtandi alliance revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mCRPC, nmCRPC, mCSPC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i537596ddf57f4a02b104006ed602b6aa_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzExLTQtMS0xLTQyMQ_7b83ff17-208f-493a-9933-90d9502a39eb">267</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i23ef789e0d534d02a1d7359c4552b130_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzExLTYtMS0xLTQyMQ_2f4a5b71-9ec8-4cee-94a3-88c3b568e0c2">209</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inlyta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced RCC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie31e114d3b7d417390a43e68a76ebc7b_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEyLTQtMS0xLTE1NDc5_bceabdd8-7534-4cea-a052-c38e0d3e6633">229</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ica83de5b1ca741fdbb60e419050e2337_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEyLTYtMS0xLTE1NDc5_db811494-315b-4d83-a24e-549adae28480">169</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sutent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i77afd14fb72e417497c4103c75f24f02_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEyLTQtMS0xLTQyMQ_0db56c24-c460-464d-a8e2-a7b6e742ff1b">200</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2453457b9d7b4895b48538c2ca504312_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzEyLTYtMS0xLTQyMQ_c48e51fd-c9dc-4449-b947-dd36146c9671">205</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xalkori</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive and ROS1-positive advanced NSCLC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i008eb0e1b2034f1a97d37cb6b298b6e0_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE0LTQtMS0xLTQyMQ_ca32fa01-cc30-405f-ac07-b427eda4bdbd">134</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4c081afebe342a6b9d104a24173c945_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE0LTYtMS0xLTQyMQ_31f833f6-7c86-4a66-b12b-6542c47c563a">149</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Bosulif</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Philadelphia&nbsp;chromosome–positive&nbsp;chronic myelogenous leukemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibe5482ff3ca74e99a4c471902be880ff_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE1LTQtMS0xLTQyMQ_417f3cc0-13fe-4f1b-9985-eec2b6361b66">123</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6cda2992619a419ca7c9ae5072ee991f_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE1LTYtMS0xLTQyMQ_d346a5cf-775f-4676-8c95-1f09b9273b9a">100</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Retacrit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8ad7ac7bd7d14b64a515ad16d41b265b_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE2LTQtMS0xLTQyMQ_49e2457f-6199-4916-90ed-9ef32a01281a">109</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6f763c6d5acd44fb8b527b172b7e91a9_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE2LTYtMS0xLTQyMQ_749c3f1a-cb62-4705-801f-671cc447fa93">89</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ruxience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">Non-hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s Granulomatosis) and microscopic polyangiitis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1415dbe0431b4ff585e117766d30b66c_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTQtMS0xLTE1NDg4_a9b177ab-0ac4-41f0-a70f-28e31c98297b">98</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5fbb1d5760b442aeb54eaba81c729d04_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTYtMS0xLTE1NDg4_4c6b8103-ef3c-4039-a343-78e7a1d44861">7</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zirabev</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib84490e61d7441ce9086b7e638bc5377_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE4LTQtMS0xLTE1NDkz_77ca2450-768e-473f-98ee-23db6a13816f">86</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4075ba37701d4e64a9fcf6e9155c2dba_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE4LTYtMS0xLTE1NDkz_b52649c0-a128-4e02-8a16-6bca54f98db9">6</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Lorbrena</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ALK-positive metastatic NSCLC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i43b1b3aec0ed4785abc75ad1926500ec_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTQtMS0xLTQyMQ_3ade3a2d-1545-405b-b634-f67e081a3366">60</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i98ca505a108f49e5be75f181e05d725b_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE3LTYtMS0xLTQyMQ_403841b9-443a-439b-8c4c-ff0163ecaa7e">42</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Aromasin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Post-menopausal early and advanced breast cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i73a3f8cd3c9946348a58b845ed6f7e1e_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIwLTQtMS0xLTE1OTE5_739edb05-224b-4255-bbc3-e9bf50ab2d7d">52</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idaee0a8c94344749aad179a107f5379d_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIwLTYtMS0xLTE1OTIx_5cf5a222-3fff-4ab3-bc51-355906a66881">34</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Besponsa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Relapsed or refractory B-cell acute lymphoblastic leukemia </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8563afcb0c364449a9f8acafeecd9fc8_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIxLTQtMS0xLTE1OTE5_bb3a233d-7d4d-458e-9f0f-88f0c696b71c">50</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i21f664fb57c14f3eb0d15f6894cda787_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIxLTYtMS0xLTE1OTIx_988e52bd-6b03-4dfc-9ab2-d9853c4496f5">44</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Braftovi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Mektovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation and, in combination with Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> (cetuximab), for the treatment of BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">-mutant mCRC after prior therapy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0c04f02279024c998c82e2f2712f7a23_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE5LTQtMS0xLTQyNw_045f8b7a-7116-4421-a75d-65e7355959ac">47</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0efc4311285f4a58a9b66dfe1c45d6ac_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzE5LTYtMS0xLTQyNw_13d5fa33-ad3d-4226-b1d5-f7bc20b713a9">37</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Mektovi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">In combination with Braftovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">mutation</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idd8e8f340f0d4abbbc967ccada7c06fa_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIwLTQtMS0xLTQyNw_e37145f4-b52f-4d1b-8f0c-2445176083da">35</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia1ea3ea7ccfe4c16a02d1e5b63dc0790_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIwLTYtMS0xLTQyNw_a68467e4-52d7-4bb7-b8fe-7ef2b559ef1c">37</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Oncology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i27789be69eed4d90a1bb6fcbaf530eda_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIyLTQtMS0xLTQzMw_f450758b-8d5a-410b-9288-185b6a433d67">119</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1e9c2a5b4d4f4d0bb33f0e98cfa16271_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzIyLTYtMS0xLTQzMw_07090c70-f7cd-4d57-884a-d76c1575f1e1">59</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Internal Medicine</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6d86911b85754856a091d39a9a619036_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMtNC0xLTEtMA_339104d8-f2a4-4d92-84f7-27a037baaa1d">2,594</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="id6557f9893994f8b99b848935d3da8b7_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMtNi0xLTEtMA_5014e54f-62a2-4e20-98eb-ddb9f083ea7d">2,332</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Eliquis alliance revenues and direct sales</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib41c041fc3524f8a90b93fef087c22d2_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQtNC0xLTEtMA_edb58811-4e34-4158-b753-89b65192d859">1,643</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2cbd34f66a8a4776bed2e8377de9c487_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQtNi0xLTEtMA_733a49ad-6056-4006-a78f-f628caf2663d">1,300</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Chantix/Champix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">An aid to smoking cessation treatment in adults 18 years of age or older</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i15547904869341898a05e8608012fdf7_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUtNC0xLTEtMA_98ecd8b0-ce73-4f0e-ad3b-b4e6d421f10c">217</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia665187179da484eb6e599146133e64c_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUtNi0xLTEtMA_e86b12cc-2864-4a84-8391-1f89eddd02a2">270</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Premarin family</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Symptoms of menopause</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i69c7ad6f75474c3ab9031f754ef595f3_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNC0xLTEtMA_5c35c781-e928-457a-a06d-00e984fa2688">143</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="i3d6f5d1fb3b543a5aa2e3769810c7d71_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzYtNi0xLTEtMA_94c3315b-2bc4-4522-a5f5-9ea8155295f5">152</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pristiq</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Depression</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7affcb9aacad4720924821d952eff5b5_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI5LTQtMS0xLTE1OTI1_f3c4b946-e74d-4718-834d-f3aaefd26598">60</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6217a5b597e247debffac06a2be42229_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI5LTYtMS0xLTE1OTI3_0e370ed6-70bb-4668-84b9-3c50308f771d">41</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Toviaz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Overactive bladder</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iab6ee95b0dc4487192c28cf5e2a3b682_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI3LTQtMS0xLTE1NTA2_39aa5fb6-f7ab-4c36-9267-8ce00c67fe65">57</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i39d647526b664456a53481f1fcd29c09_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI3LTYtMS0xLTE1NTA2_705ed196-8bdd-4fd9-8ede-323e57b5669b">60</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Internal Medicine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6abdfcdbb14841da92a891ebbfffe427_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzktNC0xLTEtMA_33dc4f68-76c4-4c27-8126-a984b828a987">474</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i156fe6a2c9c142f59b72145e6b6d5cab_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzktNi0xLTEtMA_a1dfa7ac-d7e6-429d-bf04-d09ab44960ce">509</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Hospital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia9f9a5b9fdbd404e9d13e74900d30aa9_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI0LTQtMS0xLTA_ebc1c2d7-b856-4844-b32d-d781f550ded9">2,343</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2046e8ddbd51408ba08ecc31135c57f1_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI0LTYtMS0xLTA_6211b2d9-d19a-4b45-971b-40aa22391ee5">2,088</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sulperazon</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i94c8e4cc97e94f1591aeeffcdff6f216_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI1LTQtMS0xLTA_49b33136-137f-4266-b009-9abe46fa6a7b">192</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie83ffc748ed9440c9519ce6855fc53ce_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI1LTYtMS0xLTA_de5f1774-8826-4e53-9fd3-e3c6d33f793d">187</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Medrol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Anti-inflammatory glucocorticoid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie5a2f657b1f24eeea52ac417440d6370_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI2LTQtMS0xLTA_2b5ce3e7-021e-4d46-b192-8d36813d04d2">99</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i734d2d6b65984271810bcacb4e2423ec_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI2LTYtMS0xLTA_851f1a5b-b3a2-4039-bc1e-d270c02c061b">129</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zavicefta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9b9deb8c9634ec182507e244ef8c655_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMzLTQtMS0xLTE1NTEy_c42c1f8f-dc46-4a67-a03a-c301c52f9ac1">94</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7869ec1912fc40b5a5c2b2c112e0983d_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMzLTYtMS0xLTE1NTEy_65d30d6c-b9fb-441e-8d25-f0ab9195d9a8">49</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zithromax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0eb988cb37cf421ba9e886afde505719_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI4LTQtMS0xLTA_6374d573-a87c-4a36-bd53-98926d72ed72">89</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0137cdc4b152445aa75e142d90ce256c_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzI4LTYtMS0xLTA_f696e168-af9b-41fc-8d90-2dc8ad63a4e2">138</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vfend</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fungal infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i621a67aa4d754b1886dda75ad4da9448_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMwLTQtMS0xLTA_7040c689-76f9-435e-9e12-73c7b0f245dd">80</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ida6c3bed72aa4d57a4caa9581c28ddb4_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMwLTYtMS0xLTA_71555e69-a4a7-44e1-880f-f09dcfe9899d">74</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Fragmin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Treatment/prevention of venous thromboembolism</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if35eed0bbfbe41e0a453f1b92ef34eda_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMyLTQtMS0xLTA_58e27134-cc8c-411c-8d27-cfb478f8478e">71</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3dc26321ad144544b2f9b6dc158b96c3_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMyLTYtMS0xLTA_c121e5fe-55af-468a-87a8-47ed849c8cc7">59</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">EpiPen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Epinephrine injection used in treatment of life-threatening allergic reactions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i986fa1dea9aa41ccb4de85b6f8353db8_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQwLTQtMS0xLTE1NTE4_abd76629-91b8-4df2-9764-2f1b7d507e15">66</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia251f6f252be4fca87be237b62587e21_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQwLTYtMS0xLTE1NTE4_38330553-8b6c-4ea4-90b7-4aa3f8986b35">84</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Zyvox</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5fe2ee5e9785471286d6b2002d7635bb_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMzLTQtMS0xLTA_93246ed8-93c0-4762-8596-8ccda3564dec">55</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1ca2d88252f54285811dd499c60a38ab_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzMzLTYtMS0xLTA_c84d0308-24dd-46a9-8f30-1d958b299b8a">70</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Precedex</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sedation agent in surgery or intensive care</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7b016a02fe0d4861a331ec2814ec7032_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM0LTQtMS0xLTA_a888aabe-459b-4a99-ba25-7fc696a5a372">55</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i468ab4f9aacd4ffa939463e8952be105_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM0LTYtMS0xLTA_2467aa26-882b-48e1-9dd4-df09ca9d7188">42</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">IVIg Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9846250722404133a31c34c978297518_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQzLTQtMS0xLTE1OTQz_2dab6a30-5162-4382-9300-d08f644c3b8c">105</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i92325ad08a5f49bc9682465145b3e8f0_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQzLTYtMS0xLTE1OTQ1_40e8ebc2-4614-4da4-b723-7f92d2ccbd2d">98</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizer CentreOne</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i75641ceea2e34c678a6bb185ce58971b_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM1LTQtMS0xLTA_58ef7360-8332-446f-9bee-f9fe3b84fa0f">391</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib9903f105558492aac6500bc30eaadca_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM1LTYtMS0xLTA_dce1c85b-ec79-4fe2-bc3f-3097afcb1a19">152</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Anti-infectives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4ec32a5a6aac40fc97766a55aaac3493_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM2LTQtMS0xLTA_ca95dd51-916a-4255-bd9d-a716c45cc979">397</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i47fd13e918014bc1beff32e5257f9f57_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM2LTYtMS0xLTA_a4546b05-e2e6-4e18-a4e6-db2aa4824564">395</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Hospital</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c8c261f6f0e45e39af9f5f51c35243d_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM3LTQtMS0xLTA_61c4df76-99cb-4cb9-b405-9868e8bf29b6">648</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonfraction unitref="usd" contextref="i4810d15cbffd4e4e802a5445668fd1ea_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzM3LTYtMS0xLTA_196978d1-8811-4173-805a-cb4e89c79f3e">610</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Inflammation &amp; Immunology (I&amp;I)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i61794ea5f5cf48fab62bb32a45f1fc0d_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ0LTQtMS0xLTA_7ecad3a3-8c46-4190-8dd2-fa2e19fb293e">1,065</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9654ceb739fe46b9b9a038074b9fac50_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ0LTYtMS0xLTA_95e4717a-1518-49fc-970b-c5b38526cae5">978</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Xeljanz</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib0708bd9e2c4460398370ad240ac8c5b_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ1LTQtMS0xLTA_ddadfa0c-9ceb-4970-9c72-4859224c3b9d">538</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia324f10d774b4091bbc7a6595d84d40f_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ1LTYtMS0xLTA_935639d7-1a10-4379-8129-801d55562c24">451</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Enbrel (Outside the U.S. and Canada)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i50e8b3687c444ba79acdad03ee09eed1_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ2LTQtMS0xLTA_9a855437-f4ba-439f-88b9-eebfb24bceae">319</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id1c88ca089644d47a86f894f06a3ded6_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ2LTYtMS0xLTA_a513e818-5ce6-49b2-8931-4fdcd584d3cb">347</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PFIZER INC. AND SUBSIDIARY COMPANIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div></div><ix:continuation id="i123d02fa33c34cd0ab980020160d5226"><ix:continuation id="i8ffe1a600d0042c7b31b644dc5739386"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tbody><tr><td style="width:1.0%"></td><td style="width:31.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.856%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inflectra/Remsima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i00ea7513fe484af08288a189e3eda7f2_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ3LTQtMS0xLTA_be14bc2e-0760-49f9-a752-48d428e0d10c">177</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2017ebae1b07422f89732732bb7b67c1_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ3LTYtMS0xLTA_d72b1e89-0069-4365-8bf9-5230e168cf49">158</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other I&amp;I</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5b7ba8b676774d95816f5a4a38800825_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ4LTQtMS0xLTA_8293a04a-3b4a-46a1-b694-c678651ea32d">31</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib0ac15d44c884c33968f6d0c1d612c81_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ4LTYtMS0xLTA_4a57a4d2-851b-4e9e-9c13-45638fb3d25e">22</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Rare Disease</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9d19ebf19eb9447ba701f3dca966a943_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ5LTQtMS0xLTA_d56874f4-3998-4385-af11-fc158e9be52a">824</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i99936a11a4df47b7ae544a9001ca9265_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzQ5LTYtMS0xLTA_5b8ba429-9a55-4fa7-93e6-42409ade7405">639</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Vyndaqel/Vyndamax</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">ATTR-cardiomyopathy and polyneuropathy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1255cd3269234799ad20eb6dc24d727d_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUwLTQtMS0xLTA_aad9c342-75af-47a6-9620-bc10c9e7c4e0">453</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i43f8898c614547fa9e42f50327b951e1_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUwLTYtMS0xLTA_2d16c412-a3f1-41de-b782-cebb95709037">231</ix:nonfraction>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">BeneFIX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i690c1c21d3d94500b32a53210d291dc4_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUxLTQtMS0xLTA_e2c0992f-ed1e-4545-9c37-d622e529bb27">112</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i217f041566f14b16a835176fc12cebe4_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUxLTYtMS0xLTA_2bcb6ee4-01d5-497a-9d1c-7669f2b87f28">121</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Refacto AF/Xyntha</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hemophilia A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib4d2e2ea75bb4adcb1cb4ef2d161cabe_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUyLTQtMS0xLTE1NTM4_b7c97c54-0a5a-4451-9752-829a7a659ddf">89</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic6672c1127314ac3ad703dc29ee3f887_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUyLTYtMS0xLTE1NTM4_1d8d54d4-8fc6-4aff-93c7-7cdd6a7f7c02">89</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Genotropin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Replacement of human growth hormone</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9c1f70a9b9434f289ed936ac2da591e2_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUyLTQtMS0xLTA_bde9b100-345e-488a-b63d-754151871331">80</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5449776d21c54ff6954e42801e8440c0_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzUyLTYtMS0xLTA_e213e133-cc55-4c55-a28e-3a455669d91a">103</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Somavert</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Acromegaly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i72ef4ea1309e41eebd2560fcbcc68553_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU0LTQtMS0xLTA_ed4ac610-7ee3-4bf9-bbac-228146dd059a">65</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4045f62b3268485d984a63420d9173d9_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU0LTYtMS0xLTA_ed64a288-fd5e-4f2b-9812-25b5cddf0101">64</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">All other Rare Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib30014db01a64fe096085aec05ab20b5_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU1LTQtMS0xLTA_875bf804-d477-4808-b4b3-10d13202e587">26</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6cc0aa456d204aef9a0446f3dc171a16_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU1LTYtMS0xLTA_e8fb6c9c-3db1-40f8-9b5c-8e868eae59d5">31</ix:nonfraction>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Total Alliance revenues</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i99dc09055ced42e9a643ccb1053a29e4_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU2LTQtMS0xLTA_1f83642f-54d9-4c7e-bdf4-a904b5ac0eb4">1,770</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4c70725bb41743c3b9117721c78de8af_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU2LTYtMS0xLTA_c58ca481-4b90-46ab-a793-9fc2f7b5a2c8">1,382</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Biosimilars</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i46ee056942d049b998140d1e6ca61d11_D20210101-20210404" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU3LTQtMS0xLTA_5e84cba2-75ed-4233-89d2-054841fe56e5">530</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4aa4603d496a4463b3977ffbc8fc8ab1_D20200101-20200329" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU3LTYtMS0xLTA_e9fd7eb9-fb8f-48f6-bd7b-8da313ce7353">288</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total Sterile Injectable Pharmaceuticals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i16a3000e73e34ab596e85f929ac44904_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU4LTQtMS0xLTA_83e58576-d825-4c37-8e30-af7101c1e50c">1,482</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonfraction unitref="usd" contextref="i337a50db1f214928b242e8095a90fa5b_D20200101-20200329" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90YWJsZTpmMGE4Y2RlMTI1ZTY0YzgzOTkzZGMxYTViMmQ2OTAwNS90YWJsZXJhbmdlOmYwYThjZGUxMjVlNjRjODM5OTNkYzFhNWIyZDY5MDA1XzU4LTYtMS0xLTA_d4811ed8-85b6-4d0e-9e39-660dc6e07b3d">1,401</ix:nonfraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY0_53ae7d0d-76c7-4217-b122-8dd86b7d3a53" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt">On November&nbsp;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">. Beginning in the fourth quarter of 2020, the results of our Meridian subsidiary, which was previously included in our former Upjohn operating segment, are reported in the Hospital therapeutic area for all periods presented.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0NDQ_dd7a49f2-0b67-46aa-84b2-adc27b58f7bb" footnoterole="http://www.xbrl.org/2003/role/footnote">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Retacrit, Ruxience and Zirabev</ix:footnote>.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE1OTQyOTE4NjEyODY2_d5f7e806-d50b-47ea-a73d-f1c044face2c" footnoterole="http://www.xbrl.org/2003/role/footnote">Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig. </ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.33pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzQyODgwOTUzNTEwNjk5_d79e0e6a-f2d7-4e24-90aa-b3b16147cdf0" footnoterole="http://www.xbrl.org/2003/role/footnote">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;padding-left:3.6pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzM0MDg_8d635d1c-7c5d-42ca-8dd6-093dc2eca4fc" footnoterole="http://www.xbrl.org/2003/role/footnote">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.</ix:footnote></span></div></ix:continuation><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Deferred Revenues</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred revenues primarily relate to advance payments received or receivable in connection with contracts that we entered into during 2021 and 2020 with various government or government sponsored customers in international markets for supply of BNT162b2. The deferred revenues associated with the advance payments related to BNT162b2 total $<ix:nonfraction unitref="usd" contextref="iaa3543d0a7d3439fa27ca8d61cd453f5_I20210404" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzI5ODA_82b6ca28-7195-461b-94d1-537364e140ea">1.9</ix:nonfraction> billion as of April&nbsp;4, 2021 and $<ix:nonfraction unitref="usd" contextref="iadcb9082716e49ad8217f6c35c00c9da_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE2NDkyNjc0NDY2NjU_51ec06dc-3a69-4560-a820-b394619b1382">957</ix:nonfraction> million as of December 31, 2020 and are recorded in current liabilities. The increase in the BNT162b2 deferred revenues during the first quarter of 2021 was the result of additional advance payments received as we entered into new or amended contracts or as we invoiced customers in advance of vaccine deliveries. During the first quarter of 2021, we recognized revenue of $<ix:nonfraction unitref="usd" contextref="i1fe7d67ab99549b986734218b58c0a78_D20210101-20210404" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzE2NDkyNjc0NDc3ODU_1d94c7b1-9909-4901-92b7-865fbbbda8d2">192</ix:nonfraction> million that was included in the balance of BNT162b2 deferred revenues as of December 31, 2020. The BNT162b2 deferred revenues as of April&nbsp;4, 2021 will be recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proportionately as we deliver doses of the vaccine to our customers and satisfy our performance obligation under the contracts, which we expect to occur within the next 12 months. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the end of our fiscal first quarter of 2021 and through April 30, 2021, we received or were due additional advance payments associated with agreements to supply BNT162b2 totaling approximately $<ix:nonfraction unitref="usd" contextref="i6496cc9734fa4410878f18fd2a5cfa91_D20210405-20210430" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjBhZWY5ZWI1NmVjYTQzNjg5YWMyZWMxZTFhMTI3YWU0L3NlYzowYWVmOWViNTZlY2E0MzY4OWFjMmVjMWUxYTEyN2FlNF8xMjEvZnJhZzo4NjZhOGUwZjhkOWI0NmY5OGFjZWRhNTQ3ZjUwZjViNS90ZXh0cmVnaW9uOjg2NmE4ZTBmOGQ5YjQ2Zjk4YWNlZGE1NDdmNTBmNWI1XzEwOTk1MTE2NDAyOTY_a59c8cee-4655-44be-bb86-1c3bc049ce01">3.8</ix:nonfraction> billion.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_133"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENTS’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF<br> OPERATIONS</span></div><div><span><br></span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_136"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK</span></div><div><span><br></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business and Strategy</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our revenues come from the manufacture and sale of biopharmaceutical products. With the formation of the Consumer Healthcare JV in 2019 and the completion of the spin-off and combination of our Upjohn Business with Mylan in November 2020, Pfizer has transformed into a focused, global leader in science-based innovative medicines and vaccines. We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide. The financial results of the Upjohn Business and the Mylan-Japan collaboration are reflected as discontinued operations for all periods presented. Prior-period information has been restated to reflect our current organization structure. We expect to incur costs of approximately $700 million in connection with separating Upjohn, of which approximately 70% has been incurred since inception and through the first quarter of 2021. These charges include costs and expenses related to separation of legal entities and transaction costs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our business, strategy and operating environment, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section within MD&amp;A of our 2020 Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although foreign exchange rate changes are part of our business, they are not within our control and since they can mask positive or negative trends in the business, we believe presenting operational variances excluding these foreign exchange changes provides useful information to evaluate our results.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business Development Initiatives</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to strategically capitalizing on growth opportunities by advancing our own product pipeline and maximizing the value of our existing products, as well as through various business development activities.</span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant recent business development activities include:</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisition of Amplyx Pharmaceuticals, Inc.</span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> </span><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">(Amplyx)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––In April 2021, we announced that we acquired Amplyx, a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset in Phase 2 development for the treatment of invasive fungal infections.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, including discussion of recent significant business development activities, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the more significant recent transactions through February&nbsp;25, 2021, the filing date of our 2020 Form 10-K, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K.</span></div><div><span><br></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our First Quarter 2021 Performance</span></div><div><span><br></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased $4.5 billion, or 45%, in the first quarter of 2021, compared to the same period in 2020, reflecting an operational increase of $4.2 billion, or 42%, as well as a favorable impact of foreign exchange of $284 million, or 3%. Excluding revenues from BNT162b2 of $3.5 billion, revenues increased 8% operationally, including a negative 5% impact from pricing. The 8% operational growth reflects strong growth in Eliquis, Vyndaqel/Vyndamax, Xeljanz, Xtandi, Inlyta, Biosimilars and the Hospital therapeutic area, partially offset by Prevnar 13/Prevenar 13, Ibrance and Chantix in the U.S. and Enbrel internationally. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues were favorably impacted by approximately $400 million as a result of the first quarter of 2021 having three additional selling days in the U.S. and four additional selling days in international markets as compared to the first quarter of 2020. This increase in selling days will be offset in the fourth quarter of 2021 resulting in essentially the same number of selling days in the full year of 2021 as full year 2020. The favorable impact in the first quarter of 2021 from selling days was partially offset by the non-recurrence of favorable impacts related to COVID-19 on the first quarter of 2020, including increased demand for certain products of approximately $150 million and additional wholesaler inventories of approximately $100 million. The net favorable impact on the first of quarter 2021 revenues of all of the above factors was approximately $150 million, accounting for approximately 1.5 percentage points of operational growth.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Condensed Consolidated Statements of Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Geography</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selected Product Discussion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sections for more information, including a discussion of key drivers of our revenue performance. For information regarding the primary indications or class of certain products, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13B.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income from continuing operations before provision for taxes on income</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $2.8&nbsp;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations before provision for taxes on income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the first quarter of 2021, compared to the same period in 2020, was primarily attributable to higher revenues, net gains in the first quarter of 2021 versus net losses in the first quarter of 2020 on equity securities, higher net periodic benefit credits related to pension and postretirement plans and higher income from collaborations, partially offset by higher</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Cost of sales, Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Research and development expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Analysis of the Condensed Consolidated Statements of Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within this MD&amp;A and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our tax provision and effective tax rate, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for Taxes on Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Operating Environment</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, like other businesses in our industry, are subject to certain industry-specific challenges. These include, among others, the topics listed below and in our 2020 Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Rights and Collaboration/Licensing Rights</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss, expiration or invalidation of intellectual property rights, patent litigation settlements with manufacturers and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues. Certain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face significantly increased generic competition over the next few years. For example, the basic product patent for Chantix in the U.S. expired in November 2020. While multi-source generic competition for Chantix has not yet begun, it could commence at any time. Also, the basic product patent for Sutent in the U.S. will expire in August 2021. While additional patent expiries will continue, we expect a moderate impact of reduced revenues due to patent expiries from 2021 through 2025. We continue to vigorously defend our patent rights against infringement, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking necessary steps to ensure appropriate patient access.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on patent rights we consider most significant in relation to our business as a whole, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business––Patents and Other Intellectual Property Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2020 Form 10-K. For a discussion of recent developments with respect to patent litigation, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12A1.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Environment/Pricing and Access––Government and Other Payer Group Pressures</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing of medicines and vaccines by pharmaceutical manufacturers and the cost of healthcare, which includes medicines, vaccines, medical services and hospital services, continues to be important to payers, governments, patients, and other stakeholders. Federal and state governments and private third-party payers in the U.S. continue to take action to manage the utilization of drugs and cost of drugs, including increasingly employing formularies to control costs by taking into account discounts in connection with decisions about formulary inclusion or favorable formulary placement. We consider a number of factors impacting the pricing of our medicines and vaccines. Within the U.S., we often engage with patients, doctors and healthcare plans. We also often provide significant discounts from the list price to insurers, including PBMs and MCOs. The price that patients pay in the U.S. for prescribed medicines and vaccines is ultimately set by healthcare providers and insurers. Governments globally may use a variety of measures, including proposing pricing reform or legislation, cross country collaboration and procurement, price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access, “international reference pricing” (i.e., the practice of a country linking its regulated medicine prices to those of other countries), quality consistency evaluation processes and volume-based procurement. In the U.S., we expect to see continued focus on regulating pricing resulting in additional legislation and regulation under the newly elected Congress and the Biden Administration. We anticipate that these and similar initiatives will continue to increase pricing pressures globally. For additional information, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pricing Pressures and Managed Care Organizations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation and Price Constraints</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sections in our 2020 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Global Economic Environment</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the industry-specific factors discussed above, we, like other businesses of our size and global extent of activities, are exposed to the economic cycle. For additional information, please see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Global Economic Environment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of the MD&amp;A of our 2020 Form 10-K.</span></div><div><span><br></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">COVID-19 Pandemic</span></div><div><span><br></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuation of the COVID-19 pandemic has impacted our business, operations and financial condition and results. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Our Response to COVID-19</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to confronting the public health challenge posed by the pandemic by collaborating with industry partners, global regulators and academic institutions to develop potential approaches to prevent and treat COVID-19. We have made some important advances, including, among others:</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">As discussed in our 2020 Form 10-K, in December 2020, the FDA authorized the distribution and use of BNT162b2 in the U.S. to help prevent COVID-19 for individuals 16 years of age and older under an EUA. In May 2021, the FDA expanded the EUA to authorize the use in individuals 12 to 15 years of age. BNT162b2 has not been approved or licensed by the FDA. The EUA authorizes distribution and use of this product subject to the conditions set forth in the EUA, and only for the duration of the declaration by the Department of Health &amp; Human Services that circumstances exist justifying authorization of emergency use of drugs and biological products (such as BNT162b2) during the COVID-19 pandemic under Section 564 of the U.S. Federal Food, Drug and Cosmetic Act (the Declaration), or until revocation of the EUA by the FDA. The FDA has issued EUAs to certain other companies for products intended for the prevention or treatment of COVID-19 and may continue to do so during the duration of the Declaration. The FDA expects EUA holders to work towards submission of a BLA as soon as possible. BNT162b2 has now been granted a CMA, EUA or temporary authorization in many other countries around the world. In addition, the companies have requested similar amendments to expand the authorizations for use in individuals 12 to 15 years of age by other regulatory authorities worldwide. We also announced in May 2021 the initiation of a rolling submission of a BLA with the FDA seeking full approval for BNT162b2 for individuals 16 years of age and older. We are continuing to study vaccines to help prevent COVID-19, including evaluating BNT162b2 in additional populations, booster doses and emerging variants. Subject to continuous process improvements, expansion at current facilities and adding new suppliers and contract manufacturers, the companies believe that they can potentially manufacture at least 2.5 billion doses in total by the end of 2021 and at least 3 billion doses in 2022. The companies have entered into agreements to supply pre-specified doses of BNT162b2 with multiple developed and emerging nations around the world and are continuing to deliver doses of BNT162b2 to governments under such agreements. We also signed agreements with Israel and Canada to supply BNT162b2 doses in 2022 and beyond and are currently negotiating similar potential agreements with multiple other countries. As of May 4, 2021, based on the 1.6 billion doses that are to be delivered in 2021 under agreements that have been signed through mid-April 2021, we forecasted approximately $26 billion in revenues in 2021 from BNT162b2, with gross margin to be split evenly with BioNTech. This forecast may be adjusted in the future as additional agreements are signed and as circumstances warrant.</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">In March 2021, we initiated a Phase 1 study in healthy adults to evaluate the safety and tolerability of an investigational, novel oral antiviral therapeutic for COVID-19, PF-07321332, which is a SARS-CoV2-3CL protease inhibitor. This Phase 1 trial is being conducted in the U.S. We also have an ongoing Phase 1b clinical trial for an intravenously administered investigational protease inhibitor for COVID-19, PF-07304814.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our significant investments and efforts, any of our ongoing development programs related to COVID-19 may not be successful as the risk of failure is significant, and there can be no certainty these efforts will yield a successful product or that costs will ultimately be recouped.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Impact of COVID-19 on Our Business and Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our on-going monitoring and assessment, we have made certain assumptions regarding the pandemic for purposes of our operational planning and financial projections, including assumptions regarding the duration, severity and the global macroeconomic impact of the pandemic, as well as COVID-19 vaccine supply and contracts, which remain dynamic. Despite careful tracking and planning, we are unable to accurately predict the extent of the impact of the pandemic on our business, operations and financial condition and results due to the uncertainty of future developments. We are focused on all aspects of our business and are implementing measures aimed at mitigating issues where possible, including by using digital technology to assist in operations for our commercial, manufacturing, R&amp;D and enabling functions globally.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in our 2020 Form 10-K, our business and operations were impacted in 2020 by the pandemic in various ways, which is ongoing in 2021. For detail on the impact of the COVID-19 pandemic on our products, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Consolidated Statements of Income—Revenues—Selected Product Discussion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within this MD&amp;A. In 2021, we have continued not to see a significant disruption to our supply chain to date, and all of our manufacturing sites globally have continued to operate at or near normal levels. However, we are seeing an increase in overall demand in the industry for certain components and raw materials potentially constraining available supply, which could have a future impact on our business. We are continuing to monitor and implement mitigation strategies in an effort to reduce any potential impact. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to pursue efforts to maintain the continuity of our operations while monitoring for new developments related to the pandemic. Future developments could result in additional favorable or unfavorable impacts on our business, operations or financial condition and results. If we experience significant disruption in our manufacturing or supply chains or significant disruptions in clinical trials or other operations, or if demand for our products is significantly reduced as a result of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 pandemic, we could experience a material adverse impact on our business, operations and financial condition and results. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please see the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Item 1A. Risk Factors—COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of the MD&amp;A of our 2020 Form 10-K.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_142"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our significant accounting policies, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2020 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and the most complex judgments: Acquisitions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Fair Value (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Revenues (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Asset Impairments (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Tax Assets and Liabilities and Income Tax Contingencies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); Pension and Postretirement Benefit Plans (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1Q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); and Legal and Environmental Contingencies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A in our 2020 Form 10-K. See also </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K for a discussion about the risks associated with estimates and assumptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of a recently adopted accounting standard, a change in accounting principle related to our pension and postretirement plans, and significant accounting policies, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes 1B, 1C </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 1D.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_145"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_148"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenues by Geography</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tbody><tr><td style="width:1.0%"></td><td style="width:16.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="57" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents worldwide revenues by geography:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="51" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">World-wide</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inter-national</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% Change in Revenues</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,582&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,083&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,597&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,289&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,985&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,793&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">First Quarter of 2021 vs. First Quarter of 2020</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.639%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following provides an analysis of the worldwide change in revenues by geographic areas in the first quarter of 2021:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended April 4, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Operational growth/(decline):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Growth from BNT162b2, Eliquis, Vyndaqel/Vyndamax, Xeljanz, Xtandi, Inlyta, Biosimilars and the Hospital therapeutic area, partially offset by declines from Prevnar 13/Prevenar 13 and Ibrance. See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Analysis of the Condensed Consolidated Statements of Income––Revenues––Selected Product Discussion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> within MD&amp;A for additional analysis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,339&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,384&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,956&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lower revenues for Chantix/Champix and Enbrel. The decrease in Chantix/Champix was driven by the U.S. and primarily reflects a negative impact of the COVID-19 pandemic resulting in a decline in patient visits to doctors for preventative health purposes, as well as the loss of patent protection in the U.S. in November 2020. The decrease for Enbrel internationally primarily reflects continued biosimilar competition in most developed Europe markets and Japan, which is expected to continue</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other operational factors, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operational growth/(decline), net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,216&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,308&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,907&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Favorable impact of foreign exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> increase/(decrease)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,499&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,308&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,192&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging markets revenues increased $658 million, or 30%, in the first quarter of 2021 to $2.8 billion from $2.2 billion in the first quarter of 2020, reflecting an operational increase of $672 million, or 31%, and an unfavorable impact from foreign exchange of approximately 1%. The operational increase in emerging markets was primarily driven by revenues from BNT162b2 and growth from Eliquis.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue Deductions</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. These deductions represent estimates of related obligations and, as such, knowledge </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Historically, adjustments to these estimates to reflect actual results or updated expectations, have not been material to our overall business and generally have been less than 1% of revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product revenue growth trends.</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following presents information about revenue deductions:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid and related state program rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based contract rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,031&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales returns and cash discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,087&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,371&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue deductions are primarily a function of product sales volume, mix of products sold, contractual or legislative discounts and rebates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on our accruals for revenue deductions, including the balance sheet classification of these accruals, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1D.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_163"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenues––Selected Product Discussion</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tbody><tr><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global<br>Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Region</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 4, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oper.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operational Results Commentary</span></td></tr><tr style="height:11pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BNT162b2</span></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$3,462</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">*</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,038&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Driven by global uptake, following a CMA, EUA or temporary authorization. </span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,424&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,462&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliquis</span></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1,643</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 25%</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">981&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">805&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily driven by continued increased adoption in non-valvular atrial fibrillation as well as oral anti-coagulant market share gains, as well as a favorable adjustment related to the Medicare “coverage gap” provision resulting from lower than previously expected discounts in prior periods.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">662&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">495&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,643&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,300&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Prevnar 13/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prevenar 13</span></div></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$1,284</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Down 12% </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(operationally)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">638&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">794&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily driven by decline in the U.S., resulting from:</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">disruptions to wellness visits due to COVID-19-related mobility restrictions or limitations, including adults delaying other vaccinations while receiving COVID-19 inoculations due to CDC guidance;</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">impact of the revised ACIP recommendation for the adult indication to shared clinical decision making, which means the decision to vaccinate should be made at the individual level between healthcare providers and their patients, as well as the continued impact of a lower remaining eligible adult population; and</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">decline for the pediatric indication, primarily reflecting the unfavorable impact of COVID-19 and lower year-over-year birth rates. </span></div></td></tr><tr style="height:39pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">646&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">656&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:39pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,284&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,450&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:26pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ibrance</span></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1,254</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Down 1%</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:100%">&nbsp;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">794&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">852&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily driven by decline in the U.S., which reflects relatively stable U.S. prescription volume demand and Ibrance’s continued strong leadership position within the CDK 4/6 class, but also an increase in the proportion of patients accessing Ibrance through our Patient Assistance Program due to economic hardships brought on by the COVID-19 pandemic which is expected to normalize over time as the economic impact of the pandemic subsides. Also reflects continued strong volume growth internationally, partially offset by pricing pressures.</span></div></td></tr><tr style="height:26pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">460&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:26pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,254&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,248&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Xeljanz</span></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$538</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 18% </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">286&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily driven by the U.S., reflecting higher volumes within the RA, PsA and UC indications, enabled by improvements in formulary access. Also reflects operational growth internationally mainly driven by continued uptake in the RA indication and, to a lesser extent, the UC indication in certain developed markets.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">538&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">451&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vyndaqel/ <br>Vyndamax</span></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$453</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 88%</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily driven by the approval in February 2020 of the ATTR-CM indication in the EU, as well as continued strong uptake of the ATTR-CM indication in the U.S. and Japan.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">105&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Xtandi</span></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$267</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 28% </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">267&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily driven by continued strong demand for Xtandi in the mCRPC and nmCRPC indications, as well as the mCSPC indication, which was approved in the U.S. in December 2019. </span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">267&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inlyta</span></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$229</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 34% </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily due to increased demand in the U.S. and developed Europe following the approvals in 2019 for combinations of certain immune checkpoint inhibitors and Inlyta for the first-line treatment of patients with advanced RCC.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biosimilars</span></td><td colspan="3" rowspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$530</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 79% </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">327&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily driven by recent oncology monoclonal antibody biosimilar launches globally and continued growth from Retacrit in the U.S.</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">530&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">288&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospital</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$2,343</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 10% </span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">905&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">890&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&nbsp;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Primarily driven by Pfizer CentreOne, our contract manufacturing operation, reflecting sales of legacy Upjohn products to Viatris under manufacturing and supply agreements and remdesivir to Gilead Sciences Inc., as well as growth from recent anti-infective product launches in international markets, partially offset by lower year-over-year volume for certain products globally due to a COVID-19-related surge in demand in the prior-year quarter. </span></div></td></tr><tr style="height:23pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,437&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,198&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,343&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,088&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Calculation is not meaningful or results are equal to or greater than 100%.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patents and Other Intellectual Property Rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2020 Form 10-K for information regarding the expiration of various patent rights, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a discussion of recent developments concerning patent and product litigation relating to certain of the products discussed above, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information regarding the primary indications or class of the selected products discussed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_172"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Developments</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A comprehensive update of Pfizer’s development pipeline was published as of May&nbsp;4, 2021 and is available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of our research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides information about significant marketing application-related regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan. The table below includes only approvals for products that have occurred in the last twelve months and does not include approvals that may have occurred prior to that time. The table includes filings with regulatory decisions pending (even if the filing occurred outside of the last twelve-month period).</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tbody><tr><td style="width:1.0%"></td><td style="width:14.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.652%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PRODUCT</span></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">DISEASE AREA</span></td><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">APPROVED/FILED*</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">U.S.</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">EU</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">JAPAN</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">PF-07302048 (COVID-19 Vaccine)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent COVID-19 (16 years of age and older)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%">EUA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">Dec. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%">CMA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">Dec. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">Feb. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">2021</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Bavencio </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(avelumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">First-line maintenance urothelial cancer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">June </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Jan. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Feb. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Nyvepria<br>(pegfilgrastim-apgf)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Neutropenia in patients undergoing cancer chemotherapy (biosimilar)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">June </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Nov. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Braftovi (encorafenib)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(c) </span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Second or third-line BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">v600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">-mutant mCRC (combination with Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> (cetuximab))</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"><div style="text-align:center"><span><br></span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">June </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Nov. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Braftovi (encorafenib) and Mektovi (binimetinib)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(c) </span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Second or third-line BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">-mutant mCRC (combination with Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> (cetuximab))</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Nov. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Xtandi</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(enzalutamide)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%"> </span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">mCSPC</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">April </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&nbsp;2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">abrocitinib (PF-04965842)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Atopic dermatitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oct.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oct.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Infliximab Pfizer (infliximab)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Ankylosing spondylitis (biosimilar)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Oct.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Bevacizumab Pfizer (bevacizumab)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">NSCLC (biosimilar)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Sept.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Rituximab Pfizer (rituximab)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Chronic idiopathic thrombocytopenic purpura (biosimilar)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Aug.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">tanezumab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Chronic pain due to moderate-to-severe osteoarthritis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">March</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&nbsp;2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">March</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&nbsp;2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Aug.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Bosulif <br>(bosutinib)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">First-line chronic myelogenous leukemia</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">June </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Daurismo <br>(glasdegib)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Combination with low-dose cytarabine for AML</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">June </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Xeljanz <br>(tofacitinib)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Ankylosing spondylitis</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Aug.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Feb.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Relugolix fixed dose combination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Uterine fibroids (combination with estradiol and norethindrone acetate)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Aug.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Lorbrena </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(lorlatinib)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">First- line ALK-positive NSCLC</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mar. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Feb.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">somatrogon</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(PF-06836922)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Pediatric growth hormone deficiency</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Feb.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">PF-06482077</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(Vaccine)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent invasive and non-invasive pneumococcal infections (adults)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2020</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&nbsp;Feb. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">TicoVac<br>(Vaccine)</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent tick-borne encephalitis</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&nbsp;Feb. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.5pt">For the U.S., the filing date is the date on which the FDA accepted our submission. For the EU, the filing date is the date on which the EMA validated our submission. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">PF-07302048 or BNT162b2 (Pfizer/BioNTech COVID-19 vaccine) received EUA from the FDA in December 2020 and CMA from the EMA in December 2020 for use in individuals 16 years of age and older. In May 2021, the FDA expanded the EUA to include the use of BNT162b2 in individuals 12 to 15 years of age. Pfizer and BioNTech have  requested similar amendments to expand the authorizations for use in individuals 12 to 15 years of age by other regulatory authorities worldwide. In May 2021, Pfizer and BioNTech initiated a rolling submission of a BLA with the FDA for approval of the COVID-19 vaccine in individuals 16 years of age and older. The Prescription Drug User Fee Act goal date for a decision by the FDA will be set once the BLA is complete and formally accepted for review by the FDA.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Being developed in collaboration with Merck KGaA, Germany.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is a registered trademark of ImClone LLC. In the EU, we are developing in collaboration with the Pierre Fabre Group. In Japan, we are developing in collaboration with Ono Pharmaceutical Co., Ltd. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Being developed in collaboration with Astellas. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">Being developed in collaboration with Lilly. In March 2021, the FDA Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab resulted in a 19:1 against vote on whether the proposed risk evaluation and mitigation strategy (REMS) for tanezumab will ensure benefits outweigh risks. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.47pt">Being developed in collaboration with Myovant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Being developed in collaboration with OPKO. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following provides information about additional indications and new drug candidates in late-stage development:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tbody><tr><td style="width:1.0%"></td><td style="width:12.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PRODUCT/CANDIDATE</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PROPOSED DISEASE AREA</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="11" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:7.2pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS<br>FOR IN-LINE AND IN-REGISTRATION PRODUCTS</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Bavencio (avelumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">First-line NSCLC</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Ibrance (palbociclib)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">ER+/HER2+ metastatic breast cancer</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Xtandi (enzalutamide)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Non-metastatic high-risk castration sensitive prostate cancer</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Talzenna (talazoparib)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Combination with Xtandi (enzalutamide) for first-line mCRPC</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PF-06482077 (Vaccine)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Invasive and non-invasive pneumococcal infections (pediatric)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">somatrogon (PF-06836922)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Adult growth hormone deficiency</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">tanezumab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Cancer pain</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Braftovi (encorafenib) and Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> (cetuximab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">First-line BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">v600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">-mutant mCRC</span></div></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Relugolix fixed dose combination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Combination with estradiol and norethindrone acetate for endometriosis</span></div></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Relugolix fixed dose combination</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Combination with estradiol and norethindrone acetate for contraceptive efficacy </span></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Braftovi (encorafenib) and Mektovi (binimetinib) and Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> (pembrolizumab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">BRAF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">v600E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">-mutant metastatic or unresectable locally advanced melanoma</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="11" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;text-indent:5.65pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">aztreonam-avibactam<br>(PF-06947387)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Treatment of infections caused by Gram-negative bacteria </span></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">fidanacogene elaparvovec (PF-06838435)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Hemophilia B</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">giroctocogene fitelparvovec </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(PF-07055480)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Hemophilia A</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PF-06425090 (Vaccine)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Primary clostridioides difficile infection</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PF-06886992 (Vaccine)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Serogroups meningococcal (adolescent and young adults)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PF-06928316 (Vaccine)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Respiratory syncytial virus infection (maternal)</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PF-07265803</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Dilated cardiomyopathy due to Lamin A/C gene mutation</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ritlecitinib (PF-06651600)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Alopecia areata</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">sasanlimab (PF-06801591)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Combination with Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">fordadistrogene movaparvovec (PF-06939926)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Duchenne muscular dystrophy</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">marstacimab (PF-06741086)</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Hemophilia</span></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">Being developed in collaboration with Merck KGaA, Germany.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Being developed in collaboration with the Alliance Foundation Trial.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">Being developed in collaboration with Astellas.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Being developed in collaboration with OPKO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.97pt">Being developed in collaboration with Lilly. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.47pt">Erbitux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is a registered trademark of ImClone LLC. In the EU, we are developing in collaboration with the Pierre Fabre Group. In Japan, we are developing in collaboration with Ono Pharmaceutical Co., Ltd. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Being developed in collaboration with Myovant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is a registered trademark of Merck Sharp &amp; Dohme Corp. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information about our R&amp;D organization, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our 2020 Form 10-K.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_178"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COSTS AND EXPENSES</span></div><div style="margin-bottom:5pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:63.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.823%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses follow:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%<br>&nbsp;Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,211&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,940&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Percentage of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">28.9&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19.2&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,783&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,541&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,014&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,672&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">872&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">849&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">54&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(57)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions—net</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">190&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="21" style="border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">* Indicates calculation not meaningful or results are equal to or greater than 100%.</span></td></tr></tbody></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased $2.3 billion, primarily due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of BNT162b2, which includes a charge for the 50% gross margin split with BioNTech and royalty expenses;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">increased sales volumes of other products, driven by Pfizer CentreOne; and</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the unfavorable impact of foreign exchange and hedging activity on intercompany inventory.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a percentage of revenues in the first quarter of 2021, compared to the same period in 2020, was primarily due to all of the factors discussed above, partially offset by an increase in alliance revenues, which have no associated cost of sales.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, Informational and Administrative Expenses</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI&amp;A expenses increased $242 million, mostly due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an increase to expense resulting from the increase in our liability to be paid to participants of our supplemental savings plan; </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">costs related to BNT162b2, primarily driven by a higher provision for healthcare reform fees based on sales; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an increase in external, incremental costs directly related to implementing our cost-reduction/productivity initiatives,</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">lower spending on Chantix following the loss of patent protection in the U.S. in November 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development (R&amp;D) Expenses</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses increased $342 million, primarily due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">external spending on Pfizer’s efforts to develop BNT162b2 and therapeutics to help treat COVID-19; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">an increase in the value of the portfolio performance share grants reflecting changes in the price of Pfizer’s common stock.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets was relatively flat.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives </span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transforming to a More Focused Company Program</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our program, as well as the anticipated and actual costs, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The program savings discussed below may be rounded and represent approximations. In connection with the costs primarily related to the corporate enabling functions initiatives, we expect gross cost savings of $1.0 billion, or net cost savings, excluding merit and inflation growth and certain real estate cost increases, of $700 million, to be achieved primarily from 2021 through 2022. In connection with manufacturing network optimization, including legacy cost reduction initiatives, we expect net cost savings of $300 million to be achieved primarily from 2020 through 2022.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain qualifying costs for this program were recorded in the first quarters of 2021 and 2020 and are reflected as Certain Significant Items and excluded from our non-GAAP measure of Adjusted Income. See the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measure: Adjusted Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of this MD&amp;A.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to this program, we continuously monitor our operations for cost reduction and/or productivity opportunities, especially in light of the losses of exclusivity and the expiration of collaborative arrangements for various products.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (Income)/Deductions—Net</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income—net increased $1.2 billion, mainly due to:</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">net gains on equity securities in the first quarter of 2021 versus net losses recorded in the first quarter of 2020;</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">higher net periodic benefit credits other than service costs related to pension and postretirement plans; and</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">higher income from collaborations, out-licensing arrangements and sales of compound/product rights.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_184"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROVISION FOR TAXES ON INCOME</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:62.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.846%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%<br>Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">805&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">359&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effective tax rate on continuing operations</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14.2&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12.6&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="21" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">* Indicates calculation not meaningful or results are equal to or greater than 100%.</span></td></tr></tbody></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about our effective tax rate and the events and circumstances contributing to the changes between periods, as well as details about discrete elements that impacted our tax provisions, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DISCONTINUED OPERATIONS </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about our discontinued operations, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_187"></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NON-GAAP FINANCIAL MEASURE: ADJUSTED INCOME</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income is an alternative measure of performance used by management to evaluate our overall performance in conjunction with other performance measures. As such, we believe that investors’ understanding of our performance is enhanced by disclosing this measure. We use Adjusted income, certain components of Adjusted income and Adjusted diluted EPS to present the results of our major operations––the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide––prior to considering certain income statement elements as follows:</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Measure</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Definition</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Illustrative Use</span></td></tr><tr style="height:57pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before the impact of purchase accounting for acquisitions, acquisition-related items, discontinued operations and certain significant items</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Monthly managerial analysis of our operating results and our annual budgets are prepared using these non-GAAP measures</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Senior management’s compensation is determined, in part, using these non-GAAP measures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td></tr><tr style="height:86pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted cost of sales, Adjusted selling, informational and administrative expenses, Adjusted research and development expenses, Adjusted amortization of intangible assets and Adjusted other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of sales, Selling, informational and administrative expenses, Research and development expenses, Amortization of intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Other (income)/deductions––net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, each before the impact of purchase accounting for acquisitions, acquisition-related items, discontinued operations and certain significant items, which are components of the Adjusted income measure</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:48pt"><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjusted diluted EPS</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">EPS attributable to Pfizer Inc. common shareholders––diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> before the impact of purchase accounting for acquisitions, acquisition-related items, discontinued operations and certain significant items</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Most directly comparable GAAP measure.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The short-term incentive plans for substantially all non-sales-force employees worldwide are funded from a pool based on our performance, measured in significant part by three metrics, one of which is Adjusted diluted EPS, which is derived from Adjusted income and accounts for 40% of the bonus pool funding. Additionally, the payout for Performance Share Awards is determined in part by Adjusted net income, which is derived from Adjusted income. Effective for the 2020 performance year and consistent with shareholder feedback received in 2019, the Compensation Committee of the BOD approved adding an R&amp;D pipeline achievement factor to the existing short-term incentive financial metrics.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income, and its components and Adjusted diluted EPS, are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, they may not be comparable to the calculation of similar measures of other companies and are presented solely to permit investors to more fully understand how management assesses performance. A limitation of these measures is that they provide a view of our operations without including all events during a period, and do not provide a comparable view of our performance to peers. These measures are not, and should not be viewed as, substitutes for their directly comparable GAAP measures of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, components of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EPS attributable to Pfizer Inc. common shareholders—diluted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. See the accompanying reconciliations of certain GAAP reported to non-GAAP adjusted information for the first quarters of 2021 and 2020 below. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recognize that, as internal measures of performance, these measures have limitations, and we do not restrict our performance-management process solely to these measures. We also use other tools designed to achieve the highest levels of performance. For example, our R&amp;D organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on an absolute basis and relative to a publicly traded pharmaceutical index, plays a significant role in determining payouts under certain of our incentive compensation plans.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Purchase Accounting Adjustments</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income excludes certain significant purchase accounting impacts resulting from business combinations and net asset acquisitions. These impacts can include the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, amortization related to the increase in fair value of the acquired finite-lived intangible assets, and to a much lesser extent, depreciation related to the increase/decrease in fair value of the acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value changes for contingent consideration. Therefore, the Adjusted income measure includes the revenues earned upon the sale of the acquired products without considering the acquisition cost of those products.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisition-Related Items</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income excludes acquisition-related items, which are comprised of transaction, integration, restructuring charges and additional depreciation costs for business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate businesses as a result of an acquisition. We have made no adjustments for resulting synergies.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Discontinued Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income excludes the results of discontinued operations, as well as any related gains or losses on the disposal of such operations. We believe that this presentation is meaningful to investors because, while we review our therapeutic areas and product lines for strategic fit with our operations, we do not build or run our business with the intent to discontinue parts of our business. Restatements due to discontinued operations do not impact compensation or change the Adjusted income measure for the compensation in respect of the restated periods, but are presented for consistency across all periods.</span></div><div><span><br></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Certain Significant Items</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted income excludes certain significant items representing substantive and/or unusual items that are evaluated individually on a quantitative and qualitative basis. Certain significant items may be highly variable and difficult to predict. Furthermore, in some cases it is reasonably possible that they could reoccur in future periods. For example, although major non-acquisition-related cost-reduction programs are specific to an event or goal with a defined term, we may have subsequent programs based on reorganizations of the business, cost productivity or in response to LOE or economic conditions. Legal charges to resolve litigation are also related to specific cases, which are facts and circumstances specific and, in some cases, may also be the result of litigation matters at acquired companies that were inestimable, not probable or unresolved at the date of acquisition. Unusual items represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell. For a non-inclusive list of certain significant items see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below. </span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2021, we exclude pension and postretirement actuarial remeasurement gains and losses from our measure of Adjusted income because of their inherent market volatility, which we do not control and cannot predict with any level of certainty and because we do not believe including these gains and losses assists investors in understanding our business or is reflective of our core operations and business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, see the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Non-GAAP Financial Measure: Adjusted Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of the MD&amp;A of our 2020 Form 10-K for additional information.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Reconciliations of GAAP Reported to Non-GAAP Adjusted Information––Certain Line Items</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="39" style="padding:0 1pt"></td></tr></tbody></table></div><div style="margin-bottom:5pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Three Months Ended April 4, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">GAAP Reported</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchase Accounting Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisition-Related Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain Significant Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP Adjusted</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14,582</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,582&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,211</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,177&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,783</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(124)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,659&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,014</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,013&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">872</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(763)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">109&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income)/deductions––net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,004)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">350&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(600)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from continuing operations before provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,683</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">704&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(160)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,225&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for taxes on income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">805</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">187&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(38)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">954&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,877</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">517&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(122)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,271&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from discontinued operations––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,877</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">517&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(122)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,262&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders––diluted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">0.86</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.09&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.02)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.93&nbsp;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:28.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Three Months Ended March 29, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">GAAP Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchase Accounting Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisition-Related Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain Significant Items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP Adjusted</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10,083</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,083&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,940</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,917&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,541</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(92)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,450&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,673&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">849</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(778)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">54</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income)/deductions––net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">190</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(449)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(262)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from continuing operations before provision for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,842</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">776&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">602&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,233&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Provision for taxes on income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">359</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">175&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">140&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">678&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">601&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">462&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,555&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from discontinued operations––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">881</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(881)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,355</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">601&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(881)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">462&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,546&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders––diluted</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">0.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.11&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.16)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.08&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.63&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">For details of adjustments, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The effective tax rate on Non-GAAP Adjusted income was 15.3% in the first quarter of 2021, compared to 16.0% in the first quarter of 2020. The decrease was primarily due to a favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:3pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:28.225%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.607%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="39" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29,<br>2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase accounting adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization, depreciation and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">709&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">780&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total purchase accounting adjustments––pre-tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">704&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">776&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(175)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total purchase accounting adjustments––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">601&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transaction costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Integration costs and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total acquisition-related items––pre-tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total acquisition-related items––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from discontinued operations––net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(881)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Certain significant items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">––</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">cost reduction initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Implementation costs and additional depreciation––asset restructuring</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(399)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain legal matters, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Business and legal entity alignment costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)/losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(j)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(k)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total certain significant items––pre-tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total certain significant items––net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total purchase accounting adjustments, acquisition-related items, discontinued operations and certain significant items––net of tax, attributable to Pfizer Inc.</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included primarily in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision for taxes on income.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying the applicable tax rate. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations––net of tax. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 2A.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">Includes employee termination costs, asset impairments and other exit costs not associated with acquisitions, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.81pt">Relates to our cost-reduction and productivity initiatives not related to acquisitions (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). For the three months ended April&nbsp;4, 2021, primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($21 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($64 million). For the three months ended March&nbsp;29, 2020, primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($14 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($15 million).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">For the three months ended April&nbsp;4, 2021, primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($17 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($53 million) and for the three months ended March&nbsp;29, 2020, primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($11 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($61 million)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and mainly represents costs for consulting, legal, tax and advisory services associated with the internal reorganization of legal entities.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.1pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the three months ended April&nbsp;4, 2021, includes a $47 million interim actuarial remeasurement pre-tax gain and for the three months ended March&nbsp;29, 2020, includes an $81 million interim actuarial remeasurement pre-tax loss. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.1pt">Included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">For the three months ended April&nbsp;4, 2021, primarily included in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Other (income)/deductions––net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($77 million). For the three months ended March&nbsp;29, 2020, primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($17 million) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($164 million). Among other things, the three months ended April&nbsp;4, 2021 includes charges of $49 million and the three months ended March&nbsp;29, 2020 includes charges of $160 million recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions––net, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">primarily</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">representing our pro rata share of restructuring and business combination accounting charges recorded by the Consumer Healthcare JV. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_199"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Continuing Operations</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:21.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:49.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drivers of change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by/(used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,530&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,155&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change is driven primarily by higher net income and advance payments in 2021 for BNT162b2 recorded in deferred revenue. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change also reflects the impact of timing of receipts and payments in the ordinary course of business.</span></div><div><span><br></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other adjustments, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is driven primarily by an increase in net unrealized gains on equity securities and an increase in equity income, partially offset by an increase in equity method dividends received and an increase in net losses on foreign exchange contracts hedging a portion of our forecasted intercompany inventory sales.</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,747)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change is driven mainly by a $3.5&nbsp;billion increase in purchases of short-term investments with original maturities of greater than three months and a $580&nbsp;million increase in net purchases of short-term investments with original maturities of three months or less, partially offset by a $2.2&nbsp;billion increase in redemptions of short-term investments with original maturities of greater than three months.</span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities from continuing operations</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,807)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,200)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change is driven mostly by a $3.2&nbsp;billion decrease in proceeds from short-term borrowings with maturities of three months or less, a $1.2&nbsp;billion decrease in proceeds from issuances of long-term debt, and a $277 million payment to Viatris in connection with the spin-off of the Upjohn business, partially offset by a $2.2&nbsp;billion net reduction in repayments of short-term borrowings with maturities of greater than three months and a $2.2&nbsp;billion reduction in principal repayments on long-term debt.</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Discontinued Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from discontinued operations relate to our former Upjohn Business and the Mylan-Japan collaboration (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_205"></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANALYSIS OF FINANCIAL CONDITION, LIQUIDITY, CAPITAL RESOURCES AND MARKET RISK</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely largely on operating cash flows, short-term investments or commercial paper borrowings and long-term debt to provide for our liquidity requirements. We strive to improve cash inflows through working capital efficiencies. Due to our significant operating cash flows as well as our financial assets, access to capital markets and available lines of credit and revolving credit agreements, we believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future. We have taken and will continue to take a conservative approach to our financial investments and monitoring of our liquidity position in response to market changes. Our debt investments consist primarily of high-quality, highly liquid, well-diversified available-for-sale debt securities.</span></div><div><span><br></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Debt Capacity––Lines of Credit</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have available lines of credit and revolving credit agreements with a group of banks and other financial intermediaries. We typically maintain cash and cash equivalent balances and short-term investments which, together with our available revolving credit facilities, are in excess of our commercial paper and other short-term borrowings. As of April&nbsp;4, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we had access to a $7 billion U.S. revolving credit facility expiring in 2025. In addition, our lenders have provided us an additional $317 million in lines of credit, of which $283 million expire within one year. Essentially all lines of credit were unused as of April&nbsp;4, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Selected Measures of Liquidity and Capital Resources</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tbody><tr><td style="width:1.0%"></td><td style="width:71.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The following presents certain relevant measures of our liquidity and capital resources:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT RATIOS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 4,<br>2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selected financial assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,768&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,784&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,899&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,437&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term investments, excluding private equity securities at cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,229&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,973&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,895&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15,195&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Debt:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,352&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,703&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,347&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37,133&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">39,699&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">39,835&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selected net financial liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(22,803)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(24,641)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Working capital</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,880&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,147&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ratio of current assets to current liabilities</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.48:1</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.35:1</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for a description of certain assets held and for a description of credit risk related to our financial instruments held.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">The increase in working capital was primarily driven by an increase in short-term investments due to operating cash flow generation, and the timing of accruals, cash receipts and payments in the ordinary course of business, partially offset by capital expenditures.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about the sources and uses of our funds, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Condensed Consolidated Statements of Cash Flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about credit ratings, interest rate risk and LIBOR, global economic conditions, and market risk, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk—Selected Measures of Liquidity and Capital Resources</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within MD&amp;A in our 2020 Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Off-Balance Sheet Arrangements</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities. For more information on guarantees and indemnifications, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, certain of our co-promotion or license agreements give our licensors or partners the rights to negotiate for, or in some cases to obtain under certain financial conditions, co-promotion or other rights in specified countries with respect to certain of our products.</span></div><div><span><br></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Purchase Plans and Accelerated Share Repurchase Agreements</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&nbsp;4, 2021, our remaining share-purchase authorization was approximately $5.3 billion, with no repurchases in the first three months of 2021. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2020 Form 10-K for more information on our publicly announced share-purchase plans.</span></div><div><span><br></span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends on Common Stock</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, our BOD declared a dividend of $0.39 per share, payable on June 4, 2021, to shareholders of record at the close of business on May 7, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BOD decided to maintain Pfizer’s quarterly dividend at its current level for the second quarter of 2021 despite the recent declaration of a dividend payment by Viatris that is payable to those Pfizer shareholders that continue to hold, as of the Viatris dividend record date, Viatris shares received from the combination of Upjohn and Mylan.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and projected dividends provide a return to shareholders while maintaining sufficient capital to invest in growing our business. Our dividends are not restricted by debt covenants. While the dividend level remains a decision of Pfizer’s BOD and will continue to be evaluated in the context of future business performance, we currently believe that we can support future annual dividend increases, barring significant unforeseen events. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_211"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS</span></div><div><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently Adopted Accounting Standard</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1B.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recently Issued Accounting Standard, Not Adopted as of April&nbsp;4, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard/Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect on the Financial Statements</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference rate reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> provides temporary optional expedients and exceptions to the guidance for contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued after 2021 because of reference rate reform.</span></div><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The new guidance provides the following optional expedients: </span></div><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:2.25pt">Simplify accounting analyses under current U.S. GAAP for contract modifications.</span></div><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:2.25pt">Simplify the assessment of hedge effectiveness and allow hedging relationships affected by reference rate reform to continue.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:2.25pt">Allow a one-time election to sell or transfer debt securities classified as held to maturity that reference a rate affected by reference rate reform.</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Elections can be adopted prospectively at any time through December 31, 2022.</span></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">We are assessing the impact of the provisions of this new guidance on our consolidated financial statements.</span></td></tr></tbody></table></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_214"></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q contains forward-looking statements. We also provide forward-looking statements in other materials we release to the public, as well as public oral statements. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have tried, wherever possible, to identify such statements by using words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek” and other words and terms of similar meaning or by using future dates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include forward-looking information in our discussion of the following, among other topics:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our anticipated operating and financial performance, reorganizations, business plans and prospects;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, post-approval clinical trial results and other developing data that become available, revenue contribution, growth, performance, timing of exclusivity and potential benefits;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">strategic reviews, capital allocation objectives, dividends and share repurchases;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on these opportunities; </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">sales, expenses, interest rates, foreign exchange rates and the outcome of contingencies, such as legal proceedings;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expectations for impact of or changes to existing or new government regulations or laws;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to anticipate and respond to macroeconomic, geopolitical, health and industry trends, pandemics, acts of war and other large-scale crises; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">manufacturing and product supply. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, forward-looking information in this Form 10-Q includes statements relating to specific future actions and effects, including, among others, our efforts to respond to COVID-19, including our development of a vaccine to help prevent COVID-19 and our investigational protease inhibitors, the forecasted revenue contribution of BNT162b2 and the potential number of doses that we and BioNTech believe can be manufactured; our expectations regarding the impact of COVID-19 on our business; the expected impact of patent expiries and competition from generic manufacturers; the benefits expected from our business development transactions; our anticipated liquidity position; our expectations regarding Ibrance; the anticipated costs and savings from certain of our initiatives, including our Transforming to a More Focused Company program; our planned capital spending; and the expectations for our quarterly dividend payments.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. Actual outcomes may vary materially from past results and those anticipated, estimated, implied or projected. These forward-looking statements may be affected by underlying assumptions that may prove inaccurate or incomplete, or by known or unknown risks and uncertainties, including those described in this section and in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section in our 2020 Form 10-K.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, you are cautioned not to unduly rely on forward-looking statements, which speak only as of the date of this Form  10-Q. We undertake no obligation to update forward-looking statements, whether as a result of new information, future events </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or otherwise, except as required by applicable securities law. You are advised, however, to consult any further disclosures we make on related subjects.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the factors that could cause actual results to differ are identified below, as well as those discussed in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section in our 2020 Form 10-K and within this MD&amp;A. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. The occurrence of any of the risks identified below or in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section in our 2020 Form 10-K, or other risks currently unknown, could have a material adverse effect on our business, financial condition or results of operations, or we may be required to increase our accruals for contingencies. It is not possible to predict or identify all such factors. Consequently, you should not consider the following to be a complete discussion of all potential risks or uncertainties:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Our Business, Industry and Operations, and Business Development:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the outcome of R&amp;D activities, including, the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, and/or regulatory approval and/or launch dates, as well as the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to successfully address comments received from regulatory authorities such as the FDA or the EMA, or obtain approval from regulators on a timely basis or at all; regulatory decisions impacting labeling, manufacturing processes, safety and/or other matters; the impact of recommendations by technical or advisory committees; and the timing of pricing approvals and product launches;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the outcome of post-approval clinical trials, which could impact marketing approval, product labeling, and/or availability or commercial potential, including uncertainties regarding the commercial or other impact of the results of the Xeljanz ORAL Surveillance (A3921133) study or any potential actions by regulatory authorities based on analysis of ORAL Surveillance or other data;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the success and impact of external business development activities, including the ability to identify and execute on potential business development opportunities; the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all; the ability to realize the anticipated benefits of any such transactions in the anticipated time frame or at all; the potential need for and impact of additional equity or debt financing to pursue these opportunities, which could result in increased leverage and/or a downgrade of our credit ratings; challenges integrating the businesses and operations; disruption to business and operations relationships; risks related to growing revenues for certain acquired products; significant transaction costs; and unknown liabilities;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">competition, including from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat diseases and conditions similar to those treated by our in-line drugs and drug candidates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the ability to successfully market both new and existing products, including biosimilars;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">difficulties or delays in manufacturing, sales or marketing; supply disruptions, shortages or stock-outs at our or our third party suppliers’ facilities; and legal or regulatory actions; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of public health outbreaks, epidemics or pandemics (such as the COVID-19 pandemic) on our business, operations and financial condition and results, including impacts on our employees, manufacturing, supply chain, marketing, research and development and clinical trials;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">risks and uncertainties related to our efforts to develop a vaccine to help prevent COVID-19 and potential treatments for COVID-19, as well as challenges related to their manufacturing, supply and distribution;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in countries experiencing high inflation rates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant issues involving our largest wholesale distributors, which account for a substantial portion of our revenues;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of the increased presence of counterfeit medicines in the pharmaceutical supply chain;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant issues related to the outsourcing of certain operational and staff functions to third parties; and any significant issues related to our JVs and other third-party business arrangements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our foreign-exchange and interest-rate agreements of challenging global economic conditions and recent and possible future changes in global financial markets;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any changes in business, political and economic conditions due to actual or threatened terrorist activity, civil unrest or military action;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of product recalls, withdrawals and other unusual items;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">trade buying patterns;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments;</span></div><div style="margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs or organizational disruption;</span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Government Regulation and Legal Proceedings:</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of any U.S. healthcare reform or legislation or any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs or changes in the tax treatment of employer-sponsored health insurance that may be implemented;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access or restrictions on U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals and other industry stakeholders; as well as pricing pressures for our products as a result of highly competitive insurance markets;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">legislation or regulatory action in markets outside of the U.S., including China, affecting pharmaceutical product pricing, intellectual property, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the exposure of our operations globally to possible capital and exchange controls, economic conditions, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, as well as political unrest, unstable governments and legal systems and inter-governmental disputes;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">legal defense costs, insurance expenses, settlement costs and contingencies, including those related to actual or alleged environmental contamination;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk and impact of an adverse decision or settlement and the adequacy of reserves related to legal proceedings;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk and impact of tax related litigation;</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">governmental laws and regulations affecting our operations, including, without limitation, changes in laws and regulations or their interpretation, including, among others, changes in tax laws and regulations, including, among others, any potential changes to the existing tax law by the current U.S. Presidential administration and Congress increasing the corporate tax rate and/or the tax rate on foreign earnings;</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Intellectual Property, Technology and Security:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">any significant breakdown, infiltration or interruption of our information technology systems and infrastructure;</span></div><div style="margin-bottom:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the risk that our currently pending or future patent applications may not be granted on a timely basis or at all, or any patent-term extensions that we seek may not be granted on a timely basis, if at all; and</span></div><div style="padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to protect our patents and other intellectual property, including against claims of invalidity that could result in LOE, unasserted intellectual property claims and in response to any pressure, or legal or regulatory action by, various stakeholders or governments that could potentially result in us not seeking intellectual property protection for or agreeing not to enforce or being restricted from enforcing intellectual property related to our products, including our vaccine to help prevent COVID-19 and potential treatments for COVID-19.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_220"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item is incorporated by reference from the discussion in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk—Selected Measures of Liquidity and Capital Resources—Market Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section within MD&amp;A of our 2020 Form 10-K.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_223"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procedures are effective in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During our most recent fiscal quarter, there has not been any change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_226"></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:36.111%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #05497c;border-top:1pt dotted #05497c;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#05497c;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PART II.&nbsp; OTHER INFORMATION</span></td></tr></tbody></table></div><div><span><br></span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_229"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="text-align:justify"><span><br></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain legal proceedings in which we are involved are discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_232"></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to the “Our Operating Environment”, “The Global Economic Environment”, “COVID-19 Pandemic” and “Forward-Looking Information and Factors That May Affect Future Results” sections of the MD&amp;A of this Form 10-Q and to Part I, Item 1A, “Risk Factors” of our 2020 Form 10-K.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_238"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes purchases of our common stock during the first quarter of 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:30.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total Number of</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(b</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:700;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Average Price</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Paid per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Approximate Value of Shares That May Yet Be Purchased Under the Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:100%;position:relative;top:-2.97pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">January 1 through January 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">17,147&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">26.60&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5,292,881,709&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">February 1 through February 28, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">7,967,778&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">33.96&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5,292,881,709&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">March 1 through April&nbsp;4, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">2,654,032&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">33.78&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5,292,881,709&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">10,638,957&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">33.90&nbsp;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.24pt">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our 2020 Form 10-K.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represents (i) 10,633,238 shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii) the open market purchase by the trustee of 5,719 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who deferred receipt of performance share awards.</span></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_250"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh18x0404202110q.htm">Exhibit 18</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferability Letter of KPMG dated May 13, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh22x0404202110q.htm">Exhibit 22</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subsidiary Issuers of Guaranteed Securities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh311x0404202110q.htm">Exhibit 31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh312x0404202110q.htm">Exhibit 31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh321x0404202110q.htm">Exhibit 32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section<br>1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh322x0404202110q.htm">Exhibit 32.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section<br>1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 101:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.SCH<br>EX-101.CAL<br>EX-101.LAB<br>EX-101.PRE<br>EX-101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema<br>Inline XBRL Taxonomy Extension Calculation Linkbase<br>Inline XBRL Taxonomy Extension Label Linkbase<br>Inline XBRL Taxonomy Extension Presentation Linkbase<br>Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr></tbody></table></div><div><span><br></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i0aef9eb56eca43689ac2ec1e1a127ae4_253"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.877%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jennifer B. Damico</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer B. Damico, Senior Vice President and<br>Controller<br>(Principal Accounting Officer and<br>Duly Authorized Officer)</span></td></tr></tbody></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div>
</div>


	</div>

	<div id="form-information-modal" data-test="form-information-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="form-information-modal-title" data-test="form-information-modal-title" class="reboot lead mb-0"></p>
			<div class="reboot dialog-header-actions">
				<i id="form-information-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="14"></i>

				<i id="dialog-box-copy-content" title="Click to Copy all Dialog Box Content." class="reboot fas fa-copy m-1 click" tabindex="14"></i>

				<i id="dialog-box-close" data-name="Form Information Modal" title="Click to Close this Dialog Box." class="reboot fas fa-times m-1 click" tabindex="14"></i>

			</div>
		</div>
		<div class="reboot dialog-content">
			<div id="form-information-copy-paste" class="reboot form-group d-none">
				<label class="reboot">Copy and Paste Below Content.</label>
				<a id="dialog-content-copy-content" class="reboot float-right click color-inherit" tabindex="14">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="14"></textarea>
			</div>
			<div id="form-information-modal-carousel" class="reboot carousel pointer-event" data-interval="false" data-ride="carousel">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-1" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-bordered table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-2" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-3" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-4" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around">
			<button id="form-information-prev" class="reboot btn btn-link text-dark" href="#form-information-modal-carousel" role="button" data-slide="prev" tabindex="14">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="form-information-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
			</ol>
			<button id="form-information-next" data-test="form-information-next" class="reboot btn btn-link text-dark" href="#form-information-modal-carousel" role="button" data-slide="next" tabindex="14">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>

	<div id="settings-modal" data-test="settings-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="settings-modal-title" data-test="settings-modal-title" class="reboot lead mb-0">Settings</p>
			<div class="reboot dialog-header-actions">
				<i id="settings-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="15"></i>

				<i id="settings-modal-close" data-name="Settings Modal" title="Click to Close this Dialog Box." class="reboot fas fa-times m-1 click" tabindex="15"></i>
			</div>
		</div>
		<div class="reboot dialog-content">
			<form class="reboot">
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">Hover
						over Fact for quick information.</label>
					<select id="hover-option-select" class="reboot col-sm-8 form-control" tabindex="15">
						<option class="reboot" value="true">On</option>
						<option class="reboot" value="false">Off</option>
					</select>
				</div>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">Auto
						Scrolling Position</label>
					<select id="scroll-position-select" class="reboot col-sm-8 form-control" tabindex="15">
						<option class="reboot" value="start">Top</option>
						<option class="reboot" value="center">Center</option>
					</select>
					<small class="reboot form-text text-muted col-sm-12" tabindex="15">Selecting
						a fact from the Sections Menu or the Fact Menu will automatically
						scroll that element to the (Top, or Middle) of the viewer window.
						This setting will have no use on IE 10, or Safari.</small>
				</div>
				<hr class="reboot">
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot tagged-data-example-1">Tagged Data</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="tagged-data-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 102, 0);"><div class="picker_selector" style="left: 6.66667%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 102, 0); color: rgb(255, 102, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 102, 0), rgba(255, 102, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(255, 102, 0);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot search-results-example-1">Search
							Results</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="search-results-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 215, 0);"><div class="picker_selector" style="left: 14.0523%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 215, 0); color: rgb(255, 215, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 215, 0), rgba(255, 215, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(255, 215, 0);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot selected-fact-example-1">Selected Fact</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="selected-fact-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(0, 135, 255);"><div class="picker_selector" style="left: 57.8526%;"></div></div><div class="picker_sl" style="background-color: rgb(0, 135, 255); color: rgb(0, 55, 104);"><div class="picker_selector" style="left: 100%; top: 79.6078%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(0, 55, 104), rgba(0, 55, 104, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(0, 55, 104);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot tag-shading-exmple-1">Tag Shading
							(hover)</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="tag-shading-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 0, 0);"><div class="picker_selector" style="left: 0%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 0, 0); color: rgb(255, 0, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 0, 0), rgba(255, 0, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 70%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgba(255, 0, 0, 0.3);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot text-block-exmple-1">Text Block Indicators</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="text-block-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(0, 135, 255);"><div class="picker_selector" style="left: 57.8526%;"></div></div><div class="picker_sl" style="background-color: rgb(0, 135, 255); color: rgb(0, 55, 104);"><div class="picker_selector" style="left: 100%; top: 79.6078%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(0, 55, 104), rgba(0, 55, 104, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(0, 55, 104);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
			</form>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around"></div>
	</div>

	<div id="taxonomy-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="taxonomy-modal-title" class="reboot lead mb-0"></p>
			<div class="reboot dialog-header-actions">

				<i id="taxonomy-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="16"></i>

				<i id="taxonomy-modal-jump" title="Click to see this in the Facts sidebar." class="reboot fas fa-directions m-1 click" tabindex="16"></i>
				<i id="taxonomy-modal-copy-content" class="reboot fas fa-copy m-1 click" tabindex="16"></i>

				<i id="taxonomy-modal-compress" class="reboot fas fa-compress m-1 click d-none" tabindex="16"></i>

				<i id="taxonomy-modal-expand" class="reboot fas fa-expand m-1 click d-none" tabindex="16"></i>

				<i id="taxonomy-modal-close" class="reboot fas fa-times m-1 click" tabindex="16"></i>
			</div>
		</div>
		<div class="reboot dialog-content">
			<p id="taxonomy-modal-subtitle" class="reboot text-center font-weight-bold"></p>
			<div id="taxonomy-copy-paste" class="reboot form-group d-none">
				<label>Copy and Paste Below Content.</label>
				<a id="taxonomy-copy-content" class="reboot float-right click color-inherit" tabindex="16">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="16"></textarea>
			</div>
			<div id="taxonomy-modal-carousel" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-1" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-2" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-3" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-4" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around">
			<button data-test="modal-taxonomy-prev" class="reboot btn btn-link text-dark" href="#taxonomy-modal-carousel" role="button" data-slide="prev" tabindex="16">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="taxonomy-modal-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
			</ol>
			<button data-test="modal-taxonomy-next" class="reboot btn btn-link text-dark" href="#taxonomy-modal-carousel" role="button" data-slide="next" tabindex="16">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>

	<div id="taxonomy-nested-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p class="reboot lead mb-0">
				Nested Facts
				<span class="reboot" id="nested-page"></span>
				<span class="reboot">/</span>
				<span class="reboot" id="nested-count"></span>
			</p>
			<div class="reboot dialog-header-actions">
				<i id="taxonomy-nested-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="17"></i>

				<i id="nested-taxonomy-modal-jump" title="Click to see this in the Facts sidebar." class="reboot fas fa-directions m-1 click" tabindex="17"></i>

				<i id="taxonomy-nested-modal-copy-content" class="reboot fas fa-copy m-1 click" tabindex="17"></i>

				<i id="taxonomy-nested-modal-compress" class="reboot fas fa-compress m-1 click d-none" tabindex="17"></i>

				<i id="taxonomy-nested-modal-expand" class="reboot fas fa-expand m-1 click d-none" tabindex="17"></i>

				<i id="taxonomy-nested-modal-close" class="reboot fas fa-times m-1 click" tabindex="17"></i>
			</div>
		</div>
		<div class="reboot dialog-content pt-0">
			<div id="modal-nested-fact-labels" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot d-flex">
					<button data-test="modal-taxonomy-nested-prev" class="reboot btn btn-link text-dark" href="#modal-nested-fact-labels" role="button" data-slide="prev" tabindex="17">
						<i class="reboot fas fa-chevron-left" title="Previous"></i>
						<span class="reboot sr-only">Previous</span>
					</button>
					<div id="modal-taxonomy-nested-label-carousel" class="reboot carousel-inner">
						<!-- Below is populated dynamically VIA JS -->
					</div>
					<button data-test="modal-taxonomy-nested-next" class="reboot btn btn-link text-dark" href="#modal-nested-fact-labels" role="button" data-slide="next" tabindex="17">
						<i class="reboot fas fa-chevron-right" title="Next"></i>
						<span class="reboot sr-only">Next</span>
					</button>
				</div>
			</div>
			<div id="taxonomy-nested-copy-paste" class="reboot form-group d-none">
				<label class="reboot">Copy and Paste Below Content.</label>
				<a id="taxonomy-nested-copy-content" class="reboot float-right click color-inherit" tabindex="17">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="17"></textarea>
			</div>
			<div id="modal-taxonomy-nested-content-carousel" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-1" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-bordered table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-2" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-3" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-4" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div id="taxonomy-nested-nav-controls" class="reboot dialog-footer d-flex justify-content-around">
			<button data-test="modal-taxonomy-prev" class="reboot btn btn-link text-dark" href="#modal-taxonomy-nested-content-carousel" role="button" data-slide="prev" tabindex="17">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="taxonomy-nested-modal-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
				<!-- Below is populated dynamically VIA JS -->
			</ol>
			<button data-test="modal-taxonomy-next" class="reboot btn btn-link text-dark" href="#modal-taxonomy-nested-content-carousel" role="button" data-slide="next" tabindex="17">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>



</body></html>